<SEC-DOCUMENT>0000939767-23-000048.txt : 20230509
<SEC-HEADER>0000939767-23-000048.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509161523
ACCESSION NUMBER:		0000939767-23-000048
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		23902196

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:fbc3dff4-5359-4115-877c-cd80f1d37686,g:9f45ed8a-1512-41a6-b3b1-f3d762602463,d:040dd4c33333480ba1e8d94e558984f1--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:exel="http://www.exelixis.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80L2ZyYWc6ZDk4YmU1MmNiOWU4NGU0MTg5OGZjMDhiMGQ3YTdiOGMvdGFibGU6MzgzMTczZjY1MWI5NDhkOTk1MTgxZmJjODRmMWVlMjgvdGFibGVyYW5nZTozODMxNzNmNjUxYjk0OGQ5OTUxODFmYmM4NGYxZWUyOF8yLTEtMS0xLTExMDk1Mg_7fabae71-998d-49c7-8521-bc695a76b1b6">false</ix:nonNumeric><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80L2ZyYWc6ZDk4YmU1MmNiOWU4NGU0MTg5OGZjMDhiMGQ3YTdiOGMvdGFibGU6MzgzMTczZjY1MWI5NDhkOTk1MTgxZmJjODRmMWVlMjgvdGFibGVyYW5nZTozODMxNzNmNjUxYjk0OGQ5OTUxODFmYmM4NGYxZWUyOF80LTEtMS0xLTExMDk1Mg_1caa9f5d-ca57-43f7-9513-78fa2fdaf4c2">2023</ix:nonNumeric><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80L2ZyYWc6ZDk4YmU1MmNiOWU4NGU0MTg5OGZjMDhiMGQ3YTdiOGMvdGFibGU6MzgzMTczZjY1MWI5NDhkOTk1MTgxZmJjODRmMWVlMjgvdGFibGVyYW5nZTozODMxNzNmNjUxYjk0OGQ5OTUxODFmYmM4NGYxZWUyOF81LTEtMS0xLTExMDk1Mg_31dc9ae5-122e-4e5e-bafd-4af2753ca98e">Q1</ix:nonNumeric><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80L2ZyYWc6ZDk4YmU1MmNiOWU4NGU0MTg5OGZjMDhiMGQ3YTdiOGMvdGFibGU6MzgzMTczZjY1MWI5NDhkOTk1MTgxZmJjODRmMWVlMjgvdGFibGVyYW5nZTozODMxNzNmNjUxYjk0OGQ5OTUxODFmYmM4NGYxZWUyOF82LTEtMS0xLTExMDk1Mg_6bb76e1c-7408-4238-a2d2-e57aeb0cd219">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80L2ZyYWc6ZDk4YmU1MmNiOWU4NGU0MTg5OGZjMDhiMGQ3YTdiOGMvdGFibGU6MzgzMTczZjY1MWI5NDhkOTk1MTgxZmJjODRmMWVlMjgvdGFibGVyYW5nZTozODMxNzNmNjUxYjk0OGQ5OTUxODFmYmM4NGYxZWUyOF83LTEtMS0xLTExMDk1Mg_ea078b61-59cd-47e1-adfa-46f257093060">December 31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ad1baf4c4a4f2bb5640105c86601f8_I20230501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0a3d041b493744caa9156b79d698c6f6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i47c0db749b524417a3bfe38e87216ea8_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie6dd521484284a028aab45ea8772360e_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7906589f9aa479c9565c72719ef21e6_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c85c6827b024c629f44a06755732c29_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if392acf72a7a4ae486acfef62c1ccfe2_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54ef24bfa5d431b8c16060a36cc40fd_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if94929e9ad634418bfded9c801d3fa56_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbadf347b2924c4a9fa6d3b424d3a4c4_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb2995a2816463f841ef310714ba472_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5df39c1ea61544ecb8c1f7e27e281c22_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7e6ca96ef1649d09aee4df309e35b73_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f40f89d45a494aa04db7f773107207_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica0a8eca365b40568b15c0188a145fb2_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfe186f4510a478e9f6676e77aa16a5d_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03ef2d0eca0349a592744851911a54b3_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e2ccc06faab42c1b72c84f6d8fc6554_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e3410e9e21c40998b84e3d69601d355_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idccb5b94d16a46fdb0cf63047d4d0a35_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife8714608e344dc7971babe1680ab27e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1508ac4b174b4c78a254a72746c9b9ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied50145a7df5459d92fa66f1d9a3a632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb2a2cfb158540ca9584fae8239e375c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3118a17fe82743f4a08ef8bc281df1cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56e9094b4beb4a8fb455ed26efa4b4dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia02620eae926413ab03c9415bcccade7_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cf2d5e95a2d4758b7b8e19ee1dc13cd_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20dd40ea4f824fdc9ef3a7e851b32b65_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79c3cf115f4f41eda883262bfbc8069a_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b9b0ed7a4840709f0a21fddfa8f9b7_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95578fef614f423aad1a9a09bc7a0471_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i009fe3cdc57c4356822574ede853c0a5_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4f89c6cd5174469a45a0fee83e965f9_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40f7e105971f40d2884d061c483a0023_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>exel:country</xbrli:measure></xbrli:unit><xbrli:context id="i88c7f65af0d44b9ebe6c0bfcbaf1bcc8_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>exel:product</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>exel:segment</xbrli:measure></xbrli:unit><xbrli:context id="i8d27cdd49640469c8f242f09214a609a_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida032638ed6145e19d54c570bc2b9d93_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i595a452dffec43ddacb9c075ff6b480b_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbe685ef22c941cba593e7a64e54dbf3_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06debfc85b9342daa487a13cc47e36de_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib55727874d5a4f308e9616357e398771_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa7500ddcb0b4d0db3443cc56170ff61_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iced7a06ad4e4417e870e84a67ede1244_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe37fc8620b94da8b2fc78d1941a9030_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9022e3a517a4086aadbb0f76b987860_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic354cd8d9401435bb4bef5aa134d8b18_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i145518f569754dcab3e0530961014f83_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac68a66c51c45aaafa439d76a88823b_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadcb287071b8482091481fd721d6437b_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i887d25b5c3eb476fac598042e121ae9e_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f6c3de32bb5469faa5988e472ba8294_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03edf15c3de14b84b45b07e5d3a6783b_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief8ad52c39a04dbb97764e462472ac81_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f99cf5241b6466788f894b2abc4f8ed_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cd8710c99944d47a9e0d4b3f5b26afc_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30663220db714d0f884ca85a30e97ed2_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e8676ff223f403889416c0afd319b61_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia17b8615b9f449ae815574e6e809f6f7_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe97f6cf8ca84e36a31f8ac01af69488_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia09f023283744b868559533749bfb478_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id32f197bc1034297a1205ca6bff7d001_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1dfd4d591884f079548cf36ab7d515a_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25cc695fcf37474383a6d4d015d235e0_D20220101-20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i005e52f0aa9441e9b404ce8f42adc3d6_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c2ff2123a5e43459fdf372396cef270_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f1ae657918947af907f5f8fab6b57fe_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0b5d0c4ace24841940333ae7904c072_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i936cbc93158847ce8d03042dab8d6d3d_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73abd557fa874e57af0091d9dd6409f3_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a5140525004434a113a31a2b6f9fec_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie93c1a4da62d4e91aada27293fc54993_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b3ca2a0d827408a96d2c203c0c3d713_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieca193774391470aaad49e0c557cd653_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie23bc89dd4ed466bb9e19cbc8ccf8e79_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i561a3686c8c54aaa9930ddcb0186d034_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb98cc6df0964b9dbc447c72a27d45d2_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf790da88c7f48bebd710b720e67b732_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6803b211b6ba46c0b060c8ef10832fa3_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab3dde5c402a452ca70d75ca56511047_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75a9ae3fb4354c558afa5652356fc857_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37a339e12ecb401f86dd0d2f2d5819d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec98443a01d9484790def9f44b69d198_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2931f6876e343439ec8b11809eebdf1_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864cb8fb17554a37a8adaea7c33b4efc_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1696dcf966747e3b865502c27c29aad_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i021d57f0be044f67974550e7d885e1d1_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d81ebf2e8e74fce85e25162934a4d6f_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff535a866b2c41fdb6f8646e8b488292_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4acc2ee076ef40faac1edea03e68040c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7033584518df402d9b63ad9da059f49e_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8c875584853425eba6bda6cacea2afd_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8956cc8ef7304e6e94df23b6ddff9882_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6df88e437a14a5e9a085f6a41e74f2a_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c0ff70d2a2430fa83299f494f4c105_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff2c6bd8205a44e2adb86297f4e43f30_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa11613f3ae54abb9a1445d4727f95f1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b291b148d264039a3e055bce29bb22b_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i700fe89825964bcf972c48b666c81680_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceabd35baaac41af956c98f0f6f9a4c6_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9ade2259f534177966ecdd8ce949ae1_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffd1fa8ae2c3489f966e69cc776984e3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia307bf0c6b5b4e379b3b2fd963c7ec10_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5231ebc5b9954e8e86f1f3347d082aea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd8e3d17820d48979b53c203807b119a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a661a40ef35452e91e33372e447bb37_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia77b0e4b2fe042139d6e224f2fba485d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d0849b362ce4562bfa01261a0459178_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cdebc21ace046518b4cec11c922421e_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaf7287be2844027815aaad0c091426c_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee3723a2aa5d463ba5688d589dda3b7d_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed11edd9a934cdead36351f09d723ae_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a53bc620960402191b67550fd79e525_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>exel:investment</xbrli:measure></xbrli:unit><xbrli:unit id="bond"><xbrli:measure>exel:bond</xbrli:measure></xbrli:unit><xbrli:context id="id2bb0b5859e94e8a936be047b130cf62_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7332d7a5938d414dabe83a5e6080938c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i289d8780126e4649aa6123219a3a320f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b9c63d0e80744719b3825cef5d5d14b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a7c1a85b9741668be6b1244cb03182_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ff6643a21e3422a80cdf082d9960ef4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fc468b967af4e86a80786a9c3aa6c5c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06d5bb9bf05744909898ab9b06c87bd6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i036daf539dfc49c8b73722fa3dae40a1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if87f0d005430404db06bb3f461851a1f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3329a69fdc8a47cba0eb64acea2395f6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie516d60b14c7478095d3f58b37428a68_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31039ff71e764360b58c4edb8693ba2f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ae4221be8d44a8a7c7a3c9e9f180ec_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide3e32d66598443986f9b93c38b9a643_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4fae3311f344cb085dfbc49e046ce18_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7acd21d036a3477aac89ae6ccd15d11b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66f34ea6b40143b8b73529584d025afc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b40425343ab4840a5a2065cac546d59_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41e491600bbd4af79605cfbcf83d1913_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69089dbb95ad41858db9a2acea999f10_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed964b6ac9e45588d0755f26b3a0530_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i957abfeaf90a4f888c7d6eb2f35c48b5_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie92282b3812a4c52a5eb1714922f4607_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b5995c0541b401eb07d6d421025aa64_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65cbedaff73f4c8baa47313cf71881be_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3936dfce8e401ba8d8f7c22abbb987_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2074852d3fc4146a552e1020fed749a_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9899d00466704758b0d0844ee5256ef0_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i456848174e4b411d97e0d18790a81449_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49a9b1c8da4d4daf938376135d589190_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc80802ed0064fbe90e139d4e9f11c0d_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i711f7b4d4689414894669fee3ce78b88_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b1713646d824564b9adee7955a921c9_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a589a297c4b471ba55f3c7b0af708c3_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1532e94710824cf39b3266528be43ba1_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a61c4734ba4ebcb0ef504886ba6de1_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eed0c8fb3e145b8afc025317b02b47c_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6fb00cb8a194a00aac07f85c0714ec1_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b9c7f8a02e440d198176572c5aa2a9b_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf6dfcf5d186443cb89d5d13bbf74fcc_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1777597937c24d058481cbd71160126e_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id59bda9dff304a61a0e935254d1873e1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="derivative_instrument"><xbrli:measure>exel:derivative_instrument</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i6f2a0a5e0af9493ca0f227fed931a4ed_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64066d08939c412ea45c0e2ce3a1376f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e165e45ccd64b35b0258752fdd33d0a_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i048b471b1b074d82bde14df2ea6b910d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc2748b521d641c1bb32f1e95b036970_I20221230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f1f77b69c154581ba20fe6d66b88637_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exel:AmendedAndRestated2017EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib798adcf0e30410e9cf0c303568c4dd8_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i077b175796d8467ebd7f57f08b70e854_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a8b33f363d4bc0ac9b67d04c777bda_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i453291ae47804d32a67ac7c2f2eefef5_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd484e891fd418a8ed42f45f84ec5bb_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia944468359d74f13b7a8031ab2b2ec81_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a18b8eece6d4b23bde7637cca5faffd_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5664ad32e75748ecabb161d218d96696_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b8feeeff3a844ed994dd23909d3c10b_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedfbdcf573f646959d5ef701c8bc3a1f_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2ed501ae6df49f8accd5863263afcf6_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f6f3af4e1e4419cb5a9e743245418f9_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a8da2045b84694bcd4b8144997fa91_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e6bbea2638d44e18d8bead2fc43515b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b919b2777644b8ebe2bfda500054c0f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesTargetAchievedOrProbableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08af1f4087d548b2a2c27bd855c5a14f_D20221231-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7027abb1b44144f58c42fe80ea5b4fe8_D20220101-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb5f735f185d4a9dbe1cc597da942150_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i040dd4c33333480ba1e8d94e558984f1_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:199.50pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6MTg5Y2MxN2MyYTY2NDRkZDk2ZjFkZTIyODU0YzNmYzAvdGFibGVyYW5nZToxODljYzE3YzJhNjY0NGRkOTZmMWRlMjI4NTRjM2ZjMF8wLTEtMS0xLTExMDk1Mg_aa57deae-33ac-4309-b7c7-e75fc6da3c12">10-Q</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6Y2QzNmIwODJiY2UyNGI0ODk5MWQ1YjIxYzVlYWZiNDIvdGFibGVyYW5nZTpjZDM2YjA4MmJjZTI0YjQ4OTkxZDViMjFjNWVhZmI0Ml8wLTAtMS0xLTExMDk1Mg_48acc6c6-d347-45d1-9b27-912b51a4c1a6">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the quarterly period ended <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xMTU_6dafdf31-aa9a-4dba-8310-e896878c738f">March 31, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6NzAxMmE1NzE1MzdkNGUzMWJiZTkwNjM0NTg2NjgzM2UvdGFibGVyYW5nZTo3MDEyYTU3MTUzN2Q0ZTMxYmJlOTA2MzQ1ODY2ODMzZV8wLTAtMS0xLTExMDk1Mg_67f6139e-6578-4c50-b6a8-63c06ec5d887">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODcy_9145a2b9-a312-4f16-b8a1-17fb0be04766">000-30235</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:48pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-top:9pt;text-align:center"><img src="exel-20230331_g1.jpg" alt="Exelixis_Logo_RGB_2023.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:177px"/></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6YjNhMDY0OTkzY2Q2NDFkNmI3YjlkODQ2MzM5ZmJiZmIvdGFibGVyYW5nZTpiM2EwNjQ5OTNjZDY0MWQ2YjdiOWQ4NDYzMzlmYmJmYl8xLTAtMS0xLTExMDk1Mg_eaed3404-eafd-4f52-853f-9e7f99d67bc2">EXELIXIS, INC.</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:39.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6NDA3MGEyZDk2ZjIyNDhjZjg5OWFjMzFkODJiN2ViZDAvdGFibGVyYW5nZTo0MDcwYTJkOTZmMjI0OGNmODk5YWMzMWQ4MmI3ZWJkMF8wLTAtMS0xLTExMDk1Mg_6965f541-66a7-4c88-b880-e4740ba63600">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6NDA3MGEyZDk2ZjIyNDhjZjg5OWFjMzFkODJiN2ViZDAvdGFibGVyYW5nZTo0MDcwYTJkOTZmMjI0OGNmODk5YWMzMWQ4MmI3ZWJkMF8wLTItMS0xLTExMDk1Mg_9d13fa24-1a1c-4cc9-966a-82b79cb93639">04-3257395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODcz_794384ea-965e-4f81-94c4-1e63d5a25276">1851 Harbor Bay Parkway</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODc4_b81a8f3e-9770-47f0-92e6-fb46b4db2bf5">Alameda,</ix:nonNumeric> <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODc5_1e0e5e84-84f0-48a4-be16-cbe58c2301c9">CA</ix:nonNumeric> <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODc0_bb1811f3-64fc-4d0a-99db-fe52e2f4991b">94502</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODgw_35ace888-f8ed-41e7-a3da-4bb9ed904d8f">650</ix:nonNumeric>) <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODgx_b7f827dd-a9e4-437c-99ee-90a4f08f7b73">837-7000</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6OWEzY2Y2M2FlNTJkNDVhNzk2MDAyMTAwYTQzODcyNGEvdGFibGVyYW5nZTo5YTNjZjYzYWU1MmQ0NWE3OTYwMDIxMDBhNDM4NzI0YV8xLTAtMS0xLTExMDk1Mg_e347c637-5812-49ce-849b-d313257012ab">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6OWEzY2Y2M2FlNTJkNDVhNzk2MDAyMTAwYTQzODcyNGEvdGFibGVyYW5nZTo5YTNjZjYzYWU1MmQ0NWE3OTYwMDIxMDBhNDM4NzI0YV8xLTEtMS0xLTExMDk1Mg_0e64b942-c5ee-4c13-a2f2-a2ef6132bf5b">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6OWEzY2Y2M2FlNTJkNDVhNzk2MDAyMTAwYTQzODcyNGEvdGFibGVyYW5nZTo5YTNjZjYzYWU1MmQ0NWE3OTYwMDIxMDBhNDM4NzI0YV8xLTItMS0xLTExMDk1Mg_9ca38342-e1e7-4f61-995c-d19c16e30502">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160; &#160;<ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODgy_d661d815-a38d-481a-9d64-663f8bfa8332">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODc3_4e7b1815-d0c3-4bc3-967f-9d3793c5b68d">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.208%"><tr><td style="width:1.0%"></td><td style="width:31.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.169%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6ZTdkZjA0Y2JiZWEzNGZhN2JhNjNiZDE3MDRkMDA1YTMvdGFibGVyYW5nZTplN2RmMDRjYmJlYTM0ZmE3YmE2M2JkMTcwNGQwMDVhM18wLTAtMS0xLTExMDk1Mg_17f1d53a-f28d-4177-a949-d898eb6ad169">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6ZTdkZjA0Y2JiZWEzNGZhN2JhNjNiZDE3MDRkMDA1YTMvdGFibGVyYW5nZTplN2RmMDRjYmJlYTM0ZmE3YmE2M2JkMTcwNGQwMDVhM18xLTQtMS0xLTExMDk1Mg_1c0fe38a-ba48-46b6-8762-be84577a6e4e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6ZTdkZjA0Y2JiZWEzNGZhN2JhNjNiZDE3MDRkMDA1YTMvdGFibGVyYW5nZTplN2RmMDRjYmJlYTM0ZmE3YmE2M2JkMTcwNGQwMDVhM18yLTQtMS0xLTExMDk1Mg_4aa52a34-80c9-40f9-9c2f-0150d4c67ff5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act.    </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODc2_8e62989d-5472-4f7c-afec-28a15cd896b4">&#253;</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of May 1, 2023, there were <ix:nonFraction unitRef="shares" contextRef="ie8ad1baf4c4a4f2bb5640105c86601f8_I20230501" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODE3_651e2ce9-9cdd-4ced-84c2-6eff9453ab8f">325,636,738</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div></div></div><div id="i040dd4c33333480ba1e8d94e558984f1_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_10">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_16">Condensed Consolidated Balance Sheets (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_19">Condensed Consolidated Statements of Income (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_22">Condensed Consolidated Statements of Comprehensive Income (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_25">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_28">Condensed Consolidated Statements of Cash Flows (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_31">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_67">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_82">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_82">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_85">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_85">34</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_88">PART II - OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_91">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_91">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_94">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_94">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_97">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_97">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_100">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_100">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_103">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_103">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_106">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_106">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_109">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_109">41</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_112">SIGNATURES</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i040dd4c33333480ba1e8d94e558984f1_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_13"></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item 1. Financial Statements</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_16"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNy0xLTEtMS0xMTA5NTI_92eaffd2-9602-4da8-98d6-e738e339465b">540,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNy0zLTEtMS0xMTA5NTI_c763d141-77c3-45dc-aef0-a3893f31f4a6">501,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfOC0xLTEtMS0xMTA5NTI_9125f4cd-2b35-4249-bc6a-6c82979c8292">772,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfOC0zLTEtMS0xMTA5NTI_58144ea4-d38f-4e5b-b145-701ad10c94d2">807,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfOS0xLTEtMS0xMTA5NTI_c54dbddb-63ae-4aa1-b78b-0664aefc8e92">233,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfOS0zLTEtMS0xMTA5NTI_90947b63-0e29-41cd-a671-9f9d191d2419">214,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTAtMS0xLTEtMTEwOTUy_0534d37e-622d-491e-83d7-51be3f0dd2a8">29,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTAtMy0xLTEtMTEwOTUy_94ff8814-aa8a-444f-b173-12068d9f1a3e">33,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTItMS0xLTEtMTEwOTUy_f786c400-816c-4a0f-9b45-87af6ec70df2">60,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTItMy0xLTEtMTEwOTUy_ce1df59f-dd76-4714-b9a3-5ec1468bc0b8">62,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTMtMS0xLTEtMTEwOTUy_32472153-b987-4dbe-adb0-649ca518576a">1,637,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTMtMy0xLTEtMTEwOTUy_a9bfb43f-0ca8-4580-8722-e31663f8d9aa">1,618,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTQtMS0xLTEtMTEwOTUy_ec183836-e2fa-48c3-b7e5-c0d755fd4c3b">806,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTQtMy0xLTEtMTEwOTUy_7d6e4d86-b21f-418d-8652-8c1d3c10c99b">756,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTUtMS0xLTEtMTEwOTUy_5312bd69-d940-4fbb-b324-17d5b8aa16f1">116,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTUtMy0xLTEtMTEwOTUy_306681d6-334a-4c50-a20d-eabd02a73b32">110,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTYtMS0xLTEtMTEwOTUy_50fb5698-4e8c-43ba-8017-a2a52fc93046">229,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTYtMy0xLTEtMTEwOTUy_0887f0f3-0ef3-4f81-9d95-5b75c503047a">231,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTctMS0xLTEtMTEwOTUy_97ba3135-ab5b-49b7-b16a-8fb7a0bb161b">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTctMy0xLTEtMTEwOTUy_b2f88a48-4383-4366-8a80-f695badc0f76">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="exel:OperatingLeaseRightOfUseAssetAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTgtMS0xLTEtMTEwOTUy_22cd5b30-b472-487f-8fe6-cfc4d2b5f35c">289,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="exel:OperatingLeaseRightOfUseAssetAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTgtMy0xLTEtMTEwOTUy_1cfcfe74-3c20-4a02-94d5-77f0d9d73df0">290,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTktMS0xLTEtMTEwOTUy_feb94338-775e-4064-9dbe-32f3607ed0f9">3,143,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTktMy0xLTEtMTEwOTUy_e406f7ab-47e1-4581-bb1f-5a8d086946c3">3,071,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjItMS0xLTEtMTEwOTUy_6db26d95-a4d9-4d72-b366-438935cc446a">32,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjItMy0xLTEtMTEwOTUy_ea92cae6-2183-42cc-9554-5fe60df5bdf5">32,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjMtMS0xLTEtMTEwOTUy_b96587be-6af4-43d5-be0d-174694bff6d6">56,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjMtMy0xLTEtMTEwOTUy_3207dcfe-e4ab-4a11-b7c0-704eb15a4f8e">77,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjQtMS0xLTEtMTEwOTUy_4fb8f720-d576-4192-946f-42c1b3850113">64,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="exel:AccruedClinicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjQtMy0xLTEtMTEwOTUy_e8529aaa-adc6-40c0-94e5-2c7b0c6f0392">65,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and fees due to customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjUtMS0xLTEtMTEwOTUy_19db461d-f7e3-4fa6-a762-2ef062b69349">66,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:CustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjUtMy0xLTEtMTEwOTUy_f5fe4d20-4974-44dc-9a0f-a2998bb62233">50,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjYtMS0xLTEtMTEwOTUy_a1a3df6a-58d5-4967-81ea-8f1b384f3c89">18,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="exel:AccruedCollaborationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjYtMy0xLTEtMTEwOTUy_ce18ffaa-1bbf-4419-8676-a39aaf0d4fbd">20,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjgtMS0xLTEtMTEwOTUy_91b96a95-2ad9-4be6-aced-56c0b5fe3e77">89,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjgtMy0xLTEtMTEwOTUy_8f123792-0e28-4d86-939e-05b422fc52a1">78,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjktMS0xLTEtMTEwOTUy_c6f56038-3a03-432e-b750-a03d20474371">327,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjktMy0xLTEtMTEwOTUy_63edb6b3-4e9b-4b83-ad29-48f653c1ed3c">324,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzAtMS0xLTEtMTEwOTUy_0755d3bf-447d-443d-97bc-c3962b620d8c">6,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzAtMy0xLTEtMTEwOTUy_b1016e33-8dd8-43fc-9629-e1b3ea200b45">6,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzEtMS0xLTEtMTEwOTUy_1b8d975d-e9cc-4e85-a69c-81b2d2256021">186,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzEtMy0xLTEtMTEwOTUy_7039fa3b-1370-4e03-9c03-c0f199d1b826">190,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzItMS0xLTEtMTEwOTUy_f0cb52d3-15de-44c5-8a24-c41f0c7e0611">67,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzItMy0xLTEtMTEwOTUy_7b5252cf-fa36-4894-917a-af7805ba80f5">61,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzMtMS0xLTEtMTEwOTUy_8f8ddf4c-2f8b-440b-bfc9-61e37b9addc9">588,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzMtMy0xLTEtMTEwOTUy_2d70611b-25bd-408c-a670-ce60cc13080f">583,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzQtMS0xLTEtMTEwOTUy_1fc3b4bd-053b-4422-b1bb-310a825962cf"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzQtMy0xLTEtMTEwOTUy_0bc5e69d-a784-4b4e-83fd-31b11beff3a2"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfMjE_19c015e6-8de3-425a-8685-0d5479d85356"><ix:nonFraction unitRef="usdPerShare" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfMjE_b657e6d9-f91b-4018-9a44-62a9c20c563e">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfMzU_1b994aaa-8cff-4b86-9e0a-4f1461440417"><ix:nonFraction unitRef="shares" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfMzU_5c4105e8-5bf6-4c0c-a0d4-da743450c164">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfNjA_60cf156b-68da-4bf2-ab70-6160ae2f9532"><ix:nonFraction unitRef="shares" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt-sec:numwordsen" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfNjA_d806db59-9f86-47c7-879f-933441e8ecc7">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMS0xLTEtMTEwOTUy_c1ecedbe-9849-457d-adfd-b3aab24b168c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMy0xLTEtMTEwOTUy_7b23eb48-6fb3-4962-8ca9-45fd0bccbf3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfMTg_55b953ab-cb75-4c00-8f26-2a75d2b5e0fe"><ix:nonFraction unitRef="usdPerShare" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfMTg_b07cd6d3-907a-49ad-955f-c18280afe111">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfMzI_8a0a096b-c5b1-4bf9-bd58-c547e75596a1"><ix:nonFraction unitRef="shares" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfMzI_e2cb03da-a5bc-4e02-bc5a-4ca8476834ef">400,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfNzg_64a0bf00-aac1-42a4-9e2b-128a942feea5"><ix:nonFraction unitRef="shares" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfNzg_c487a96f-6b55-4e47-8ce1-fc1311b6b7f6">324,985</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfODU_3dc3df6c-e779-4d03-9e8d-f9a42880d330"><ix:nonFraction unitRef="shares" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfODU_fe19621e-8d67-4241-bf0b-f52d88976c8d">323,951</ix:nonFraction></ix:nonFraction> at March&#160;31, 2023, and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMS0xLTEtMTEwOTUy_1ac3f688-ddc4-4b79-8cc4-26271963a51e">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMy0xLTEtMTEwOTUy_8d2218da-b13e-4ebf-bca1-6e8fcd1eb96f">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzgtMS0xLTEtMTEwOTUy_3f709bf3-aa75-4976-8a52-28f50a9595a9">2,558,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzgtMy0xLTEtMTEwOTUy_de15c9fa-4a49-4aeb-8f56-7180d4a98c60">2,536,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzktMS0xLTEtMTEwOTUy_eb59d8d7-e016-4421-9b59-65ff37dc20c3">9,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzktMy0xLTEtMTEwOTUy_9fdbe531-7b5f-43ea-adf8-e7807daa959c">14,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (Accumulated deficit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDAtMS0xLTEtMTEwOTUy_4d8aa7e2-755f-43d4-b374-e6b1332c1dbb">5,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDAtMy0xLTEtMTEwOTUy_f7602c5c-9eab-465f-8436-5d5fec5bd0a1">34,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDEtMS0xLTEtMTEwOTUy_73308da1-4294-4a3b-913f-f1fb3ee78358">2,555,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDEtMy0xLTEtMTEwOTUy_49702e56-f937-4eda-bbcf-fffe5eec0abd">2,488,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDItMS0xLTEtMTEwOTUy_6641144a-01f3-4e9c-aacc-945db49568bf">3,143,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDItMy0xLTEtMTEwOTUy_59c5055b-f3e4-4d9b-ac78-79764dff508a">3,071,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i040dd4c33333480ba1e8d94e558984f1_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6dd521484284a028aab45ea8772360e_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMy0xLTEtMS0xMTA5NTI_4ec3e6d1-6ee9-4e74-a2f0-a9d558f632eb">363,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7906589f9aa479c9565c72719ef21e6_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMy0zLTEtMS0xMTA5NTI_640d39da-ef04-4e9c-a762-4ad5f1a8a812">310,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c85c6827b024c629f44a06755732c29_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNC0xLTEtMS0xMTA5NTI_266f3169-da28-46b9-bbad-901fe1555dc0">38,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if392acf72a7a4ae486acfef62c1ccfe2_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNC0zLTEtMS0xMTA5NTI_de42ea05-0b72-46d2-86ba-c66eff8b4085">32,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54ef24bfa5d431b8c16060a36cc40fd_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNS0xLTEtMS0xMTA5NTI_b10b04a3-6dbc-42f4-be61-98459859d911">7,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if94929e9ad634418bfded9c801d3fa56_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNS0zLTEtMS0xMTA5NTI_e8458e8f-d880-491e-8595-bf0a93c9dfb6">13,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNi0xLTEtMS0xMTA5NTI_1f4c630e-169a-42af-8a3b-8d0dd5c5ddea">408,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNi0zLTEtMS0xMTA5NTI_de6f39a6-164d-47e6-9264-0ed1e6a834e1">355,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfOC0xLTEtMS0xMTA5NTI_f572015e-56f6-4aae-b49f-31cd1a29b376">14,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfOC0zLTEtMS0xMTA5NTI_46e7f618-9bd8-49da-b593-46c14cd6571b">13,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfOS0xLTEtMS0xMTA5NTI_6693420b-9f35-48c5-aa0e-1014e0e6dfd7">234,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfOS0zLTEtMS0xMTA5NTI_9fe1f91b-4f6a-471f-b359-b227c54f8342">156,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTAtMS0xLTEtMTEwOTUy_55f401c5-e530-43f7-9b36-69728998d67e">131,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTAtMy0xLTEtMTEwOTUy_45891aa5-42fa-4506-a9bd-4e49ba33bbc1">102,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTEtMS0xLTEtMTEwOTUy_31f5c3ec-4ff1-4693-8ddb-95acf11d39c3">379,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTEtMy0xLTEtMTEwOTUy_18495f8a-5c0f-444f-ad11-ee958316579f">272,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTItMS0xLTEtMTEwOTUy_bff35fdf-ed81-4cd0-83a7-4f4fd35dd69d">28,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTItMy0xLTEtMTEwOTUy_d3bae032-7efc-43ad-b5f1-232dfc7386ab">83,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTMtMS0xLTEtMTEwOTUy_603930c5-62a7-4814-b544-c0419a70f133">19,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTMtMy0xLTEtMTEwOTUy_87da7e1f-55db-4666-a187-bffd8249be15">1,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTQtMS0xLTEtMTEwOTUy_a2409133-476a-4d05-8a76-1530ec6bfce8">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTQtMy0xLTEtMTEwOTUy_5aabe985-2f6f-4fa8-9dcf-61fa74928df6">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTUtMS0xLTEtMTEwOTUy_4432d986-8873-4cbc-87be-e7debf844366">48,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTUtMy0xLTEtMTEwOTUy_5fbc0bff-a69b-4c64-8ea6-c20bcc2714eb">85,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTYtMS0xLTEtMTEwOTUy_935e8e59-d734-4f88-950b-2ac136a11c30">8,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTYtMy0xLTEtMTEwOTUy_220dc343-9bdd-4a3f-b98c-1c0aa67e72a0">16,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTctMS0xLTEtMTEwOTUy_99b3b0e7-afd3-4112-a3b2-aa7f959e400a">40,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTctMy0xLTEtMTEwOTUy_05ebc1ae-1b64-4cc0-8e77-e56bfba62097">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTktMS0xLTEtMTEwOTUy_75591a3f-3c0a-41d3-a384-a14c9cb5e104">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTktMy0xLTEtMTEwOTUy_fcb130aa-716c-4bae-b80e-7523ec23a461">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjAtMS0xLTEtMTEwOTUy_f2a0bb0e-ff77-4fe4-b6e6-772868b144d5">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjAtMy0xLTEtMTEwOTUy_e7c3d43c-eb82-4795-a7eb-6c7af4d96b95">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjItMS0xLTEtMTEwOTUy_48fb676b-7a4f-401b-8c0d-85faf9bfcf0d">324,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjItMy0xLTEtMTEwOTUy_a97725bc-811c-44e8-a213-6ee3b05d19e5">319,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjMtMS0xLTEtMTEwOTUy_25e10703-be63-48e8-9747-d6521bbbf8ba">326,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjMtMy0xLTEtMTEwOTUy_3c043758-ece8-421b-a015-cf6de91c6ccd">323,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_22"></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfMi0xLTEtMS0xMTA5NTI_99b3b0e7-afd3-4112-a3b2-aa7f959e400a">40,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfMi0zLTEtMS0xMTA5NTI_aedbe45a-2902-4bab-bc45-01bbb426c8f8">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNC0wLTEtMS0xMTA5NTIvdGV4dHJlZ2lvbjo1YTMxN2E0YzVhNDM0M2U4OGQzY2VmOGNhOTAxMDgyNl81NDk3NTU4MTQ0NjA_86dc483e-8db7-4910-85c8-89689aea3d01">1,507</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNC0wLTEtMS0xMTA5NTIvdGV4dHJlZ2lvbjo1YTMxN2E0YzVhNDM0M2U4OGQzY2VmOGNhOTAxMDgyNl81NDk3NTU4MTQ0Njk_caca1e35-7255-4bbd-a508-a981d59d348b">1,656</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNC0xLTEtMS0xMTA5NTI_619a7245-4ba4-4b04-8bc1-7f3082e83d52">5,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNC0zLTEtMS0xMTA5NTI_88b6f604-7665-4bbb-b2fb-0d2d747b06ad">5,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNi0xLTEtMS0xMTA5NTI_9ba18439-0514-4dc1-9810-4874382a9f0b">45,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNi0zLTEtMS0xMTA5NTI_508b9c6e-83f3-4330-9afa-d312d9626c89">62,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i040dd4c33333480ba1e8d94e558984f1_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbadf347b2924c4a9fa6d3b424d3a4c4_I20221230" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy0xLTEtMS0xMTA5NTI_c68947db-295b-4ba8-a4fb-2bda3a34dbf4">323,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbadf347b2924c4a9fa6d3b424d3a4c4_I20221230" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy0zLTEtMS0xMTA5NTI_fb489127-f17c-40ac-a8a8-c7c5f503e915">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cb2995a2816463f841ef310714ba472_I20221230" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy01LTEtMS0xMTA5NTI_fe5bdaa6-92ed-4ac2-86fa-627a0e7e4c12">2,536,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5df39c1ea61544ecb8c1f7e27e281c22_I20221230" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy03LTEtMS0xMTA5NTI_e51da0b2-fb9d-4eaf-b58d-fd7402b86d0c">14,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7e6ca96ef1649d09aee4df309e35b73_I20221230" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy05LTEtMS0xMTA5NTI_ec841a74-ad0b-488c-b2f0-ba20fce657d8">34,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy0xMS0xLTEtMTEwOTUy_0529c8c5-d681-4baa-bf1e-e3073fb48169">2,488,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f40f89d45a494aa04db7f773107207_D20221231-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNC05LTEtMS0xMTA5NTI_12070859-eed7-4ed0-9273-4253d40b89ab">40,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNC0xMS0xLTEtMTEwOTUy_cd1d377e-4bae-4ceb-89ce-3460dd6d2f74">40,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0a8eca365b40568b15c0188a145fb2_D20221231-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNS03LTEtMS0xMTA5NTI_123162d9-b77d-4bd3-a507-debba80515be">5,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNS0xMS0xLTEtMTEwOTUy_cbeb360b-0b1b-4e40-8682-9763c4fab06b">5,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfe186f4510a478e9f6676e77aa16a5d_D20221231-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNi0xLTEtMS0xMTA5NTI_41c4c0a7-08d2-4144-8934-4626a80481d0">1,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe186f4510a478e9f6676e77aa16a5d_D20221231-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNi0zLTEtMS0xMTA5NTI_4ad2b121-6184-4a44-a063-92a84c3c28b4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ef2d0eca0349a592744851911a54b3_D20221231-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNi01LTEtMS0xMTA5NTI_f5259ba8-f5d2-4630-868f-4f41b8a9d34a">7,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNi0xMS0xLTEtMTEwOTUy_b4dbc783-7492-4531-b326-a3420815af96">7,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03ef2d0eca0349a592744851911a54b3_D20221231-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNy01LTEtMS0xMTA5NTI_bd0313d0-87a4-4d52-87fa-2cfdfb922ade">2,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNy0xMS0xLTEtMTEwOTUy_1f6ee792-09fe-4c72-ae21-e3be15f80c3f">2,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03ef2d0eca0349a592744851911a54b3_D20221231-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOC01LTEtMS0xMTA5NTI_f902d693-aab6-4cbc-a7ae-d8d723b0ef0d">16,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOC0xMS0xLTEtMTEwOTUy_f5bc2704-65b8-40bb-a8f2-6ae43a923351">16,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e2ccc06faab42c1b72c84f6d8fc6554_I20230331" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS0xLTEtMS0xMTA5NTI_41f7ecd1-7103-4b6e-8dd6-133406e7e0aa">324,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e2ccc06faab42c1b72c84f6d8fc6554_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS0zLTEtMS0xMTA5NTI_e5e7b4cd-e48d-4ec0-b385-ded65844c3da">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3410e9e21c40998b84e3d69601d355_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS01LTEtMS0xMTA5NTI_6ade9ad3-32ff-4c27-b95a-f8b5ba120337">2,558,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idccb5b94d16a46fdb0cf63047d4d0a35_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS03LTEtMS0xMTA5NTI_7c3f32de-25a1-411d-aab4-e9fd4ecb801f">9,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife8714608e344dc7971babe1680ab27e_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS05LTEtMS0xMTA5NTI_801b6a8b-1bb0-4048-8b49-b61e27e18ed9">5,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS0xMS0xLTEtMTEwOTUy_88f32bdc-0c14-4504-a200-93515fda8a1d">2,555,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2022</span></div></td></tr><tr style="height:31pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1508ac4b174b4c78a254a72746c9b9ca_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtMS0xLTEtMTEwOTUy_cfa6b13d-2e0a-477d-946f-3f8d39d15e22">318,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1508ac4b174b4c78a254a72746c9b9ca_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtMy0xLTEtMTEwOTUy_e7eebc4b-0972-46a2-9f75-dbd4d0d3636a">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied50145a7df5459d92fa66f1d9a3a632_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtNS0xLTEtMTEwOTUy_c55ca9b2-707f-4a1c-b373-728d87df0056">2,427,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb2a2cfb158540ca9584fae8239e375c_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtNy0xLTEtMTEwOTUy_d40deabb-f5cb-4522-a312-5e215a24d943">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3118a17fe82743f4a08ef8bc281df1cc_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtOS0xLTEtMTEwOTUy_f46b0dc7-6663-40a3-93b5-0452312b113b">216,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e9094b4beb4a8fb455ed26efa4b4dc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtMTEtMS0xLTExMDk1Mg_06559ee4-1d24-4d55-be2a-a268ead6b772">2,210,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02620eae926413ab03c9415bcccade7_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTUtOS0xLTEtMTEwOTUy_82a5b823-c44a-4912-86bc-5c495cd36fb2">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTUtMTEtMS0xLTExMDk1Mg_2c45c77a-e7a1-4566-9293-3599f06698ff">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cf2d5e95a2d4758b7b8e19ee1dc13cd_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTYtNy0xLTEtMTEwOTUy_1e6d28a6-08e2-45d3-8b01-df53d64fa7f2">5,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTYtMTEtMS0xLTExMDk1Mg_9abfd654-d265-4965-acfb-405f4a48dfce">5,907</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20dd40ea4f824fdc9ef3a7e851b32b65_D20220101-20220401" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTctMS0xLTEtMTEwOTUy_a8fd8dac-a365-4b03-8e7f-b4d9704a7a8b">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20dd40ea4f824fdc9ef3a7e851b32b65_D20220101-20220401" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTctMy0xLTEtMTEwOTUy_4e26e2ec-bf32-49de-b925-ca2664af6e2f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79c3cf115f4f41eda883262bfbc8069a_D20220101-20220401" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTctNS0xLTEtMTEwOTUy_7ace56cc-9d60-448b-a45c-0c6488447b85">5,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTctMTEtMS0xLTExMDk1Mg_b3f4f175-145b-480a-9c55-864cbe0cbd25">5,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79c3cf115f4f41eda883262bfbc8069a_D20220101-20220401" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTgtNS0xLTEtMTEwOTUy_5413b336-ed80-4163-9e60-473557756d9d">4,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTgtMTEtMS0xLTExMDk1Mg_2c60693b-0f55-4113-8c65-81d2919cdc44">4,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79c3cf115f4f41eda883262bfbc8069a_D20220101-20220401" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTktNS0xLTEtMTEwOTUy_0e49c5f5-f1d2-41f1-8d73-a21464fbfe88">20,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTktMTEtMS0xLTExMDk1Mg_07c5e0b2-bc3c-4355-be3a-40e53c8ce277">20,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22b9b0ed7a4840709f0a21fddfa8f9b7_I20220401" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtMS0xLTEtMTEwOTUy_18b166d9-15ad-4c24-9661-474139dad95a">320,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22b9b0ed7a4840709f0a21fddfa8f9b7_I20220401" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtMy0xLTEtMTEwOTUy_b354286a-145f-4513-ba41-9fb90b0ee59a">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95578fef614f423aad1a9a09bc7a0471_I20220401" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtNS0xLTEtMTEwOTUy_ee91f2a1-06c1-465d-87cd-27c3325f4d8d">2,448,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i009fe3cdc57c4356822574ede853c0a5_I20220401" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtNy0xLTEtMTEwOTUy_27636a78-ad09-4877-867e-5bb90a2a6d87">6,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4f89c6cd5174469a45a0fee83e965f9_I20220401" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtOS0xLTEtMTEwOTUy_bd64011e-25af-42a4-9265-9288bdb7898f">147,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40f7e105971f40d2884d061c483a0023_I20220401" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtMTEtMS0xLTExMDk1Mg_ca270fd6-0017-492e-878e-f2127e4c2316">2,293,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i040dd4c33333480ba1e8d94e558984f1_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMi0xLTEtMS0xMTA5NTI_96fa1189-6381-407f-a56c-59e5f551a230">40,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMi0zLTEtMS0xMTA5NTI_8a5b6549-1293-4a78-9f6e-ef5f64fb3b50">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNC0xLTEtMS0xMTA5NTI_ffcd914e-33e9-49c8-952c-c7868f6b1f93">6,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNC0zLTEtMS0xMTA5NTI_a5632ea3-24a5-472e-8072-2b56df9485ea">4,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNS0xLTEtMS0xMTA5NTI_8291b38b-32cc-4ffd-baa1-311444e1aa8d">16,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNS0zLTEtMS0xMTA5NTI_6440e8fa-0cc1-4a65-99cd-451dc1de8787">19,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNi0xLTEtMS0xMTA5NTI_5388b0e5-1d08-4a4a-b0b5-91093106903d">6,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="exel:NoncashLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNi0zLTEtMS0xMTA5NTI_79276bb3-6924-4813-8dec-0983c572abfc">1,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNy0xLTEtMS0xMTA5NTI_0d03d4dc-1a46-489f-932b-398ea5d68cdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNy0zLTEtMS0xMTA5NTI_2774983b-8611-4414-af58-524dee3256d2">15,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfOC0xLTEtMS0xMTU3NTU_fdd40b56-c16c-4c28-8958-fa7572f0fc10">36,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfOC0zLTEtMS0xMTU3NTg_d3e9926b-252b-45a2-9207-c09921b52303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfOC0xLTEtMS0xMTA5NTI_5fa7852f-931a-4aff-a335-fb3abf333bf2">3,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfOC0zLTEtMS0xMTA5NTI_aa6eaa36-ae3d-4c05-9deb-a95f723f2540">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTAtMS0xLTEtMTEwOTUy_243ff06d-11c1-4cea-9cf5-de5da626a5f0">19,178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTAtMy0xLTEtMTEwOTUy_7c5b88dc-fc32-467f-ba54-5f229f504505">91,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTEtMS0xLTEtMTEwOTUy_e2f16134-897b-4da1-b498-733249866603">8,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTEtMy0xLTEtMTEwOTUy_c9292f8f-7a16-4d62-9492-8494ea8b0ad2">3,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTMtMS0xLTEtMTEwOTUy_142171e6-92fb-4e8b-ba72-e9e03fe16e90">10,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTMtMy0xLTEtMTEwOTUy_ef3daefd-6bd8-4413-b769-d95329ddd3ed">3,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTUtMS0xLTEtMTEwOTUy_3c46604d-85b9-4b52-a50b-39da04462773">707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTUtMy0xLTEtMTEwOTUy_0717a7b1-6305-469e-8aa3-3afb23602ba7">1,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" sign="-" name="exel:IncreaseDecreaseInAccruedCollaborationLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTYtMS0xLTEtMTEwOTUy_2b3803f1-cfcd-4449-be3c-78a3027fd263">1,864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" sign="-" name="exel:IncreaseDecreaseInAccruedCollaborationLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTYtMy0xLTEtMTEwOTUy_68b2cf7b-618d-41a2-9165-d4fdfd2f3475">54,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTctMS0xLTEtMTEwOTUy_c0ce3eaa-5298-42b4-866c-1ba84c6d0749">1,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTctMy0xLTEtMTEwOTUy_ff949b0e-03fc-41a9-9299-d4e4d8036465">7,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTktMS0xLTEtMTEwOTUy_b665ce27-0882-4388-a5f3-b99909445a50">84,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTktMy0xLTEtMTEwOTUy_53a76b8a-52f9-4425-823b-ce6c4c047535">147,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjEtMS0xLTEtMTEwOTUy_fc2d5ca9-6488-4d3a-8216-bc0abdf817d4">12,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjEtMy0xLTEtMTEwOTUy_bdbacff9-c6cb-4a5c-9f45-9c134b35771d">5,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjItMS0xLTEtMTE1NDU4_13f6417c-43a2-4908-aa76-9cfe6e737876">36,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjItMy0xLTEtMTE1NDY1_d880d2a9-72fd-4ce6-8a60-ae0ed8867e9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjMtMS0xLTEtMTEwOTUy_54379bda-d181-4a30-b04d-56cc3c6b70ff">311,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjMtMy0xLTEtMTEwOTUy_4f6f7130-ffb6-4b06-8540-07d23cf33922">336,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjQtMS0xLTEtMTEwOTUy_cbc4ab8d-49b5-4750-8688-a23bcb7809e6">310,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjQtMy0xLTEtMTEwOTUy_5270b24a-9291-4bb7-bf3b-e04560686c99">267,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjUtMS0xLTEtMTEwOTUy_fab996f3-69d0-4f8d-a8f3-87d1048cf7c9">49,592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjUtMy0xLTEtMTEwOTUy_64f54853-d65d-4d6d-85a8-b765f849b146">74,539</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjctMS0xLTEtMTEwOTUy_4138c33e-e6fb-482a-b3e0-d43253a949ab">7,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjctMy0xLTEtMTEwOTUy_26653e5b-e0c5-4385-842e-a336c92eedeb">4,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjgtMS0xLTEtMTEwOTUy_9eb3fa0d-9d8d-472f-8e4b-3935362bc4ce">2,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjgtMy0xLTEtMTEwOTUy_1f2673ec-7162-4b4f-8012-f4cec436d63d">4,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzEtMS0xLTEtMTEwOTUy_5978884d-c084-4e8a-a8c6-8561e3100052">4,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzEtMy0xLTEtMTEwOTUy_9c47af53-8652-458c-ba68-965dc3aea08c">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzItMS0xLTEtMTEwOTUy_30f09c68-5a75-46b2-aece-ed6a56234cdc">39,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzItMy0xLTEtMTEwOTUy_eb513d6a-0293-4315-a462-ce0838593672">73,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzMtMS0xLTEtMTEwOTUy_d0c02b17-85e6-45b7-93a9-31830ba2b07d">502,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e9094b4beb4a8fb455ed26efa4b4dc_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzMtMy0xLTEtMTEwOTUy_b6f0fd07-24c1-43f1-83ab-dad35aefc7f5">663,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzQtMS0xLTEtMTEwOTUy_9d5e0536-9a73-48db-bbfd-71277780260a">542,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40f7e105971f40d2884d061c483a0023_I20220401" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzQtMy0xLTEtMTEwOTUy_685e4efa-2904-418f-9926-89dba35e49c9">737,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i040dd4c33333480ba1e8d94e558984f1_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_34"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjkxMg_54feda03-31ee-4c02-b674-06de2d018a91" continuedAt="id25b9a19bcf541fd84bf6f64082ff134" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="id25b9a19bcf541fd84bf6f64082ff134" continuedAt="ibfc84a40f6334e73af5159bd1ca1a508"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. Through the commitment of our drug discovery, development and commercialization resources, we have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib. We continue to evolve our product portfolio, leveraging our investments, expertise and strategic partnerships, to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in <ix:nonFraction unitRef="country" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="INF" name="exel:NumberOfCountriesWithDrugApprovalExcludingTheUS" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNTQ5NzU1ODI2MzUy_7b693b43-ca69-41c0-987f-118c14f49860">67</ix:nonFraction> other countries as of the date of this Quarterly Report on Form 10-Q: as CABOMETYX&#174; (cabozantinib) tablets for advanced renal cell carcinoma (both alone and in combination with Bristol-Myers Squibb Company&#8217;s OPDIVO&#174; (nivolumab)), for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer; and as COMETRIQ&#174; (cabozantinib) capsules for progressive, metastatic medullary thyroid cancer. For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other <ix:nonFraction unitRef="product" contextRef="i88c7f65af0d44b9ebe6c0bfcbaf1bcc8_D20221231-20230331" decimals="INF" name="exel:NumberofProductsinCommercialMarket" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfMTc0Mg_05a97109-0786-4bf2-afb9-2f767da85d34">two</ix:nonFraction> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjkxNg_889b8de1-359e-4cb8-a2c4-9ccc11ea2ac7" escape="true">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjg5MA_163587b5-5a8a-4d2b-a39a-a531598e5eeb" escape="true">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2022, included in Part II, Item 8 of our Annual Report on Form 10-K, filed with the SEC on February&#160;7, 2023 (Fiscal 2022 Form 10-K).</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:FiscalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjkwMQ_1b5805e0-c508-462e-8509-8f868a45e8c8" continuedAt="i71292188040c41ff88ceb541cf5518a5" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i71292188040c41ff88ceb541cf5518a5">. Fiscal year 2023, which is a 52-week fiscal year, will end on December&#160;29, 2023 and fiscal year 2022, which was a 52-week fiscal year, ended on December&#160;30, 2022. For convenience, references in this report as of and for the fiscal period ended April 1, 2022, and as of and for the fiscal years ending December&#160;29, 2023 and ended December&#160;30, 2022 are indicated as being as of and for the period ended March&#160;31, 2022, and the years ending December&#160;31, 2023 and ended December&#160;31, 2022, respectively.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjkwOA_1ceb76de-b96a-4654-8b6c-30873b95a890" continuedAt="i52b2753c9e3947ac8b3226ce2541bae5" escape="true">We operate in <ix:nonFraction unitRef="segment" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNDE1NQ_6da178d4-24f8-407c-9cc7-8fd043fbcb37">one</ix:nonFraction> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><ix:continuation id="ibfc84a40f6334e73af5159bd1ca1a508"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i52b2753c9e3947ac8b3226ce2541bae5">allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</ix:continuation></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about sales of products, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjkxMw_7db2aa47-ab5b-4b34-a108-f34979e4297d" escape="true">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies during the three months ended March 31, 2023, as compared to the significant accounting policies disclosed in &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2022 Form 10-K.</span></div><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjg5Ng_4201201c-9d0f-4cc8-9a40-9b37f20944e8" escape="true"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since our filing of the Fiscal 2022 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Fiscal 2022 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div id="i040dd4c33333480ba1e8d94e558984f1_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDk0Mg_cf59775b-7173-4898-be53-76bdbe9595d7" continuedAt="ifa9f72f6d64c41c8a50a432174113c80" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="ifa9f72f6d64c41c8a50a432174113c80" continuedAt="i3a61bf91833c4ff79036e47632816946"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDkzNA_75d2e167-b2b4-4497-8fe3-20e00319a938" continuedAt="i32722e60d8ca4775be597164a13ecd8a" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d27cdd49640469c8f242f09214a609a_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfMy0xLTEtMS0xMTA5NTI_1088172b-c067-4916-b4f7-dcbfb18d2a8a">521,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida032638ed6145e19d54c570bc2b9d93_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfMy0zLTEtMS0xMTA5NTI_434a69d1-5dc6-4131-b9f8-ba9b4e88a970">448,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i595a452dffec43ddacb9c075ff6b480b_D20221231-20230331" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNC0xLTEtMS0xMTA5NTI_8ce46d98-4f62-42b5-9714-89580ea1bc3d">157,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbe685ef22c941cba593e7a64e54dbf3_D20220101-20220401" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNC0zLTEtMS0xMTA5NTI_367fc322-63bb-4b5e-8a9d-103c2f3a9285">137,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6dd521484284a028aab45ea8772360e_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNS0xLTEtMS0xMTA5NTI_4ec3e6d1-6ee9-4e74-a2f0-a9d558f632eb">363,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7906589f9aa479c9565c72719ef21e6_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNS0zLTEtMS0xMTA5NTI_640d39da-ef04-4e9c-a762-4ad5f1a8a812">310,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c85c6827b024c629f44a06755732c29_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNy0xLTEtMS0xMTA5NTI_266f3169-da28-46b9-bbad-901fe1555dc0">38,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if392acf72a7a4ae486acfef62c1ccfe2_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNy0zLTEtMS0xMTA5NTI_de42ea05-0b72-46d2-86ba-c66eff8b4085">32,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54ef24bfa5d431b8c16060a36cc40fd_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfOC0xLTEtMS0xMTA5NTI_b10b04a3-6dbc-42f4-be61-98459859d911">7,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if94929e9ad634418bfded9c801d3fa56_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfOC0zLTEtMS0xMTA5NTI_e8458e8f-d880-491e-8595-bf0a93c9dfb6">13,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06debfc85b9342daa487a13cc47e36de_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfOS0xLTEtMS0xMTA5NTI_cdcf010c-41f5-4e01-b194-135fd57b822b">45,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55727874d5a4f308e9616357e398771_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfOS0zLTEtMS0xMTA5NTI_e1e3e8db-41da-4ff4-9416-1222118e51bf">45,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfMTAtMS0xLTEtMTEwOTUy_1f4c630e-169a-42af-8a3b-8d0dd5c5ddea">408,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfMTAtMy0xLTEtMTEwOTUy_de6f39a6-164d-47e6-9264-0ed1e6a834e1">355,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><ix:continuation id="i3a61bf91833c4ff79036e47632816946" continuedAt="i79444a98a5854a47bc5ade3b2508dc92"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDkzMg_25c3e9db-7025-4a4d-ab3b-a0716de4bad5" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa7500ddcb0b4d0db3443cc56170ff61_D20221231-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfMi0xLTEtMS0xMTA5NTI_540c95cf-bccb-4cf7-90d4-daf1f4f0216e">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iced7a06ad4e4417e870e84a67ede1244_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfMi0zLTEtMS0xMTA5NTI_823654bd-67bf-4e33-9c1c-db042db12a1f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe37fc8620b94da8b2fc78d1941a9030_D20221231-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfMy0xLTEtMS0xMTA5NTI_c35b1fea-50dd-456f-a471-ef5aff2f07c7">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9022e3a517a4086aadbb0f76b987860_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfMy0zLTEtMS0xMTA5NTI_8460454c-c5d4-47ac-805d-68cb070d1ec1">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic354cd8d9401435bb4bef5aa134d8b18_D20221231-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNC0xLTEtMS0xMTA5NTI_9e51545e-a33f-467d-99a0-70d98c1ae45d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i145518f569754dcab3e0530961014f83_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNC0zLTEtMS0xMTA5NTI_a432a148-e499-41cb-bba1-80d0d281bea1">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ac68a66c51c45aaafa439d76a88823b_D20221231-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0xLTEtMS0xMjE1MzY_a91870da-07b0-4962-8356-c9cf2fe79c36">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iadcb287071b8482091481fd721d6437b_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0zLTEtMS0xMjE1MzY_0d5fe927-1ec9-4983-9544-549db57e78d1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i887d25b5c3eb476fac598042e121ae9e_D20221231-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0xLTEtMS0xMjEzMjc_57a14c28-1e29-4b6c-8d49-e023d7cb76ec">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f6c3de32bb5469faa5988e472ba8294_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0zLTEtMS0xMjEzMjc_fbff282f-c412-43b4-b9b3-720ecb42f29c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03edf15c3de14b84b45b07e5d3a6783b_D20221231-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0xLTEtMS0xMTA5NTI_8d78ba1c-04b5-402e-873a-4690edbe23b9">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief8ad52c39a04dbb97764e462472ac81_D20220101-20220401" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0zLTEtMS0xMTA5NTI_e66c569f-6df3-4e2f-99f0-e6ffa8a8f471">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f99cf5241b6466788f894b2abc4f8ed_D20221231-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMS0xLTEtMS0xMTA5NTI_041e8edf-3825-471b-824e-b4d02897653c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4cd8710c99944d47a9e0d4b3f5b26afc_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMS0zLTEtMS0xMTA5NTI_b2e4fcf4-dc8d-47e8-b9da-4bdfdca813c7">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i30663220db714d0f884ca85a30e97ed2_D20221231-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMi0xLTEtMS0xMjEzMzk_7090e063-62b1-4dfc-b8c9-9fce88e6c3a3">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e8676ff223f403889416c0afd319b61_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMi0zLTEtMS0xMjEzMzk_3363d9ff-3dd0-4f9a-b04d-1ee2f312d5aa">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia17b8615b9f449ae815574e6e809f6f7_D20221231-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMi0xLTEtMS0xMTA5NTI_26aa70fa-4539-4a5e-8541-b21522b12482">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe97f6cf8ca84e36a31f8ac01af69488_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMi0zLTEtMS0xMTA5NTI_3cb54bac-1245-46e9-94d7-4a494872c9c1">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia09f023283744b868559533749bfb478_D20221231-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfNC0xLTEtMS0xMTA5NTI_edb6661f-dc08-4505-8279-faa451eb633f">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id32f197bc1034297a1205ca6bff7d001_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfNC0zLTEtMS0xMTA5NTI_b92e6bda-ffd3-4b36-ba64-175df9759a87">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1dfd4d591884f079548cf36ab7d515a_D20221231-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfNS0xLTEtMS0xMTA5NTI_ec7371bd-e7c8-4be2-8e24-b0b81f2df19b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25cc695fcf37474383a6d4d015d235e0_D20220101-20221230" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfNS0zLTEtMS0xMTA5NTI_b449b19a-4ce0-479d-8d5e-d7c6135318a3">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDk0NA_cee5dcb9-f30c-4cb3-8885-c55ef71e5036" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i005e52f0aa9441e9b404ce8f42adc3d6_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfMi0xLTEtMS0xMTA5NTI_2750046f-e86c-407e-9ef7-7550edaadeaf">367,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c2ff2123a5e43459fdf372396cef270_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfMi0zLTEtMS0xMTA5NTI_6454dc1f-601a-4028-8b7d-0e0351db12bd">314,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f1ae657918947af907f5f8fab6b57fe_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfMy0xLTEtMS0xMTA5NTI_c4bf5767-61e7-4765-a69d-24ce74cbe682">33,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0b5d0c4ace24841940333ae7904c072_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfMy0zLTEtMS0xMTA5NTI_1230c07d-fb9d-4a89-96e5-96a3341b2b35">34,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i936cbc93158847ce8d03042dab8d6d3d_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfNC0xLTEtMS0xMTA5NTI_2f985df0-3699-4ac8-97ce-595288acc259">7,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73abd557fa874e57af0091d9dd6409f3_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfNC0zLTEtMS0xMTA5NTI_073b5a9b-8533-40c4-92dc-a09570f397e8">7,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfNS0xLTEtMS0xMTA5NTI_2dad2680-415e-4c89-9091-f3a6cb7e3fab">408,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfNS0zLTEtMS0xMTA5NTI_82a43de1-3b3d-4e19-a494-88fa5735c288">355,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDkyOA_e17cb73e-7cfe-4c27-9baf-2a8c610baded" continuedAt="i46a7c441c52546ceaad8e938c236ce2f" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues are recorded in accordance with ASC Topic 808, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs and the royalties we pay on sales of products containing cabozantinib by our collaboration partners.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><ix:continuation id="i79444a98a5854a47bc5ade3b2508dc92" continuedAt="ice74626175484222a67e90eb2caa90ad"><ix:continuation id="i32722e60d8ca4775be597164a13ecd8a"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a5140525004434a113a31a2b6f9fec_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfMi0xLTEtMS0xMTA5NTI_c193014d-6367-4378-9917-4637ab445b0c">361,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93c1a4da62d4e91aada27293fc54993_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfMi0zLTEtMS0xMTA5NTI_09b0dabb-cda3-417b-8f7c-d2cb1c3a18e8">302,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3ca2a0d827408a96d2c203c0c3d713_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfMy0xLTEtMS0xMTA5NTI_0ffb76d0-09fb-4344-9545-baaab637a732">1,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca193774391470aaad49e0c557cd653_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfMy0zLTEtMS0xMTA5NTI_9d504c5f-671b-4294-b798-19f4ad298243">7,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6dd521484284a028aab45ea8772360e_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfNC0xLTEtMS0xMTA5NTI_39d6c2c2-a067-4598-84ea-2350b425381c">363,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7906589f9aa479c9565c72719ef21e6_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfNC0zLTEtMS0xMTA5NTI_6377cc84-a013-4d9d-9609-f0de3a2921c0">310,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDk1NA_a356603f-35d4-4801-bb32-fd42f3246662" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:41.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23bc89dd4ed466bb9e19cbc8ccf8e79_I20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMS0xLTEtMS0xMTA5NTI_5d584701-58f5-4adb-97c9-e85eacf6e3bf">26,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561a3686c8c54aaa9930ddcb0186d034_I20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMS0zLTEtMS0xMTA5NTI_8587631f-1210-4a0e-a573-e23e5508afed">14,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb98cc6df0964b9dbc447c72a27d45d2_I20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMS01LTEtMS0xMTA5NTI_64062327-8c78-4df0-acb8-6d6798a586b5">35,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMS05LTEtMS0xMTA5NTI_63a30203-df64-4ac9-b460-09a8de9ffe9d">77,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf790da88c7f48bebd710b720e67b732_D20221231-20230331" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMy0xLTEtMS0xMTA5NTI_89aee9e0-52bc-4699-900c-662d03ad255c">94,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6803b211b6ba46c0b060c8ef10832fa3_D20221231-20230331" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMy0zLTEtMS0xMTA5NTI_2a83bc42-bacf-48ba-b3fe-a0181751ad26">14,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3dde5c402a452ca70d75ca56511047_D20221231-20230331" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMy01LTEtMS0xMTA5NTI_75fa53c3-d74a-4558-9699-b05cf458fbb9">49,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMy05LTEtMS0xMTA5NTI_332d7d73-1a5a-4fb0-8a77-a9bc7ccb26f0">158,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf790da88c7f48bebd710b720e67b732_D20221231-20230331" decimals="-3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNC0xLTEtMS0xMTA5NTI_861eafbb-7e3d-493a-903a-26484b6e4f36">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6803b211b6ba46c0b060c8ef10832fa3_D20221231-20230331" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNC0zLTEtMS0xMTA5NTI_a1a501bb-6a17-4759-a3ec-9372205053ec">1,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab3dde5c402a452ca70d75ca56511047_D20221231-20230331" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNC01LTEtMS0xMTA5NTI_296e5ac8-9efd-410e-a73d-fb75f0884c61">87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNC05LTEtMS0xMTA5NTI_177a0456-6e60-4afc-a17a-542da93acdfa">1,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf790da88c7f48bebd710b720e67b732_D20221231-20230331" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNS0xLTEtMS0xMTA5NTI_f7ba2096-19ca-4381-8ba4-741d85d50660">100,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6803b211b6ba46c0b060c8ef10832fa3_D20221231-20230331" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNS0zLTEtMS0xMTA5NTI_e252b95a-e629-4308-8dd1-98fb85799be2">13,637</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab3dde5c402a452ca70d75ca56511047_D20221231-20230331" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNS01LTEtMS0xMTA5NTI_f6178d70-ab39-4545-9402-67710c803893">33,130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNS05LTEtMS0xMTA5NTI_788afa03-ac15-4ca8-9972-e941d77badb1">147,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75a9ae3fb4354c558afa5652356fc857_I20230331" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNi0xLTEtMS0xMTA5NTI_05d65785-3716-4498-a000-3338c5cb01ec">21,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a339e12ecb401f86dd0d2f2d5819d9_I20230331" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNi0zLTEtMS0xMTA5NTI_e06cbde6-c549-4817-b02c-12de29d53441">15,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec98443a01d9484790def9f44b69d198_I20230331" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNi01LTEtMS0xMTA5NTI_3ac818eb-0a8f-4354-aa63-eb6387afa51d">51,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNi05LTEtMS0xMTA5NTI_8473d677-91cd-4259-be30-b0b6d9d7f93b">87,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="i46a7c441c52546ceaad8e938c236ce2f"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDk0MA_96e1dfd3-3d52-4bd3-b3de-e4f722ce2baa" continuedAt="i0b656ae775924b76b76492595589d425" escape="true">Contract assets and liabilities were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i0b656ae775924b76b76492595589d425" continuedAt="ib6d2b6fb8f354ee2975899da0ce543ac"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfNC0xLTEtMS0xMTA5NTI_1bb61a90-6a06-4b7f-a45c-0ac26de7c7ee">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfNC0zLTEtMS0xMTA5NTI_3b8d1dde-b296-444a-a6d1-86fd4ad803e0">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfNy0xLTEtMS0xMTA5NTI_21871696-a9da-4d62-a612-ac9d32723c9e">7,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfNy0zLTEtMS0xMTA5NTI_547f0a68-c3c0-42d2-b697-1c2ded0406c5">7,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfOC0xLTEtMS0xMTA5NTI_5bebeb47-3ef7-4b32-8031-09706813b16e">6,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfOC0zLTEtMS0xMTA5NTI_feba945e-90e8-41d2-8c2f-f8dc65823514">6,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfOS0xLTEtMS0xMTA5NTI_cfd04d81-c955-49f8-8035-b50e967824b0">13,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfOS0zLTEtMS0xMTA5NTI_0beee80c-f715-46a6-90a6-190fa8c7818c">14,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:continuation id="ib6d2b6fb8f354ee2975899da0ce543ac"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets.</span></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNzE0NjgyNTU4NjYyOA_8c33556f-a6dc-4dbd-ade7-69b67a60d617">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-5" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNTQ5NzU1ODE4OTY2_f46bab7c-c1e6-440e-8efa-ec09193433f1">2.4</ix:nonFraction>&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><ix:continuation id="ice74626175484222a67e90eb2caa90ad"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNzE0NjgyNTU4NjY1Nw_3ce6bbab-f8cb-46c2-9c15-45af2193c4a5">37.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNTQ5NzU1ODE5MDgx_f56f6ef0-820a-4323-b2e1-0dbc4fa700db">31.7</ix:nonFraction>&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to our license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNzE0NjgyNTU4NjY4Ng_b9651e54-e016-4ffb-be7c-96a624f2ab0f">69.0</ix:nonFraction>&#160;million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he co</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mbined transaction prices for our Ipsen a</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Takeda collaborations were allocated to research and development services performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2022 Form 10-K for additional information about the expected timing to satisfy these performance obligations.</span></div></ix:continuation><div id="i040dd4c33333480ba1e8d94e558984f1_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNzM3NQ_d7967e20-10ab-49b4-8846-bddf56672984" continuedAt="i6c72baac85424d33b01dabdc7e009a43" escape="true">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="i6c72baac85424d33b01dabdc7e009a43" continuedAt="iaa7a7f8c138a4b629b7140c405a72fd1"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading biopharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading biopharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2022 Form 10-K, as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Under the collaboration and license agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development.</span></div><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNzM3Nw_92b8e55a-bdd4-45b2-b309-177066986cd4" continuedAt="i643b704a43ef41ce8cb231a4b6257b68" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration and license agreement, as amended, with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2931f6876e343439ec8b11809eebdf1_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfMi0xLTEtMS0xMTA5NTI_04407593-9575-4521-a6a4-dd4c6902ce42">29,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864cb8fb17554a37a8adaea7c33b4efc_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfMi0zLTEtMS0xMTA5NTI_d50c28da-15b5-4ccf-80f5-19267320248e">24,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1696dcf966747e3b865502c27c29aad_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfMy0xLTEtMS0xMTA5NTI_28e35767-e2a3-4106-ab08-974dd7d7d9be">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i021d57f0be044f67974550e7d885e1d1_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfMy0zLTEtMS0xMTA5NTI_1e6eaf5e-bfa9-4ea9-bcc4-99883d0cad29">9,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d81ebf2e8e74fce85e25162934a4d6f_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfNC0xLTEtMS0xMTA5NTI_68ba6824-6a29-4327-aadd-38ec3f58ecaa">33,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff535a866b2c41fdb6f8646e8b488292_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfNC0zLTEtMS0xMTA5NTI_1c49e364-f3d9-4d2c-9b37-b14d8c8238da">34,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="i4acc2ee076ef40faac1edea03e68040c_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNDM5ODA0NjUyODIwOA_a3420906-7ca8-4314-a45c-48914bb3739e">33.9</ix:nonFraction>&#160;million of the transaction price for this collaboration and license agreement, as amended, was allocated to our research and development services performance obligation that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Under the collaboration and license agreement, as amended, Takeda received exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><ix:continuation id="iaa7a7f8c138a4b629b7140c405a72fd1"><ix:continuation id="i643b704a43ef41ce8cb231a4b6257b68"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration and license agreement, as amended, with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7033584518df402d9b63ad9da059f49e_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfMi0xLTEtMS0xMTA5NTI_1f5e50a8-8121-4f4f-9f2b-b271e350118d">2,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c875584853425eba6bda6cacea2afd_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfMi0zLTEtMS0xMTA5NTI_55c620f2-3b8f-49dd-b554-353c77066112">2,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8956cc8ef7304e6e94df23b6ddff9882_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfMy0xLTEtMS0xMTA5NTI_daf2b9a6-8462-4231-9346-3cfa2eb1f344">3,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6df88e437a14a5e9a085f6a41e74f2a_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfMy0zLTEtMS0xMTA5NTI_3bf92c46-7eac-49ff-81c9-b447a98a5aef">3,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c0ff70d2a2430fa83299f494f4c105_D20221231-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfNC0xLTEtMS0xMTA5NTI_93328f29-7824-4ba3-b192-4a2f3427d7db">6,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff2c6bd8205a44e2adb86297f4e43f30_D20220101-20220401" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfNC0zLTEtMS0xMTA5NTI_d9daac67-df05-44da-b518-80052a07358f">6,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="ifa11613f3ae54abb9a1445d4727f95f1_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNDM5ODA0NjUyODIyMg_cdce9828-7d9b-4382-b65b-7eb1409d4a5c">35.0</ix:nonFraction>&#160;million of the transaction price for this collaboration and license agreement, as amended, was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a <ix:nonFraction unitRef="number" contextRef="i2b291b148d264039a3e055bce29bb22b_D20221231-20230331" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfMTY0OTI2NzQ1NTg5MA_6df22343-8b35-4442-b467-3a3afd6d9a38">3</ix:nonFraction>% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib sold by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalty fees earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalty fees earned by Royalty Pharma were $<ix:nonFraction unitRef="usd" contextRef="i700fe89825964bcf972c48b666c81680_D20221231-20230331" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNzE0NjgyNTU5NzYzNA_fb80e389-34cb-4037-a9ad-718c7bf019ce">15.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iceabd35baaac41af956c98f0f6f9a4c6_D20220101-20220401" decimals="-5" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfMjE5OTAyMzI2Mzc3Mw_a03c152e-f22c-4327-972d-20369e4bdf1f">13.1</ix:nonFraction>&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaborative arrangements with other pharmaceutical or biotechnology companies to develop and commercialize drug candidates or intellectual property. Our research collaborations and in-licensing arrangements are intended to enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Our research collaborations, in-licensing arrangements and other strategic transactions generally include upfront payments, development, regulatory and commercial milestone payments, and royalty payments, in each case contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs or acquire the intellectual property developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent development, manufacturing and commercialization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023, we recognized $<ix:nonFraction unitRef="usd" contextRef="if9ade2259f534177966ecdd8ce949ae1_D20221231-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNzE0NjgyNTU5NzYwNQ_727344e2-e7d9-4ce7-8613-71448ae7dc46">44.7</ix:nonFraction>&#160;million within research and development expenses on the Condensed Consolidated Statements of Income, primarily related to development milestones, research and development funding and other fees, including a $<ix:nonFraction unitRef="usd" contextRef="if9ade2259f534177966ecdd8ce949ae1_D20221231-20230331" decimals="-5" name="exel:IncreaseDecreaseInResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNTQ5NzU1ODI4MDQx_3ba31677-6596-4326-8d2d-26476b5555e8">35.0</ix:nonFraction>&#160;million development milestone to our partner, Sairopa B.V., upon the effective date of the initial new drug application (IND) for the ADU-1805 program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March&#160;31, 2023, in conjunction with these collaborative in-licensing arrangements we are subject to potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="iffd1fa8ae2c3489f966e69cc776984e3_I20230331" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNjA0NzMxMzk2OTczMw_6fc324a4-53e3-4c8b-bb69-5785455277e9">650.6</ix:nonFraction>&#160;million, regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="iffd1fa8ae2c3489f966e69cc776984e3_I20230331" decimals="-5" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNjA0NzMxMzk2OTczNA_089dac67-b495-4d5a-b197-d792f11e74fc">634.4</ix:nonFraction>&#160;million and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="iffd1fa8ae2c3489f966e69cc776984e3_I20230331" decimals="-8" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfMTY0OTI2NzQ2MDM0NA_9296f638-1829-4234-bb63-e2b1dab53d9f">3.2</ix:nonFraction>&#160;billion, each in the aggregate per product or target, as well as royalties on future net sales of products.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i040dd4c33333480ba1e8d94e558984f1_43"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjg3Mw_3069b4bb-d28a-4d2b-a461-df79e7d05854" continuedAt="i24c65a84da344c21a98c92934b35b656" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="i24c65a84da344c21a98c92934b35b656" continuedAt="i1e692d9aff4a4fe986b9995c96e9c2dd"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjg4Mg_ed29aee4-4979-441a-b8a9-5b2dead7cf65" continuedAt="i22566cf00e7545838c97d2968e54e07d" escape="true"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjg4NA_2a5b8448-c738-473c-aece-d99f1de07ee6" continuedAt="i3f1af466b7964c97b14caa614191b258" escape="true">A reconciliation of cash, cash equivalents and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i22566cf00e7545838c97d2968e54e07d"><ix:continuation id="i3f1af466b7964c97b14caa614191b258"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfMS0xLTEtMS0xMTA5NTI_35fd8062-5a6d-4949-8bbd-72b6bebe818f">540,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfMS0zLTEtMS0xMTA5NTI_cdb99e51-a08b-4448-a87b-63cb93aae738">501,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfMy0xLTEtMS0xMTA5NTI_7934ebf2-7f3c-4659-a34f-c8c9a9777ad7">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfMy0zLTEtMS0xMTA5NTI_4370f171-2907-4ca4-babb-829eafb84614">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfNC0xLTEtMS0xMTA5NTI_18f94f12-dff9-4ef9-8fce-c1e82c88f4e8">542,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfNC0zLTEtMS0xMTA5NTI_2dc15d8b-5be7-4d19-b548-cdd8d334bc06">502,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit agreements and are invested primarily in certificates of deposit with original maturity of 90 days or less. The restricted cash equivalents are classified as other long-term assets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjg3Nw_f73140c7-4a10-4589-981f-0ace132fda0c" continuedAt="ib95496eaaa8646ee8b100edaf0f8151a" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia307bf0c6b5b4e379b3b2fd963c7ec10_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMy0xLTEtMS0xMTA5NTI_13b89343-52fc-41af-9e34-8061c807df28">684,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia307bf0c6b5b4e379b3b2fd963c7ec10_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMy0zLTEtMS0xMTA5NTI_eae3a747-996d-42c3-8413-7d6047358244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia307bf0c6b5b4e379b3b2fd963c7ec10_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMy01LTEtMS0xMTA5NTI_ba75ce66-ce35-462d-b07e-b7ade5e88a9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia307bf0c6b5b4e379b3b2fd963c7ec10_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMy03LTEtMS0xMTA5NTI_006881a2-9175-4402-9374-653d3910b398">684,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNC0xLTEtMS0xMTA5NTI_d19ad82b-3002-4ce8-94ad-73771313e596">823,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNC0zLTEtMS0xMTA5NTI_0a29fb2f-9012-435a-be05-54728b4e3fce">2,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNC01LTEtMS0xMTA5NTI_e2c555b8-4d10-405c-9432-76732997d805">10,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNC03LTEtMS0xMTA5NTI_dfe12fb1-c571-4e08-9f39-33d14bc4e0ee">814,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNS0xLTEtMS0xMTA5NTI_d50e5531-bf98-43ef-a796-99a3985bd0c0">367,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNS0zLTEtMS0xMTA5NTI_6e3d5750-87f3-4f8a-bf43-e9f5fc073035">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNS01LTEtMS0xMTA5NTI_0f628791-7428-4137-b431-7d0286b9e61b">3,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNS03LTEtMS0xMTA5NTI_657c88af-5736-4408-b405-fa3484d2ef31">364,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNi0xLTEtMS0xMTA5NTI_3c7c5693-b465-4c25-9057-fb0d8a9cdf39">11,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNi0zLTEtMS0xMTA5NTI_af107c8c-d4ac-4bad-9c38-da38cf7d9930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNi01LTEtMS0xMTA5NTI_bc63af92-88a4-4d5e-81d9-c017c6a1be78">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNi03LTEtMS0xMTA5NTI_a642b7f3-0a59-4412-80fc-2780e81dc0f4">11,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNy0xLTEtMS0xMTA5NTI_5177164d-1d53-4bf1-a1b3-35eecce5bdd6">1,886,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNy0zLTEtMS0xMTA5NTI_04892f4c-8d49-49db-aa2e-a9dcef418c31">2,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNy01LTEtMS0xMTA5NTI_2f635f28-ea4f-4ba9-90e6-f9d7c4ba96e7">14,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNy03LTEtMS0xMTA5NTI_95fcec5e-2f07-4ab6-bf4d-3d5d13510edc">1,875,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8e3d17820d48979b53c203807b119a_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOC0xLTEtMS0xMTA5NTI_a99dce0c-3a1a-4c22-99da-98ba70af3a8c">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8e3d17820d48979b53c203807b119a_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOC0zLTEtMS0xMTA5NTI_5e08c6bf-128d-431e-9bde-f7ddb9fca5c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8e3d17820d48979b53c203807b119a_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOC01LTEtMS0xMTA5NTI_9e6940c4-62b7-42ae-ab9d-10f53f58762c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8e3d17820d48979b53c203807b119a_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOC03LTEtMS0xMTA5NTI_d1f4d5fc-4d09-4834-b642-1412ae8738ac">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a661a40ef35452e91e33372e447bb37_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOS0xLTEtMS0xMTA5NTI_c692ca31-031a-42ef-afff-e45efb4f2f10">165,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a661a40ef35452e91e33372e447bb37_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOS0zLTEtMS0xMTA5NTI_040c405d-4b92-4ba3-99de-a9cb7f53072c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a661a40ef35452e91e33372e447bb37_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOS01LTEtMS0xMTA5NTI_40d8558a-d31b-44ba-aef5-efe1d128fba1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a661a40ef35452e91e33372e447bb37_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOS03LTEtMS0xMTA5NTI_9c1429b4-48e2-475d-ac8e-a19bf189f3e6">165,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77b0e4b2fe042139d6e224f2fba485d_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTAtMS0xLTEtMTEwOTUy_478128dc-46f0-4594-b30b-87d14e3ef35d">79,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77b0e4b2fe042139d6e224f2fba485d_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTAtMy0xLTEtMTEwOTUy_30e05793-65aa-41de-ad0c-8ae329c1814c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77b0e4b2fe042139d6e224f2fba485d_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTAtNS0xLTEtMTEwOTUy_ae6a3487-7ce2-47df-bfe5-c458e07fcfd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia77b0e4b2fe042139d6e224f2fba485d_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTAtNy0xLTEtMTEwOTUy_ad00e96d-377f-47be-ab84-9f93d099ed52">79,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTEtMS0xLTEtMTEwOTUy_f85171b1-9ae7-43db-aaf0-048c4345c428">2,132,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTEtMy0xLTEtMTEwOTUy_5b12dd0a-ebf8-4de2-bd68-87d410c3adcd">2,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTEtNS0xLTEtMTEwOTUy_e0272a0d-dede-4ee1-a420-dace19560fc0">14,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTEtNy0xLTEtMTEwOTUy_df4e17bc-ae55-4b8a-9b75-1263b32697be">2,121,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><ix:continuation id="i1e692d9aff4a4fe986b9995c96e9c2dd" continuedAt="i438bf80f984f491396898fba3fff0c9b"><div style="margin-top:9pt;text-align:center"><ix:continuation id="ib95496eaaa8646ee8b100edaf0f8151a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0849b362ce4562bfa01261a0459178_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMy0xLTEtMS0xMTA5NTI_92e7ab33-1340-49ce-9838-d729bc05d3b0">722,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0849b362ce4562bfa01261a0459178_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMy0zLTEtMS0xMTA5NTI_de8a4289-6998-4955-90a3-22a92d4def23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0849b362ce4562bfa01261a0459178_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMy01LTEtMS0xMTA5NTI_93d8ad40-a619-4861-91f7-7a47e12a3427">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d0849b362ce4562bfa01261a0459178_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMy03LTEtMS0xMTA5NTI_690c85f9-4b8e-49ce-94f9-49819eb2346c">722,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNC0xLTEtMS0xMTA5NTI_6301c4b9-a028-45d2-b4ea-b167650b5685">810,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNC0zLTEtMS0xMTA5NTI_ce5fdc0b-0265-4c87-9b21-ed63681ffbf6">541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNC01LTEtMS0xMTA5NTI_10d52ad8-8cb5-4772-9352-b61436ca77de">13,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNC03LTEtMS0xMTA5NTI_164679e6-81bf-4f46-8794-853561ffc2f4">797,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNS0xLTEtMS0xMTA5NTI_e166ff23-fa4d-448d-9e32-71065e848d36">338,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNS0zLTEtMS0xMTA5NTI_aa3d6130-f6ef-440f-97bb-3bb62f85917d">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNS01LTEtMS0xMTA5NTI_8a88d572-9126-43c4-aac4-433b9617807b">5,679</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNS03LTEtMS0xMTA5NTI_1311fe69-7349-4420-8dc5-2b90310c741f">332,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf7287be2844027815aaad0c091426c_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNi0xLTEtMS0xMTA5NTI_919aa278-b581-4465-b034-dd5d9ddb7d3c">16,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf7287be2844027815aaad0c091426c_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNi0zLTEtMS0xMTA5NTI_1a824968-5a91-4129-b3fd-936e67a95bd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaf7287be2844027815aaad0c091426c_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNi01LTEtMS0xMTA5NTI_c68e2d28-bfed-4977-9fd5-7b870ddffe02">223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf7287be2844027815aaad0c091426c_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNi03LTEtMS0xMTA5NTI_5376fa13-6a9b-4a25-84fb-19f5cf808d8f">16,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNy0xLTEtMS0xMTA5NTI_275d3ca3-e644-4294-a2fb-d2b3443b30f3">1,887,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNy0zLTEtMS0xMTA5NTI_48e5c619-4ff3-4237-829e-7f8ee374310c">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNy01LTEtMS0xMTA5NTI_3a5c6db3-8811-486d-99d3-965243c1e507">19,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNy03LTEtMS0xMTA5NTI_c55c9d7f-ecac-4ffa-b762-b0a0f6996624">1,868,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee3723a2aa5d463ba5688d589dda3b7d_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOC0xLTEtMS0xMTA5NTI_a162f9db-8954-4166-89ee-02c98bfd68be">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee3723a2aa5d463ba5688d589dda3b7d_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOC0zLTEtMS0xMTA5NTI_a69cca42-e1d2-4487-8873-633d4e79a6cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee3723a2aa5d463ba5688d589dda3b7d_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOC01LTEtMS0xMTA5NTI_4da1119a-ab73-4bde-9cdb-199e81114f88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee3723a2aa5d463ba5688d589dda3b7d_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOC03LTEtMS0xMTA5NTI_8a4ace60-d8a2-4694-aff8-adafc576a2cb">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed11edd9a934cdead36351f09d723ae_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOS0xLTEtMS0xMTA5NTI_e8695ecc-28ce-49ff-8847-0241f9d23159">94,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed11edd9a934cdead36351f09d723ae_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOS0zLTEtMS0xMTA5NTI_fab29d81-050d-44f0-824c-6e5423cc1ac9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed11edd9a934cdead36351f09d723ae_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOS01LTEtMS0xMTA5NTI_3314e16d-69c7-4730-b75e-8e5a729080f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed11edd9a934cdead36351f09d723ae_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOS03LTEtMS0xMTA5NTI_d918904f-5028-4204-b1c3-aeb906c42cfc">94,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a53bc620960402191b67550fd79e525_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTAtMS0xLTEtMTEwOTUy_c33c3cad-db3f-4fd0-bc74-50ecd565a613">103,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a53bc620960402191b67550fd79e525_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTAtMy0xLTEtMTEwOTUy_2c6d3973-d96a-47f2-aa08-668109d50e9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a53bc620960402191b67550fd79e525_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTAtNS0xLTEtMTEwOTUy_9f40fd8f-5465-4572-a350-b4182d32a833">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a53bc620960402191b67550fd79e525_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTAtNy0xLTEtMTEwOTUy_bedaf7fb-e431-4199-9063-59137e9d94a5">103,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTEtMS0xLTEtMTEwOTUy_50c85dd2-6bb8-4f2e-b263-c73af57c2460">2,085,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTEtMy0xLTEtMTEwOTUy_b1b79094-2da0-46ea-a3e9-ddbb4636c027">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTEtNS0xLTEtMTEwOTUy_cfb7e409-f1a9-431c-af71-484dbfec6ed1">19,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTEtNy0xLTEtMTEwOTUy_07d5ab16-7557-4b93-a964-ebca09a6c012">2,066,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $<ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMTIyOQ_759c236a-730c-4beb-9b7e-cba7de516be4">10.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-5" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMTIzNg_549ad1e9-f932-4033-a24e-a21081e21b6c">7.3</ix:nonFraction> million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2022, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were immaterial during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjkwMg_cf05a11c-fe8a-4ed7-82cf-b2bac96bb200" continuedAt="ie9434817f23b4e00bd237096e63e0b4e" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="ie9434817f23b4e00bd237096e63e0b4e"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfMi05LTEtMS0xMTA5NTI_3d11324c-0286-4db5-bae3-e68b52d9919c">551,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfMi0xMS0xLTEtMTEwOTUy_80adcafa-a273-4561-98f6-96e8c876352a">10,274</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfNC05LTEtMS0xMTA5NTI_dcfea0ab-c670-423b-a98b-08d71f0660a9">283,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfNC0xMS0xLTEtMTEwOTUy_32e0bdfa-aac7-4ab8-8731-50d8275eef3d">3,859</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfNi05LTEtMS0xMTA5NTI_32fe4344-f3ec-4d31-99b1-4188e02883b0">11,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfNi0xMS0xLTEtMTEwOTUy_0bc3c637-384e-4672-af2a-90d4836f942e">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfOC05LTEtMS0xMTA5NTI_125506b0-1169-49ec-9c5a-4e8824920998">845,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfOC0xMS0xLTEtMTEwOTUy_1fe0d65d-9594-45a4-96bd-108cdb85d782">14,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfMi05LTEtMS0xMTA5NTI_d02848d2-96ad-4fe2-bfec-5337ac8b468b">706,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfMi0xMS0xLTEtMTEwOTUy_74f7f3bf-3c01-4dd3-b911-ac6ec20dfc79">13,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNC05LTEtMS0xMTA5NTI_9ac20843-cc92-4200-b8dc-7ea68586aeb5">308,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNC0xMS0xLTEtMTEwOTUy_b476ef97-74bb-46a8-9166-1de5a2dd7cb4">5,679</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf7287be2844027815aaad0c091426c_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNS05LTEtMS0xMTA5NTI_cfddb7ea-de84-4442-b291-f62bfca90f54">15,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaf7287be2844027815aaad0c091426c_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNS0xMS0xLTEtMTEwOTUy_432bfd6a-0f17-49a0-8603-1f403dac1429">223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNi05LTEtMS0xMTA5NTI_4449ef30-ed1e-47bb-a461-4c4b7b05248a">1,030,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNi0xMS0xLTEtMTEwOTUy_f48750a0-ac02-4e65-bacf-d556fd4f65ce">19,034</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="investment" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMTY0OTI2NzQ0ODQ2Ng_b17b5643-f4b3-4375-85a0-4ca6b499fcd8">237</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNzI5OQ_71f1c6be-f473-46d6-91ff-0b8bc8039d85">285</ix:nonFraction> debt securities available-for-sale in an unrealized loss position as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023 and </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, respectively. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> all securities have been in an unrealized loss position for less than twelve months except for <ix:nonFraction unitRef="bond" contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331" decimals="INF" name="exel:NumberOfBondSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMzI5ODUzNDg5MDkwNw_73ace392-7f8b-4bda-9941-51312a7f5231">91</ix:nonFraction> debt securities available-for-sale with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNTQ5NzU1ODE5NTk3_70bc4bde-ee0c-434c-a1de-4d34dd988d88">317.1</ix:nonFraction> million and an aggregate $<ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNTQ5NzU1ODE5NjA0_a9e4fc55-b46d-462b-93be-7038b85a4f9e">6.3</ix:nonFraction> million unrealized loss. As of December&#160;31, 2022, all securities have been in an unrealized loss position for less than twelve months except for <ix:nonFraction unitRef="bond" contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230" decimals="INF" name="exel:NumberOfBondSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNTQ5NzU1ODIwNTMy_dce7e626-9818-426d-983b-a1bacd529a56">81</ix:nonFraction> debt securities available-for-sale with an aggregate fair value of $<ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNTQ5NzU1ODIwNjMx_eaaa77dc-14b6-4d64-a0eb-bd96b938fef7">237.6</ix:nonFraction>&#160;million and an aggregate $<ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNTQ5NzU1ODIwNjQ5_3309cb66-a25a-4674-8112-72de729dc466">6.1</ix:nonFraction>&#160;million unrealized loss. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we did <ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjI0Nw_d68ab2c7-36d7-47bb-a7bf-8d2a8ef7ab1b">no</ix:nonFraction>t record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><ix:continuation id="i438bf80f984f491396898fba3fff0c9b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjg5NQ_b9e03ae8-4348-48a9-8579-43fa167ea500" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMS0xLTEtMS0xMTA5NTI_1f62d054-eb21-46dc-a71d-ab3ee2cfc527">1,071,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMS0zLTEtMS0xMTA5NTI_38c36d37-cc4d-4409-a89f-5e5b0a3e5652">1,114,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMi0xLTEtMS0xMTA5NTI_efd520f1-0922-48f7-95b0-cbf7772f91ad">803,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMi0zLTEtMS0xMTA5NTI_9208941e-230d-42c0-90ce-749ae2e77813">753,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMy0xLTEtMS0xMTA5NTI_07a49bf6-ae9f-4ad4-9f2e-9539cbd9de95">1,875,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMy0zLTEtMS0xMTA5NTI_4ab03518-2c7d-4208-b22f-367de329daa2">1,868,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i040dd4c33333480ba1e8d94e558984f1_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RleHRyZWdpb246Y2I5OTc1MDVhMDU5NGUxMmEwNjNmZmU5ZjhjYjUzZGNfMjQ1Nw_a225782d-828a-4354-b699-ac9034aace65" continuedAt="ib82397d7d37e4f40bc6cc127b495f3d8" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ib82397d7d37e4f40bc6cc127b495f3d8" continuedAt="i8ee22721431a4186a73e6e245de7e018"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RleHRyZWdpb246Y2I5OTc1MDVhMDU5NGUxMmEwNjNmZmU5ZjhjYjUzZGNfMjQ1MA_d3e67dac-65d5-4966-8269-b5888748d1e8" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2bb0b5859e94e8a936be047b130cf62_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMi0xLTEtMS0xMTA5NTI_a6245f96-0fd4-4f18-a205-d11591c2c621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7332d7a5938d414dabe83a5e6080938c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMi0zLTEtMS0xMTA5NTI_619332eb-51a2-4473-81e9-f383a6a8c2be">684,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i289d8780126e4649aa6123219a3a320f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMi01LTEtMS0xMTA5NTI_41c3efa8-d7c2-4d59-94c1-433b7c1d0e3c">684,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9c63d0e80744719b3825cef5d5d14b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMy0xLTEtMS0xMTA5NTI_f2ed08dc-07c1-4222-b1dd-d8503aef9ebb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a7c1a85b9741668be6b1244cb03182_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMy0zLTEtMS0xMTA5NTI_d665c7c5-26e2-4685-99c6-4598e8791b5e">814,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ff6643a21e3422a80cdf082d9960ef4_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMy01LTEtMS0xMTA5NTI_cade9844-32cb-4a61-81fc-d47a00a4793b">814,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fc468b967af4e86a80786a9c3aa6c5c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNC0xLTEtMS0xMTA5NTI_78b0d77c-9bff-4367-b0cc-4d3dbbc08d84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d5bb9bf05744909898ab9b06c87bd6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNC0zLTEtMS0xMTA5NTI_6efe591b-8332-4d74-ab1b-df24d37bebfc">364,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i036daf539dfc49c8b73722fa3dae40a1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNC01LTEtMS0xMTA5NTI_580d535b-f0d4-44ab-ad2b-5a631c693df3">364,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87f0d005430404db06bb3f461851a1f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNS0xLTEtMS0xMTA5NTI_a0e0b407-fd74-47f9-94db-61ab57a586f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3329a69fdc8a47cba0eb64acea2395f6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNS0zLTEtMS0xMTA5NTI_905c3875-9168-46b8-8395-42a1a0cfec3d">11,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie516d60b14c7478095d3f58b37428a68_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNS01LTEtMS0xMTA5NTI_fb76ffe2-ec4f-404d-ae76-5b4e7bd6c752">11,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31039ff71e764360b58c4edb8693ba2f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNi0xLTEtMS0xMTA5NTI_8d3746c7-33b3-4399-be7a-de56f8f2583d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ae4221be8d44a8a7c7a3c9e9f180ec_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNi0zLTEtMS0xMTA5NTI_88204163-eca7-4d30-b0cb-aac6e955a5f3">1,875,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide3e32d66598443986f9b93c38b9a643_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNi01LTEtMS0xMTA5NTI_ddf03602-844a-4abf-9fcf-4bb2ff613245">1,875,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4fae3311f344cb085dfbc49e046ce18_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNy0xLTEtMS0xMTA5NTI_11903239-53c7-44b9-a945-7f2ff7dd770f">165,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7acd21d036a3477aac89ae6ccd15d11b_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNy0zLTEtMS0xMTA5NTI_a6d51ca1-5e28-43ac-979a-d87abc2fd6bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66f34ea6b40143b8b73529584d025afc_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNy01LTEtMS0xMTA5NTI_b0a4b949-bfb7-46c3-8906-58e25bff386d">165,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b40425343ab4840a5a2065cac546d59_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOC0xLTEtMS0xMTA5NTI_5a085826-efbc-4906-8cae-021a070541c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41e491600bbd4af79605cfbcf83d1913_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOC0zLTEtMS0xMTA5NTI_85f11a2f-7564-44da-9e88-ebbe5d7f0b82">79,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69089dbb95ad41858db9a2acea999f10_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOC01LTEtMS0xMTA5NTI_b19bcf8f-129d-40e7-b1ff-05a3d2e13e74">79,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31039ff71e764360b58c4edb8693ba2f_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOS0xLTEtMS0xMTA5NTI_26ebbe97-00e7-4ab1-a7cf-f659a4ec6a4b">165,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ae4221be8d44a8a7c7a3c9e9f180ec_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOS0zLTEtMS0xMTA5NTI_eb35c52e-09b3-4219-a3b4-c96f85bda2c7">1,955,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide3e32d66598443986f9b93c38b9a643_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOS01LTEtMS0xMTA5NTI_fe13e463-870e-4118-8ba9-e270c454868c">2,121,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ed964b6ac9e45588d0755f26b3a0530_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMi0xLTEtMS0xMTA5NTI_258448b5-8687-45c7-a306-682bb51de541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i957abfeaf90a4f888c7d6eb2f35c48b5_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMi0zLTEtMS0xMTA5NTI_434a0505-e4d3-4783-8a4c-98869d912ee2">722,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92282b3812a4c52a5eb1714922f4607_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMi01LTEtMS0xMTA5NTI_5fee1961-ce26-4c52-b07f-491797eac8d6">722,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5995c0541b401eb07d6d421025aa64_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMy0xLTEtMS0xMTA5NTI_9377043e-72f0-43ee-ad32-0e3e32acf4bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65cbedaff73f4c8baa47313cf71881be_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMy0zLTEtMS0xMTA5NTI_d2a96d31-643d-4d52-b0dd-772f5c21a5dd">797,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd3936dfce8e401ba8d8f7c22abbb987_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMy01LTEtMS0xMTA5NTI_ad090a5f-4736-4fe5-9702-e17d9900f406">797,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2074852d3fc4146a552e1020fed749a_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNC0xLTEtMS0xMTA5NTI_ed12ec25-52a6-49aa-8e48-f654e2d00ed2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9899d00466704758b0d0844ee5256ef0_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNC0zLTEtMS0xMTA5NTI_0e298185-f391-4036-a199-0447569110ee">332,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i456848174e4b411d97e0d18790a81449_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNC01LTEtMS0xMTA5NTI_80fc2b42-977f-4b13-8679-2b3df15de655">332,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a9b1c8da4d4daf938376135d589190_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNS0xLTEtMS0xMTA5NTI_b1f21361-ccbb-4bc7-8be7-cd3e378a671e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc80802ed0064fbe90e139d4e9f11c0d_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNS0zLTEtMS0xMTA5NTI_c41ae773-9152-43a2-b7f8-600bee184c37">16,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711f7b4d4689414894669fee3ce78b88_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNS01LTEtMS0xMTA5NTI_c3d60002-dea2-43da-8935-2bc9cbfdfc5a">16,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1713646d824564b9adee7955a921c9_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNi0xLTEtMS0xMTA5NTI_4c70d077-6688-429e-aecf-ae4611e03ea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a589a297c4b471ba55f3c7b0af708c3_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNi0zLTEtMS0xMTA5NTI_2b2b9717-025e-4ada-b1bd-05e3a44bda2c">1,868,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1532e94710824cf39b3266528be43ba1_I20221230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNi01LTEtMS0xMTA5NTI_c90c0893-c0eb-4e19-af44-4111dba6728f">1,868,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a61c4734ba4ebcb0ef504886ba6de1_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNy0xLTEtMS0xMTA5NTI_7cb85957-86ae-4bfe-acc1-791455a85763">94,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eed0c8fb3e145b8afc025317b02b47c_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNy0zLTEtMS0xMTA5NTI_c5028a46-5866-403c-8601-a25b9b3db2a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6fb00cb8a194a00aac07f85c0714ec1_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNy01LTEtMS0xMTA5NTI_63e8a7df-137b-4ddd-8c2b-84ca34e44b69">94,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9c7f8a02e440d198176572c5aa2a9b_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOC0xLTEtMS0xMTA5NTI_25d7ba92-d833-4465-ade8-5a05ff39f860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6dfcf5d186443cb89d5d13bbf74fcc_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOC0zLTEtMS0xMTA5NTI_8b821ab2-af39-4271-99a8-1535c90438fe">103,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1777597937c24d058481cbd71160126e_I20221230" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOC01LTEtMS0xMTA5NTI_43446709-529a-49e3-a667-0933ccdb4a77">103,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1713646d824564b9adee7955a921c9_I20221230" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOS0xLTEtMS0xMTA5NTI_8d891966-970d-4c82-923d-52e212677574">94,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a589a297c4b471ba55f3c7b0af708c3_I20221230" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOS0zLTEtMS0xMTA5NTI_8f7a0c4c-b866-404a-bec9-d5faadee45fe">1,972,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1532e94710824cf39b3266528be43ba1_I20221230" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOS01LTEtMS0xMTA5NTI_6e96ff49-72b9-4bae-9714-368ac528666d">2,066,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><ix:continuation id="i8ee22721431a4186a73e6e245de7e018"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchange rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had <ix:nonFraction unitRef="derivative_instrument" contextRef="id59bda9dff304a61a0e935254d1873e1_I20230331" decimals="INF" name="us-gaap:DerivativeNumberOfInstrumentsHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RleHRyZWdpb246Y2I5OTc1MDVhMDU5NGUxMmEwNjNmZmU5ZjhjYjUzZGNfMTgxNw_ac3eee5b-3abd-4bf8-b179-3fd2496365d7">one</ix:nonFraction> forward contract outstanding to sell &#8364;<ix:nonFraction unitRef="eur" contextRef="id59bda9dff304a61a0e935254d1873e1_I20230331" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RleHRyZWdpb246Y2I5OTc1MDVhMDU5NGUxMmEwNjNmZmU5ZjhjYjUzZGNfNzE0NjgyNTU4MzE5NQ_7188ff15-058b-4ca6-baff-449ce145b3e4">4.1</ix:nonFraction>&#160;million. The forward contract with a maturity of <ix:nonNumeric contextRef="i6f2a0a5e0af9493ca0f227fed931a4ed_D20221231-20230331" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RleHRyZWdpb246Y2I5OTc1MDVhMDU5NGUxMmEwNjNmZmU5ZjhjYjUzZGNfMTkwMQ_d3acd4cd-bfca-4aa3-9e6f-6bb82302e280">three months</ix:nonNumeric> is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized loss on the forward contract is immaterial as of March&#160;31, 2023. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. The realized loss and gain we recognized on the maturity of our forward contract was immaterial for each of the three months ended March&#160;31, 2023 and 2022, respectively, and are included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div></ix:continuation><div id="i040dd4c33333480ba1e8d94e558984f1_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RleHRyZWdpb246NDQ3N2FlZDU0NTRmNGZiYWFhMmJjYWI3NmQ0YWM5ZjJfODk_c6280ea9-97a1-4d9b-955b-20a5baf15a4e" continuedAt="i44ea4e8f953e4252bf98f58eb2eac7ae" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="i44ea4e8f953e4252bf98f58eb2eac7ae"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RleHRyZWdpb246NDQ3N2FlZDU0NTRmNGZiYWFhMmJjYWI3NmQ0YWM5ZjJfODc_20b96b6c-9433-463e-bb0a-588f5e0e7a0a" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMS0xLTEtMS0xMTA5NTI_27b3a34f-5a11-4ecf-b53e-5a78f325c793">8,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMS0zLTEtMS0xMTA5NTI_540a9412-6834-4eea-a217-272274291280">8,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMi0xLTEtMS0xMTA5NTI_78b85983-686b-43ae-b151-9bbe6ed4e94c">53,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMi0zLTEtMS0xMTA5NTI_0eb15f99-c7d2-42ba-a0a6-e2c067d36a4d">43,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMy0xLTEtMS0xMTA5NTI_f0df5279-fac7-4f52-b910-0567bd25ed7c">8,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMy0zLTEtMS0xMTA5NTI_b63143ea-a169-4fc3-a6d7-4f3e92f021c5">10,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfNC0xLTEtMS0xMTA5NTI_d4c1deef-b593-4f96-9f8f-309c31448811">70,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfNC0zLTEtMS0xMTA5NTI_c7254f71-d419-49f3-9440-e2dd28b3b680">62,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64066d08939c412ea45c0e2ce3a1376f_I20230331" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfNy0xLTEtMS0xMTA5NTI_57ab1d18-3dfb-4e26-8382-90b05a25f589">29,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e165e45ccd64b35b0258752fdd33d0a_I20221230" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfNy0zLTEtMS0xMTA5NTI_424a2fe2-3829-4809-a60c-5629cf9dcb48">33,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048b471b1b074d82bde14df2ea6b910d_I20230331" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfOC0xLTEtMS0xMTA5NTI_ea6f2a5f-647b-4686-a093-a776ffa4a9ee">40,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc2748b521d641c1bb32f1e95b036970_I20221230" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfOC0zLTEtMS0xMTA5NTI_51e5b164-5810-48ee-a78f-54bdaa06caef"><ix:nonFraction unitRef="usd" contextRef="icc2748b521d641c1bb32f1e95b036970_I20221230" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfOC0zLTEtMS0xMTA5NTI_6aaf5c70-2721-4a95-b858-34ea44226861">28,977</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfOS0xLTEtMS0xMTA5NTI_25c5c26a-04a4-4e78-8bd3-8e4924967892">70,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfOS0zLTEtMS0xMTA5NTI_83b3e473-ebe6-4357-83a7-ff4b7062c069">62,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i040dd4c33333480ba1e8d94e558984f1_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfMzgxOQ_0db38291-2e73-4c40-867e-289adc6e0fab" continuedAt="i3ec57be4e51a4a3abf40e6de0d218597" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i3ec57be4e51a4a3abf40e6de0d218597" continuedAt="i46b54b34409943e892756ce60609b4e7"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several equity incentive plans under which we granted stock options and restricted stock units (RSUs), including performance-based restricted stock units (PSUs), to employees and directors. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="i2f1f77b69c154581ba20fe6d66b88637_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNTQ5NzU1ODMzODk1_07ead383-8e6a-4670-99b8-43f1b9d56821">31,678,788</ix:nonFraction> sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by <ix:nonFraction unitRef="shares" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNTQ5NzU1ODMzOTAy_acb32676-9977-4970-b1cf-9451314b180d">1</ix:nonFraction> share for each share issued pursuant to a stock option and <ix:nonFraction unitRef="shares" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNTQ5NzU1ODMzOTA3_0f42168d-65e6-45be-8d26-383fd37c5c3c">2</ix:nonFraction> shares for full value awards, including RSUs. </span></div><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfMzgzNQ_b9ca5b8f-228b-4693-b250-e524614ba7f4" continuedAt="i0310bc10456e4ef99055d43659c72a8c" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib798adcf0e30410e9cf0c303568c4dd8_D20221231-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfMy0xLTEtMS0xMTA5NTI_946c6341-324d-4d62-8b83-be58e9046c36">3,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077b175796d8467ebd7f57f08b70e854_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfMy0zLTEtMS0xMTA5NTI_34829000-dc2c-4ca1-b641-9918ec768577">8,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a8b33f363d4bc0ac9b67d04c777bda_D20221231-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfNC0xLTEtMS0xMTA5NTI_1b3793c6-63b1-452b-8b8b-13d9de0a1d03">13,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453291ae47804d32a67ac7c2f2eefef5_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfNC0zLTEtMS0xMTA5NTI_e0fe74fd-e33c-4b8f-952d-f393e0777275">10,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfNS0xLTEtMS0xMTA5NTI_87326b8f-21a4-4c07-854c-90df6f7af3c4">16,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfNS0zLTEtMS0xMTA5NTI_d487923b-2647-4841-b1a4-42de055c7e41">19,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><ix:continuation id="i46b54b34409943e892756ce60609b4e7"><ix:continuation id="i0310bc10456e4ef99055d43659c72a8c"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd484e891fd418a8ed42f45f84ec5bb_D20221231-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfMi0xLTEtMS0xMTA5NTI_a2cb8e3d-7a65-431e-a830-0badf94662f8">2,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia944468359d74f13b7a8031ab2b2ec81_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfMi0zLTEtMS0xMTA5NTI_e4021e23-a5ea-4dee-bd46-b046076302eb">3,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a18b8eece6d4b23bde7637cca5faffd_D20221231-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfMy0xLTEtMS0xMTA5NTI_3c832f02-35c4-48c5-a48a-5e3a9da3775a">12,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5664ad32e75748ecabb161d218d96696_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfMy0zLTEtMS0xMTA5NTI_14a543a5-1a1e-43de-b4e6-d84b9dce35ad">13,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8feeeff3a844ed994dd23909d3c10b_D20221231-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNC0xLTEtMS0xMTA5NTI_39156876-33b7-4f22-ba07-048066757b5b">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedfbdcf573f646959d5ef701c8bc3a1f_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNC0zLTEtMS0xMTA5NTI_20f3ea86-232f-4cd7-9bc0-34c791986537">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ed501ae6df49f8accd5863263afcf6_D20221231-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNS0xLTEtMS0xMTA5NTI_c06e9ed8-4d4e-4d07-9965-468f2cca5421">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f6f3af4e1e4419cb5a9e743245418f9_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNS0zLTEtMS0xMTA5NTI_5e221734-719d-4454-853e-4afdf0a41d74">1,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNi0xLTEtMS0xMTA5NTI_fdfc4afe-1791-445c-97dd-280280388b80">16,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNi0zLTEtMS0xMTA5NTI_fbab00de-0b20-47bc-8b9b-9f3010da8059">19,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were <ix:nonFraction unitRef="shares" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNzE0NjgyNTU5NTIwOQ_09742957-87a4-4eda-a568-f04f0274929f">9,738,700</ix:nonFraction> stock options outstanding and $<ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNzE0NjgyNTU5NTIxMw_8d03fe66-148d-471f-b09b-69979b599beb">14.0</ix:nonFraction>&#160;million of related unrecognized compensation expense. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we granted <ix:nonFraction unitRef="shares" contextRef="i8a18b8eece6d4b23bde7637cca5faffd_D20221231-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNjA0NzMxMzk2MzI2OQ_1c8bf62d-447c-45f8-8b85-5e37942ad2b0">576,960</ix:nonFraction> service-based RSUs with a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8a18b8eece6d4b23bde7637cca5faffd_D20221231-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNjA0NzMxMzk2MzI3MA_f7391932-4cff-412b-a1b7-fba89f874b78">17.08</ix:nonFraction> per share. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were <ix:nonFraction unitRef="shares" contextRef="ib0a8da2045b84694bcd4b8144997fa91_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNjA0NzMxMzk2MzI3MQ_075423a7-35c1-4662-b128-5a816596e26f">11,315,085</ix:nonFraction> RSUs outstanding, including RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs), and $<ix:nonFraction unitRef="usd" contextRef="ib0a8da2045b84694bcd4b8144997fa91_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNjA0NzMxMzk2MzI3Mg_a4b3b7fc-cd54-4eb0-87f1-3306a05038ae">172.0</ix:nonFraction>&#160;million of related unrecognized compensation expense. Service-based RSUs granted to employees during the three months ended March 31, 2023 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2022 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i0e6bbea2638d44e18d8bead2fc43515b_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNzE0NjgyNTU5NTI1NQ_f8fa61e6-f21a-455d-940e-0badbcd4fb95">4,688,349</ix:nonFraction> PSUs outstanding, of which <ix:nonFraction unitRef="shares" contextRef="i6b919b2777644b8ebe2bfda500054c0f_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNzE0NjgyNTU5NTI0OA_c9c6b222-d041-43e9-832e-db520a4afb54">1,277,755</ix:nonFraction> PSUs relate to awards that we either achieved the performance goal or determined that attainment of the performance goal was probable. Expense recognition for PSUs commences when it is determined that attainment of the performance goal is probable. As of&#160;March&#160;31, 2023, the remaining unrecognized stock-based compensation expense for the PSUs either achieved or deemed probable of achievement was $<ix:nonFraction unitRef="usd" contextRef="i0e6bbea2638d44e18d8bead2fc43515b_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNjA0NzMxMzk2MzI3NQ_de935d31-80d5-4897-b764-5e8c95cebd86">9.0</ix:nonFraction>&#160;million. The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance goal is probable was $<ix:nonFraction unitRef="usd" contextRef="i6b919b2777644b8ebe2bfda500054c0f_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNTQ5NzU1ODM0NjAx_c97106e8-3f41-440c-a766-7a482a067154">76.2</ix:nonFraction>&#160;million. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2022 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, our Board of Directors authorized a share repurchase program to acquire up to $<ix:nonFraction unitRef="usd" contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331" decimals="-6" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNTQ5NzU1ODI4NTEy_3091e775-ca8e-4fa6-b249-3d0f53a6f58a">550</ix:nonFraction>&#160;million of our outstanding common stock before the end of 2023. The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of our common stock and general market conditions. Share repurchases under the program may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, 10b5-1 trading plans, exchange transactions, or any combination of such methods. The program does not obligate us to acquire any particular amount of our common stock, and the share repurchase program may be modified, suspended or discontinued at any time without prior notice. During the three months ended March 31, 2023, we did not repurchase any shares.</span></div></ix:continuation><div id="i040dd4c33333480ba1e8d94e558984f1_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81NS9mcmFnOjllYWViOTU5MGJiMjQ1NjM5MWQ3OWIyMTExMzYzN2QxL3RleHRyZWdpb246OWVhZWI5NTkwYmIyNDU2MzkxZDc5YjIxMTEzNjM3ZDFfNzgw_840b9a60-de3e-4c04-aa39-b5422479655d" continuedAt="i220e3d9af15a4e409216ff60ff3dca43" escape="true">PROVISION FOR INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i220e3d9af15a4e409216ff60ff3dca43">The effective tax rate for the three months ended March&#160;31, 2023, was <ix:nonFraction unitRef="number" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81NS9mcmFnOjllYWViOTU5MGJiMjQ1NjM5MWQ3OWIyMTExMzYzN2QxL3RleHRyZWdpb246OWVhZWI5NTkwYmIyNDU2MzkxZDc5YjIxMTEzNjM3ZDFfNzE0NjgyNTU4MTcxMw_f7097034-5d84-4e8c-a232-b93f1f3abe61">17.1</ix:nonFraction>%, as compared to <ix:nonFraction unitRef="number" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81NS9mcmFnOjllYWViOTU5MGJiMjQ1NjM5MWQ3OWIyMTExMzYzN2QxL3RleHRyZWdpb246OWVhZWI5NTkwYmIyNDU2MzkxZDc5YjIxMTEzNjM3ZDFfMTY0OTI2NzQ0MjgwOA_fca6bff0-b1fb-4bae-af6a-e50aa2bda01c">19.5</ix:nonFraction>% for the corresponding period in 2022. The effective tax rate for each of the three months ended March&#160;31, 2023 and 2022, differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, partially offset by state taxes.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i040dd4c33333480ba1e8d94e558984f1_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RleHRyZWdpb246YzY1M2UzOTM2NjkxNGVkNDk4MzcwMmFhM2E5N2E0MDZfNzQ0_1d7ec239-4f17-4d9d-9857-15a0a24f9f8c" continuedAt="ia1ec9fe8ebb84c18bfde4584942b7b5a" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ia1ec9fe8ebb84c18bfde4584942b7b5a"><ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RleHRyZWdpb246YzY1M2UzOTM2NjkxNGVkNDk4MzcwMmFhM2E5N2E0MDZfNzQ3_c718c09d-918c-45e9-8e89-26bf16ab8a8e" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfMy0xLTEtMS0xMTA5NTI_99b3b0e7-afd3-4112-a3b2-aa7f959e400a">40,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfMy0zLTEtMS0xMTA5NTI_4cad5fab-d9c2-4e2c-9cec-2497e6050fa9">68,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNS0xLTEtMS0xMTA5NTI_48fb676b-7a4f-401b-8c0d-85faf9bfcf0d">324,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNS0zLTEtMS0xMTA5NTI_a97725bc-811c-44e8-a213-6ee3b05d19e5">319,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNi0xLTEtMS0xMTA5NTI_521204c9-d39c-4236-9f5c-172b5ffc7dc3">1,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNi0zLTEtMS0xMTA5NTI_a6a103de-3fd9-47ac-b91c-e560dcf19f3d">3,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNy0xLTEtMS0xMTA5NTI_25e10703-be63-48e8-9747-d6521bbbf8ba">326,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNy0zLTEtMS0xMTA5NTI_3c043758-ece8-421b-a015-cf6de91c6ccd">323,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfOS0xLTEtMS0xMTA5NTI_75591a3f-3c0a-41d3-a384-a14c9cb5e104">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfOS0zLTEtMS0xMTA5NTI_fdc7a084-1e40-47c0-ac40-a724bfdbfd2a">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfMTAtMS0xLTEtMTEwOTUy_f2a0bb0e-ff77-4fe4-b6e6-772868b144d5">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfMTAtMy0xLTEtMTEwOTUy_25f515d5-f419-42ac-a1bd-f01404951aeb">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs (including TSR-based RSUs), PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RleHRyZWdpb246YzY1M2UzOTM2NjkxNGVkNDk4MzcwMmFhM2E5N2E0MDZfNzU3_9132bdc3-2342-429d-94fa-ecb5654f7c51" continuedAt="i2b6eefb30e204d689d926d7357a30b29" escape="true">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i2b6eefb30e204d689d926d7357a30b29"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08af1f4087d548b2a2c27bd855c5a14f_D20221231-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmIxNTBlMmQ3NjE2YzQzMjFhNTc3NGVlODExZGE4MWM0L3RhYmxlcmFuZ2U6YjE1MGUyZDc2MTZjNDMyMWE1Nzc0ZWU4MTFkYTgxYzRfMi0xLTEtMS0xMTA5NTI_d479d3c8-2afa-45c4-80a4-00dbdf08a73c">15,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7027abb1b44144f58c42fe80ea5b4fe8_D20220101-20220401" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmIxNTBlMmQ3NjE2YzQzMjFhNTc3NGVlODExZGE4MWM0L3RhYmxlcmFuZ2U6YjE1MGUyZDc2MTZjNDMyMWE1Nzc0ZWU4MTFkYTgxYzRfMi0zLTEtMS0xMTA5NTI_8628ab36-93e3-41e0-9596-10a0aa42a1a3">16,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div id="i040dd4c33333480ba1e8d94e558984f1_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV82MS9mcmFnOjJlZjc1ZWY4ZTNlMzQwNGE5ZTczMGU5MmQwOGU3NTkxL3RleHRyZWdpb246MmVmNzVlZjhlM2UzNDA0YTllNzMwZTkyZDA4ZTc1OTFfMTM1NjY_f50b825e-066d-4a6d-9ee1-68ffbdd6c09b" continuedAt="i14ec3f2bff214d748506eb7a4f6eeb6b" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i14ec3f2bff214d748506eb7a4f6eeb6b" continuedAt="id1fa7e562c574db798aa18dd78f772e9"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MSN I ANDA Litigation </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (individually and collectively with certain of its affiliates, including MSN Laboratories Private Limited, referred to as MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><ix:continuation id="id1fa7e562c574db798aa18dd78f772e9" continuedAt="ia4a2da24e6dd45ccab21ba8918d9c19f"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The <ix:nonFraction unitRef="segment" contextRef="icb5f735f185d4a9dbe1cc597da942150_I20210430" decimals="INF" name="exel:LossContingencyNumberOfLawsuitsConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV82MS9mcmFnOjJlZjc1ZWY4ZTNlMzQwNGE5ZTczMGU5MmQwOGU3NTkxL3RleHRyZWdpb246MmVmNzVlZjhlM2UzNDA0YTllNzMwZTkyZDA4ZTc1OTFfNTQ5NzU1ODE5NTA0NA_64e8ad5f-df3f-488e-a0a8-5be6ee5eda87">two</ix:nonFraction> lawsuits comprising this litigation (collectively referred to as MSN I), numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we sought, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and on January 19, 2023, the Delaware District Court issued a ruling rejecting MSN&#8217;s invalidity challenge to U.S. Patent No. 7,759,473. The Delaware District Court also ruled that MSN&#8217;s proposed ANDA product does not infringe U.S. Patent No. 8,877,776 and entered judgment that the effective date of any final FDA approval of MSN&#8217;s ANDA shall not be a date earlier than August 14, 2026, the expiration date of U.S. Patent No. 7,759,473. Final judgment was entered January 30, 2023. This ruling in MSN I does not impact our separate and ongoing MSN II lawsuit (as defined below).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MSN II ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 are invalid and not infringed. On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 11,298,349 are invalid and not infringed and amended its challenges to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 to allege that these patents are not enforceable based on equitable grounds. The two lawsuits comprising this litigation (collectively referred to as MSN II), numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032, and equitable relief enjoining MSN from infringing these patents. A bench trial for MSN II has been scheduled for October 2023.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><ix:continuation id="ia4a2da24e6dd45ccab21ba8918d9c19f"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On September 2, 2022, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#8217;s amended ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the two lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cipla ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2023, we received a notice letter regarding an ANDA submitted to the FDA by Cipla, Ltd. and Cipla USA, Inc. (individually and collectively referred to as Cipla), including a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,039,757 (methods of treatment), 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition), 11,098,015 (methods of treatment) and 11,298,349 (pharmaceutical composition). Cipla&#8217;s notice letter did not provide a Paragraph IV certification against any additional CABOMETYX patents. On March 16, 2023, we filed a complaint in the Delaware District Court for patent infringement against Cipla asserting infringement of U.S. Patents No. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349 arising from Cipla&#8217;s ANDA filing with the FDA. Cipla&#8217;s ANDA requests approval to market a generic version of CABOMETYX tablets prior to the expiration of the aforementioned patents. We are seeking, among other relief, an order that the effective date of any FDA approval of Cipla&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032, and equitable relief enjoining Cipla from infringing these patents. Cipla&#8217;s response to the complaint is due on May 19, 2023. On May 4, 2023, we filed, under seal, a stipulation and proposed order to stay all proceedings, and the Delaware District Court, in a sealed order, granted the proposed order and administratively closed the case.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div id="i040dd4c33333480ba1e8d94e558984f1_67"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (Exelixis, we, our or us) current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q as well as those discussed elsewhere in this report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and the consolidated financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December&#160;31, 2022, filed with the Securities and Exchange Commission (SEC) on February 7, 2023 (Fiscal 2022 Form 10-K).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. Through the commitment of our drug discovery, development and commercialization resources, we have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib. We continue to evolve our product portfolio, leveraging our investments, expertise and strategic partnerships, to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates (ADCs) and other biotherapeutics.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 67 other countries as of the date of this Quarterly Report on Form 10-Q: as CABOMETYX&#174; (cabozantinib) tablets for advanced renal cell carcinoma (RCC) (both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab)), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); and as COMETRIQ&#174; (cabozantinib) capsules for progressive, metastatic medullary thyroid cancer. For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue leveraging our operating cash flows to support the ongoing investigation of cabozantinib in phase 3 trials for new indications and the advancement of a broad array of diverse biotherapeutics and small molecule programs for the treatment of cancer exploring multiple modalities and mechanisms of action. Of the clinical-stage assets that have emerged from our drug discovery and preclinical activities thus far, the furthest along are zanzalintinib, a next-generation oral tyrosine kinase inhibitor (TKI), and XB002, an ADC that targets tissue factor (TF). Both of these programs are next-generation approaches that build on our prior clinical experience, which we believe reduces program risk. We are also focused on conserving cash and managing risks of clinical failure by securing options to acquire other investigational drug candidates from third parties if those assets demonstrate evidence of clinical success. Two examples of this approach are: CBX-12 (alphalex</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> exatecan), a clinical-stage, first-in-class peptide-drug conjugate (PDC) invented by Cybrexa Therapeutics (Cybrexa) that utilizes Cybrexa&#8217;s proprietary alphalex technology to enhance the delivery of exatecan, a highly potent, second-generation topoisomerase I inhibitor, to tumor cells; and ADU-1805, a clinical-stage and potentially best-in-class monoclonal antibody developed by Sairopa B.V. (Sairopa) that targets SIRP&#945;. The FDA cleared Sairopa&#8217;s Investigational New Drug (IND) filing in February 2023, paving the way for an exploration of ADU-1805&#8217;s applicability across multiple tumor types, as well as the potential to combine ADU-1805 with zanzalintinib and approved ICIs.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Franchise</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA first approved CABOMETYX as a monotherapy for previously treated patients with advanced RCC in April 2016, and then for previously untreated patients with advanced RCC in December 2017. In January 2021, the CABOMETYX label was expanded to include first-line advanced RCC in combination with OPDIVO, which was the first CABOMETYX regimen approved for treatment in combination with an immune checkpoint inhibitor (ICI). In addition to RCC, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC previously treated with sorafenib, and then in September 2021, the FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with locally advanced or metastatic DTC that has progressed following prior VEGF receptor-targeted therapy and who are RAI-refractory or ineligible.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Limited (Takeda). We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda we granted the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of the cabozantinib franchise in other potential indications, and we work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the European Union (EU), the United Kingdom and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. In addition, in March 2021, Ipsen and BMS received regulatory approval from the EC for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC, followed by additional regulatory approvals for the combination in other territories beyond the EU. Most recently, in May 2022, we announced that Ipsen received regulatory approval from the EC for CABOMETYX as a monotherapy for the treatment of adult patients with locally advanced or metastatic, RAI-refractory or ineligible DTC and who have progressed during or after prior systemic therapy, which followed an approval from Health Canada in April 2022 for a similar DTC indication. With respect to the Japanese market, Takeda received Manufacturing and Marketing Approvals in 2020 from the Japanese Ministry of Health, Labour and Welfare (MHLW) of CABOMETYX as a treatment of patients with curatively unresectable or metastatic RCC and as a treatment of patients with unresectable HCC who progressed after cancer chemotherapy. In August 2021, Takeda and Ono Pharmaceutical Co., Ltd., BMS&#8217; development and commercialization partner in Japan, received Manufacturing and Marketing Approval from the MHLW of CABOMETYX in combination with OPDIVO as a treatment for unresectable or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could potentially benefit from this medicine. We are continuing to evaluate cabozantinib in combination with ICIs in late-stage clinical trials that we sponsor across RCC and metastatic castration-resistant prostate cancer (mCRPC). Beyond clinical trials that we or our collaboration partners sponsor, independent investigators also conduct trials evaluating cabozantinib through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator sponsored trial (IST) program. Over time, the data we have obtained from these investigator-sponsored clinical trials have helped advance our development program for the cabozantinib franchise by informing subsequent label-enabling trials, including COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib in previously treated patients with RAI-refractory DTC, from which positive results served as the basis for the FDA&#8217;s and EC&#8217;s approvals of CABOMETYX for DTC. Moreover, these data sets may also prove valuable by informing our development plans for zanzalintinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building on preclinical and clinical observations that cabozantinib in combination with ICIs may promote a more immune-permissive tumor environment, we initiated several pivotal studies to further explore these combination regimens. The first of these studies to deliver results was CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of CABOMETYX and OPDIVO compared to sunitinib in previously untreated, advanced or metastatic RCC, and positive results from CheckMate -9ER served as the basis for the FDA&#8217;s, EC&#8217;s and MHLW&#8217;s approvals of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC in January 2021, March 2021 and August 2021, respectively. We are also collaborating with BMS on COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and BMS&#8217; CTLA-4 ICI, ipilimumab, versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. We announced top-line results from COSMIC-313 in July 2022, and in September 2022 we presented the data at the Presidential Symposium III at the 2022 European Society for Medical Oncology Congress (the 2022 ESMO Congress). The trial met its primary endpoint, demonstrating significant improvement in blinded independent radiology committee (BIRC)-assessed progression-free survival (PFS) at the primary analysis for the triplet combination. At a prespecified interim analysis for the secondary endpoint of overall survival (OS), the triplet combination did not demonstrate a significant benefit, and therefore, the trial will continue to the next analysis of OS, expected in the second half of 2023. The safety profile observed in the trial was reflective of the known safety profiles for each single agent, as well as the combination regimens used in this study. Based on feedback from the FDA, we do not intend to submit a supplemental new drug application (sNDA) for the combination regimen based on the currently available data, and we plan to discuss a potential regulatory submission with the FDA when the results of the next OS analysis are available, provided such results are supportive.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further expand our exploration of combinations with ICIs, we also initiated multiple trials evaluating cabozantinib in combination with F. Hoffmann-La Roche Ltd. (Roche)&#8217;s ICI, atezolizumab, beginning in 2017 with COSMIC-021, a broad phase 1b study evaluating the safety and tolerability of the cabozantinib and atezolizumab combination with atezolizumab in patients with a wide variety of locally advanced or metastatic solid tumors. The encouraging efficacy and safety data that emerged from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs. We are currently evaluating the cabozantinib and atezolizumab combination in CONTACT-02, a phase 3 pivotal trial that we sponsor and is co-funded by Roche, which focuses on patients with mCRPC who have been previously treated with one novel hormonal therapy (NHT). We anticipate completing enrollment for CONTACT-02 and announcing results of the primary PFS analysis in the second half of 2023. Two other phase 3 trials sponsored by Roche and co-founded by us, CONTACT-01, which focused on patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an ICI and platinum-containing chemotherapy, and CONTACT-03, which focused on patients with inoperable, locally advanced or metastatic RCC who have progressed during or following treatment with an ICI as the immediate preceding therapy, did not meet their respective primary endpoints. Detailed findings from CONTACT-01 were presented at the European Lung Cancer Congress in March 2023, and detailed findings from CONTACT-03 will be presented at a future medical meeting.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zanzalintinib</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first compound to enter the clinic following our re-initiation of drug discovery activities in 2017 was zanzalintinib, a next-generation oral TKI that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing zanzalintinib, we sought to build upon our experience with cabozantinib, retaining a similar target profile while improving key characteristics, including the pharmacokinetic half-life. To date, we have initiated two large phase 1b clinical trials studying zanzalintinib: STELLAR-001 and STELLAR-002. STELLAR-001 is a phase 1b clinical trial evaluating zanzalintinib, both as a monotherapy and in combination with atezolizumab. We have established a recommended dose of 100 mg for both single-agent zanzalintinib and zanzalintinib in combination with atezolizumab, and we have completed enrollment in an expansion cohort for patients with clear cell RCC while continuing to enroll patients in expansion cohorts for patients with non-clear cell RCC, hormone-receptor positive breast cancer, mCRPC and colorectal cancer (CRC). STELLAR-001 had previously included additional dose-escalation cohorts evaluating the combination of zanzalintinib and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">avelumab, an ICI developed by Merck KGaA, Darmstadt, Germany and Pfizer Inc., but those cohorts have since been discontinued.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We previously presented data from STELLAR-001 during poster sessions at the 2022 ESMO Congress in September 2022, which showed zanzalintinib has demonstrated preliminary clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors and dose levels, with a manageable safety profile. In addition, preliminary efficacy data from the clear cell RCC expansion cohort from STELLAR-001, with a median follow-up of seven months, demonstrated an objective response rate (ORR) of 34% for the full cohort and an ORR of 50% for those patients who had not been previously treated with cabozantinib. We also continue to be encouraged by zanzalintinib&#8217;s emerging safety profile and plan to submit these data for presentation at an upcoming medical conference, likely later in 2023. STELLAR-002 is a phase 1b clinical trial evaluating zanzalintinib in combination with either nivolumab, nivolumab and ipilimumab, or a fixed-dose combination of nivolumab and BMS&#8217; relatlimab. We have established a recommended dose of 100 mg for zanzalintinib in combination with nivolumab, and we have begun enrolling patients in expansion cohorts for patients with clear cell and non-clear cell RCC, HCC, NSCLC and squamous cell carcinoma of head and neck (SCCHN). The dose-escalation stage for zanzalintinib in the other combination regimens is ongoing and is continuing to enroll patients with advanced solid tumors in dose-escalation cohorts. Depending on the dose-escalation results, these other combination regimens in STELLAR-002 may enroll expansion cohorts for patients with clear cell and non-clear cell RCC, mCRPC, urothelial carcinoma, HCC, NSCLC, CRC and SCCHN. To better understand the individual contribution of the therapies, treatment arms in the expansion cohorts may include zanzalintinib as a single agent in addition to the ICI combination regimens.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also initiated two phase 3 pivotal trials evaluating zanzalintinib in combination with ICIs in 2022. The first trial, STELLAR-303, was initiated in June 2022 and is evaluating zanzalintinib in combination with atezolizumab versus regorafenib in patients with metastatic non-microsatellite instability-high or non-mismatch repair-deficient CRC who have progressed after, or are intolerant to, the current standard of care. The trial aims to enroll approximately 600 patients worldwide with documented RAS status at approximately 137 sites globally. The primary objective of STELLAR-303 is to evaluate the efficacy of the combination in patients with RAS wild-type disease, and outcomes in patients with RAS-mutated disease will also be evaluated. The primary efficacy endpoint of STELLAR-303 is OS, and additional efficacy endpoints include PFS, ORR and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1, in each case as assessed by the investigator. The second trial, STELLAR-304, was initiated in December 2022 and is evaluating zanzalintinib in combination with nivolumab versus sunitinib in previously untreated patients with advanced non-clear cell RCC. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he trial aims to enroll </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately 291 patients at approximately 170 sites globally. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary efficacy endpoints of STELLAR-304 are PFS and ORR per RECIST v 1.1, in each case as assessed by </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BIRC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The secondary efficacy endpoint is OS. Beyond STELLAR-303 and STELLAR-304, we intend to explore a series of early-stage and pivotal trials evaluating zanzalintinib in novel combination regimens across a broad array of future potential indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biotherapeutics</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Much of our drug discovery activity focuses on discovering and advancing various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, ADCs and other innovative treatments. ADCs in particular present a unique opportunity for new cancer treatments, given their capabilities to deliver anti-cancer payload drugs to targets with increased precision while minimizing impact on healthy tissues. This approach has been validated by multiple regulatory approvals for the commercial sale of ADCs in the past several years. Furthest along amongst our biotherapeutics programs is XB002, our lead TF-targeting ADC program, in-licensed from Iconic Therapeutics, Inc. (Iconic), now a wholly owned subsidiary of Endpoint Health, Inc. We are evaluating XB002, both as a single agent and in combination with either nivolumab or Roche&#8217;s bevacizumab, in JEWEL-101, a phase 1 study in patients with advanced solid tumors for which therapies are unavailable, ineffective or intolerable. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced promising initial dose-escalation results from JEWEL-101 during the Antibody-drug Conjugates Poster Session at the 2022 ENA Symposium. The data demonstrated that XB002 was well-tolerated at multiple dose levels, and a pharmacokinetic analysis confirmed that XB002 was stable with low levels of free payload. The planned cohort-expansion phase, which we expect to initiate during 2023, is designed to further explore the selected dose of XB002, both as a single agent and in combination with either nivolumab or bevacizumab, in individual tumor cohorts, which may include forms of NSCLC, cervical cancer, ovarian cancer, UC, SCCHN, pancreatic cancer, esophageal cancer, mCRPC, triple negative breast cancer and hormone-receptor positive breast cancer, and we also intend to initiate additional dose-escalation and expansion cohorts to evaluate the potential of XB002 in combination with additional ICIs and other targeted therapies across a wide range of tumor types, including indications other than those currently addressed by commercially available TF-targeted therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we executed two option deals that exemplify our strategy to access clinical- or near-clinical-stage assets: an exclusive collaboration agreement with Cybrexa providing us with the right to acquire CBX-12; and an exclusive clinical development and option agreement with Sairopa to develop ADU-1805. Both CBX-12 and ADU-1805 are currently being evaluated in phase 1 clinical trials to explore each compound&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmacokinetics, safety, tolerability and preliminary anti-tumor activity in patients with advanced or metastatic refractory solid tumors.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To facilitate the growth of our various biotherapeutics programs, we have established multiple research collaborations and in-licensing arrangements and entered into other strategic transactions that provide us with access to antibodies, binders, payloads and conjugation technologies, which are the components employed to generate next-generation ADCs or multispecific antibodies. In addition to the option deals with Cybrexa and Sairopa, some of our active research collaborations for biotherapeutics programs include collaborations with: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Adagene Inc. (Adagene), which is focused on using Adagene&#8217;s SAFEbody technology to develop novel masked ADCs or other innovative biotherapeutics with potential for improved therapeutic index;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">BioInvent International AB (BioInvent), which is intended to expand our portfolio of antibody-based therapies and will utilize BioInvent&#8217;s proprietary n-CoDeR antibody library and patient-centric F.I.R.S.T screening platform, which together are designed to allow for parallel target and antibody discovery; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Catalent, Inc. (Catalent), which is focused on the discovery and development of multiple ADCs using Catalent&#8217;s proprietary SMARTag site-specific bioconjugation technology; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Invenra, Inc. (Invenra), which is focused on the discovery and development of novel binders and multispecific antibodies for the treatment of cancer; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">NBE-Therapeutics AG (NBE), which is focused on the discovery and development of multiple ADCs by leveraging NBE&#8217;s unique expertise and proprietary platforms in ADC discovery, including NBE&#8217;s SMAC-Technology and novel payloads.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have already made significant progress under these and other research collaborations and in-licensing arrangements and believe we will continue to do so in 2023 and in future years. For example, as a direct result of these arrangements, we are advancing four biotherapeutics development candidates: XB010, XB014, XB628 and XB371. XB010, our first ADC advanced internally, targets the tumor antigen 5T4 and incorporates antibodies sourced from Invenra and was constructed using Catalent&#8217;s SMARTag site-specific bioconjugation platform. XB014 and XB628 are bispecific antibodies: XB014 combines a PD-L1 targeting arm with a CD47 targeting arm to block a macrophage checkpoint; and XB628 targets PD-L1 and NKG2A, identified as key regulator of natural killer cell activity. Both XB014 and XB628 were developed through our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration with Invenra. XB371 is a next-generation, TF-targeting ADC, which is differentiated from XB002 by its topoisomerase inhibitor payload, and was developed through our collaboration with Catalent. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Small Molecules</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its formation in 2000, our drug discovery group has advanced 25 compounds to the IND stage, either independently or with collaboration partners, and today we deploy our drug discovery expertise to advance small molecule drug candidates toward and through preclinical development. These efforts are led by our experienced scientists, including some of the same scientists who led the efforts to discover cabozantinib, cobimetinib and esaxerenone, each of which are now commercially distributed drug products. For example, zanzalintinib, which was discovered at Exelixis, has now entered into phase 3 clinical trials. We augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies engaged in small molecule discovery, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">STORM Therapeutics LTD (STORM), which is focused on the discovery and development of inhibitors of novel RNA modifying enzymes, including ADAR1;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Aurigene Oncology, Ltd. (Aurigene), which is focused on the discovery and development of novel small molecules as therapies for cancer; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">StemSynergy Therapeutics, Inc. (StemSynergy), which is focused on the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting CK1&#945; and the Notch pathway.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most advanced compounds to emerge from these arrangements is XL102, our lead program targeting CDK7, in-licensed from Aurigene. We are evaluating XL102, both as a single agent and in combination with other anti-cancer therapies, in QUARTZ-101, a phase 1 study in patients with inoperable, locally advanced or metastatic solid tumors. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we announced initial dose-escalation results from QUARTZ-101 during the Poster Session at the 2022 San Antonio Breast Cancer Symposium. The data demonstrated that XL102 was well-tolerated at multiple dose levels and a pharmacokinetic analysis supported adding investigation of twice-daily oral dosing. We are continuing to evaluate the efficacy of XL102 in additional patients during this initial dose-escalation phase. The subsequent cohort-expansion phase is designed to further explore the selected dose of XL102 as a single agent and in combination regimens in individual tumor cohorts, including ovarian cancer, triple-negative breast cancer, hormone-receptor positive breast cancer and mCRPC. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report on Form 10-Q, we are currently working on more than 20 discovery programs and, pending data warranting further exploration, we anticipate advancing up to five new development candidates into preclinical development during 2023. In addition, we will continue to engage in business development initiatives with the goal of acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter 2023 Business Updates and Financial Highlights</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter-end include:</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In January 2023, the United States District Court for the District of Delaware (the Delaware District Court) issued a ruling in our patent infringement lawsuit against </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (individually and collectively referred to as MSN, and such lawsuit referred to as MSN I)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, rejecting MSN&#8217;s challenge to U.S. Patent No. 7,759,473, which expires August 14, 2026. The Delaware District Court also ruled that MSN&#8217;s proposed Abbreviated New Drug Application (ANDA) product does not infringe U.S. Patent No. 8,877,776, which expires October 8, 2030, and entered judgment that the effective date of any final FDA approval of MSN&#8217;s ANDA shall not be a date earlier than August 14, 2026, the expiration date of U.S. Patent No. 7,759,473. This ruling in MSN I does not address the parties&#8217; claims in our separate, consolidated patent infringement lawsuit filed in the Delaware District Court against MSN in 2022 (MSN II). For a more detailed discussion of the MSN litigation matters, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In February 2023, cabozantinib in patients with forms of RCC was the subject of multiple data presentations at the 2023 ASCO Genitourinary Cancers Symposium.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2023, Sairopa initiated a phase 1 clinical trial evaluating ADU-1805, a potentially best-in-class monoclonal antibody developed by Sairopa that targets SIRP&#945;, following the FDA's clearance Sairopa&#8217;s IND filing in February 2023.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2023, we announced results from the phase 3 CONTACT-03 trial evaluating cabozantinib in combination with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic clear cell or non-clear cell, papillary or unclassified only, RCC who progressed during or after immune checkpoint inhibitor therapy, either combination or monotherapy, in which the combination did not meet its primary endpoint of PFS.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2023, we filed a patent lawsuit in the Delaware District Court against Cipla, Ltd. and Cipla USA, Inc. (individually and collectively referred to as Cipla) asserting infringement of U.S. Patents No. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349 arising from Cipla&#8217;s February 2023 notice letter, which notified us that Cipla filed an ANDA with the FDA requesting approval to market a generic version of CABOMETYX tablets prior to the expiration of the aforementioned patents. For a more detailed discussion of the Cipla litigation matter, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In March 2023, we announced the repurchase of up to $550 million of the company&#8217;s common stock before the end of 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net product revenues for the first quarter of 2023 were $363.4 million, as compared to $310.3 million for the first quarter of 2022.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Total revenues for the first quarter of 2023 were $408.8 million, as compared to $356.0 million for the first quarter of 2022.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Research and development expenses for the first quarter of 2023 were $234.2 million, as compared to $156.7&#160;million for the first quarter of 2022.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Selling, general and administrative expenses for the first quarter of 2023 were $131.4 million, as compared to $102.9 million for the first quarter of 2022.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Provision for income taxes for the first quarter of 2023 was $8.3 million, as compared to $16.7 million for the first quarter of 2022.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net income for the first quarter of 2023 was $40.0 million, or $0.12 per share, basic and diluted, as compared to net income of $68.6 million, or $0.21 per share, basic and diluted, for the first quarter of 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Results of Operations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outlook, Challenges and Risks</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to face numerous challenges and risks that may impact our ability to execute on our business objectives. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. However, we cannot be certain that the clinical trials we and our collaboration partners are conducting will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if the required regulatory approvals to market CABOMETYX for additional indications are achieved, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. As is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets. In addition, healthcare policymakers in the U.S. are increasingly expressing concern over healthcare costs and corresponding legislative and policy initiatives and activities have been launched aimed at increasing the healthcare cost burdens borne by pharmaceutical manufacturers, as well as expanding access to, and restricting the prices and growth in prices of, pharmaceuticals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of our business objectives will also depend on our ability to maintain a competitive position in the shifting landscape of therapeutic strategies for the treatment of cancer, which we may not be able to do. On an ongoing basis, we assess the constantly evolving landscape of other approved and investigational cancer therapies that could be competitive, or complementary in combination, with our products, and then we adapt our development strategies for the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cabozantinib franchise and our pipeline product candidates accordingly, such as by modifying our clinical trials to include evaluation of our therapies with ICIs and other targeted agents. Even if our current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in mCRPC or evaluating zanzalintinib in combination with an ICI in CRC and RCC, produce positive results sufficient to obtain marketing approval by the FDA and other global regulatory authorities, it is uncertain whether physicians will choose to prescribe regimens containing our products instead of competing products and product combinations in approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic versions of CABOMETYX tablets that are the subject of ANDAs submitted to the FDA by MSN, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Teva) and Cipla. The approval of any of these ANDAs and subsequent launch of any generic version of CABOMETYX could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with drug discovery operations, especially on the global level. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these challenges and risks are specific to our business, others are common to companies in the biopharmaceutical industry with development and commercial operations, and an additional category are macroeconomic, affecting all companies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Convention</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2023, which is a 52-week fiscal year, will end on December&#160;29, 2023 and fiscal year 2022, which was a 52-week fiscal year, ended on December&#160;30, 2022. For convenience, references in this report as of and for the fiscal period ended April 1, 2022, and as of and for the fiscal years ending December&#160;29, 2023 and ended December&#160;30, 2022 are indicated as being as of and for the period ended March&#160;31, 2022, and the years ending December&#160;31, 2023 and ended December&#160;31, 2022, respectively.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_70"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:57.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues, discounts and allowances and net product revenues were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:57.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,922)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:57.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net product revenues for the three months ended March 31, 2023, as compared to the corresponding prior year period, was primarily related to a 10% increase in the number of CABOMETYX units sold as a result of the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, in part due to the longer duration of therapy for this combination and an increase in related market share reflecting the continued evolution of the metastatic RCC, HCC and DTC treatment landscapes, and, to a lesser extent, a 8% increase in the average net selling price of CABOMETYX.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project that our net product revenues may increase for the remainder of 2023, as compared to the corresponding prior year period, for similar reasons noted above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;included in Part II, Item 8 of our Fiscal 2022 Form 10-K. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and allowances as a percentage of gross revenues have increased over time as the number of patients participating in government programs has increased and as the discounts given and rebates paid to government payers have also increased. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the amount of discounts and allowances for the three months ended March 31, 2023, as compared to the corresponding prior year period, was primarily the result of an increase </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in volume of units sold and an increase in Medicare utilization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our discounts and allowances as a percentage of gross revenues will increase during the remainder of 2023, as compared to the corresponding prior year period, for similar reasons noted above. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues include: (a) the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable, in the related period, that a milestone would be achieved and a significant reversal of revenues would not occur in future periods; (b) royalty revenues; and (c) the profit on the U.S. commercialization of COTELLIC from Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no milestone payments recognized in license revenues during the three months ended March 31, 2023 and 2022. Royalty revenues increased primarily as a result of increases in Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalties were $29.8&#160;million for the three months ended March 31, 2023, as compared to $24.6&#160;million for the corresponding prior year period. Ipsen&#8217;s net sales of cabozantinib have continued to grow since Ipsen&#8217;s first commercial sale of CABOMETYX in the fourth quarter of 2016, primarily due to regulatory approvals in new territories, including regulatory approval in the EU for the combination therapy of CABOMETYX and OPDIVO received in March 2021. Royalty revenues for the three months ended March 31, 2023 also included $2.9&#160;million related to Takeda&#8217;s net sales of CABOMETYX, as compared to $2.4&#160;million for the corresponding prior year period. Takeda royalty revenues have continued to grow since Takeda&#8217;s first commercial sale of CABOMETYX in Japan in 2020. CABOMETYX is approved and is commercially available in 67 countries outside the U.S. as of the date of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was $2.9&#160;million for the three months ended March 31, 2023, respectively, as compared to $2.1 million for the corresponding prior year period. We also earned royalties on ex-U.S. net sales of COTELLIC by Genentech of $1.1&#160;million for the three months ended March 31, 2023 as compared to $1.6 million for the corresponding prior year period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and milestones can vary significantly from period to period. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, development cost reimbursements earned under our collaboration agreements and product supply revenues, which are net of product supply costs and the royalties we pay to Royalty Pharma on sales by Ipsen and Takeda of products containing cabozantinib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development cost reimbursements were $10.5&#160;million for the three months ended March 31, 2023 as compared to $17.3&#160;million for the corresponding prior year period. The decrease in development cost reimbursements for the three months ended March 31, 2023, as compared to the corresponding prior year period, was primarily attributable to decreases in spending on the COSMIC-312, COSMIC-021 and COSMIC-311 studies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues were reduced by $4.5&#160;million for the three months ended March 31, 2023 as compared to $3.8&#160;million for the corresponding prior year period, for the 3% royalty we are required to pay on the net sales by Ipsen and Takeda of any product incorporating cabozantinib. As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments have also increased.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our collaboration services revenues may decrease for the remainder of 2023, as compared to the corresponding prior year period, primarily as a result of a decrease in development cost reimbursement revenues.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of goods sold and our gross margin were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:57.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin %</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists of a 3% royalty payable on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring, excess and obsolete inventory and other third-party logistics costs. The increase in cost of goods sold for the three months ended March 31, 2023, as compared to the corresponding prior year period, was primarily due to an increase in </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oyalties as a result of increased U.S. CABOMETYX sales. We project our gross margin will not change significantly during the remainder of 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development expenses on a project-by-project basis. We group our research and development expenses into three categories: (1) development; (2) drug discovery; and (3) other research and development. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Development expenses include clinical trial costs, personnel expenses, consulting and outside services and other development costs including manufacturing costs of our drug development candidates. Our drug discovery group utilizes a variety of technologies, including in-licensed technologies, to enable the rapid discovery, optimization and extensive characterization of lead compounds and biotherapeutics such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development. Drug discovery expenses include license and other collaboration costs primarily comprised of upfront license fees, research funding commitments, development milestones and other payments associated with our in-licensing collaboration programs in preclinical development stage. Other drug discovery costs include personnel expenses, consulting and outside services and laboratory supplies. Other research and development include the allocation of general corporate costs to research and development services and development cost reimbursements in connection with certain of our collaboration arrangements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:57.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total development</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other drug discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he increase in research </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and development expenses for the three months ended March 31, 2023, as compared to the corresponding prior year period, was primarily related to increases in license and other collaboration costs, personnel expenses, other development costs and other research and development expenses, partially offset by lower stock-based compensation expense. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug discovery-related license and other collaboration costs increased primarily due to a $35.0 million milestone payment to Sairopa </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon the IND effective date for ADU-1805</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Personnel expenses increased primarily due to an increase in headcount to support our expanding discovery and development organization. Other development costs increased primarily due to manufacturing costs to support our drug development candidates. Other research and development expenses increased primarily related to technology costs, including our investments in business technology initiatives to support productivity and efficiency in our organization, and an increase in facility expenses. Stock-based compensation expense decreased for the three months ended March 31, 2023, as compared to the corresponding prior year period, primarily due to higher forfeitures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. These factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential market indications and overall clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to focus our development efforts on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we project that a substantial portion of our research and development expenses will relate to the clinical development of our small molecule drug candidate zanzalintinib and our first biotherapeutics product candidate, XB002. Notable ongoing company-sponsored studies resulting from this program include: CONTACT-02, for which Roche is sharing the development costs and providing atezolizumab free of charge; and COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are expanding our oncology product pipeline through drug discovery efforts, which encompass both biotherapeutics and small molecule programs with multiple modalities and mechanisms of action, with the goal of identifying new product candidates to advance into clinical trials. We also continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets, with the goal of utilizing our established preclinical and clinical development infrastructure to further characterize and develop such platforms and assets.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our research and development expenses may increase for the remainder of 2023, as compared to the corresponding prior year period, primarily driven by an increase in personnel expenses to support our expanding discovery and development organization and an increase in clinical trial costs including the planned initiation of multiple additional phase 3 pivotal trials and current early-stage trials evaluating zanzalintinib, as well as business development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:57.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,863&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Excludes stock-based compensation allocated to selling, general and administrative expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs and certain other administrative costs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in selling, general and administrative expenses for the three months ended March 31, 2023, as compared to the corresponding prior year period, was primarily related to increases in personnel expenses, technology costs and facility expenses. Personnel expenses increased primarily due to an increase in administrative headcount to support our commercial and research and development organizations. The increase in technology costs include our investments in business technology initiatives to support productivity and efficiency in our organization. The increase in facility expenses was primarily due to the commencement of new leases in 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our selling, general and administrative expenses may increase for the remainder of 2023, as compared to the corresponding prior year period, primarily driven by our continuing commercial investment in CABOMETYX and the growth of the broader organization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income was as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:57.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in non-operating income for the three months ended March 31, 2023, as compared to the corresponding prior year period, was primarily the result of an increase in interest income due to higher interest rates and higher investment balances.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:57.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rates for the three months ended March 31, 2023 and 2022, differed from the U.S. federal statutory rate of 21%, respectively, primarily due to excess tax benefits related to the exercise of certain stock options during the period and the generation of federal tax credits, partially offset by state taxes.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, we had $2.1&#160;billion in cash, cash equivalents, restricted cash equivalents and investments. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, net product revenues and collaboration revenues will enable us to maintain our operations for at least 12 months and thereafter for the foreseeable future. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary cash requirements for operating activities, which we project will increase for the remainder of 2023, as compared to the corresponding period in 2022, are for: employee related expenditures; costs related to our development and discovery programs; royalty payments on our net product sales; and our leased facilities. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act, signed into law on December 22, 2017, modified the tax treatment of research and development expenditures beginning in 2022. Research and development expenditures are no longer currently deductible but instead must be amortized ratably over five years for domestic expenditures or 15 years for foreign expenditures. As a result, we anticipate a higher federal income tax liability in 2023 and expect to pay higher estimated federal taxes by the end of 2023. We will realize a reduction of our federal income tax liability in future years as the capitalized research and development expenditures are amortized for tax purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of operating cash are: cash collections from customers related to net product sales, which we project will increase for the remainder of 2023, as compared to the corresponding period in 2022; cash collections related to royalties earned from our commercial collaboration arrangements with Ipsen, Takeda and others; and cash collections for cost reimbursements under certain of our development programs which we project may decrease for the remainder of 2023, as compared to the corresponding period in 2022. The timing of cash generated from commercial collaborations and cash payments required for in-licensing collaborations relative to upfront license fee payments, research funding commitments, cost reimbursements, exercise of option payments and other contingent payments such as development milestone payments may vary from period to period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have cash requirements related to capital expenditures to support the planned growth of our business including investments in facilities and equipment. We project that we may continue to spend significant amounts of cash to fund the development and commercialization of cabozantinib and the development of other product candidates in our pipeline, including zanzalintinib. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including additional research collaborations, in-licensing arrangements and other strategic transactions that align with our oncology drug development, and regulatory and commercial expertise. In March 2023, our Board of Directors authorized the repurchase of up to $550 million of our common stock before the end of 2023. The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of Exelixis&#8217; common stock and general market conditions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity based on market conditions or strategic considerations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations for $1.5&#160;million as of March&#160;31, 2023 and December&#160;31, 2022. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:57.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.906%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310,021&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,294,403&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working capital</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase in working capital as of March&#160;31, 2023, as compared to December&#160;31, 2022, was primarily due to the favorable impact to our net current assets resulting from our net income, partially offset by purchases of long-term investments, purchases of property and equipment and the reclassification of certain inventory to long-term assets. In the future, our working capital may be impacted by one of these factors or other factors, including common stock repurchases, the amounts and timing of which are variable.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash and cash equivalents primarily consist of cash deposits held at major banks, commercial paper, money market funds and other securities with original maturities 90 days or less. Restricted cash equivalents relate to our letters of credit agreements and are invested primarily in short-term certificates of deposit. Investments primarily consist of debt securities available-for-sale. For additional information regarding our cash, cash equivalents, restricted cash equivalents and investments, see &#8220;Note 4. Cash and Investments,&#8221; in our &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in Part I, Item 1 of this Quarterly Report on Form 10-Q. The increase in cash, cash equivalents, restricted cash equivalents and investments at March 31, 2023 as compared to December 31, 2022, was primarily due to cash inflows generated by our operations from sales of our products and our commercial collaboration arrangements, partially offset by operating cash payments for employee-related expenditures, cash payments to support our development and discovery programs, cash payments for capital expenditures and lease payments. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow activities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:64.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities is derived by adjusting our net income for non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense and changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities for the three months ended March 31, 2023 decreased, as compared to the corresponding prior year period, primarily due to the collection of a $100.0&#160;million milestone payment from Ipsen in the first quarter of 2022 and an increase in cash paid for certain operating expenses, which was partially offset by an increase in cash received on sales of our products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from investing activities primarily relates to the timing of marketable securities investment activity, acquisition of acquired in-process research and development technology and capital expenditures. Our capital expenditures primarily consist of investments to expand our operations and acquire assets that further support our research and development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased, as compared to the corresponding prior year period, primarily due to an increase in cash proceeds from maturities and sales of investments and a decrease in purchases of investments, which were partially offset by an increase in purchases of in-process research and development technology related to certain of our in-licensing collaboration arrangements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in cash flows from financing activities primarily relate to proceeds from employee stock programs and taxes paid related to net share settlement of equity awards.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased, as compared to the corresponding prior year period, primarily due to an increase in proceeds received from the issuance of common stock </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under our equity incentive plans and a decrease in withholding taxes remitted to the government related to net share settlements of equity awards.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes outside of the ordinary course of business in our contractual obligations as of March&#160;31, 2023 from those disclosed in our Fiscal 2022 Form 10-K. For more information about our Leases, and our other contractual obligations, see &#8220;Note 10. Commitments and contingencies&#8221; in &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in Part I, Item I of this Quarterly Report on Form 10-Q and see &#8220;Note 11. Commitments and contingencies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2022 Form 10-K.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liabilities; valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market and/or performance conditions; and the amounts of deferred tax assets and liabilities including the related valuation allowance. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the three months ended March 31, 2023, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Part II, Item 7 of our Fiscal 2022 Form 10-K.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_82"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks as of March&#160;31, 2023 have not changed significantly from those described in Item&#160;7A of our Fiscal 2022 Form 10-K.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_85"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the effectiveness of controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i040dd4c33333480ba1e8d94e558984f1_88"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_91"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MSN I ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The two lawsuits comprising the MSN I litigation, numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we sought, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and on January 19, 2023, the Delaware District Court issued a ruling rejecting MSN&#8217;s invalidity challenge to U.S. Patent No. 7,759,473. The Delaware District Court also ruled that MSN&#8217;s proposed ANDA product does not infringe U.S. Patent No. 8,877,776 and entered judgment that the effective date of any final FDA approval of MSN&#8217;s ANDA shall not be a date earlier than August 14, 2026, the expiration date of U.S. Patent No. 7,759,473. Final judgment was entered on January 30, 2023. This ruling in MSN I does not impact our separate and ongoing MSN II lawsuit.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MSN II ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). On February 23, 2022, we filed a complaint in the Delaware District Court for patent </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringement against MSN asserting infringement of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 are invalid and not infringed. On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 11,298,349 are invalid and not infringed and amended its challenges to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 to allege that these patents are not enforceable based on equitable grounds. The two lawsuits comprising the MSN II litigation, numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032, and equitable relief enjoining MSN from infringing these patents. A bench trial for MSN II has been scheduled for October 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,298,349 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(pharmaceutical composition). On September 2, 2022, we filed</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#8217;s amended ANDA filing with the FDA.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the two lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cipla ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2023, we received a notice letter regarding an ANDA submitted to the FDA by Cipla, including a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,039,757 (methods of treatment), 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition), 11,098,015 (methods of treatment) and 11,298,349 (pharmaceutical composition). Cipla&#8217;s notice letter did not provide a Paragraph IV certification against any additional CABOMETYX patents. On March 16, 2023, we filed a complaint in the Delaware District Court for patent infringement against Cipla asserting infringement of U.S. Patents No. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349 arising from Cipla&#8217;s ANDA filing with the FDA. Cipla&#8217;s ANDA requests approval to market a generic version of CABOMETYX tablets prior to the expiration of the aforementioned patents. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking, among other relief, an order that the effective date of any FDA approval of Cipla&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032, and equitable relief enjoining Cipla from infringing these patents. Cipla&#8217;s response to the complaint is due on May 19, 2023. On May 4, 2023, we filed, under seal, a stipulation and proposed order to stay all proceedings, and the Delaware District Court, in a sealed order, granted the proposed order and administratively closed the case.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_94"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to the information discussed elsewhere and the risks set forth below in this report, you should carefully review and consider the &#8220;Risk Factors&#8221; included under Item 1A to Part I of our Fiscal 2022 Form 10-K. Other than the risks set forth below, there have been no material changes to the risk factors disclosed in our Fiscal 2022 Form 10-K. The risks and uncertainties described therein and below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. Initiatives arising from this scrutiny may result in changes that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continue to be U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders, designed to, among other things: reevaluate, reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying drug prices to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits; implement additional data collection and transparency reporting regarding drug pricing, rebates, fees and other remuneration provided by drug manufacturers; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid and make other changes to the Medicaid Drug Rebate Program that could increase manufacturer rebate liability; eliminate the Anti-Kickback Statute (AKS) discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers. For instance in August 2022, President Biden signed the Inflation Reduction Act, which among other things: allows for the Centers for Medicare &amp; Medicaid Services (CMS) to control the prices of certain single-source drugs and biotherapeutics reimbursed under Medicare Part B and Part D; subjects drug manufacturers to potential civil monetary penalties and a significant excise tax for offering a price that is not equal to or less than the government-imposed &#8220;maximum fair price&#8221; under the law; imposes Medicare rebates for certain Part B and Part D drugs where relevant pricing metrics associated with the products increase faster than inflation; and redesigns the funding and benefit structure of the Medicare Part D program, potentially increasing manufacturer liability while capping annual out-of-pocket drug expenses for Medicare beneficiaries. These provisions have started taking effect incrementally in late 2022 and may be subject to various legal challenges. As of the date of this report, CMS has begun to implement aspects of the Inflation Reduction Act and, in February 2023, CMS released initial guidance addressing the Medicare Part B and Medicare Part D inflation rebate provisions of the Inflation Reduction Act. These provisions generally require manufacturers of Medicare Part B and Part D rebatable drugs to pay inflation rebates to the Medicare program if pricing metrics associated with their products increase faster than the rate of inflation. In addition, in March 2023, CMS released initial guidance setting forth the requirements and procedures for implementing the Medicare Drug Price Negotiation Program for the first round of drug pricing negotiations, which will occur during 2023 and 2024 and result in prices effective in 2026. Among other things, the initial guidance specifies how CMS intends to identify selected drugs, consider factors in negotiation, conduct the negotiation process, and establish the requirements for manufacturers of selected drugs. Overtime, the Inflation Reduction Act could reduce the revenues we are able to collect from sales of our products and increase our government discount and rebate liabilities; however, the degree of impact that the Inflation Reduction Act will ultimately have upon our business remains unclear. In addition, we cannot know the final form or timing of any other legislative, regulatory and/or administrative measures, and some of these pending and enacted legislative proposals or executive rulemaking, if implemented without successful legal challenges, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biotherapeutic product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. In particular, the obligation to provide notices of price increases to purchasers under laws such as California&#8217;s SB-17 may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of these drug pricing transparency regulations, and our associated compliance obligations, may increase our general and administrative costs and/or diminish our revenues. Implementation of these federal and/or state cost-containment measures or other healthcare reforms may limit our ability to generate product revenue or commercialize our products, and in the case of drug pricing transparency regulations, may result in fluctuations in our results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Growth of Our Product Portfolio and Research and Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory and pricing approval processes of the FDA and comparable foreign regulatory authorities are lengthy, uncertain and subject to change, and may not result in regulatory and pricing approvals for additional cabozantinib indications or for our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with the research, development and commercialization of the cabozantinib franchise, zanzalintinib and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable regulatory authorities in other territories. The processes of obtaining regulatory and pricing approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the European Medicines Agency or any application or submission to comparable regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for zanzalintinib or our other product candidates. For example, the FDA launched Project Optimus in 2021 as an initiative to reform the dose optimization and dose selection paradigm in oncology drug development, which was driven by the FDA&#8217;s concerns that the current paradigm for dose selection may result in doses and schedules of molecularly targeted therapies that are inadequately characterized before initiating pivotal trials. Through collaboration with the biopharmaceutical industry, academia and other stakeholders, the FDA&#8217;s goal for this initiative is to advance an oncology dose-finding and dose optimization paradigm that emphasizes dose selections that maximize efficacy as well as safety and tolerability. In support of this initiative, the FDA may request sponsors of oncology product candidates to conduct dose optimization studies pre- or post-approval, and the FDA also continues to develop and finalize guidance documents and implement initiatives regarding the development and clinical research of oncology product candidates. In January 2023, the FDA issued Draft Guidance for Industry, Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases, intended to assist sponsors in identifying the optimal dosages for these products during clinical development and prior to submitting an application for approval for a new indication and usage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, in part due to questions raised by the process underlying the approval of an Alzheimer&#8217;s disease drug,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government authorities and other stakeholders have been scrutinizing the accelerated approval pathway, with some stakeholders advocating for reforms. Even prior to this, the FDA has held Oncologic Drugs Advisory Committee meetings to discuss accelerated approvals for which confirmatory trials have not verified clinical benefit. Such scrutiny, among other factors, has resulted in voluntary withdrawals of certain products and indications approved on an accelerated basis. Spurred by the Alzheimer&#8217;s drug controversy, the HHS Office of Inspector General has also initiated, and partially completed, an assessment of how the FDA implements the accelerated approval pathway. In addition, Section 3210 of the Food and Drug Omnibus Reform Act of 2022 (incorporated in the 2023 Appropriations Act) revised the accelerated approval pathway. Although this legislation did not change the standard for accelerated approval, it, among other things: requires the FDA to specify the conditions for required post-marketing trials; permits the FDA to require such trials to be underway prior to approval, or within a specific period after approval; requires sponsors to provide reports on post-marketing trial progress no later than 180 days after approval and every 180 days thereafter until such trials are completed; makes the failure to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conduct required post-marketing trials with due diligence and the failure to submit the required reports prohibited acts; and details procedures the FDA must follow to withdraw an accelerated approval on an expedited basis. While it is not clear at this time how these legislative and regulatory initiatives will affect our plans to pursue accelerated approval for one or more of our product candidates, these developments may have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications or approves one of our other product candidates, including zanzalintinib, for use, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-marketing studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib, zanzalintinib or our other product candidates in any new indications. Failure to complete post-marketing requirements of the FDA in connection with a specific approval in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib, zanzalintinib or another product candidate in the approved indication. Regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Further, current or any future laws or executive orders governing FDA or foreign regulatory approval processes that may be enacted or executed could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We lack our own manufacturing and distribution capabilities necessary for us to produce materials required for certain preclinical activities and to produce and distribute our products for clinical development or for commercial sale, and our reliance on third parties for these services subjects us to various risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not operate our own current GMP manufacturing or distribution facilities for chemistry, manufacturing and control (CMC) development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we mostly rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we are advancing internal CMC development laboratories to augment our external network, while continuing to expand our external manufacturing and supply chain network through additional third-party contract manufacturers, distributors and suppliers. To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party contract manufacturers may not be able to produce or deliver material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements. Although we have not yet experienced significant production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic or the ongoing Russo-Ukrainian War, our third-party contract manufacturers, distributors and suppliers could experience operational delays due to lack of capacity or resources, facility closures and other hardships as a result of these types of global events, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our preclinical, clinical or commercial products. If our third-party contract manufacturers, distributors and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing, distribution and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude meeting commercial or clinical product supply requirements for us or our partners, which could delay product development and future commercialization efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA) and its foreign equivalents where applicable. If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and its foreign equivalents, as well as any future electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_97"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i040dd4c33333480ba1e8d94e558984f1_100"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_103"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_106"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i040dd4c33333480ba1e8d94e558984f1_109"></div><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.250%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000076/exel20210526ex31restatedce.htm">Restated Certificate of Incorporation of Exelixis,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000076/exel20210526ex31restatedce.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000076/exel20210526ex31restatedce.htm">Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8/5/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000028/exhibit31amendedandrestate.htm">Amended and Restated Bylaws of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/3/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20230331exhibit31110q.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20230331exhibit31210q.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20230331exhibit32110q.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i040dd4c33333480ba1e8d94e558984f1_112"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i040dd4c33333480ba1e8d94e558984f1_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-top:5pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher J. Senner</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief&#160;Financial&#160;Officer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Duly Authorized Officer and Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exel20230331exhibit31110q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2145bc4ac938493c9349368ddc2de88d_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael M. Morrissey, Ph.D., certify that&#58;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.22pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2023 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exel20230331exhibit31210q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib45284b7c9244d7aa9a5cdc1fd81b237_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher J. Senner, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.22pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:31.5pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.65pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:63pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.19pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;9, 2023 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exel20230331exhibit32110q.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie20eeee174c34d62b1c07f037fa1f54f_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.92pt">The Company&#8217;s Quarterly Report on Form 10-Q for the period ended March&#160;31, 2023, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.92pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Witness Whereof, the undersigned have set their hands hereto as of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of May 2023.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>exel-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fbc3dff4-5359-4115-877c-cd80f1d37686,g:9f45ed8a-1512-41a6-b3b1-f3d762602463-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>0000010 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivities" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities">
        <link:definition>0000011 - Disclosure - Collaboration Agreements And Business Development Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestments" roleURI="http://www.exelixis.com/role/CashandInvestments">
        <link:definition>0000012 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>0000014 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.exelixis.com/role/StockholdersEquity">
        <link:definition>0000015 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxes" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes">
        <link:definition>0000016 - Disclosure - Provision For Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>0000017 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exelixis.com/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>0000020 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables">
        <link:definition>0000021 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsTables" roleURI="http://www.exelixis.com/role/CashandInvestmentsTables">
        <link:definition>0000022 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>0000023 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>0000024 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.exelixis.com/role/StockholdersEquityTables">
        <link:definition>0000025 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>0000026 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails">
        <link:definition>0000028 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails">
        <link:definition>0000029 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
        <link:definition>0000030 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedbyProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
        <link:definition>0000031 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
        <link:definition>0000032 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails">
        <link:definition>0000033 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
        <link:definition>0000034 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
        <link:definition>0000035 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
        <link:definition>0000036 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
        <link:definition>0000037 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails">
        <link:definition>0000038 - Disclosure - Collaboration Agreements And Business Development Activities -Royalty Pharma Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails">
        <link:definition>0000039 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000040 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails">
        <link:definition>0000041 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails_1" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1">
        <link:definition>0000041 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails">
        <link:definition>0000042 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
        <link:definition>0000043 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails">
        <link:definition>0000044 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueHierarchyDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails">
        <link:definition>0000045 - Disclosure - Fair Value Measurements (Fair Value Hierarchy) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativesDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails">
        <link:definition>0000046 - Disclosure - Fair Value Measurements - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>0000047 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.exelixis.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000048 - Disclosure - Stockholders&#8217; Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>0000049 - Disclosure - Stockholders&#8217; Equity - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
        <link:definition>0000050 - Disclosure - Stockholders&#8217; Equity - Schedule of Employee Service Share - Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails">
        <link:definition>0000051 - Disclosure - Provision For Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>0000052 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails">
        <link:definition>0000053 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000054 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exel_LossContingencyNumberOfLawsuitsConsolidated" abstract="false" name="LossContingencyNumberOfLawsuitsConsolidated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" abstract="false" name="NumberOfCountriesWithDrugApprovalExcludingTheUS" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_IncreaseDecreaseInResearchAndDevelopmentExpense" abstract="false" name="IncreaseDecreaseInResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" abstract="true" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OtherLongtermAssetsMember" abstract="true" name="OtherLongtermAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CardinalHealthMember" abstract="true" name="CardinalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" abstract="false" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_ProductGrossMember" abstract="true" name="ProductGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AccredoHealthIncorporatedMember" abstract="true" name="AccredoHealthIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AffiliatesofOptumSpecialtyPharmacyMember" abstract="true" name="AffiliatesofOptumSpecialtyPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AllowanceForProductRebatesMember" abstract="true" name="AllowanceForProductRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithIpsenMember" abstract="true" name="CollaborativeArrangementwithIpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" abstract="false" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_CabometyxMember" abstract="true" name="CabometyxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ChargebacksAndDiscountsForPromptPaymentMember" abstract="true" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_RoyalPharmaMember" abstract="true" name="RoyalPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" abstract="true" name="ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" abstract="true" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_IpsenMember" abstract="true" name="IpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OperatingLeaseRightOfUseAssetAndOtherAssets" abstract="false" name="OperatingLeaseRightOfUseAssetAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_NumberofProductsinCommercialMarket" abstract="false" name="NumberofProductsinCommercialMarket" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofCVSHealthCorporationMember" abstract="true" name="AffiliatesofCVSHealthCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductSalesDiscountsAndAllowancesMember" abstract="true" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AmendedAndRestated2017EquityIncentivePlanMember" abstract="true" name="AmendedAndRestated2017EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesOfAmerisourceBergenCorporationMember" abstract="true" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CometriqMember" abstract="true" name="CometriqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_IncreaseDecreaseInAccruedCollaborationLiabilities" abstract="false" name="IncreaseDecreaseInAccruedCollaborationLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_ProductsDerivedFromOtherCompoundsMember" abstract="true" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AccruedClinicalLiabilitiesCurrent" abstract="false" name="AccruedClinicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithTakedaMember" abstract="true" name="CollaborativeArrangementwithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AffiliatesofMcKessonCorporationMember" abstract="true" name="AffiliatesofMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" abstract="true" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_AccruedCollaborationLiabilityCurrent" abstract="false" name="AccruedCollaborationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_PerformanceSharesTargetAchievedOrProbableMember" abstract="true" name="PerformanceSharesTargetAchievedOrProbableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_NumberOfBondSecurities" abstract="false" name="NumberOfBondSecurities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>exel-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fbc3dff4-5359-4115-877c-cd80f1d37686,g:9f45ed8a-1512-41a6-b3b1-f3d762602463-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1a996795-2a87-4265-81d9-197fdca1b0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_81a10b40-cf78-4764-99c6-0965b5619f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1a996795-2a87-4265-81d9-197fdca1b0fc" xlink:to="loc_us-gaap_LiabilitiesCurrent_81a10b40-cf78-4764-99c6-0965b5619f11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1d1f11c3-2bed-4f02-ba52-4bcc0c8c20aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1a996795-2a87-4265-81d9-197fdca1b0fc" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1d1f11c3-2bed-4f02-ba52-4bcc0c8c20aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9322d372-fc65-490e-9d6e-abff3c2a419d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1a996795-2a87-4265-81d9-197fdca1b0fc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9322d372-fc65-490e-9d6e-abff3c2a419d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ad66ee17-d73a-4bf4-a384-95e730d5bf93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1a996795-2a87-4265-81d9-197fdca1b0fc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ad66ee17-d73a-4bf4-a384-95e730d5bf93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c9e59e95-65eb-4ba2-beab-9be0bb2b6d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f4a91eb2-0326-4604-9195-ca16b77ac970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c9e59e95-65eb-4ba2-beab-9be0bb2b6d3e" xlink:to="loc_us-gaap_PreferredStockValue_f4a91eb2-0326-4604-9195-ca16b77ac970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_29e78cf9-e189-405f-9da5-a8cf24c79e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c9e59e95-65eb-4ba2-beab-9be0bb2b6d3e" xlink:to="loc_us-gaap_CommonStockValue_29e78cf9-e189-405f-9da5-a8cf24c79e3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e86cf0d6-8e54-4ddb-b7ec-6aeccce8eb08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c9e59e95-65eb-4ba2-beab-9be0bb2b6d3e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e86cf0d6-8e54-4ddb-b7ec-6aeccce8eb08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ae8f8041-174a-4230-bee5-05835abea13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c9e59e95-65eb-4ba2-beab-9be0bb2b6d3e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ae8f8041-174a-4230-bee5-05835abea13d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7c50a31a-443d-42b8-b4d3-65e6af922ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c9e59e95-65eb-4ba2-beab-9be0bb2b6d3e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7c50a31a-443d-42b8-b4d3-65e6af922ebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d145a136-63d2-40c0-9356-75904284dc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7bf111d6-7ae3-4395-9423-1df53ae18c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d145a136-63d2-40c0-9356-75904284dc6a" xlink:to="loc_us-gaap_Liabilities_7bf111d6-7ae3-4395-9423-1df53ae18c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e22f8e80-b0dc-4a09-8dd4-985dc19f659d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d145a136-63d2-40c0-9356-75904284dc6a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e22f8e80-b0dc-4a09-8dd4-985dc19f659d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f0aa6375-e47a-4255-9f8f-4ee8b6722d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d145a136-63d2-40c0-9356-75904284dc6a" xlink:to="loc_us-gaap_StockholdersEquity_f0aa6375-e47a-4255-9f8f-4ee8b6722d65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fdd05020-99d8-4ee1-8dce-d2af73120e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ab6561eb-b8ef-4703-94bf-6e7155c93524" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fdd05020-99d8-4ee1-8dce-d2af73120e97" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ab6561eb-b8ef-4703-94bf-6e7155c93524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_700490db-1c6c-4662-bf44-1c4ecc142a53" xlink:href="exel-20230331.xsd#exel_OperatingLeaseRightOfUseAssetAndOtherAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fdd05020-99d8-4ee1-8dce-d2af73120e97" xlink:to="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_700490db-1c6c-4662-bf44-1c4ecc142a53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d9a34b18-2ccd-4dc1-93b0-d5ccf1de6344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fdd05020-99d8-4ee1-8dce-d2af73120e97" xlink:to="loc_us-gaap_Goodwill_d9a34b18-2ccd-4dc1-93b0-d5ccf1de6344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_2e1ac338-fe0f-4b9f-aed1-7a4c43e83492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fdd05020-99d8-4ee1-8dce-d2af73120e97" xlink:to="loc_us-gaap_LongTermInvestments_2e1ac338-fe0f-4b9f-aed1-7a4c43e83492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_42820de7-59c8-4383-b981-f4fcc74f7b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fdd05020-99d8-4ee1-8dce-d2af73120e97" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_42820de7-59c8-4383-b981-f4fcc74f7b70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5541a1cb-fa41-41c5-88d5-391a8ac56a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fdd05020-99d8-4ee1-8dce-d2af73120e97" xlink:to="loc_us-gaap_AssetsCurrent_5541a1cb-fa41-41c5-88d5-391a8ac56a66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cbc6123d-991a-472b-b408-977500ee41ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5e6cab06-da25-40a6-9ed4-69d101e94855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cbc6123d-991a-472b-b408-977500ee41ca" xlink:to="loc_us-gaap_AccountsPayableCurrent_5e6cab06-da25-40a6-9ed4-69d101e94855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_d89cbc12-b2e7-47f9-abfa-575220aff062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cbc6123d-991a-472b-b408-977500ee41ca" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_d89cbc12-b2e7-47f9-abfa-575220aff062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_b8e233ac-120b-4ba2-9cc7-a0a6bcd688d7" xlink:href="exel-20230331.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cbc6123d-991a-472b-b408-977500ee41ca" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_b8e233ac-120b-4ba2-9cc7-a0a6bcd688d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_c817baca-790d-4243-9ee5-6b645f50c50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cbc6123d-991a-472b-b408-977500ee41ca" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_c817baca-790d-4243-9ee5-6b645f50c50d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_cf2d7ce8-5b5b-4f72-8776-87186f16ab84" xlink:href="exel-20230331.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cbc6123d-991a-472b-b408-977500ee41ca" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_cf2d7ce8-5b5b-4f72-8776-87186f16ab84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b4a670aa-8761-4875-bb94-012e7a5eb413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cbc6123d-991a-472b-b408-977500ee41ca" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b4a670aa-8761-4875-bb94-012e7a5eb413" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0960511e-4f2c-4c94-92b8-7565525d1e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_7e6b0c52-b859-4ead-9f4e-2516fc491184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0960511e-4f2c-4c94-92b8-7565525d1e10" xlink:to="loc_us-gaap_ShortTermInvestments_7e6b0c52-b859-4ead-9f4e-2516fc491184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_e3a83fd3-82a8-4e72-8311-6a4799b9ad8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0960511e-4f2c-4c94-92b8-7565525d1e10" xlink:to="loc_us-gaap_ReceivablesNetCurrent_e3a83fd3-82a8-4e72-8311-6a4799b9ad8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_be7e8a0b-d22e-4076-ba0f-005a74db2855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0960511e-4f2c-4c94-92b8-7565525d1e10" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_be7e8a0b-d22e-4076-ba0f-005a74db2855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6cfc0a20-9c48-4f6d-af27-faa70f8fbc96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0960511e-4f2c-4c94-92b8-7565525d1e10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6cfc0a20-9c48-4f6d-af27-faa70f8fbc96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c47ebbe3-eb5d-4702-8be0-34169fe26b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0960511e-4f2c-4c94-92b8-7565525d1e10" xlink:to="loc_us-gaap_InventoryNet_c47ebbe3-eb5d-4702-8be0-34169fe26b9c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_254a118c-8f99-44b4-8a9a-d49c452fd529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c0a547ac-3e08-4066-aa51-0c899fd5a985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_254a118c-8f99-44b4-8a9a-d49c452fd529" xlink:to="loc_us-gaap_OperatingIncomeLoss_c0a547ac-3e08-4066-aa51-0c899fd5a985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_f1c823c6-eb27-480f-995a-48e0ff9ff59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_254a118c-8f99-44b4-8a9a-d49c452fd529" xlink:to="loc_us-gaap_InterestIncomeOther_f1c823c6-eb27-480f-995a-48e0ff9ff59c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_89e4de33-287c-4843-b626-42b7494a0db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_254a118c-8f99-44b4-8a9a-d49c452fd529" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_89e4de33-287c-4843-b626-42b7494a0db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_94f2f9f8-8058-4421-8d0e-a9091d6b9b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4a4dab0e-a057-4951-b212-5d304fa4ca8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_94f2f9f8-8058-4421-8d0e-a9091d6b9b83" xlink:to="loc_us-gaap_CostsAndExpenses_4a4dab0e-a057-4951-b212-5d304fa4ca8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_57576337-1611-4849-8c11-b3d7cd24251d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_94f2f9f8-8058-4421-8d0e-a9091d6b9b83" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_57576337-1611-4849-8c11-b3d7cd24251d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0e6ccf6a-1452-46db-b2b2-46707d9738a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d545e5a7-7082-4ac7-9ad7-99cf7bfaaa35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0e6ccf6a-1452-46db-b2b2-46707d9738a0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d545e5a7-7082-4ac7-9ad7-99cf7bfaaa35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0b056c37-dd61-488f-a17c-8395c262e9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0e6ccf6a-1452-46db-b2b2-46707d9738a0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0b056c37-dd61-488f-a17c-8395c262e9a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e71ce455-d6a3-4e51-90d8-7473c787e2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0e6ccf6a-1452-46db-b2b2-46707d9738a0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e71ce455-d6a3-4e51-90d8-7473c787e2a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1829454c-6259-464a-a7c5-ec67d21d3643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_56eb2aa6-c469-4d81-b3f2-2b2958a204c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1829454c-6259-464a-a7c5-ec67d21d3643" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_56eb2aa6-c469-4d81-b3f2-2b2958a204c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b0f703d4-be42-48b6-bc6d-e06787e82bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1829454c-6259-464a-a7c5-ec67d21d3643" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b0f703d4-be42-48b6-bc6d-e06787e82bf4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_74352f96-c190-4a02-a99c-ceea72e14921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ea15b75c-c77c-43fd-8248-f3f06828c66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_74352f96-c190-4a02-a99c-ceea72e14921" xlink:to="loc_us-gaap_NetIncomeLoss_ea15b75c-c77c-43fd-8248-f3f06828c66d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9c170373-bafd-4f02-9504-30326fbdc328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_74352f96-c190-4a02-a99c-ceea72e14921" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9c170373-bafd-4f02-9504-30326fbdc328" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e5f81ea2-49c7-4f1b-9320-01cccdf223ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_us-gaap_NetIncomeLoss_e5f81ea2-49c7-4f1b-9320-01cccdf223ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f0bf2f99-d1aa-42e7-befc-2144c8f439a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f0bf2f99-d1aa-42e7-befc-2144c8f439a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1fd1e46b-7ed2-42a0-a474-437af7137468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_us-gaap_ShareBasedCompensation_1fd1e46b-7ed2-42a0-a474-437af7137468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_500fc07e-927e-44df-93f9-14a145005822" xlink:href="exel-20230331.xsd#exel_NoncashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_exel_NoncashLeaseExpense_500fc07e-927e-44df-93f9-14a145005822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_69bd8c0f-0174-4c4e-93a6-e80d640b1fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_69bd8c0f-0174-4c4e-93a6-e80d640b1fd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b2148907-430a-4b58-8aaa-095dd3593bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b2148907-430a-4b58-8aaa-095dd3593bf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b87bae50-93a7-4bd4-9eb0-d19c4968595c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b87bae50-93a7-4bd4-9eb0-d19c4968595c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2da80017-3775-4f37-9894-c340e7508c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2da80017-3775-4f37-9894-c340e7508c41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_19149159-5dd2-42d4-b7da-b63fac076bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_19149159-5dd2-42d4-b7da-b63fac076bb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8147633e-6d1d-4fe1-a9b1-699e010eeeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8147633e-6d1d-4fe1-a9b1-699e010eeeb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b117497a-88d1-4507-81cc-a31a176f77bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b117497a-88d1-4507-81cc-a31a176f77bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_9f28a089-bbde-49b4-a73a-591b0169898a" xlink:href="exel-20230331.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_9f28a089-bbde-49b4-a73a-591b0169898a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_d055fefa-02cf-4fa2-9696-c24949fae310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d58507e4-893d-4a90-a279-5ed6228f82cb" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_d055fefa-02cf-4fa2-9696-c24949fae310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99964d70-76d2-4b22-820f-12161923d877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e57114e-b774-4e03-a47e-1e0143f16cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99964d70-76d2-4b22-820f-12161923d877" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e57114e-b774-4e03-a47e-1e0143f16cd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c500976f-b653-448a-94fc-1a90abc8b0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99964d70-76d2-4b22-820f-12161923d877" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c500976f-b653-448a-94fc-1a90abc8b0cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a1ab910-a1ce-4e4b-a0b5-b260d001c9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99964d70-76d2-4b22-820f-12161923d877" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a1ab910-a1ce-4e4b-a0b5-b260d001c9dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b57772e3-f8de-40d7-8fec-7ed977b0e566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e3886c2f-be52-4bda-8bfb-dff4dd4ff7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b57772e3-f8de-40d7-8fec-7ed977b0e566" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e3886c2f-be52-4bda-8bfb-dff4dd4ff7bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d9e26032-84a0-4c1a-b973-17c7ac96569e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b57772e3-f8de-40d7-8fec-7ed977b0e566" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d9e26032-84a0-4c1a-b973-17c7ac96569e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_116880bc-0c21-475c-8814-c0f411e77716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8b6a9335-24ee-47a5-8605-6d2cab7831bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_116880bc-0c21-475c-8814-c0f411e77716" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8b6a9335-24ee-47a5-8605-6d2cab7831bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5bc8ee9c-8609-4c53-af45-232a4787819f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_116880bc-0c21-475c-8814-c0f411e77716" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5bc8ee9c-8609-4c53-af45-232a4787819f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b1b27040-96c3-4572-bb3a-c43783caa11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_116880bc-0c21-475c-8814-c0f411e77716" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b1b27040-96c3-4572-bb3a-c43783caa11e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_a3f235e4-6c29-4dbe-819a-a84d06f0a472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_116880bc-0c21-475c-8814-c0f411e77716" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_a3f235e4-6c29-4dbe-819a-a84d06f0a472" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a45d6b26-5b6d-403a-99dd-bb56092ffe74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_118a8118-2f1c-473a-9745-4e93b312cb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_a45d6b26-5b6d-403a-99dd-bb56092ffe74" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_118a8118-2f1c-473a-9745-4e93b312cb84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5903dc18-a559-4629-86e3-4506e6d14d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_a45d6b26-5b6d-403a-99dd-bb56092ffe74" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5903dc18-a559-4629-86e3-4506e6d14d08" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2132f63b-908d-4b3e-9add-eda7f55bf658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d84b0462-2873-4f6d-afc2-9328504a1f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2132f63b-908d-4b3e-9add-eda7f55bf658" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d84b0462-2873-4f6d-afc2-9328504a1f4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49b5fcbc-e695-470d-b4c3-5495fd74e22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2132f63b-908d-4b3e-9add-eda7f55bf658" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49b5fcbc-e695-470d-b4c3-5495fd74e22f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_e56a0ed7-7ac4-4582-aab9-f8135b150bde" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_4f19479e-dfb1-4651-9e05-948e7115a0f5" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_e56a0ed7-7ac4-4582-aab9-f8135b150bde" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_4f19479e-dfb1-4651-9e05-948e7115a0f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_53ce2a63-1092-430f-b4bc-fa9ee291614b" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_e56a0ed7-7ac4-4582-aab9-f8135b150bde" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_53ce2a63-1092-430f-b4bc-fa9ee291614b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f714dc08-1d71-4549-9214-a112ed573df2" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_e56a0ed7-7ac4-4582-aab9-f8135b150bde" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f714dc08-1d71-4549-9214-a112ed573df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ebf0387d-a070-4aec-90ce-a06040fff620" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_0a0d91c5-6e04-4b21-a785-a9ac3da662c9" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ebf0387d-a070-4aec-90ce-a06040fff620" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_0a0d91c5-6e04-4b21-a785-a9ac3da662c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_27a0481c-17d5-4ac1-9330-0e1d34c32e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ebf0387d-a070-4aec-90ce-a06040fff620" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_27a0481c-17d5-4ac1-9330-0e1d34c32e3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef17b100-aca0-4c6b-9b40-11399af9c408" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_714a0f04-01bf-47f3-a22d-f24c184228fc" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef17b100-aca0-4c6b-9b40-11399af9c408" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_714a0f04-01bf-47f3-a22d-f24c184228fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4d09ace9-e4e9-423e-b46f-9d0bf0bacd29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ef17b100-aca0-4c6b-9b40-11399af9c408" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4d09ace9-e4e9-423e-b46f-9d0bf0bacd29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_8b9069be-73e9-4962-afac-c95125c532df" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_6527b8a6-8558-4a61-bd37-cf8b10fb6b2f" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_8b9069be-73e9-4962-afac-c95125c532df" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_6527b8a6-8558-4a61-bd37-cf8b10fb6b2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_ae233fad-a9be-42d4-9d0e-0521f03e01a2" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_8b9069be-73e9-4962-afac-c95125c532df" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_ae233fad-a9be-42d4-9d0e-0521f03e01a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_7e30c40d-f50f-4b33-bb84-c6d8d34c8b71" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_8b9069be-73e9-4962-afac-c95125c532df" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_7e30c40d-f50f-4b33-bb84-c6d8d34c8b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9f52eec6-8cae-4500-b621-47839346c6f1" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0272061e-846b-4c18-96d5-34bc2f88b772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9f52eec6-8cae-4500-b621-47839346c6f1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0272061e-846b-4c18-96d5-34bc2f88b772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_683bcafb-b462-4ae7-8459-46bd4a4418c6" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_9f52eec6-8cae-4500-b621-47839346c6f1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_683bcafb-b462-4ae7-8459-46bd4a4418c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_941413b8-fd0f-4d5a-8c2c-e94c39e187af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bcb2bb7e-8a14-43d5-9601-cc0ce53f0c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_941413b8-fd0f-4d5a-8c2c-e94c39e187af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bcb2bb7e-8a14-43d5-9601-cc0ce53f0c76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e484b02-6575-4dd4-b3a1-25d84d9df4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_941413b8-fd0f-4d5a-8c2c-e94c39e187af" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6e484b02-6575-4dd4-b3a1-25d84d9df4b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fb43b56-c159-42cb-98d9-ec60467c4037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_941413b8-fd0f-4d5a-8c2c-e94c39e187af" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2fb43b56-c159-42cb-98d9-ec60467c4037" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_8cfa0c4a-5df1-49ec-92c5-33f09152edbf" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_8d218975-ed51-4930-81d5-c4408206d941" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_8cfa0c4a-5df1-49ec-92c5-33f09152edbf" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_8d218975-ed51-4930-81d5-c4408206d941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b905b90d-ccd1-40ae-b6e7-cc782072bf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_8cfa0c4a-5df1-49ec-92c5-33f09152edbf" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b905b90d-ccd1-40ae-b6e7-cc782072bf13" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_546bf037-f65c-494c-b18c-01d8460c01d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_cddc29c4-b017-40dc-93e3-d9fc933f388f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_546bf037-f65c-494c-b18c-01d8460c01d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_cddc29c4-b017-40dc-93e3-d9fc933f388f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7da94ab5-3cd5-48d5-aa4e-03d90c6e37c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_546bf037-f65c-494c-b18c-01d8460c01d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7da94ab5-3cd5-48d5-aa4e-03d90c6e37c3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#FairValueMeasurementsFairValueHierarchyDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9768a6df-971c-4e1e-94d4-5a7611249785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a7db0290-80ce-423d-a8ee-d71c6f0c24f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9768a6df-971c-4e1e-94d4-5a7611249785" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a7db0290-80ce-423d-a8ee-d71c6f0c24f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3248ca45-6f0c-4502-9eff-a2d8a725ae5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_9768a6df-971c-4e1e-94d4-5a7611249785" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3248ca45-6f0c-4502-9eff-a2d8a725ae5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_c0886510-1aa5-4452-8d6f-05f420b55d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ebbced70-0555-4deb-93cc-7d6c1253c94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c0886510-1aa5-4452-8d6f-05f420b55d1d" xlink:to="loc_us-gaap_InventoryRawMaterials_ebbced70-0555-4deb-93cc-7d6c1253c94c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_8bc5329b-c55b-4221-bb5d-ab37acbc5552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c0886510-1aa5-4452-8d6f-05f420b55d1d" xlink:to="loc_us-gaap_InventoryWorkInProcess_8bc5329b-c55b-4221-bb5d-ab37acbc5552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_6f698c12-b1c3-4d7e-978f-a54bb53f54de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_c0886510-1aa5-4452-8d6f-05f420b55d1d" xlink:to="loc_us-gaap_InventoryFinishedGoods_6f698c12-b1c3-4d7e-978f-a54bb53f54de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2287766c-ea51-4f9b-8741-955e9eef9b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1f79cdc6-8be6-414c-ac9e-776c38b12626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2287766c-ea51-4f9b-8741-955e9eef9b80" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1f79cdc6-8be6-414c-ac9e-776c38b12626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_31a7c5c6-5871-43e7-92ac-560fd42f90cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2287766c-ea51-4f9b-8741-955e9eef9b80" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_31a7c5c6-5871-43e7-92ac-560fd42f90cf" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>exel-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fbc3dff4-5359-4115-877c-cd80f1d37686,g:9f45ed8a-1512-41a6-b3b1-f3d762602463-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended" id="i95885af0347b446c9a9c4349c5b963ef_CondensedConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8d82e19e-dbc7-4080-9c61-d8a2ceacdbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_RevenuesAbstract_8d82e19e-dbc7-4080-9c61-d8a2ceacdbf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8a3fb5e5-18dd-4d9a-9ecb-db9a2770b743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8d82e19e-dbc7-4080-9c61-d8a2ceacdbf1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8a3fb5e5-18dd-4d9a-9ecb-db9a2770b743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_90794643-5446-40a1-a48b-57cbeb1e6fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_90794643-5446-40a1-a48b-57cbeb1e6fba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_faec3808-86c5-4e5d-a400-adb87ef006c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_faec3808-86c5-4e5d-a400-adb87ef006c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0a4fed19-59b5-497c-a7f3-102acba2acbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0a4fed19-59b5-497c-a7f3-102acba2acbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_63ac42cd-f13b-424a-8925-7ece1fee941e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:to="loc_us-gaap_CostsAndExpenses_63ac42cd-f13b-424a-8925-7ece1fee941e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ce078e74-237a-4004-a025-14e3294c34ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_OperatingIncomeLoss_ce078e74-237a-4004-a025-14e3294c34ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_9d281eb0-d6dc-45bd-aac5-b9f18edc6224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_InterestIncomeOther_9d281eb0-d6dc-45bd-aac5-b9f18edc6224" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d2a235ad-432e-4ca3-a018-cb71c2f7b8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d2a235ad-432e-4ca3-a018-cb71c2f7b8fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_f3067cd3-a77b-401e-bc13-38ca9a9d8e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_f3067cd3-a77b-401e-bc13-38ca9a9d8e4f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b20137b8-dfd4-4aa4-8b49-5562eebffd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b20137b8-dfd4-4aa4-8b49-5562eebffd1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ad5b70bb-c386-44d3-b66d-ad39b62951dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_NetIncomeLoss_ad5b70bb-c386-44d3-b66d-ad39b62951dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_96400bae-e30a-4908-a7ff-8308739ad280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_EarningsPerShareAbstract_96400bae-e30a-4908-a7ff-8308739ad280" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d5337745-2e3c-4373-8d87-560df3cb108c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_96400bae-e30a-4908-a7ff-8308739ad280" xlink:to="loc_us-gaap_EarningsPerShareBasic_d5337745-2e3c-4373-8d87-560df3cb108c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4da7f2a1-c40b-492e-906e-ee7d1451fd55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_96400bae-e30a-4908-a7ff-8308739ad280" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4da7f2a1-c40b-492e-906e-ee7d1451fd55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4f0abc59-e8b2-4b0a-b782-1506a38cadd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4f0abc59-e8b2-4b0a-b782-1506a38cadd0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91f86d69-abcd-49f9-86c0-85d38d306c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4f0abc59-e8b2-4b0a-b782-1506a38cadd0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91f86d69-abcd-49f9-86c0-85d38d306c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0465d8dd-caa7-4b50-bbdd-5d308373c88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4f0abc59-e8b2-4b0a-b782-1506a38cadd0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0465d8dd-caa7-4b50-bbdd-5d308373c88c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fed2ba47-c2eb-485d-ab1c-bf988e335245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_StatementTable_fed2ba47-c2eb-485d-ab1c-bf988e335245" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_66bea905-f0de-47f6-813f-99ff0b03aef1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fed2ba47-c2eb-485d-ab1c-bf988e335245" xlink:to="loc_srt_ProductOrServiceAxis_66bea905-f0de-47f6-813f-99ff0b03aef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_66bea905-f0de-47f6-813f-99ff0b03aef1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_66bea905-f0de-47f6-813f-99ff0b03aef1" xlink:to="loc_srt_ProductsAndServicesDomain_66bea905-f0de-47f6-813f-99ff0b03aef1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_59b7da54-9a66-492a-a3f9-935fae8e380f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_66bea905-f0de-47f6-813f-99ff0b03aef1" xlink:to="loc_srt_ProductsAndServicesDomain_59b7da54-9a66-492a-a3f9-935fae8e380f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_22254f41-710e-47de-b3e1-f0da255038ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_59b7da54-9a66-492a-a3f9-935fae8e380f" xlink:to="loc_us-gaap_ProductMember_22254f41-710e-47de-b3e1-f0da255038ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_20df8f19-389a-435b-81c5-c907542a8699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_59b7da54-9a66-492a-a3f9-935fae8e380f" xlink:to="loc_us-gaap_LicenseMember_20df8f19-389a-435b-81c5-c907542a8699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_29227f35-419a-4056-ae40-3aaf35890e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_59b7da54-9a66-492a-a3f9-935fae8e380f" xlink:to="loc_us-gaap_ServiceMember_29227f35-419a-4056-ae40-3aaf35890e1c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="if9e565c0766545fbbcf88512a374ff5d_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6797a96c-4bac-4051-a5dd-e5bcb39f37eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6797a96c-4bac-4051-a5dd-e5bcb39f37eb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ff67625a-4c22-4153-b1b6-2a67220557c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ff67625a-4c22-4153-b1b6-2a67220557c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e4d115f6-8918-46ef-a1d3-d5297d6b78a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_StockholdersEquity_e4d115f6-8918-46ef-a1d3-d5297d6b78a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ec4fdc3c-6956-4ad1-a971-f660a2a09ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_NetIncomeLoss_ec4fdc3c-6956-4ad1-a971-f660a2a09ca8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a8cdc8df-8ce6-43aa-a73f-0567b41aca2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a8cdc8df-8ce6-43aa-a73f-0567b41aca2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_439754a1-0b55-4cfa-bdcd-c96558fd575d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_439754a1-0b55-4cfa-bdcd-c96558fd575d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c8bb68e1-b06a-4fa8-a940-e9dba0c66e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c8bb68e1-b06a-4fa8-a940-e9dba0c66e8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_9776c346-2cd4-444b-80ae-92bf97f35b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_9776c346-2cd4-444b-80ae-92bf97f35b26" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_91c60f22-717e-4361-a744-04ebbc300d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_91c60f22-717e-4361-a744-04ebbc300d4e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9c60dafe-5d6e-4a87-9b3c-80e28972aa34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c49dedc7-43af-4e08-9fbe-7add6235e47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4eb3c060-00b8-4ba2-811c-3a429a41b71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6797a96c-4bac-4051-a5dd-e5bcb39f37eb" xlink:to="loc_us-gaap_StatementTable_4eb3c060-00b8-4ba2-811c-3a429a41b71f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1f649eb1-1ccb-495c-8669-70ba274b2bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4eb3c060-00b8-4ba2-811c-3a429a41b71f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1f649eb1-1ccb-495c-8669-70ba274b2bcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1f649eb1-1ccb-495c-8669-70ba274b2bcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f649eb1-1ccb-495c-8669-70ba274b2bcd" xlink:to="loc_us-gaap_EquityComponentDomain_1f649eb1-1ccb-495c-8669-70ba274b2bcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f649eb1-1ccb-495c-8669-70ba274b2bcd" xlink:to="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_211676ba-6198-47fe-8d1c-b097c3b5be3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:to="loc_us-gaap_CommonStockMember_211676ba-6198-47fe-8d1c-b097c3b5be3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fd007812-d43c-4d84-9f8a-24c043a7ddef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fd007812-d43c-4d84-9f8a-24c043a7ddef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ad0334d2-cd1c-429e-8be1-852ddde962b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ad0334d2-cd1c-429e-8be1-852ddde962b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_90820aea-fcd6-4900-8344-8485032833cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:to="loc_us-gaap_RetainedEarningsMember_90820aea-fcd6-4900-8344-8485032833cd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="ibaf1f9814f6446e78fdc455f42757001_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_c789b9aa-2fd3-4575-a043-8cb245a9072c" xlink:href="exel-20230331.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_78bd9c82-6bf0-432c-9ffc-f145e19030fe" xlink:href="exel-20230331.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_c789b9aa-2fd3-4575-a043-8cb245a9072c" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_78bd9c82-6bf0-432c-9ffc-f145e19030fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_eb924d76-8b0b-4636-8420-dca4a9cdb8d6" xlink:href="exel-20230331.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_c789b9aa-2fd3-4575-a043-8cb245a9072c" xlink:to="loc_exel_NumberofProductsinCommercialMarket_eb924d76-8b0b-4636-8420-dca4a9cdb8d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_fb1b99f9-505a-4ee4-ad70-9c3116414980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_c789b9aa-2fd3-4575-a043-8cb245a9072c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_fb1b99f9-505a-4ee4-ad70-9c3116414980" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_327e59cc-af19-4df4-87ee-fbc3286f6ae5" xlink:href="exel-20230331.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_c789b9aa-2fd3-4575-a043-8cb245a9072c" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_327e59cc-af19-4df4-87ee-fbc3286f6ae5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3eab9be2-2dcb-494f-8dca-db36b93f5539" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_327e59cc-af19-4df4-87ee-fbc3286f6ae5" xlink:to="loc_srt_ProductOrServiceAxis_3eab9be2-2dcb-494f-8dca-db36b93f5539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3eab9be2-2dcb-494f-8dca-db36b93f5539_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3eab9be2-2dcb-494f-8dca-db36b93f5539" xlink:to="loc_srt_ProductsAndServicesDomain_3eab9be2-2dcb-494f-8dca-db36b93f5539_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b74591b8-de41-4b0b-94c9-7001a47e0a65" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3eab9be2-2dcb-494f-8dca-db36b93f5539" xlink:to="loc_srt_ProductsAndServicesDomain_b74591b8-de41-4b0b-94c9-7001a47e0a65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_196a738d-534f-48ab-bd27-102d63e9b98a" xlink:href="exel-20230331.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b74591b8-de41-4b0b-94c9-7001a47e0a65" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_196a738d-534f-48ab-bd27-102d63e9b98a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended" id="i7b17966528b347ab9aa371a3fac54b73_RevenuesRevenuesbyDisaggregatedCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bff03881-655e-4b9d-b884-2ce06afafdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fda55100-aeea-4e0d-8608-ac525b473fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bff03881-655e-4b9d-b884-2ce06afafdf6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fda55100-aeea-4e0d-8608-ac525b473fd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d3017c6a-ff2e-4703-a5df-299865a45ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bff03881-655e-4b9d-b884-2ce06afafdf6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d3017c6a-ff2e-4703-a5df-299865a45ee6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5fef914b-c84e-426e-ac33-e13f3ac2523f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d3017c6a-ff2e-4703-a5df-299865a45ee6" xlink:to="loc_srt_ProductOrServiceAxis_5fef914b-c84e-426e-ac33-e13f3ac2523f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5fef914b-c84e-426e-ac33-e13f3ac2523f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5fef914b-c84e-426e-ac33-e13f3ac2523f" xlink:to="loc_srt_ProductsAndServicesDomain_5fef914b-c84e-426e-ac33-e13f3ac2523f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5fef914b-c84e-426e-ac33-e13f3ac2523f" xlink:to="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_8fb5c03f-a136-402d-98c4-e8ebb1bbd471" xlink:href="exel-20230331.xsd#exel_ProductGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_exel_ProductGrossMember_8fb5c03f-a136-402d-98c4-e8ebb1bbd471" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_f811b9fe-8800-4c22-9b9d-954a67abafb1" xlink:href="exel-20230331.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_f811b9fe-8800-4c22-9b9d-954a67abafb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d38a1eee-06ae-4ac1-a05f-019bc6edfa76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_us-gaap_ProductMember_d38a1eee-06ae-4ac1-a05f-019bc6edfa76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_67b4ef8f-41fd-4451-b49c-52c1e30df945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_us-gaap_LicenseMember_67b4ef8f-41fd-4451-b49c-52c1e30df945" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ac2a659f-721c-4e24-8db8-0fd26a4b6f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_us-gaap_ServiceMember_ac2a659f-721c-4e24-8db8-0fd26a4b6f21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_bfaa419e-1d25-4421-9e81-15a292422516" xlink:href="exel-20230331.xsd#exel_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_exel_CollaborationMember_bfaa419e-1d25-4421-9e81-15a292422516" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="extended" id="i577c06bdef96439c97d7ebc3a0e16abb_RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_d0cd897f-3551-479b-891e-6e6c5350a4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9af67907-6b19-463d-810b-3f8d1976180f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d0cd897f-3551-479b-891e-6e6c5350a4e8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9af67907-6b19-463d-810b-3f8d1976180f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_09fc385c-e72c-4547-88df-9b2cfe69b6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d0cd897f-3551-479b-891e-6e6c5350a4e8" xlink:to="loc_us-gaap_ConcentrationRiskTable_09fc385c-e72c-4547-88df-9b2cfe69b6e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ad245fea-5a79-4213-85e5-7e9cab0da5db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_09fc385c-e72c-4547-88df-9b2cfe69b6e2" xlink:to="loc_srt_MajorCustomersAxis_ad245fea-5a79-4213-85e5-7e9cab0da5db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ad245fea-5a79-4213-85e5-7e9cab0da5db_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ad245fea-5a79-4213-85e5-7e9cab0da5db" xlink:to="loc_srt_NameOfMajorCustomerDomain_ad245fea-5a79-4213-85e5-7e9cab0da5db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ad245fea-5a79-4213-85e5-7e9cab0da5db" xlink:to="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_3363178d-babb-4afe-a4f7-8fbcdf75fdbb" xlink:href="exel-20230331.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_3363178d-babb-4afe-a4f7-8fbcdf75fdbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_c7f447b5-747a-42bf-955c-8fd80981a91a" xlink:href="exel-20230331.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_c7f447b5-747a-42bf-955c-8fd80981a91a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_67dee3a0-9c9b-494b-b969-5534adc086e9" xlink:href="exel-20230331.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_67dee3a0-9c9b-494b-b969-5534adc086e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_14bf8ad1-3341-44c5-ace4-a4c850d3fb58" xlink:href="exel-20230331.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_AccredoHealthIncorporatedMember_14bf8ad1-3341-44c5-ace4-a4c850d3fb58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_6bb71ec7-b5a7-49c9-9588-6f7ce2db6cd9" xlink:href="exel-20230331.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_6bb71ec7-b5a7-49c9-9588-6f7ce2db6cd9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_98d361f2-4a9f-4a54-badf-829fc0a9817f" xlink:href="exel-20230331.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_IpsenMember_98d361f2-4a9f-4a54-badf-829fc0a9817f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CardinalHealthMember_fe4b08ce-36a2-4478-ac06-c95f5a1d2b0c" xlink:href="exel-20230331.xsd#exel_CardinalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_CardinalHealthMember_fe4b08ce-36a2-4478-ac06-c95f5a1d2b0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abb0a3b2-c1e6-4434-aea0-0de9eeb94be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_09fc385c-e72c-4547-88df-9b2cfe69b6e2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abb0a3b2-c1e6-4434-aea0-0de9eeb94be3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_abb0a3b2-c1e6-4434-aea0-0de9eeb94be3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abb0a3b2-c1e6-4434-aea0-0de9eeb94be3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_abb0a3b2-c1e6-4434-aea0-0de9eeb94be3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9354e4fb-8113-4b7e-9738-d1fc6621d672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abb0a3b2-c1e6-4434-aea0-0de9eeb94be3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9354e4fb-8113-4b7e-9738-d1fc6621d672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_115c069a-6b5c-43f5-b3bb-a065c2216c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9354e4fb-8113-4b7e-9738-d1fc6621d672" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_115c069a-6b5c-43f5-b3bb-a065c2216c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2bbf9b65-6782-4da1-b13d-77b459c2d9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9354e4fb-8113-4b7e-9738-d1fc6621d672" xlink:to="loc_us-gaap_AccountsReceivableMember_2bbf9b65-6782-4da1-b13d-77b459c2d9f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_993c7a23-e49d-4ef5-8df7-d53ddd35529e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_09fc385c-e72c-4547-88df-9b2cfe69b6e2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_993c7a23-e49d-4ef5-8df7-d53ddd35529e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_993c7a23-e49d-4ef5-8df7-d53ddd35529e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_993c7a23-e49d-4ef5-8df7-d53ddd35529e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_993c7a23-e49d-4ef5-8df7-d53ddd35529e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_59102456-2d0a-485f-916b-e42d26b70224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_993c7a23-e49d-4ef5-8df7-d53ddd35529e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_59102456-2d0a-485f-916b-e42d26b70224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_370e0474-bace-483b-9679-6ce6d33e9a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_59102456-2d0a-485f-916b-e42d26b70224" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_370e0474-bace-483b-9679-6ce6d33e9a59" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended" id="i453b3f10ed17407285191b86528c05e8_RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8dbca970-7923-48af-8c14-791cfdd2b35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e2ca8f0-47b2-4a45-a6e4-abe0715dbdea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8dbca970-7923-48af-8c14-791cfdd2b35e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e2ca8f0-47b2-4a45-a6e4-abe0715dbdea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_903831ef-81de-4a14-b3bf-d5d03d5e1e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8dbca970-7923-48af-8c14-791cfdd2b35e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_903831ef-81de-4a14-b3bf-d5d03d5e1e74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_389ba217-2f04-4e2b-98af-2d4402c5821f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_903831ef-81de-4a14-b3bf-d5d03d5e1e74" xlink:to="loc_srt_StatementGeographicalAxis_389ba217-2f04-4e2b-98af-2d4402c5821f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_389ba217-2f04-4e2b-98af-2d4402c5821f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_389ba217-2f04-4e2b-98af-2d4402c5821f" xlink:to="loc_srt_SegmentGeographicalDomain_389ba217-2f04-4e2b-98af-2d4402c5821f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0474d0f4-5339-4408-a0b9-456f1d6ac175" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_389ba217-2f04-4e2b-98af-2d4402c5821f" xlink:to="loc_srt_SegmentGeographicalDomain_0474d0f4-5339-4408-a0b9-456f1d6ac175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_bc3519f9-df34-4e2c-8e0a-1866abc1bd31" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0474d0f4-5339-4408-a0b9-456f1d6ac175" xlink:to="loc_country_US_bc3519f9-df34-4e2c-8e0a-1866abc1bd31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_50ea287c-6a7c-4181-aace-b18cdc159775" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0474d0f4-5339-4408-a0b9-456f1d6ac175" xlink:to="loc_srt_EuropeMember_50ea287c-6a7c-4181-aace-b18cdc159775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_3207b8d6-8639-4cfc-9351-bb28caf54dea" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0474d0f4-5339-4408-a0b9-456f1d6ac175" xlink:to="loc_country_JP_3207b8d6-8639-4cfc-9351-bb28caf54dea" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended" id="iaff409eb29ad4ec29a09c98c733b4d0d_RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0821a24b-3774-4914-964e-88e21ff4e69c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7c21bba-1e65-426c-8014-03c26b649f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0821a24b-3774-4914-964e-88e21ff4e69c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7c21bba-1e65-426c-8014-03c26b649f7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_566f7dc5-8f0b-42f3-8414-354764e7f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0821a24b-3774-4914-964e-88e21ff4e69c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_566f7dc5-8f0b-42f3-8414-354764e7f8bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ff8b30d4-4b70-41ed-b61b-1d8278e465a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_566f7dc5-8f0b-42f3-8414-354764e7f8bf" xlink:to="loc_srt_ProductOrServiceAxis_ff8b30d4-4b70-41ed-b61b-1d8278e465a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ff8b30d4-4b70-41ed-b61b-1d8278e465a9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ff8b30d4-4b70-41ed-b61b-1d8278e465a9" xlink:to="loc_srt_ProductsAndServicesDomain_ff8b30d4-4b70-41ed-b61b-1d8278e465a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c59aa42-0c5d-4603-8b6a-4ee3067d05aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ff8b30d4-4b70-41ed-b61b-1d8278e465a9" xlink:to="loc_srt_ProductsAndServicesDomain_5c59aa42-0c5d-4603-8b6a-4ee3067d05aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_25be1425-990f-464b-ad8b-074f98486c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c59aa42-0c5d-4603-8b6a-4ee3067d05aa" xlink:to="loc_us-gaap_ProductMember_25be1425-990f-464b-ad8b-074f98486c52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_68f73b45-186c-431c-bc62-da51141a8f69" xlink:href="exel-20230331.xsd#exel_CabometyxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_25be1425-990f-464b-ad8b-074f98486c52" xlink:to="loc_exel_CabometyxMember_68f73b45-186c-431c-bc62-da51141a8f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_05375eff-ad9f-48f3-a32d-7fb382f17185" xlink:href="exel-20230331.xsd#exel_CometriqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_25be1425-990f-464b-ad8b-074f98486c52" xlink:to="loc_exel_CometriqMember_05375eff-ad9f-48f3-a32d-7fb382f17185" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended" id="i42b5ba20743c43f88e5bbbd0ef9f3504_RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4cc575a9-f462-458f-8129-fd275fe5e550" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c09863e9-6d83-4113-93b0-4352c36c5f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4cc575a9-f462-458f-8129-fd275fe5e550" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c09863e9-6d83-4113-93b0-4352c36c5f52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0f60e3fe-3329-4bd7-8dd6-795ce2e7f3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c09863e9-6d83-4113-93b0-4352c36c5f52" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_0f60e3fe-3329-4bd7-8dd6-795ce2e7f3eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_f126757a-41c6-4782-ad76-c0b9c8f0e310" xlink:href="exel-20230331.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c09863e9-6d83-4113-93b0-4352c36c5f52" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_f126757a-41c6-4782-ad76-c0b9c8f0e310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_983c130e-6866-4d8e-bde1-201eb6ff7e12" xlink:href="exel-20230331.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_f126757a-41c6-4782-ad76-c0b9c8f0e310" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_983c130e-6866-4d8e-bde1-201eb6ff7e12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_85682307-df51-4001-8265-59c182260415" xlink:href="exel-20230331.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_f126757a-41c6-4782-ad76-c0b9c8f0e310" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_85682307-df51-4001-8265-59c182260415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9fb00f21-9f08-4758-8d94-43cc79c35386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c09863e9-6d83-4113-93b0-4352c36c5f52" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9fb00f21-9f08-4758-8d94-43cc79c35386" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_528f0e3f-05a5-44e5-a390-f168847dca0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b84199d7-1e18-4c07-a2e7-b931732ff5be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4cc575a9-f462-458f-8129-fd275fe5e550" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b84199d7-1e18-4c07-a2e7-b931732ff5be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3b76979-bcf2-46a7-8cdd-b9632d02a384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b84199d7-1e18-4c07-a2e7-b931732ff5be" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3b76979-bcf2-46a7-8cdd-b9632d02a384" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_f3b76979-bcf2-46a7-8cdd-b9632d02a384_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3b76979-bcf2-46a7-8cdd-b9632d02a384" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_f3b76979-bcf2-46a7-8cdd-b9632d02a384_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_ed50a522-e0db-42a4-8aef-8e3e7a97d75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3b76979-bcf2-46a7-8cdd-b9632d02a384" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_ed50a522-e0db-42a4-8aef-8e3e7a97d75a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5e5c32e6-61ed-4f82-9043-0dae398632fc" xlink:href="exel-20230331.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ed50a522-e0db-42a4-8aef-8e3e7a97d75a" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5e5c32e6-61ed-4f82-9043-0dae398632fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_9eca8ab6-b91b-4983-a1e6-6aa9a6af0825" xlink:href="exel-20230331.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ed50a522-e0db-42a4-8aef-8e3e7a97d75a" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_9eca8ab6-b91b-4983-a1e6-6aa9a6af0825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_bf45c208-b976-46d8-8c76-6bc7d0b5928b" xlink:href="exel-20230331.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ed50a522-e0db-42a4-8aef-8e3e7a97d75a" xlink:to="loc_exel_AllowanceForProductRebatesMember_bf45c208-b976-46d8-8c76-6bc7d0b5928b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended" id="ic9a95c3ce48c476fa13894715fe069a6_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90513ec3-450f-4ddc-a1e4-4193b7893a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_276ce98c-c639-4f9a-94ae-3419971f67b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90513ec3-450f-4ddc-a1e4-4193b7893a05" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_276ce98c-c639-4f9a-94ae-3419971f67b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a933862-08e6-422e-afa8-63ec100ca839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90513ec3-450f-4ddc-a1e4-4193b7893a05" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a933862-08e6-422e-afa8-63ec100ca839" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7a20317-f58a-4682-ae95-41228fb6792d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a933862-08e6-422e-afa8-63ec100ca839" xlink:to="loc_srt_ProductOrServiceAxis_a7a20317-f58a-4682-ae95-41228fb6792d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a7a20317-f58a-4682-ae95-41228fb6792d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a7a20317-f58a-4682-ae95-41228fb6792d" xlink:to="loc_srt_ProductsAndServicesDomain_a7a20317-f58a-4682-ae95-41228fb6792d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d369ef09-0e38-475f-82c9-9028b6bd44bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a7a20317-f58a-4682-ae95-41228fb6792d" xlink:to="loc_srt_ProductsAndServicesDomain_d369ef09-0e38-475f-82c9-9028b6bd44bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_bf23294e-3932-4255-9a37-74550105582c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d369ef09-0e38-475f-82c9-9028b6bd44bf" xlink:to="loc_us-gaap_LicenseMember_bf23294e-3932-4255-9a37-74550105582c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ae9e7a9f-2d3f-474f-bf16-8b9e01894c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d369ef09-0e38-475f-82c9-9028b6bd44bf" xlink:to="loc_us-gaap_ServiceMember_ae9e7a9f-2d3f-474f-bf16-8b9e01894c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_250adb3b-df0f-403a-a308-c6097e53d9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a933862-08e6-422e-afa8-63ec100ca839" xlink:to="loc_us-gaap_TypeOfArrangementAxis_250adb3b-df0f-403a-a308-c6097e53d9e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_250adb3b-df0f-403a-a308-c6097e53d9e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_250adb3b-df0f-403a-a308-c6097e53d9e5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_250adb3b-df0f-403a-a308-c6097e53d9e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28e424c6-a370-40fc-944c-26c462687058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_250adb3b-df0f-403a-a308-c6097e53d9e5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28e424c6-a370-40fc-944c-26c462687058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_a9322b90-efab-4afe-8121-b2cbd6a123bd" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28e424c6-a370-40fc-944c-26c462687058" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_a9322b90-efab-4afe-8121-b2cbd6a123bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended" id="i29cb01a2ce0b45519e4741981f12403f_CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a825c1-c9d9-4fd6-9ed9-efaa2e65b0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3ce84dcb-0d3a-4234-9735-8a06b7170239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a825c1-c9d9-4fd6-9ed9-efaa2e65b0fb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3ce84dcb-0d3a-4234-9735-8a06b7170239" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20d32c44-ebb1-46c2-8632-a89c23c8dc58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a825c1-c9d9-4fd6-9ed9-efaa2e65b0fb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20d32c44-ebb1-46c2-8632-a89c23c8dc58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_de19757e-10f7-41bb-8b3c-701b686ecd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20d32c44-ebb1-46c2-8632-a89c23c8dc58" xlink:to="loc_us-gaap_TypeOfArrangementAxis_de19757e-10f7-41bb-8b3c-701b686ecd9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de19757e-10f7-41bb-8b3c-701b686ecd9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_de19757e-10f7-41bb-8b3c-701b686ecd9c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_de19757e-10f7-41bb-8b3c-701b686ecd9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68a92a56-baa8-49ba-b6bf-04b00cbf5ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_de19757e-10f7-41bb-8b3c-701b686ecd9c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68a92a56-baa8-49ba-b6bf-04b00cbf5ca4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_4ee517e2-a809-4e3c-930e-22368eb28e26" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68a92a56-baa8-49ba-b6bf-04b00cbf5ca4" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_4ee517e2-a809-4e3c-930e-22368eb28e26" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended" id="i2e9cdc6997e24e4382faeb0f77c0a8bd_CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0c61ab7-d18e-407d-944e-787b8ecb9624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19277997-e307-478b-a515-a0e421fa5809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0c61ab7-d18e-407d-944e-787b8ecb9624" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19277997-e307-478b-a515-a0e421fa5809" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95d89f1e-eba0-4eae-9e80-2f5d28f7b77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0c61ab7-d18e-407d-944e-787b8ecb9624" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95d89f1e-eba0-4eae-9e80-2f5d28f7b77e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d39c701-e6bb-41f5-bdba-c1e2487d7d6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95d89f1e-eba0-4eae-9e80-2f5d28f7b77e" xlink:to="loc_srt_ProductOrServiceAxis_9d39c701-e6bb-41f5-bdba-c1e2487d7d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d39c701-e6bb-41f5-bdba-c1e2487d7d6d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9d39c701-e6bb-41f5-bdba-c1e2487d7d6d" xlink:to="loc_srt_ProductsAndServicesDomain_9d39c701-e6bb-41f5-bdba-c1e2487d7d6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9ddadfb5-11ae-42b6-b549-29a345e72698" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9d39c701-e6bb-41f5-bdba-c1e2487d7d6d" xlink:to="loc_srt_ProductsAndServicesDomain_9ddadfb5-11ae-42b6-b549-29a345e72698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_568b7897-e6c5-4f3e-94e0-e14387c4498f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9ddadfb5-11ae-42b6-b549-29a345e72698" xlink:to="loc_us-gaap_LicenseMember_568b7897-e6c5-4f3e-94e0-e14387c4498f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_09adee11-c0c5-43cd-b70a-e147791b3ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9ddadfb5-11ae-42b6-b549-29a345e72698" xlink:to="loc_us-gaap_ServiceMember_09adee11-c0c5-43cd-b70a-e147791b3ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_62740fd8-e1df-465f-a680-05425e53d678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95d89f1e-eba0-4eae-9e80-2f5d28f7b77e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_62740fd8-e1df-465f-a680-05425e53d678" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_62740fd8-e1df-465f-a680-05425e53d678_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_62740fd8-e1df-465f-a680-05425e53d678" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_62740fd8-e1df-465f-a680-05425e53d678_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19eb62c3-5fab-43c5-83bd-5a0c6aeaa49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_62740fd8-e1df-465f-a680-05425e53d678" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19eb62c3-5fab-43c5-83bd-5a0c6aeaa49f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_23c69ac9-1089-419c-b51c-fce916fa5b69" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19eb62c3-5fab-43c5-83bd-5a0c6aeaa49f" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_23c69ac9-1089-419c-b51c-fce916fa5b69" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended" id="ie1e3315d666f4707ad82bb6992ff98da_CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38553d03-1919-46ba-8845-1137caa999f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_29fa6ca8-4bef-4460-b075-20dcf0b24883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38553d03-1919-46ba-8845-1137caa999f6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_29fa6ca8-4bef-4460-b075-20dcf0b24883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220bb5d4-8fcb-441b-90a2-4f23fddbb566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38553d03-1919-46ba-8845-1137caa999f6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220bb5d4-8fcb-441b-90a2-4f23fddbb566" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2efe49d6-7b3a-44f2-b0d1-5f4badaa2aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220bb5d4-8fcb-441b-90a2-4f23fddbb566" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2efe49d6-7b3a-44f2-b0d1-5f4badaa2aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2efe49d6-7b3a-44f2-b0d1-5f4badaa2aac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2efe49d6-7b3a-44f2-b0d1-5f4badaa2aac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2efe49d6-7b3a-44f2-b0d1-5f4badaa2aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1db76f65-6afb-4b0d-9136-9a4a1f05b41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2efe49d6-7b3a-44f2-b0d1-5f4badaa2aac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1db76f65-6afb-4b0d-9136-9a4a1f05b41c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_5436742a-1800-4445-a07e-ba596be3392a" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1db76f65-6afb-4b0d-9136-9a4a1f05b41c" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_5436742a-1800-4445-a07e-ba596be3392a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails" xlink:type="extended" id="i96e8de74237e4cc5ad156430bf3ba712_CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bbacdd05-08bc-421b-b9ee-abc3f453756f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b96ed93e-8bee-495d-80c5-d5b054510df0" xlink:href="exel-20230331.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bbacdd05-08bc-421b-b9ee-abc3f453756f" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b96ed93e-8bee-495d-80c5-d5b054510df0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_c739b4f2-b021-4d01-a990-b26acd9c8784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bbacdd05-08bc-421b-b9ee-abc3f453756f" xlink:to="loc_us-gaap_RoyaltyExpense_c739b4f2-b021-4d01-a990-b26acd9c8784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a039cd39-ddc4-487d-9b3e-48cf7a59484f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bbacdd05-08bc-421b-b9ee-abc3f453756f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a039cd39-ddc4-487d-9b3e-48cf7a59484f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9aa8ada0-f2d2-4a5c-92e4-1e321ecacf84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a039cd39-ddc4-487d-9b3e-48cf7a59484f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9aa8ada0-f2d2-4a5c-92e4-1e321ecacf84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9aa8ada0-f2d2-4a5c-92e4-1e321ecacf84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9aa8ada0-f2d2-4a5c-92e4-1e321ecacf84" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9aa8ada0-f2d2-4a5c-92e4-1e321ecacf84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d9f7ad8-eb37-4f36-b109-067e3021147e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9aa8ada0-f2d2-4a5c-92e4-1e321ecacf84" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d9f7ad8-eb37-4f36-b109-067e3021147e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_1a29e7fd-59f8-4380-a8f8-08b4f5bccf43" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d9f7ad8-eb37-4f36-b109-067e3021147e" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_1a29e7fd-59f8-4380-a8f8-08b4f5bccf43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember_14d15e93-75d9-43cf-b1d5-db754f34b0d9" xlink:href="exel-20230331.xsd#exel_RoyalPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d9f7ad8-eb37-4f36-b109-067e3021147e" xlink:to="loc_exel_RoyalPharmaMember_14d15e93-75d9-43cf-b1d5-db754f34b0d9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="extended" id="i656e2ade79764f4ebd33934a263d3b6d_CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_51f40a32-040e-484a-8994-2f8fa02bfa1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_51f40a32-040e-484a-8994-2f8fa02bfa1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_ae08eb3b-6100-4df1-be34-038ccd1896c8" xlink:href="exel-20230331.xsd#exel_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:to="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_ae08eb3b-6100-4df1-be34-038ccd1896c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_b2a6ab0d-b8e7-416a-969c-c2f6be9c225c" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_b2a6ab0d-b8e7-416a-969c-c2f6be9c225c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_aa638e03-4316-4bc5-8fad-44a68a34009f" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_aa638e03-4316-4bc5-8fad-44a68a34009f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_de7be74b-24cd-4214-a114-fb3015b3822b" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_de7be74b-24cd-4214-a114-fb3015b3822b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_2e1febbf-6a54-4787-ae33-11a1d5c166a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:to="loc_us-gaap_AssetAcquisitionTable_2e1febbf-6a54-4787-ae33-11a1d5c166a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a38ac30d-c872-42ba-b56a-b21b5c02583a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2e1febbf-6a54-4787-ae33-11a1d5c166a3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a38ac30d-c872-42ba-b56a-b21b5c02583a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a38ac30d-c872-42ba-b56a-b21b5c02583a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a38ac30d-c872-42ba-b56a-b21b5c02583a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a38ac30d-c872-42ba-b56a-b21b5c02583a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c493efc4-cf06-4a2c-a817-71d78dca00a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a38ac30d-c872-42ba-b56a-b21b5c02583a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c493efc4-cf06-4a2c-a817-71d78dca00a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_3d2d2a77-48a2-4ea7-a3f6-acf17b27be73" xlink:href="exel-20230331.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c493efc4-cf06-4a2c-a817-71d78dca00a9" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_3d2d2a77-48a2-4ea7-a3f6-acf17b27be73" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended" id="idc57eecf48cd45759ab344779c361b6b_CashandInvestmentsInvestmentsbySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_de8c9ea0-dba9-4281-bd0e-2bba8d97f542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_de8c9ea0-dba9-4281-bd0e-2bba8d97f542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0286eb0d-d18d-4ad8-84d5-d16a81f6b9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0286eb0d-d18d-4ad8-84d5-d16a81f6b9a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6ab93718-11b5-4abb-a434-3aa3d5944bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6ab93718-11b5-4abb-a434-3aa3d5944bb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f2528e5-020a-4f2e-a637-b7e6b63a9728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f2528e5-020a-4f2e-a637-b7e6b63a9728" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_3fbc154b-54c6-406c-8860-6461c48e682e" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_3fbc154b-54c6-406c-8860-6461c48e682e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_815d43fa-a6cb-48c2-bbab-909df5cfb67d" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_815d43fa-a6cb-48c2-bbab-909df5cfb67d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_1655ba9c-2d9e-4826-8f13-463384013fdd" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_1655ba9c-2d9e-4826-8f13-463384013fdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_3a126834-8407-4127-afc9-e923650e9394" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_3a126834-8407-4127-afc9-e923650e9394" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_b7f1c4d7-fad2-45a6-819f-13d30f86e8bf" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_b7f1c4d7-fad2-45a6-819f-13d30f86e8bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8eb90db9-79ee-4548-86a4-2b3a5d910cdf" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8eb90db9-79ee-4548-86a4-2b3a5d910cdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d20a102d-0355-4201-85e8-1ca9642df964" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d20a102d-0355-4201-85e8-1ca9642df964" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_c4fbbff2-ba53-4fb9-980d-53742df533d1" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_c4fbbff2-ba53-4fb9-980d-53742df533d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e73197f-8bc1-4eba-9f8f-7426a97974a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e73197f-8bc1-4eba-9f8f-7426a97974a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e4bbb8dc-6b8b-4992-bba4-55c3fdc2bca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e73197f-8bc1-4eba-9f8f-7426a97974a5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e4bbb8dc-6b8b-4992-bba4-55c3fdc2bca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e4bbb8dc-6b8b-4992-bba4-55c3fdc2bca7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e4bbb8dc-6b8b-4992-bba4-55c3fdc2bca7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e4bbb8dc-6b8b-4992-bba4-55c3fdc2bca7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e4bbb8dc-6b8b-4992-bba4-55c3fdc2bca7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_28f3ed7d-d2b0-42a1-ab95-aa6b88400c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_CommercialPaperMember_28f3ed7d-d2b0-42a1-ab95-aa6b88400c6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ca492d25-c538-430e-b33f-560fe7209b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ca492d25-c538-430e-b33f-560fe7209b01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_688d1467-fadb-4f50-9fa0-7920bd6b5052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_688d1467-fadb-4f50-9fa0-7920bd6b5052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_fdf3c7fe-bee2-4d0d-82aa-014624e454aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_MunicipalBondsMember_fdf3c7fe-bee2-4d0d-82aa-014624e454aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_db775876-2427-47af-8ee2-4b4efb7415e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_CashMember_db775876-2427-47af-8ee2-4b4efb7415e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_921ba444-54a7-42a3-9428-688946213773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_921ba444-54a7-42a3-9428-688946213773" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_72f94f1d-2435-4e14-903f-d8339d6ff2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_CertificatesOfDepositMember_72f94f1d-2435-4e14-903f-d8339d6ff2cd" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended" id="i0fd844783ecc40f29e58c799b9ad3ef2_CashandInvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_3c8cbf9e-bb5f-4602-a4cf-7bcdc6abe0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_us-gaap_InterestReceivable_3c8cbf9e-bb5f-4602-a4cf-7bcdc6abe0f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8405e4d7-0e4c-484a-81ed-db675dee0259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8405e4d7-0e4c-484a-81ed-db675dee0259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfBondSecurities_1bf68b58-5ccc-47de-8928-e8370fd03f16" xlink:href="exel-20230331.xsd#exel_NumberOfBondSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_exel_NumberOfBondSecurities_1bf68b58-5ccc-47de-8928-e8370fd03f16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_47f19e10-4adc-4172-8ab5-e7103a9885c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_47f19e10-4adc-4172-8ab5-e7103a9885c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82177f83-0eac-42f1-9b24-e477b89fe34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82177f83-0eac-42f1-9b24-e477b89fe34a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_deb8eb6d-c319-4ab1-8540-2110d9b9d560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_deb8eb6d-c319-4ab1-8540-2110d9b9d560" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_df6b10e7-b698-409b-8d76-792d65304af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_df6b10e7-b698-409b-8d76-792d65304af6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_53a036d7-9fb5-4111-9cc9-872cc1156c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_df6b10e7-b698-409b-8d76-792d65304af6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_53a036d7-9fb5-4111-9cc9-872cc1156c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53a036d7-9fb5-4111-9cc9-872cc1156c22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_53a036d7-9fb5-4111-9cc9-872cc1156c22" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_53a036d7-9fb5-4111-9cc9-872cc1156c22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc9d5db1-1510-41cf-9a27-05519a2536f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_53a036d7-9fb5-4111-9cc9-872cc1156c22" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc9d5db1-1510-41cf-9a27-05519a2536f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_6be4043f-8670-4502-aeeb-3fc5d1e24e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc9d5db1-1510-41cf-9a27-05519a2536f0" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_6be4043f-8670-4502-aeeb-3fc5d1e24e68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_75b93ae2-593e-4d66-bcd1-8662c42e0544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc9d5db1-1510-41cf-9a27-05519a2536f0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_75b93ae2-593e-4d66-bcd1-8662c42e0544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_503835df-443c-4724-82a0-d6004bdb5bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc9d5db1-1510-41cf-9a27-05519a2536f0" xlink:to="loc_us-gaap_MunicipalBondsMember_503835df-443c-4724-82a0-d6004bdb5bab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended" id="iff96bcb454534dffac9d2d7201ef2051_CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a625bc5-f33e-4f03-ad94-2d7c91f56cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_e42c325e-73b2-4fd1-a27e-e63764ce0849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a625bc5-f33e-4f03-ad94-2d7c91f56cb1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_e42c325e-73b2-4fd1-a27e-e63764ce0849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f52d3f96-2364-42c8-a4c5-cb26f88f3383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_e42c325e-73b2-4fd1-a27e-e63764ce0849" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f52d3f96-2364-42c8-a4c5-cb26f88f3383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_bfb926ad-1664-4781-a47c-fdbdfbc2238f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_e42c325e-73b2-4fd1-a27e-e63764ce0849" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_bfb926ad-1664-4781-a47c-fdbdfbc2238f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59fcc1d0-34ff-4ed8-b58d-762be26e5838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a625bc5-f33e-4f03-ad94-2d7c91f56cb1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59fcc1d0-34ff-4ed8-b58d-762be26e5838" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_07ce82e2-4415-4322-af46-3da9c2f5ae56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59fcc1d0-34ff-4ed8-b58d-762be26e5838" xlink:to="loc_us-gaap_FinancialInstrumentAxis_07ce82e2-4415-4322-af46-3da9c2f5ae56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07ce82e2-4415-4322-af46-3da9c2f5ae56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_07ce82e2-4415-4322-af46-3da9c2f5ae56" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_07ce82e2-4415-4322-af46-3da9c2f5ae56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5affe8d7-b2f2-4913-ad59-408c3b0040c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_07ce82e2-4415-4322-af46-3da9c2f5ae56" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5affe8d7-b2f2-4913-ad59-408c3b0040c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_7e2d0d67-cb8c-4e0d-a7e4-b193ce57d2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5affe8d7-b2f2-4913-ad59-408c3b0040c8" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_7e2d0d67-cb8c-4e0d-a7e4-b193ce57d2b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_4c731d70-1fa4-4688-9c21-ca8939190f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5affe8d7-b2f2-4913-ad59-408c3b0040c8" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_4c731d70-1fa4-4688-9c21-ca8939190f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_5d2e49e2-1e40-4156-a3a4-405d8659616c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5affe8d7-b2f2-4913-ad59-408c3b0040c8" xlink:to="loc_us-gaap_MunicipalBondsMember_5d2e49e2-1e40-4156-a3a4-405d8659616c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#FairValueMeasurementsFairValueHierarchyDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails" xlink:type="extended" id="i5c8e50d9cbb344df8e57f679343b3941_FairValueMeasurementsFairValueHierarchyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e6df270-e453-46ea-a026-ad9379d42a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcc0f7d5-35fe-46de-ad88-838c88a336f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e6df270-e453-46ea-a026-ad9379d42a76" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcc0f7d5-35fe-46de-ad88-838c88a336f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e77f8245-3c1d-4614-a018-0a06a7b45ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e6df270-e453-46ea-a026-ad9379d42a76" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e77f8245-3c1d-4614-a018-0a06a7b45ab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_992a9177-be56-4b1b-a9e1-1710b93ba107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e6df270-e453-46ea-a026-ad9379d42a76" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_992a9177-be56-4b1b-a9e1-1710b93ba107" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6dd15fab-5db9-4751-843e-573d65b10735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e6df270-e453-46ea-a026-ad9379d42a76" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6dd15fab-5db9-4751-843e-573d65b10735" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_38a74309-7e57-46f7-b198-9d76fadd5823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6dd15fab-5db9-4751-843e-573d65b10735" xlink:to="loc_us-gaap_FinancialInstrumentAxis_38a74309-7e57-46f7-b198-9d76fadd5823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_38a74309-7e57-46f7-b198-9d76fadd5823_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38a74309-7e57-46f7-b198-9d76fadd5823" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_38a74309-7e57-46f7-b198-9d76fadd5823_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38a74309-7e57-46f7-b198-9d76fadd5823" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c5917d46-cb3f-457c-ad71-f1a2e11e5097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_CommercialPaperMember_c5917d46-cb3f-457c-ad71-f1a2e11e5097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0d4c0f75-5b59-43c7-944f-6f604adbffce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0d4c0f75-5b59-43c7-944f-6f604adbffce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b724f4e1-ae09-4d46-859f-65bccbbcb4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b724f4e1-ae09-4d46-859f-65bccbbcb4dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2e231eec-b173-4636-a29f-8d57ff05bf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_MunicipalBondsMember_2e231eec-b173-4636-a29f-8d57ff05bf0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2332a7d3-391c-4d4b-ba0d-e17996729f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2332a7d3-391c-4d4b-ba0d-e17996729f03" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_3b3d5382-6e04-480f-930d-66ea5f2d830e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_3b3d5382-6e04-480f-930d-66ea5f2d830e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9765f7a-3366-423d-8afa-804c754052c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6dd15fab-5db9-4751-843e-573d65b10735" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9765f7a-3366-423d-8afa-804c754052c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9765f7a-3366-423d-8afa-804c754052c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9765f7a-3366-423d-8afa-804c754052c5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c9765f7a-3366-423d-8afa-804c754052c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d24d7d0-1154-4e79-813b-d6f28c24dec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9765f7a-3366-423d-8afa-804c754052c5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d24d7d0-1154-4e79-813b-d6f28c24dec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_48f76115-07f2-49aa-af3b-3ef23b6582ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d24d7d0-1154-4e79-813b-d6f28c24dec4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_48f76115-07f2-49aa-af3b-3ef23b6582ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_eebfd4c4-35eb-4216-95a0-861b5a2ff12a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d24d7d0-1154-4e79-813b-d6f28c24dec4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_eebfd4c4-35eb-4216-95a0-861b5a2ff12a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7567e590-5e41-4ba7-9b32-efb6df53352e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6dd15fab-5db9-4751-843e-573d65b10735" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7567e590-5e41-4ba7-9b32-efb6df53352e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7567e590-5e41-4ba7-9b32-efb6df53352e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7567e590-5e41-4ba7-9b32-efb6df53352e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7567e590-5e41-4ba7-9b32-efb6df53352e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b04359-6d63-468c-9fba-856bb495ce51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7567e590-5e41-4ba7-9b32-efb6df53352e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b04359-6d63-468c-9fba-856bb495ce51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ad826f24-161f-42dd-b70d-186fcc37ddda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b04359-6d63-468c-9fba-856bb495ce51" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ad826f24-161f-42dd-b70d-186fcc37ddda" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended" id="ibeb5f5a83f06460893ed50230ff75c5d_FairValueMeasurementsNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b6ca1ce-6163-41d5-ad96-0ad57a4e70ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_6c417238-ed06-475f-982a-0fe7bbe69b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b6ca1ce-6163-41d5-ad96-0ad57a4e70ba" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_6c417238-ed06-475f-982a-0fe7bbe69b5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_a6b5f3c9-134c-48de-a9af-3be8ab94aa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b6ca1ce-6163-41d5-ad96-0ad57a4e70ba" xlink:to="loc_us-gaap_DerivativeNotionalAmount_a6b5f3c9-134c-48de-a9af-3be8ab94aa0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_cd290504-03d8-43ef-996b-c7e621b05624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b6ca1ce-6163-41d5-ad96-0ad57a4e70ba" xlink:to="loc_us-gaap_DerivativeTermOfContract_cd290504-03d8-43ef-996b-c7e621b05624" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8484c966-882e-41ef-b908-6115462484af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b6ca1ce-6163-41d5-ad96-0ad57a4e70ba" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8484c966-882e-41ef-b908-6115462484af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_95a76b90-580b-45b2-9f63-0be4212319a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8484c966-882e-41ef-b908-6115462484af" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_95a76b90-580b-45b2-9f63-0be4212319a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_95a76b90-580b-45b2-9f63-0be4212319a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_95a76b90-580b-45b2-9f63-0be4212319a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_95a76b90-580b-45b2-9f63-0be4212319a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0760242d-2088-42f5-96a0-18aa89271208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_95a76b90-580b-45b2-9f63-0be4212319a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0760242d-2088-42f5-96a0-18aa89271208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_f7b73479-00ea-44a5-a22c-447746666562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0760242d-2088-42f5-96a0-18aa89271208" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_f7b73479-00ea-44a5-a22c-447746666562" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended" id="i7836c9ab0f9445ff9b1f0f0a9ffc9fe7_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_5428853c-87d7-44f3-b05a-37d07a2f7528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:to="loc_us-gaap_InventoryRawMaterials_5428853c-87d7-44f3-b05a-37d07a2f7528" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_15dc587a-80ba-4b31-b67f-b5880d289fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:to="loc_us-gaap_InventoryWorkInProcess_15dc587a-80ba-4b31-b67f-b5880d289fbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_159c3a9c-eb95-43c3-81f0-31dc63d211bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:to="loc_us-gaap_InventoryFinishedGoods_159c3a9c-eb95-43c3-81f0-31dc63d211bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d929a091-e26e-4f8e-9f62-3c6761a50d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:to="loc_us-gaap_InventoryGross_d929a091-e26e-4f8e-9f62-3c6761a50d58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_e391109b-a1fa-4ebe-8e94-a616a42fe00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:to="loc_us-gaap_InventoryCurrentTable_e391109b-a1fa-4ebe-8e94-a616a42fe00b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a2ec2ec5-fffa-49d1-ab71-e786ca14d0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_e391109b-a1fa-4ebe-8e94-a616a42fe00b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a2ec2ec5-fffa-49d1-ab71-e786ca14d0f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a2ec2ec5-fffa-49d1-ab71-e786ca14d0f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a2ec2ec5-fffa-49d1-ab71-e786ca14d0f7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a2ec2ec5-fffa-49d1-ab71-e786ca14d0f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_47517e8b-1600-4c74-962f-171dcc006a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a2ec2ec5-fffa-49d1-ab71-e786ca14d0f7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_47517e8b-1600-4c74-962f-171dcc006a35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_16dd611a-5932-41fe-bc86-bcd0cafb87b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47517e8b-1600-4c74-962f-171dcc006a35" xlink:to="loc_us-gaap_InventoriesMember_16dd611a-5932-41fe-bc86-bcd0cafb87b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_bcf81f49-4ed0-4929-b5f7-e1e67c810acc" xlink:href="exel-20230331.xsd#exel_OtherLongtermAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47517e8b-1600-4c74-962f-171dcc006a35" xlink:to="loc_exel_OtherLongtermAssetsMember_bcf81f49-4ed0-4929-b5f7-e1e67c810acc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i80c95a15b141455c993a7779ffa628f4_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6c99f103-6797-47da-832a-1ac79da15325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6c99f103-6797-47da-832a-1ac79da15325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_064acc04-0033-4f34-9eb2-06b1bc440939" xlink:href="exel-20230331.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_064acc04-0033-4f34-9eb2-06b1bc440939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_128cd9f3-5e4e-42b2-aed7-f0613e8fb90d" xlink:href="exel-20230331.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_128cd9f3-5e4e-42b2-aed7-f0613e8fb90d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b490a3f1-542d-4c3c-b41e-6b130245a87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b490a3f1-542d-4c3c-b41e-6b130245a87b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fcccdfeb-f0ad-4b02-a57a-1d4634ef073c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fcccdfeb-f0ad-4b02-a57a-1d4634ef073c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7ef445b-bbd7-453e-801c-e7698c2d0017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7ef445b-bbd7-453e-801c-e7698c2d0017" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_706dcfe4-c17b-4e30-a22c-e8916768f42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_706dcfe4-c17b-4e30-a22c-e8916768f42e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5e6bb0ba-74d0-470c-86d4-7a8d1b432e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5e6bb0ba-74d0-470c-86d4-7a8d1b432e4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_bca25d40-4d59-4d43-ba5a-8973b7a8a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_bca25d40-4d59-4d43-ba5a-8973b7a8a9a0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fd034981-6e2b-4674-aff6-87f8cb487a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fd034981-6e2b-4674-aff6-87f8cb487a5c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05512dfb-3068-4fe2-855a-e1433c0c77b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05512dfb-3068-4fe2-855a-e1433c0c77b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7e47ade8-cf1b-44e6-abe8-8051a34eb72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05512dfb-3068-4fe2-855a-e1433c0c77b1" xlink:to="loc_us-gaap_AwardTypeAxis_7e47ade8-cf1b-44e6-abe8-8051a34eb72d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e47ade8-cf1b-44e6-abe8-8051a34eb72d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7e47ade8-cf1b-44e6-abe8-8051a34eb72d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e47ade8-cf1b-44e6-abe8-8051a34eb72d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe7995cd-71cc-4688-a8a5-21f041a4d8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7e47ade8-cf1b-44e6-abe8-8051a34eb72d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe7995cd-71cc-4688-a8a5-21f041a4d8e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_750d3aa6-cec5-420d-b885-cfbee52d800a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe7995cd-71cc-4688-a8a5-21f041a4d8e5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_750d3aa6-cec5-420d-b885-cfbee52d800a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5abfffd6-381f-42b6-99c0-083f688ca0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe7995cd-71cc-4688-a8a5-21f041a4d8e5" xlink:to="loc_us-gaap_PerformanceSharesMember_5abfffd6-381f-42b6-99c0-083f688ca0be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesTargetAchievedOrProbableMember_1de226bf-cf28-450a-a5b8-652074851aa4" xlink:href="exel-20230331.xsd#exel_PerformanceSharesTargetAchievedOrProbableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe7995cd-71cc-4688-a8a5-21f041a4d8e5" xlink:to="loc_exel_PerformanceSharesTargetAchievedOrProbableMember_1de226bf-cf28-450a-a5b8-652074851aa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bbc6f902-1adc-4414-a6b2-00400962778f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05512dfb-3068-4fe2-855a-e1433c0c77b1" xlink:to="loc_us-gaap_PlanNameAxis_bbc6f902-1adc-4414-a6b2-00400962778f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bbc6f902-1adc-4414-a6b2-00400962778f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_bbc6f902-1adc-4414-a6b2-00400962778f" xlink:to="loc_us-gaap_PlanNameDomain_bbc6f902-1adc-4414-a6b2-00400962778f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8ed9b3d4-32be-46c7-a703-5ff9aa2c4559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_bbc6f902-1adc-4414-a6b2-00400962778f" xlink:to="loc_us-gaap_PlanNameDomain_8ed9b3d4-32be-46c7-a703-5ff9aa2c4559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember_911f59fc-2ff5-469e-8ddf-e970eec2b12d" xlink:href="exel-20230331.xsd#exel_AmendedAndRestated2017EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8ed9b3d4-32be-46c7-a703-5ff9aa2c4559" xlink:to="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember_911f59fc-2ff5-469e-8ddf-e970eec2b12d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" id="i35ee5fe578ef442a84d6417d73ac61f1_StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_740a009c-4b0a-4d34-81b8-abcf900dcb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0b0cef8d-8c67-4b31-9eb3-24804738f9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_740a009c-4b0a-4d34-81b8-abcf900dcb84" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0b0cef8d-8c67-4b31-9eb3-24804738f9e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9adc19b9-39b0-4e1b-9b7d-8cd50036ca06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_740a009c-4b0a-4d34-81b8-abcf900dcb84" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9adc19b9-39b0-4e1b-9b7d-8cd50036ca06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_858d327e-c52c-468d-bd34-c64d69df8056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9adc19b9-39b0-4e1b-9b7d-8cd50036ca06" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_858d327e-c52c-468d-bd34-c64d69df8056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_858d327e-c52c-468d-bd34-c64d69df8056_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_858d327e-c52c-468d-bd34-c64d69df8056" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_858d327e-c52c-468d-bd34-c64d69df8056_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bcdea3ce-88f3-4021-939a-d7241c6d3510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_858d327e-c52c-468d-bd34-c64d69df8056" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bcdea3ce-88f3-4021-939a-d7241c6d3510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b08ebf94-432e-4a1d-a624-3b4a9abb476f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bcdea3ce-88f3-4021-939a-d7241c6d3510" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b08ebf94-432e-4a1d-a624-3b4a9abb476f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9a103e3a-3377-45fe-b354-cb1f2ec8bd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bcdea3ce-88f3-4021-939a-d7241c6d3510" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9a103e3a-3377-45fe-b354-cb1f2ec8bd6a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended" id="ic9922d2c75df4c06b5dbd1c39c556aba_StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0045e9-4eb7-42f5-8587-516dd62a1fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f290250-3955-4d53-bcb0-89e1e8d8c1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0045e9-4eb7-42f5-8587-516dd62a1fcc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f290250-3955-4d53-bcb0-89e1e8d8c1b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63a76d27-285f-4b65-87ea-55de66e9c593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0045e9-4eb7-42f5-8587-516dd62a1fcc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63a76d27-285f-4b65-87ea-55de66e9c593" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8ff1f927-0dc8-4c35-9ad6-c4b56ad5e415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63a76d27-285f-4b65-87ea-55de66e9c593" xlink:to="loc_us-gaap_AwardTypeAxis_8ff1f927-0dc8-4c35-9ad6-c4b56ad5e415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ff1f927-0dc8-4c35-9ad6-c4b56ad5e415_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8ff1f927-0dc8-4c35-9ad6-c4b56ad5e415" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8ff1f927-0dc8-4c35-9ad6-c4b56ad5e415_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8ff1f927-0dc8-4c35-9ad6-c4b56ad5e415" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7558f64e-23ba-495e-8e2b-6983cebd1413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7558f64e-23ba-495e-8e2b-6983cebd1413" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0e749e21-3b5c-4061-85ec-ccce4b73872c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0e749e21-3b5c-4061-85ec-ccce4b73872c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f940db62-e9ae-4852-aa00-4042d9dc4404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:to="loc_us-gaap_PerformanceSharesMember_f940db62-e9ae-4852-aa00-4042d9dc4404" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_3831fcbb-7adc-4f62-ac39-dd57c7d639c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:to="loc_us-gaap_EmployeeStockMember_3831fcbb-7adc-4f62-ac39-dd57c7d639c7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="extended" id="i777f255bbc74458a9ad874281fd7777e_NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa929935-f9b5-41f7-864b-dc3d4fcba8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_61b21bcc-f81d-4705-a526-e304a8aeb8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa929935-f9b5-41f7-864b-dc3d4fcba8ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_61b21bcc-f81d-4705-a526-e304a8aeb8aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3c3ffd74-e26e-444a-b307-fa93363629f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa929935-f9b5-41f7-864b-dc3d4fcba8ba" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3c3ffd74-e26e-444a-b307-fa93363629f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_67b16d77-88d5-4b9b-b5ed-7c898a88fcca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3c3ffd74-e26e-444a-b307-fa93363629f7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_67b16d77-88d5-4b9b-b5ed-7c898a88fcca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_67b16d77-88d5-4b9b-b5ed-7c898a88fcca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_67b16d77-88d5-4b9b-b5ed-7c898a88fcca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_67b16d77-88d5-4b9b-b5ed-7c898a88fcca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7df7d22e-a4da-460e-b98d-792ce2bd0314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_67b16d77-88d5-4b9b-b5ed-7c898a88fcca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7df7d22e-a4da-460e-b98d-792ce2bd0314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_d5d1a31d-6b32-48c0-a25e-86ccda50cfed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7df7d22e-a4da-460e-b98d-792ce2bd0314" xlink:to="loc_us-gaap_StockCompensationPlanMember_d5d1a31d-6b32-48c0-a25e-86ccda50cfed" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>exel-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fbc3dff4-5359-4115-877c-cd80f1d37686,g:9f45ed8a-1512-41a6-b3b1-f3d762602463-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_da1dd2b9-aaeb-4712-a7c1-a1a9831ea170_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5d132166-ba83-4272-a00a-8b1026edba99_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5700ff11-c98d-4e85-8728-36ae83a6fb8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_e5dee3d4-cae2-4f67-a334-0f4273064bc7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_bbe08be7-7b89-401d-bc15-de7a7ac27a65_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_99433d6a-64ae-4386-8bd0-09df3742468b_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in research and development</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Research And Development Expense</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:href="exel-20230331.xsd#exel_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="lab_exel_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_97b58000-3a95-4ea4-a4c2-3bcb04c4edbd_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0e061fd6-f289-45e1-9ae3-f61c5e7e8c8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_f3dc12c2-51ab-4828-bb32-2c3156ef944c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_b2b85e4b-ef3a-449b-89cd-2248abedc2e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_89f8dbc8-3e0c-40e2-97b9-065e78a101b4_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3a733548-3238-41ae-ba14-76009fae1261_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d81d8e0a-821e-4d05-be85-0b580f957c7d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_567dca06-ed1b-4723-8617-6c2664901910_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_d29c35a5-2403-4988-abb5-adcdc2377c16_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8fb875cf-2b67-4388-bda4-4b3ccdf28cbc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_5f28ffe7-6160-4744-88c3-aabfd33fb5b7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5515e9c7-a9b5-437c-a7c5-e91ac77cef6e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12449893-deb2-4d52-aeb9-0516b9922b83_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7c1f7890-073c-4013-a98e-76b6f5131bec_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ad55ece7-6a49-4f55-be4d-a33c2e130e91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_94aeaef8-444f-4e5b-836a-cd33ecd43ec4_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:href="exel-20230331.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_84c762f8-23cb-4ffb-b0c5-454620589b97_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products derived from other compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:href="exel-20230331.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_68fe2861-e83b-44bb-8b8d-29ecb4c71866_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue recognized, including revenue from deferred revenue beginning balance</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="exel-20230331.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IpsenMember_d771e605-839a-4aff-a32f-6076644feca6_terseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Pharma SAS</link:label>
    <link:label id="lab_exel_IpsenMember_label_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_documentation_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember" xlink:href="exel-20230331.xsd#exel_IpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember" xlink:to="lab_exel_IpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c08fc60a-50bb-4d89-930e-160220ddcafa_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_de27f452-d8bf-40c0-8bea-f896152b4262_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d1913007-0f13-4ff6-8105-174e4144218a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_6a92f422-d9b2-4928-8447-b26c71735e10_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_4b7600c6-3ba4-4b50-bbbc-c73f60b2e0d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_18148b34-e601-4b2a-ab86-a1a7aab159b0_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_8598ea63-75e1-4fbf-acaa-5c8787ff002c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_a32a8892-211d-4b0f-a495-e6cbd7aeb30e_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:href="exel-20230331.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6cb70b20-3849-4dfa-b271-e4c50eb42eb4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 324,985 and 323,951 at March&#160;31, 2023, and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_f8541bb2-349d-4f57-8acc-66f0ae873344_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:href="exel-20230331.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_8c4edd9b-bcda-43ae-bc79-3f06a8aff3e0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_9445222c-496e-4f7a-95a8-6cd3db9b956c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_5cd3e3d2-fdef-4a27-97e8-9b08d5d91490_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate development milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_48b80bb4-d860-4fc5-b9c3-6c7a73fcd3db_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_5722bd6d-e52c-4d00-8c79-12ac0f06d9f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development technology</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_0fd45fbd-4c75-4aa6-8052-6f7c221368c2_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:href="exel-20230331.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d730b979-8859-4435-bec7-08b56fc80668_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5f5c86dc-a704-4b84-b8f7-561374541248_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cbf45351-fa50-413d-812a-1eea34f5f734_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f1d6ac15-fb9e-4af6-a151-feb2fdebbdfe_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_1fbbda2e-d81e-43c2-b773-a7011650ba16_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5d238af3-be7c-427c-b6a3-1ec590cb165e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e0c6dacf-d9bb-424b-aa5f-d98b069e0f27_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6e879b1-f83c-432f-9b2f-319945667ce7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_3e433738-d27e-4eee-a904-ce1368776f0c_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f18ebabe-6243-4cf1-a26d-d828bf23f046_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6287ef88-4a8c-450f-8d34-b271bdcc8376_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_34ac3286-d864-4609-8358-95c0a0524ab8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_72671cd3-55d1-4d6d-9473-502c1820c051_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OtherLongtermAssetsMember_6bbaaf20-3fb3-436e-8685-803a1096e689_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember" xlink:href="exel-20230331.xsd#exel_OtherLongtermAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember" xlink:to="lab_exel_OtherLongtermAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_2662c2a9-0193-427a-8dad-24c275e5c770_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ba6558b1-18bd-469c-9ad9-12aecab5af2c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_22b5f19f-9a78-4a21-aa3c-0c21de95d849_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a66a2f10-ec80-4792-ad15-71dd5668aa88_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_19159a58-54a9-4ced-b583-3050305ed66a_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:href="exel-20230331.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7afd02f-7093-47e4-9bb2-662dda604a74_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_3488bb51-ea5a-44b1-9742-319ab5ab8f52_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_57b4fe29-e3de-438c-b3d5-733c5300fc0d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2d8bd96e-4ee5-4f1e-af01-9a1c0bce2364_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_90995d5f-da1b-49d5-a4f2-1e9a4890e828_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_085fb01c-be4c-41b7-99a4-b63dcb105582_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember" xlink:href="exel-20230331.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember" xlink:to="lab_exel_AllowanceForProductRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_77c642b9-06a7-415b-ab2e-3f69e37026b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6feb0d29-a9a2-443f-99ff-9a6ded24c560_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_303cbfd5-e2b0-472b-8218-d105d9c0b5ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_b8ef46c7-2cc3-46d0-9988-1c1618f44b59_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_df38e6e7-bbd7-4c16-9a07-003e4b6b0990_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_56fcf8d2-ac31-4eeb-bdd3-4936541f7b08_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_605d47b8-53b3-4e38-afb6-8809436914f7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_60c170e4-4626-4a42-9c56-b3d5fc0715d9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_30f3f279-e7da-4714-b4fd-137a0558f545_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_fd23dd47-3ebf-428a-b94a-8d54677a9c9f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_06f91766-cce7-451d-8aef-40f22b865a81_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_1413c465-69ad-4383-8b8d-7280b55d8d8a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_312c6974-a6d1-40cc-8cc9-4fbf71061840_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5d399022-7fcd-4a84-9a4c-7c4634224366_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_22671603-aed0-4d13-8dbc-ac56b615c2ec_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f3084931-ce12-40a8-832c-14cc6556dfe6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a4a572b4-2ffc-4363-a364-a87713f47055_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e1d5d2ac-10bc-45c4-93f3-6996dbaa9033_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_1b060f6b-9508-48d6-9efe-1cb5ff08a70c_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate regulatory milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_c60fc1df-c602-4ea3-8de8-cea315f92fa9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7a596260-b297-4d1f-bfd6-d8468406aeb9_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_7df4a5ba-b7ad-45ba-84a6-cfada67b9157_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Collaboration Liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Collaboration Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:href="exel-20230331.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:to="lab_exel_IncreaseDecreaseInAccruedCollaborationLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_e17a666c-278e-4231-829a-684bdb522810_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_54386438-4377-4440-bd56-1753007780e8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_00830eb7-d2e7-45a2-81e2-bd4760f85c55_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_6208abe0-d809-4f98-955d-7495933efba0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_77f32137-4985-461f-84ba-c300ea16b965_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_935cdf09-fdc7-47a2-b87d-e9b5d3f684bd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_21a92fc0-0976-4087-8181-fcae6a128163_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d0694ed9-df7a-49ba-8d4d-68033cf4c41f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_22ebafb5-86fe-4335-b6b4-0bdbb2a2dbf1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dfc0d0f1-8fc3-4ee7-909d-156b0e9f5fc4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_14e3f852-26a8-49b9-8a01-f8d229d6061f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationMember_037fa2e0-ecd8-48ac-9a6e-db53490af6e3_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_label_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_documentation_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember" xlink:href="exel-20230331.xsd#exel_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember" xlink:to="lab_exel_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_4dbf2766-020d-4b95-b6c8-66c9e08ec44b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf821a0c-4162-44d8-a44b-f12bd3164cc3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_bf814e36-17b1-4fc7-9797-798a60b1f098_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_35ebb379-16b6-4f06-a687-d268a7e4f418_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_8f41d7a5-a3b6-4d49-9fac-4aa110c3c82c_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket" xlink:href="exel-20230331.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket" xlink:to="lab_exel_NumberofProductsinCommercialMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_eec768ba-1547-4170-b105-0266aff0b116_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a33cdcaa-a8b5-4a9c-ae33-999551379cf0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_923ef8dc-52e5-45f3-93cb-0375368a3797_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_cfdf07ac-d4de-4b79-9fcf-ad81e1dd9bb4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_50133fa1-c744-4006-b8bd-c9bc6262a412_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dc82f271-3bce-4c95-a16e-8bf462288844_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7b573bd6-1200-4f93-84a0-45ee7e1b1c9b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_67386542-72a1-4d2e-96ad-ae541572916a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4742c2b5-6e60-42a5-9922-253d4e7df3d7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_dae43db6-788a-474f-8d4a-9fd83d9776ae_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d53e5d96-4e4f-44b2-be77-045a5e895027_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_90367a20-2254-4591-ad8a-a3cd2c43d81a_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_45f77d24-6772-40a1-b3ad-b9e56a1bef7b_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8013fa60-6e92-4844-8b1c-70de0aff7cd5_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_48fdc08f-685e-4c3e-8be2-08e21279ef98_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6f1bd72b-8bb5-442a-b327-0a8624c25ac1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_4ca38a0a-bd9d-4bf2-9325-26f19d182908_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12d8fddf-2b20-4f01-abc4-29fc7e87c974_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_86452e18-96c7-4feb-a088-7f9f0ef3f8e6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CabometyxMember_1789cbaa-3ddc-4fe5-b0cb-f20886f09769_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_label_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_documentation_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember" xlink:href="exel-20230331.xsd#exel_CabometyxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember" xlink:to="lab_exel_CabometyxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_PerformanceSharesTargetAchievedOrProbableMember_9523cf85-9c1e-4b99-8c2f-76e6aa650f83_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesTargetAchievedOrProbableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Target Achieved Or Probable</link:label>
    <link:label id="lab_exel_PerformanceSharesTargetAchievedOrProbableMember_label_en-US" xlink:label="lab_exel_PerformanceSharesTargetAchievedOrProbableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Target Achieved Or Probable [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesTargetAchievedOrProbableMember_documentation_en-US" xlink:label="lab_exel_PerformanceSharesTargetAchievedOrProbableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares, Target Achieved Or Probable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesTargetAchievedOrProbableMember" xlink:href="exel-20230331.xsd#exel_PerformanceSharesTargetAchievedOrProbableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesTargetAchievedOrProbableMember" xlink:to="lab_exel_PerformanceSharesTargetAchievedOrProbableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_22b0b457-1ecc-4dbc-a43b-37c8b3c6a6a8_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a6027e92-8480-46e5-b919-f192c2f664fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_edfce586-c3cc-4062-a61e-94e597ebc893_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration and License Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_f8433130-5027-4cdb-a0f9-8459c5427cce_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_4120023f-d9e5-4593-8a17-9499a09236f3_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:href="exel-20230331.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_64e3afb8-91ee-4b63-bcef-b6702ae0e2cc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3cc9153e-e675-4ca6-9d7c-4921591a8c91_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_8d450bd0-44fe-4fda-ba8b-cd505fc86e80_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_ea234a96-f6f4-4b1d-8ea7-3054b906388b_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b8d368e6-8b83-4884-aa6b-d9880807904f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f00b5ad3-2a78-44a5-b26e-8eb0014d215b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_0f2db1f9-690e-441d-8533-da503aa2f225_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_444b027b-4755-4415-a671-05516b48b7be_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_04f1c0b0-591f-43ce-84f3-eac0ad57488f_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9077fe05-8113-40c6-b906-cfadc5528e32_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_bb029aaf-a7da-4e45-a7b8-0061864dbec1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_56092bf6-4e06-49bd-81e9-2a206664d54c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_61a4b953-05cb-4f4c-b4ba-15a7e496a697_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_d1b63e6c-3c36-44e8-9da7-1905a3623d43_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4816ac2f-f9b0-403e-b622-9e929bf3505f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b19a2e3e-0287-46d2-b11c-9139c37a9012_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_f82755c1-e19d-4fa9-aacd-2e2c7487326c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_35fd2540-9add-4dac-9f40-f1ed165e2138_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:href="exel-20230331.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0826b470-1cca-4720-ba55-4de228395276_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_b1b7c54e-c22b-46e2-bea0-a26190e23a13_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration Risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_93b3c059-80e5-4304-ba12-71fe56225326_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:href="exel-20230331.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_b681b59c-c8f4-423f-a705-ce348768826c_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:href="exel-20230331.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_bdfde06a-f206-4f80-ae31-3057befc8d7f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_9f89d18f-db17-405c-a569-c17fe30d0bd9_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:href="exel-20230331.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_3a4b5aef-2639-471a-8ef8-bebdf065532b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_97b9b02c-2431-4383-96b2-b453922ca89b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5561bd9b-5e50-4b60-8e73-2b42f5f45124_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_32f7c804-7776-4a52-9d0c-833bc481c98d_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:href="exel-20230331.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_9aff8111-9975-4d17-9b10-91095628dfae_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_ac75358e-785e-4edc-ab86-65e094a71fb8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RoyalPharmaMember_398c64c5-8fc1-488a-8f8c-c77f3c86f060_terseLabel_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma</link:label>
    <link:label id="lab_exel_RoyalPharmaMember_label_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma [Member]</link:label>
    <link:label id="lab_exel_RoyalPharmaMember_documentation_en-US" xlink:label="lab_exel_RoyalPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royal Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember" xlink:href="exel-20230331.xsd#exel_RoyalPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RoyalPharmaMember" xlink:to="lab_exel_RoyalPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_2f6d2df3-3ddc-4505-b46d-b24074b0b8f8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bf58f5de-0320-473d-8004-67770ec22d2b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_d1e63683-9bb9-4887-921d-9895c5cddc66_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_a939da3a-524c-482a-9e44-a2c38ff1f671_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_7ac94a9d-e751-46a2-851b-a48c5e1738d7_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts for Prompt Payment and Other</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:href="exel-20230331.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1e67793f-97d0-4d01-a55e-2b7e84ac7d15_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_af4183d8-931a-4072-a3f9-5e73ed94d9f3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_eede7362-a487-466a-83ed-a203467fabde_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ec777bd2-080b-482c-ba4a-f6638cdd7ace_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_da55ee57-0447-4da9-88c9-979bc51a797b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_84123792-bacd-4743-94d2-6b3df9bf5024_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:href="exel-20230331.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_a9f85053-8fac-44a2-a1b1-f63a43dfd0da_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:href="exel-20230331.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_9dc56de8-2acc-40eb-9b25-022186780ef2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_c69fb361-a353-4903-96f0-67efbd56cdaa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at March&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b91341c5-c527-4595-b2d5-da43288d74e9_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_fe757ed2-6b9a-43d2-8a23-a492d5d7790e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c48c21e-eb28-45e2-b01e-a1a6b9612714_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4e705d4c-4c57-4b07-a4df-dc32fcf3872e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_d8a2a9c5-e8b2-4fbf-ab6b-f21a24a2c784_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d9f80fa2-2423-4145-9d2e-a7620a6e0471_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_e6409abe-d21f-4982-9499-9eac5494bdf4_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_9b9e874e-3547-4aed-9ad5-686b15c117f4_terseLabel_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_label_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]</link:label>
    <link:label id="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_documentation_en-US" xlink:label="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:href="exel-20230331.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:to="lab_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_f36832da-511a-4a6d-ab49-ee99118ccd1b_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a763809c-7fe6-47dd-b055-be711f55dab8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_82a5c327-b89f-4a63-9ee4-e6b9cc1172e8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_41354a32-df82-4077-acde-085abba8ce93_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2c9437ab-d05b-4c1e-affe-16b3027fc9c6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_8dc47191-d5a4-4a2a-96dd-69a52aa0a2f5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_54e37a43-97e3-4840-8670-482d8a0ca07a_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_27dc3779-4281-42c0-b096-ad7bb91e1544_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:href="exel-20230331.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_a3ed5de8-2452-4dcc-9afd-81a879199aa5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_39bf7d5c-9506-4341-b868-c612a8b23c6a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_df884dc7-ea71-43cf-84f2-f24e7e7e3e5a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e828b173-4a56-42ab-9748-48681b957cbd_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_122a37e6-45a9-4b77-88b9-2532504ab6c6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_7c6c5c5d-b4ae-496e-8c73-d93d89a23e69_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_70c65153-3723-43d2-aa4e-8ac02362f4f9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_a30330a5-9996-4fb9-bb80-fa2b63c0673b_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_4dcbf89e-0cac-420f-8543-757c6824259b_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_bf0922bb-beb7-46dd-abbd-f84fc34ab944_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberOfBondSecurities_79fe1648-f8a1-4f6a-bf3a-97c8bd3b99fe_terseLabel_en-US" xlink:label="lab_exel_NumberOfBondSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of bond securities</link:label>
    <link:label id="lab_exel_NumberOfBondSecurities_label_en-US" xlink:label="lab_exel_NumberOfBondSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Bond Securities</link:label>
    <link:label id="lab_exel_NumberOfBondSecurities_documentation_en-US" xlink:label="lab_exel_NumberOfBondSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Bond Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfBondSecurities" xlink:href="exel-20230331.xsd#exel_NumberOfBondSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberOfBondSecurities" xlink:to="lab_exel_NumberOfBondSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_17ab6647-9f9a-40d2-862f-89e806b6f613_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_8f0b4b7a-1630-4a80-ab64-69050e6f3215_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b2294f98-4991-4f63-bd75-ac29d0a09eed_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2b105e1f-25a4-46c9-9dcb-a71bfc87501d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ede6892-1e95-47fa-b15d-d0a138a677c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_8152d799-f1d3-4d30-9614-80f0dde1814e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_b6848410-df00-463f-8d7f-5f6aa9369434_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_62482278-f030-4d81-aa6e-43597a796751_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_label_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:href="exel-20230331.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:to="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_e10aadb4-186f-4f7f-a21f-b327a49d7e3f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_1a073980-f681-495e-841b-0ff50f8e2267_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c824d3d1-6cd4-42aa-8fbc-756e264b2064_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4981556a-1acc-4230-bf34-8084c32f2789_netLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_01c1cb9f-5da3-4dd7-9bf9-ad3fa24415cf_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_15285826-c2e2-462b-bf46-3634a4bf091e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8e308df3-d5d5-470e-bd63-57546a23e332_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember_5f37e25f-424b-47cf-85a1-15c2057c7ccc_terseLabel_en-US" xlink:label="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated 2017 Equity Incentive Plan</link:label>
    <link:label id="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember_label_en-US" xlink:label="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated 2017 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated 2017 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:href="exel-20230331.xsd#exel_AmendedAndRestated2017EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:to="lab_exel_AmendedAndRestated2017EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_d9a4f98c-ce6f-4b0f-b4b2-deff784d8db7_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_7f48c33a-4246-4cdd-b002-656f6eaabbad_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_ca25eae5-e5e3-4f1c-8804-7f55aec87a5b_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_ff41f7c9-2264-4d6c-95f3-9191937f3607_netLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_45eb06fb-0b1d-4448-8975-fef710ebb937_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_05b89790-ba41-4d9c-b61e-a2c20fd04c6d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NoncashLeaseExpense_5d76fd5d-4133-4463-bff3-4c6896fca3f1_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense" xlink:href="exel-20230331.xsd#exel_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense" xlink:to="lab_exel_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b7283b0c-9276-4997-b3a0-e72815aae79e_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_79b05995-8ad1-41e7-86d4-59936e41e45d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_051433ab-8acf-47d0-a71e-0d76960ad2e4_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_dbeebcbf-982a-4429-ac2b-5619d3aa7c9b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_b4273e72-3844-4805-bb90-8a4b5d15f631_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fc6e68e2-7bc2-42fa-a047-1f7f83ca3b24_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4327732a-24a9-4364-ba76-92117f9b8ea6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0f2571fb-32fd-44bf-9e98-c6c24d484392_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_b0cef514-bed0-4e8a-918c-70614eb2ed79_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_453b5db7-aad4-42a5-a19f-465f0ab5a9f6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2f3c0fdf-6761-4616-baae-d9ad87ed16f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5a618011-1cfc-434e-9ebf-09e836a0ab9c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_bc09caae-7a66-47f5-a5d7-6c0102bc72c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_26cff692-a654-4e0d-878f-474d9c5dddc7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b241420f-07f8-4a0d-8505-b9bfb2860092_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_b0a6be3d-23bd-4bc7-ac9a-34b953593fc4_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_3038732f-84b8-41c8-a31e-2f6f16e6f030_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48cbec14-99bb-4f36-bd0f-b7d7dbfba869_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fa51645f-a497-4948-bcdb-c3ec0bbdc0f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_1838b932-e15a-4dcc-a249-98226d0ce515_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3f904936-5f08-45c2-9fd2-a5e275f59f38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_48d41113-64f0-44b0-8454-880251a7a3ad_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e09e8549-47d9-4e31-9134-94ef8ae4c8b6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0410ba2b-5ee2-4f9e-a055-2af10600e8eb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_779f25ee-2085-493e-934a-984d4b76dcaa_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_9ee3c027-af79-435e-9b7d-af5b82e220c8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_28c363ee-e5c9-4d9e-bf2d-b0012170ffd0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_04cf49b4-08b6-4400-897d-691ae676dfaa_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_6254ba5e-40c4-485a-8bbe-920597f29fb2_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8828b30e-b880-41ee-8aa2-8e96b119b330_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_a687e90c-b3fb-41d6-9cfd-7431b940baa8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_abf94002-c878-49ae-bf28-bbcd71217bf1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_60f7a8d5-355a-4faf-b32e-91039dab8923_terseLabel_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_label_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Lawsuits Consolidated</link:label>
    <link:label id="lab_exel_LossContingencyNumberOfLawsuitsConsolidated_documentation_en-US" xlink:label="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Lawsuits Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:href="exel-20230331.xsd#exel_LossContingencyNumberOfLawsuitsConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:to="lab_exel_LossContingencyNumberOfLawsuitsConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_7557b908-bc68-48fa-bd4e-3866817f09a6_verboseLabel_en-US" xlink:label="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets and other</link:label>
    <link:label id="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_label_en-US" xlink:label="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset And Other Assets</link:label>
    <link:label id="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_documentation_en-US" xlink:label="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:href="exel-20230331.xsd#exel_OperatingLeaseRightOfUseAssetAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:to="lab_exel_OperatingLeaseRightOfUseAssetAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7b249225-4f04-41e1-a3dc-3bc7b0acc9ed_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ce41dacc-c3be-497e-837a-7f4498827618_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_09856eb4-9877-4a85-8b0f-662265a8bbf6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_86e1fb8a-a2cb-4212-be01-2446ec84cafd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4f86fb30-d34a-441c-adb9-3d78c0fe02a7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cb2cb9ea-c1b5-4bc6-ba57-489afb3198e4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_c34d80aa-1434-42d7-b501-bc265246368c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_14652d61-e974-4436-bc94-a62c5363ea27_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_258d897b-14c6-42a7-86f0-8558e87496c6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b9b5b500-8654-46f8-abe7-255f3c3088e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_717bb9dd-b781-47d5-a3b6-7528c4111432_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_97b930a3-9ebe-4378-93f8-e31fd953db6d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_230e1fee-4d36-4c13-aa64-cdb0daa5241e_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0c899c9c-d9bc-4e7b-bc3b-5602c8344566_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_dd74e499-3362-4645-9d82-51b7c63d1d74_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_e9e8ed94-27e4-401c-b2f2-45c9a04e6abe_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_aecd2921-9814-4cd7-b42a-3736b45615f2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_9fa4138c-5a65-47cf-8b97-bb47d287b8ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_c7443f1a-25d0-4830-959d-28d741c45217_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_62022914-b0e4-47c4-bbf8-f1553ce17643_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_cdaaedab-83b7-4227-9aa3-d22552e2bc8c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_b4c6ca26-7e5e-47c0-816b-e2e68b930a21_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_31278b03-23f8-42ec-b3d6-aa7f5e9fcbc8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_2c6ca3e1-aa25-47f5-b4ad-a795a06c00de_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1d0828f2-db41-43ee-a4b5-29459b3d915b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROVISION FOR INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_83fa8543-ac47-4acb-a828-d73d8bfda7d4_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b09b9e68-dae1-41b6-8935-2dbc11cd7486_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3fc385f4-f633-45a9-8322-758ea48c4b39_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d376180a-6e86-484b-836b-64437ee9ff03_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_3cd0685e-d857-47c0-bc7c-e997bca8b46d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_3c80d9e9-ced1-44b8-8c40-5a9fcdbad0d4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3dbf1772-3657-46e2-a748-abcf952365ab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_b5935a47-977f-4b17-902a-a3e5db554ced_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_a14486ba-7eff-4065-885a-b727ea4a2abb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_9396e6f1-6681-43c8-a104-79daf01e4e17_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_a0cd1ef0-eeec-4b94-8343-dc912aba008d_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e23df1fa-ba7a-42bd-92a7-996e8b63887b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_567afb50-0425-4531-895b-e1772097980f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b22a98c9-b4f9-42cc-bcde-437904b40bae_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_abafb9bd-b312-4b54-8d3d-74b2ef9cd87f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_dc8909a7-0ffa-4f19-9861-ed3e65f82a2f_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_e83f0d05-cede-4201-8770-f1cd38c09e3a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ae35682f-7ec9-449d-aebf-55b9435610ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fe2801be-dfc1-401b-a5bf-35234bdb706d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_edf34773-4715-42cb-b13b-685d502496c4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9c9f7e4c-ac43-4618-83ee-b2391e33fa72_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $(1,507) and $1,656, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19ed18b8-66f5-4486-ad8e-31c1bb8ecb45_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_f7186ba2-7804-44c9-b272-ffdf470c29c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_a5a9418f-3482-4162-b1e3-49d7a4a3162a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_044bfe48-effb-4697-a214-f6d61b48ff98_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_083b8c06-2951-4ffd-a8ea-8c7e69b0a2aa_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_7a9bdf2c-8085-4727-9969-b027eb80d9f2_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:href="exel-20230331.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c27cac57-6bed-4438-829f-ab01cb19d93b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_96dcac9a-9f19-46e7-a6eb-c6b0c55a1601_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_922f4c9c-5bef-4258-aa79-d96c01edba94_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_43dbe1f8-9cfb-4206-a920-8bc1eaf87af0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_a5721e1d-23cf-4547-be9b-11519618a9f1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4a1d7ec0-509c-461b-97e5-3ae8d9996937_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a2b30d6f-f84d-4989-a28b-6d63ccea7ffb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_06737c2e-2e93-461b-93e5-bae779ba36e7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4fb5e906-b1e4-4095-b883-eb984f9d9cdd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive plans and stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_48b1c413-ae98-4753-b403-3127c0d3ed86_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_aa95046d-be17-40f9-a52d-c6313582f97c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_a60402ca-a2e2-423e-b287-f036c426be15_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_783280ea-ff0a-4dcd-b046-68215ac05c6c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_c65699a8-a310-4851-965e-a627f55a026d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_3c76daa4-bb63-41cc-b341-d23e5e595351_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_416438fd-0c8f-4c12-a981-957b8c69062e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_abc37be9-6c09-4632-a63f-c99ab02a92eb_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d10bd635-66e5-44fe-91f3-acd897b5ac5e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_0599883a-9c31-4cdc-a6c7-d7bf196c8fc1_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e97c4371-b502-4a6e-88cc-3e534c0e4ade_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_e41bb4f7-6c72-43b7-9cdb-3b1f3c452582_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember" xlink:href="exel-20230331.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember" xlink:to="lab_exel_AccredoHealthIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_129cca87-521d-4fdc-98dd-c728ead903af_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_fd1d59e8-aaa4-4ab8-aa26-a0ad44a197b0_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CometriqMember_3548d4bf-b37d-4456-86a2-f9cce69f207c_terseLabel_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_label_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_documentation_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember" xlink:href="exel-20230331.xsd#exel_CometriqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember" xlink:to="lab_exel_CometriqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_f71fbc37-6dc5-4b72-b82d-b2ba6b8eb4ed_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:href="exel-20230331.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_f4445c03-9f00-455c-83d7-88337723b3c4_negatedTerseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1adeae1b-b845-4b5d-a7be-019b155c47b7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a1e33898-7c01-4ff2-aded-94ad2282253a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_3ffa9059-c207-4f2e-b87d-8c49fe68c669_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues Disaggregated by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e2b46b8b-c301-489d-abba-f1c3cb18cc13_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (Accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_b91281ec-3e8e-4ded-b6b8-4ac611319cd0_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_db07de6a-6910-4245-9512-0ca7986d983b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0b267ffc-03d0-43e4-b844-8f52d93cb17c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_030285ee-9fcf-484a-8b37-4cb9d74c6920_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_1ecfd7c9-4d2c-4cb9-8767-075c4b5cfd11_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_8f16dd75-aaf3-4368-8a26-25dcaaa2f11a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_e386ea4f-1bf7-4367-89f0-4a863a020e48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_b0948707-5f19-4ba4-8c75-ca8a8939892f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5560fcdc-a697-444a-8372-401bba693dea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32cf3a07-db93-4088-a6eb-a3e52a2efc60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_5ac0fa55-c912-42dc-a93a-7f72e2add572_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_929a3eb9-ee7a-4137-8652-8d40b182811f_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_561f52ae-f1f6-4558-83c2-72649cbe2832_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_750e336c-7c63-4063-bf05-f707d9cb62cf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0970fcc7-1934-4f07-9cf7-908ee6ca75e8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_fe60530c-4d24-41e3-abaf-57e04907cb50_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9a615e57-701f-4565-b0b2-0cb16b81fa34_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_2656d548-9a58-454a-9b97-a2f5ed394e98_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9a2d875d-44eb-4ebd-8d22-f9eebae30018_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_a691cd8f-e996-42c5-9404-bb69f6207f6e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c2184724-e682-49ec-9cf4-903bd6e3e6a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_eba8452b-74a1-4156-8a65-d2be59bfba32_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_27fbcb90-b878-41ed-a372-c5ef851eb0c1_terseLabel_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries with drug approval, excluding the u.s.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_label_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:label id="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_documentation_en-US" xlink:label="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Countries With Drug Approval, Excluding The U.S.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:href="exel-20230331.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:to="lab_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductGrossMember_73f9c548-5bd0-4213-8f12-50ab60423ce8_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_label_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_documentation_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember" xlink:href="exel-20230331.xsd#exel_ProductGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember" xlink:to="lab_exel_ProductGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_245b7b4f-c43c-4530-828c-6c5e508a57a6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_791d9487-9d59-406d-bf2d-69e8a39bd456_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_fa99efda-9260-4ed7-b476-9a63eaeebb02_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development technology</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_4d073756-b5ec-4220-95f1-c5ef5fb03676_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_783114f8-3653-4d1e-81d9-906b39e463b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_438ff976-5e66-4d99-9840-c23043461cca_netLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_230c4f85-9653-4fb5-95c0-2ec305d56cf1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0f5501b6-a3e1-4bfd-8385-70eac8673a83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_715769ee-7adc-44fe-aa61-3dffc5f8054b_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_da477d67-af6a-4bcb-b1cc-087a032a837e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0fa949dd-4f15-48ce-98dd-d8018a3990b6_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CardinalHealthMember_68244442-728d-442a-a069-d2c3ba9dd35e_terseLabel_en-US" xlink:label="lab_exel_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc.</link:label>
    <link:label id="lab_exel_CardinalHealthMember_label_en-US" xlink:label="lab_exel_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health [Member]</link:label>
    <link:label id="lab_exel_CardinalHealthMember_documentation_en-US" xlink:label="lab_exel_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CardinalHealthMember" xlink:href="exel-20230331.xsd#exel_CardinalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CardinalHealthMember" xlink:to="lab_exel_CardinalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c3f56443-4f4e-4b15-96de-dc4e49c32f66_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_da42635a-0f8d-4352-b9d2-639e78ebe59f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_23f2aa6d-cac5-4a49-ae80-ded232f59a78_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_609b9d78-3fe0-4541-9a33-2a5417032b11_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_2bcea496-1bb9-43eb-a33c-3ab62520ac32_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4ded21f1-eaf8-44ef-9932-e6dd45c71dea_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_5854e423-2198-4001-b309-47c56b2697fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f43700b9-49d9-478b-a9bf-cabede14b0e7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_622c5475-a724-4800-87c2-329bf6fc965f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_56e3e755-9b92-44d2-879a-4949e07a2bb8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e06d7411-006a-47f5-bb2f-5268648d9948_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0973c531-9bde-4543-9e36-a03f122b2cdb_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1974dc03-dc9c-493a-8cde-b85b85eeb358_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_498c09c3-be9f-4d59-a7d9-83acadda39ab_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_318c724b-296c-4385-a48c-469c90429ebb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_acb1ebe5-2bbb-40d4-b4e4-cbcc8ff5c639_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_2d2e1080-d9f5-45af-addf-6884e956d100_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_cfefe8e4-4271-4bb0-b03a-72c6d8d1e8be_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_0cf6e42d-cf84-4d0a-958b-21c4647a0958_netLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_8afdf1ec-89e9-4b3b-a486-106e78d8bbb6_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_c96edc46-0558-42d3-8108-1b8e33c61f6a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>exel-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fbc3dff4-5359-4115-877c-cd80f1d37686,g:9f45ed8a-1512-41a6-b3b1-f3d762602463-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_acd4b1fa-ee01-422c-8396-f56dcbe6bb7a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_DocumentType_acd4b1fa-ee01-422c-8396-f56dcbe6bb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a8aa6b35-d672-4a6e-9898-7a97b2bf2628" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_DocumentQuarterlyReport_a8aa6b35-d672-4a6e-9898-7a97b2bf2628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_44032eb2-746f-4984-9f13-202797b3a8e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_DocumentPeriodEndDate_44032eb2-746f-4984-9f13-202797b3a8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1837c6b5-377b-4695-a5fc-b86548442111" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_DocumentTransitionReport_1837c6b5-377b-4695-a5fc-b86548442111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_454e104b-27f9-4947-8675-0394899659b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityFileNumber_454e104b-27f9-4947-8675-0394899659b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0300910a-ddf7-4032-aea0-2d4db4e8e665" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityRegistrantName_0300910a-ddf7-4032-aea0-2d4db4e8e665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8b526d24-2544-44e2-8f52-23bedb69c394" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8b526d24-2544-44e2-8f52-23bedb69c394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_15360af9-091b-4b5e-9926-0febfd8fb171" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityTaxIdentificationNumber_15360af9-091b-4b5e-9926-0febfd8fb171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_98b9b6cf-c299-4e0c-9286-db822eb8fcd0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityAddressAddressLine1_98b9b6cf-c299-4e0c-9286-db822eb8fcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9f36c501-821f-4ff0-9ea9-7ddee8afaa7e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityAddressCityOrTown_9f36c501-821f-4ff0-9ea9-7ddee8afaa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3b187982-df8c-4b2a-adfb-f876488dc246" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityAddressStateOrProvince_3b187982-df8c-4b2a-adfb-f876488dc246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9f0548e3-d39f-4d27-a589-302c51038c3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityAddressPostalZipCode_9f0548e3-d39f-4d27-a589-302c51038c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_79afcc5b-1f11-4c57-886c-34bc856b2d60" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_CityAreaCode_79afcc5b-1f11-4c57-886c-34bc856b2d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_32000a20-cf34-47ef-a4e4-41f0938a14fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_LocalPhoneNumber_32000a20-cf34-47ef-a4e4-41f0938a14fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_daba22c1-20b5-4e2b-865e-605fa7bc66b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_Security12bTitle_daba22c1-20b5-4e2b-865e-605fa7bc66b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_443478b7-a682-4431-9ce2-a85921e14420" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_TradingSymbol_443478b7-a682-4431-9ce2-a85921e14420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b42eac87-5f94-42a9-9baa-d7b5116a5a5e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_SecurityExchangeName_b42eac87-5f94-42a9-9baa-d7b5116a5a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_fe1994a7-62a1-4be1-a70c-a0483360ba73" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityCurrentReportingStatus_fe1994a7-62a1-4be1-a70c-a0483360ba73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_333a95de-8b0a-4d4f-842d-c07c7d1c2ffa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityInteractiveDataCurrent_333a95de-8b0a-4d4f-842d-c07c7d1c2ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4f15a332-ccac-49e1-9601-5718d9c169be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityFilerCategory_4f15a332-ccac-49e1-9601-5718d9c169be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3b7b7577-2b15-4e4a-bdde-7ad619b45a6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntitySmallBusiness_3b7b7577-2b15-4e4a-bdde-7ad619b45a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_23074180-a926-49c7-b882-e320b66ee7da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityEmergingGrowthCompany_23074180-a926-49c7-b882-e320b66ee7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c4bda570-2532-4fe0-b5f8-9359740959e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityShellCompany_c4bda570-2532-4fe0-b5f8-9359740959e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7cc00f12-b114-4421-bade-f5b03390cc70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7cc00f12-b114-4421-bade-f5b03390cc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6c69317a-cd36-42ab-b010-7e5229d50945" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_AmendmentFlag_6c69317a-cd36-42ab-b010-7e5229d50945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8336a742-ba99-451d-8c42-8f80f595ed83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_DocumentFiscalYearFocus_8336a742-ba99-451d-8c42-8f80f595ed83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3dd1d222-fc40-464c-9396-4bbaa02560e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3dd1d222-fc40-464c-9396-4bbaa02560e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2160b4cf-d395-47f2-8cb3-9258438be5d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_EntityCentralIndexKey_2160b4cf-d395-47f2-8cb3-9258438be5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4efc1149-1efe-4756-acf5-c24d7b71360d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a429c8-6ed5-4924-ac5c-0f7ac8f4fd8e" xlink:to="loc_dei_CurrentFiscalYearEndDate_4efc1149-1efe-4756-acf5-c24d7b71360d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f7c6c1f1-bb94-4a3f-9ac6-d1f66c302641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9b2d46d0-6772-4205-9abf-5612aa8b926d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f7c6c1f1-bb94-4a3f-9ac6-d1f66c302641" xlink:to="loc_us-gaap_AssetsAbstract_9b2d46d0-6772-4205-9abf-5612aa8b926d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d19bfcc2-8823-4d20-ba46-8f99f01cf71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b2d46d0-6772-4205-9abf-5612aa8b926d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d19bfcc2-8823-4d20-ba46-8f99f01cf71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d473dadb-40f9-4f2d-9d40-53e17a53613c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d19bfcc2-8823-4d20-ba46-8f99f01cf71d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d473dadb-40f9-4f2d-9d40-53e17a53613c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_80a7b349-9bf1-407f-802b-e757a15d5b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d19bfcc2-8823-4d20-ba46-8f99f01cf71d" xlink:to="loc_us-gaap_ShortTermInvestments_80a7b349-9bf1-407f-802b-e757a15d5b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_fdc8e13f-e4bd-4336-812b-45c597c6fc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d19bfcc2-8823-4d20-ba46-8f99f01cf71d" xlink:to="loc_us-gaap_ReceivablesNetCurrent_fdc8e13f-e4bd-4336-812b-45c597c6fc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_391bae21-962a-47a1-85a1-afde5aa4508f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d19bfcc2-8823-4d20-ba46-8f99f01cf71d" xlink:to="loc_us-gaap_InventoryNet_391bae21-962a-47a1-85a1-afde5aa4508f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_491ce5cc-0690-4bb6-b4f7-9debe56d4866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d19bfcc2-8823-4d20-ba46-8f99f01cf71d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_491ce5cc-0690-4bb6-b4f7-9debe56d4866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_aaa0c72f-9236-4571-9e7a-5bf1f1084047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d19bfcc2-8823-4d20-ba46-8f99f01cf71d" xlink:to="loc_us-gaap_AssetsCurrent_aaa0c72f-9236-4571-9e7a-5bf1f1084047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_b4803330-c6a0-458f-a93e-8347dd4ce4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b2d46d0-6772-4205-9abf-5612aa8b926d" xlink:to="loc_us-gaap_LongTermInvestments_b4803330-c6a0-458f-a93e-8347dd4ce4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ddecc558-3d61-457a-8757-cf348ac04375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b2d46d0-6772-4205-9abf-5612aa8b926d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ddecc558-3d61-457a-8757-cf348ac04375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_10148af3-024f-42c3-bb61-5a3fd0d5fd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b2d46d0-6772-4205-9abf-5612aa8b926d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_10148af3-024f-42c3-bb61-5a3fd0d5fd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c28d0296-c83a-4303-8232-c87ca9700e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b2d46d0-6772-4205-9abf-5612aa8b926d" xlink:to="loc_us-gaap_Goodwill_c28d0296-c83a-4303-8232-c87ca9700e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_42940e63-ea6f-4875-9261-1d0889747a4d" xlink:href="exel-20230331.xsd#exel_OperatingLeaseRightOfUseAssetAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b2d46d0-6772-4205-9abf-5612aa8b926d" xlink:to="loc_exel_OperatingLeaseRightOfUseAssetAndOtherAssets_42940e63-ea6f-4875-9261-1d0889747a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_beede132-a755-4a43-9b94-f62eb75716a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b2d46d0-6772-4205-9abf-5612aa8b926d" xlink:to="loc_us-gaap_Assets_beede132-a755-4a43-9b94-f62eb75716a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96341463-28a4-4867-bbed-670b34f689df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f7c6c1f1-bb94-4a3f-9ac6-d1f66c302641" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96341463-28a4-4867-bbed-670b34f689df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_39ae3065-35e4-4b82-9e23-6477b0067897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96341463-28a4-4867-bbed-670b34f689df" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_39ae3065-35e4-4b82-9e23-6477b0067897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5d9040ec-862a-4c74-8448-b8bf2d9d1fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39ae3065-35e4-4b82-9e23-6477b0067897" xlink:to="loc_us-gaap_AccountsPayableCurrent_5d9040ec-862a-4c74-8448-b8bf2d9d1fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_24eb6a45-b298-4f21-8ad6-350fc5a473b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39ae3065-35e4-4b82-9e23-6477b0067897" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_24eb6a45-b298-4f21-8ad6-350fc5a473b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_7c98941a-a0c9-4b77-9c89-4128ab7fc647" xlink:href="exel-20230331.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39ae3065-35e4-4b82-9e23-6477b0067897" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_7c98941a-a0c9-4b77-9c89-4128ab7fc647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_9f76f474-7647-4172-8c66-59c79519008e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39ae3065-35e4-4b82-9e23-6477b0067897" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_9f76f474-7647-4172-8c66-59c79519008e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_a31791fc-9426-46fd-9d84-ddd42618cf38" xlink:href="exel-20230331.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39ae3065-35e4-4b82-9e23-6477b0067897" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_a31791fc-9426-46fd-9d84-ddd42618cf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_086bdc28-434a-4590-919e-b1d27aa36e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39ae3065-35e4-4b82-9e23-6477b0067897" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_086bdc28-434a-4590-919e-b1d27aa36e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7b218e3f-6f86-480f-a8c2-03c67a26f406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39ae3065-35e4-4b82-9e23-6477b0067897" xlink:to="loc_us-gaap_LiabilitiesCurrent_7b218e3f-6f86-480f-a8c2-03c67a26f406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_24342142-31cf-450d-9a6b-7af335e3b566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96341463-28a4-4867-bbed-670b34f689df" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_24342142-31cf-450d-9a6b-7af335e3b566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5d197943-c45f-47a2-abb5-c2e04f072c53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96341463-28a4-4867-bbed-670b34f689df" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5d197943-c45f-47a2-abb5-c2e04f072c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_05116ed0-dd6e-40f6-b32f-2a835265ea69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96341463-28a4-4867-bbed-670b34f689df" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_05116ed0-dd6e-40f6-b32f-2a835265ea69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_240eb757-21a8-4047-b96d-03ccea1fb7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96341463-28a4-4867-bbed-670b34f689df" xlink:to="loc_us-gaap_Liabilities_240eb757-21a8-4047-b96d-03ccea1fb7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a27226e1-cebd-47f4-b02f-e85efd69fecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96341463-28a4-4867-bbed-670b34f689df" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a27226e1-cebd-47f4-b02f-e85efd69fecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ea023555-79f4-4b70-959f-9e9dedcebe75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96341463-28a4-4867-bbed-670b34f689df" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ea023555-79f4-4b70-959f-9e9dedcebe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_01da3400-680b-4c47-83c4-154c9a1d4c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ea023555-79f4-4b70-959f-9e9dedcebe75" xlink:to="loc_us-gaap_PreferredStockValue_01da3400-680b-4c47-83c4-154c9a1d4c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fa1e43fd-156a-455f-9709-4903885e5511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ea023555-79f4-4b70-959f-9e9dedcebe75" xlink:to="loc_us-gaap_CommonStockValue_fa1e43fd-156a-455f-9709-4903885e5511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d95146a1-e1d2-41d8-b3ec-a32cdbece40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ea023555-79f4-4b70-959f-9e9dedcebe75" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d95146a1-e1d2-41d8-b3ec-a32cdbece40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b6bd344-0d7f-4189-b985-6a06336d8f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ea023555-79f4-4b70-959f-9e9dedcebe75" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b6bd344-0d7f-4189-b985-6a06336d8f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d5be447e-3b22-4cc9-aade-b13adb8ad891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ea023555-79f4-4b70-959f-9e9dedcebe75" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d5be447e-3b22-4cc9-aade-b13adb8ad891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0d481d89-bf73-4725-bbb4-3010a134e0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ea023555-79f4-4b70-959f-9e9dedcebe75" xlink:to="loc_us-gaap_StockholdersEquity_0d481d89-bf73-4725-bbb4-3010a134e0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6d31de8f-10cc-4ea5-9604-7568058e3aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_96341463-28a4-4867-bbed-670b34f689df" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6d31de8f-10cc-4ea5-9604-7568058e3aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea82ec-a716-4732-8015-26e5426b0a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_865c486f-5d61-4342-8d36-26049c7747d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea82ec-a716-4732-8015-26e5426b0a70" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_865c486f-5d61-4342-8d36-26049c7747d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7ef4b995-34ad-45be-a1a9-14b2ddc3cde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_865c486f-5d61-4342-8d36-26049c7747d7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7ef4b995-34ad-45be-a1a9-14b2ddc3cde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fb6ec40c-0605-4d02-9bb4-7af483f61899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_865c486f-5d61-4342-8d36-26049c7747d7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fb6ec40c-0605-4d02-9bb4-7af483f61899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_87ac8c4a-7c42-438d-89c1-90638201444e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_865c486f-5d61-4342-8d36-26049c7747d7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_87ac8c4a-7c42-438d-89c1-90638201444e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1244ef79-0731-4766-8dfe-ac2b712d2b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_35ea82ec-a716-4732-8015-26e5426b0a70" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1244ef79-0731-4766-8dfe-ac2b712d2b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2c8bfe66-5121-4bdf-9864-8050ceaa3a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1244ef79-0731-4766-8dfe-ac2b712d2b79" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2c8bfe66-5121-4bdf-9864-8050ceaa3a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_185acc76-6300-43f8-8a51-d47e7e66c7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1244ef79-0731-4766-8dfe-ac2b712d2b79" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_185acc76-6300-43f8-8a51-d47e7e66c7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c6b7af6e-6fa7-4e68-81a4-090e14c84a92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1244ef79-0731-4766-8dfe-ac2b712d2b79" xlink:to="loc_us-gaap_CommonStockSharesIssued_c6b7af6e-6fa7-4e68-81a4-090e14c84a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0f813a15-4410-49bb-a524-37a748f098b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1244ef79-0731-4766-8dfe-ac2b712d2b79" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0f813a15-4410-49bb-a524-37a748f098b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a07d7fc4-e7c2-4e4a-9ee3-4000f3c1f6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fed2ba47-c2eb-485d-ab1c-bf988e335245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a07d7fc4-e7c2-4e4a-9ee3-4000f3c1f6e7" xlink:to="loc_us-gaap_StatementTable_fed2ba47-c2eb-485d-ab1c-bf988e335245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_66bea905-f0de-47f6-813f-99ff0b03aef1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fed2ba47-c2eb-485d-ab1c-bf988e335245" xlink:to="loc_srt_ProductOrServiceAxis_66bea905-f0de-47f6-813f-99ff0b03aef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_59b7da54-9a66-492a-a3f9-935fae8e380f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_66bea905-f0de-47f6-813f-99ff0b03aef1" xlink:to="loc_srt_ProductsAndServicesDomain_59b7da54-9a66-492a-a3f9-935fae8e380f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_22254f41-710e-47de-b3e1-f0da255038ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_59b7da54-9a66-492a-a3f9-935fae8e380f" xlink:to="loc_us-gaap_ProductMember_22254f41-710e-47de-b3e1-f0da255038ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_20df8f19-389a-435b-81c5-c907542a8699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_59b7da54-9a66-492a-a3f9-935fae8e380f" xlink:to="loc_us-gaap_LicenseMember_20df8f19-389a-435b-81c5-c907542a8699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_29227f35-419a-4056-ae40-3aaf35890e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_59b7da54-9a66-492a-a3f9-935fae8e380f" xlink:to="loc_us-gaap_ServiceMember_29227f35-419a-4056-ae40-3aaf35890e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fed2ba47-c2eb-485d-ab1c-bf988e335245" xlink:to="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8d82e19e-dbc7-4080-9c61-d8a2ceacdbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_RevenuesAbstract_8d82e19e-dbc7-4080-9c61-d8a2ceacdbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8a3fb5e5-18dd-4d9a-9ecb-db9a2770b743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8d82e19e-dbc7-4080-9c61-d8a2ceacdbf1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8a3fb5e5-18dd-4d9a-9ecb-db9a2770b743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_90794643-5446-40a1-a48b-57cbeb1e6fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_90794643-5446-40a1-a48b-57cbeb1e6fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_faec3808-86c5-4e5d-a400-adb87ef006c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_faec3808-86c5-4e5d-a400-adb87ef006c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0a4fed19-59b5-497c-a7f3-102acba2acbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0a4fed19-59b5-497c-a7f3-102acba2acbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_63ac42cd-f13b-424a-8925-7ece1fee941e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_98fcab63-2665-4923-9726-f5010100d2b9" xlink:to="loc_us-gaap_CostsAndExpenses_63ac42cd-f13b-424a-8925-7ece1fee941e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ce078e74-237a-4004-a025-14e3294c34ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_OperatingIncomeLoss_ce078e74-237a-4004-a025-14e3294c34ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_9d281eb0-d6dc-45bd-aac5-b9f18edc6224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_InterestIncomeOther_9d281eb0-d6dc-45bd-aac5-b9f18edc6224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d2a235ad-432e-4ca3-a018-cb71c2f7b8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d2a235ad-432e-4ca3-a018-cb71c2f7b8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_f3067cd3-a77b-401e-bc13-38ca9a9d8e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_f3067cd3-a77b-401e-bc13-38ca9a9d8e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b20137b8-dfd4-4aa4-8b49-5562eebffd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b20137b8-dfd4-4aa4-8b49-5562eebffd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ad5b70bb-c386-44d3-b66d-ad39b62951dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_NetIncomeLoss_ad5b70bb-c386-44d3-b66d-ad39b62951dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_96400bae-e30a-4908-a7ff-8308739ad280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_EarningsPerShareAbstract_96400bae-e30a-4908-a7ff-8308739ad280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d5337745-2e3c-4373-8d87-560df3cb108c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_96400bae-e30a-4908-a7ff-8308739ad280" xlink:to="loc_us-gaap_EarningsPerShareBasic_d5337745-2e3c-4373-8d87-560df3cb108c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4da7f2a1-c40b-492e-906e-ee7d1451fd55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_96400bae-e30a-4908-a7ff-8308739ad280" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4da7f2a1-c40b-492e-906e-ee7d1451fd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4f0abc59-e8b2-4b0a-b782-1506a38cadd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_423194d6-4a47-4411-a49d-b54aba2c3067" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4f0abc59-e8b2-4b0a-b782-1506a38cadd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91f86d69-abcd-49f9-86c0-85d38d306c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4f0abc59-e8b2-4b0a-b782-1506a38cadd0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_91f86d69-abcd-49f9-86c0-85d38d306c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0465d8dd-caa7-4b50-bbdd-5d308373c88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_4f0abc59-e8b2-4b0a-b782-1506a38cadd0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0465d8dd-caa7-4b50-bbdd-5d308373c88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6f8376c5-1af3-4552-9b2b-5aa5d4026f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_42bbe532-1498-4be7-91e5-ee62d0eab554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6f8376c5-1af3-4552-9b2b-5aa5d4026f08" xlink:to="loc_us-gaap_NetIncomeLoss_42bbe532-1498-4be7-91e5-ee62d0eab554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_64edff21-a5e7-4f0d-b7c4-873bbc3065db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6f8376c5-1af3-4552-9b2b-5aa5d4026f08" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_64edff21-a5e7-4f0d-b7c4-873bbc3065db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0968c78f-d60a-43c8-882b-0476421d3551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_64edff21-a5e7-4f0d-b7c4-873bbc3065db" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0968c78f-d60a-43c8-882b-0476421d3551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9259ff62-616f-4feb-9646-6213932377b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6f8376c5-1af3-4552-9b2b-5aa5d4026f08" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9259ff62-616f-4feb-9646-6213932377b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_df428f04-17b8-43ac-95ee-d3a5409fa7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_175db418-45be-411c-9f25-d20a98d9907a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_df428f04-17b8-43ac-95ee-d3a5409fa7fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_175db418-45be-411c-9f25-d20a98d9907a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_648ece11-3545-4df7-9742-068ca8de436e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4eb3c060-00b8-4ba2-811c-3a429a41b71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_648ece11-3545-4df7-9742-068ca8de436e" xlink:to="loc_us-gaap_StatementTable_4eb3c060-00b8-4ba2-811c-3a429a41b71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1f649eb1-1ccb-495c-8669-70ba274b2bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4eb3c060-00b8-4ba2-811c-3a429a41b71f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1f649eb1-1ccb-495c-8669-70ba274b2bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1f649eb1-1ccb-495c-8669-70ba274b2bcd" xlink:to="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_211676ba-6198-47fe-8d1c-b097c3b5be3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:to="loc_us-gaap_CommonStockMember_211676ba-6198-47fe-8d1c-b097c3b5be3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fd007812-d43c-4d84-9f8a-24c043a7ddef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fd007812-d43c-4d84-9f8a-24c043a7ddef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ad0334d2-cd1c-429e-8be1-852ddde962b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ad0334d2-cd1c-429e-8be1-852ddde962b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_90820aea-fcd6-4900-8344-8485032833cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a836cd3c-0a44-4981-9478-c328153e8961" xlink:to="loc_us-gaap_RetainedEarningsMember_90820aea-fcd6-4900-8344-8485032833cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6797a96c-4bac-4051-a5dd-e5bcb39f37eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4eb3c060-00b8-4ba2-811c-3a429a41b71f" xlink:to="loc_us-gaap_StatementLineItems_6797a96c-4bac-4051-a5dd-e5bcb39f37eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6797a96c-4bac-4051-a5dd-e5bcb39f37eb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ff67625a-4c22-4153-b1b6-2a67220557c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ff67625a-4c22-4153-b1b6-2a67220557c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e4d115f6-8918-46ef-a1d3-d5297d6b78a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_StockholdersEquity_e4d115f6-8918-46ef-a1d3-d5297d6b78a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ec4fdc3c-6956-4ad1-a971-f660a2a09ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_NetIncomeLoss_ec4fdc3c-6956-4ad1-a971-f660a2a09ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a8cdc8df-8ce6-43aa-a73f-0567b41aca2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a8cdc8df-8ce6-43aa-a73f-0567b41aca2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_439754a1-0b55-4cfa-bdcd-c96558fd575d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_439754a1-0b55-4cfa-bdcd-c96558fd575d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c8bb68e1-b06a-4fa8-a940-e9dba0c66e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c8bb68e1-b06a-4fa8-a940-e9dba0c66e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_9776c346-2cd4-444b-80ae-92bf97f35b26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_9776c346-2cd4-444b-80ae-92bf97f35b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_91c60f22-717e-4361-a744-04ebbc300d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_91c60f22-717e-4361-a744-04ebbc300d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9c60dafe-5d6e-4a87-9b3c-80e28972aa34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9c60dafe-5d6e-4a87-9b3c-80e28972aa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c49dedc7-43af-4e08-9fbe-7add6235e47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d614c58c-3bb8-4db2-b592-2383360cc2a6" xlink:to="loc_us-gaap_StockholdersEquity_c49dedc7-43af-4e08-9fbe-7add6235e47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_885be6dd-a61d-47ce-b3a0-b691280caa03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c7d33095-0bf6-46ef-8c2a-149e40ad9ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_885be6dd-a61d-47ce-b3a0-b691280caa03" xlink:to="loc_us-gaap_NetIncomeLoss_c7d33095-0bf6-46ef-8c2a-149e40ad9ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d5591089-bcdf-45df-83af-8e466de4b20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_885be6dd-a61d-47ce-b3a0-b691280caa03" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d5591089-bcdf-45df-83af-8e466de4b20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f80541e1-bea4-4068-be2e-d4d73a8dff6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d5591089-bcdf-45df-83af-8e466de4b20b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f80541e1-bea4-4068-be2e-d4d73a8dff6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b47eb529-21db-4b5e-b69c-248c8c0ac219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d5591089-bcdf-45df-83af-8e466de4b20b" xlink:to="loc_us-gaap_ShareBasedCompensation_b47eb529-21db-4b5e-b69c-248c8c0ac219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_9f598d06-32a9-4003-ab32-9751a99af479" xlink:href="exel-20230331.xsd#exel_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d5591089-bcdf-45df-83af-8e466de4b20b" xlink:to="loc_exel_NoncashLeaseExpense_9f598d06-32a9-4003-ab32-9751a99af479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_43cf7745-30ca-4789-ab18-f537e8d42778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d5591089-bcdf-45df-83af-8e466de4b20b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_43cf7745-30ca-4789-ab18-f537e8d42778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c1e04bf0-227b-44df-9c9a-a5080b1caca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d5591089-bcdf-45df-83af-8e466de4b20b" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c1e04bf0-227b-44df-9c9a-a5080b1caca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b12b2223-4b3b-41e7-9ca6-faea1abebdac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d5591089-bcdf-45df-83af-8e466de4b20b" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b12b2223-4b3b-41e7-9ca6-faea1abebdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6f56d87-3671-4570-ad4d-c2f37a2bca62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d5591089-bcdf-45df-83af-8e466de4b20b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6f56d87-3671-4570-ad4d-c2f37a2bca62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e69d3082-9aaf-468f-bd87-bd17d9f45d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6f56d87-3671-4570-ad4d-c2f37a2bca62" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e69d3082-9aaf-468f-bd87-bd17d9f45d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b012bfff-c157-4f0a-b83e-2cd98da31e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6f56d87-3671-4570-ad4d-c2f37a2bca62" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b012bfff-c157-4f0a-b83e-2cd98da31e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c9fc6624-8a96-49a1-870e-8b5f777983c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6f56d87-3671-4570-ad4d-c2f37a2bca62" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c9fc6624-8a96-49a1-870e-8b5f777983c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ef7f0beb-ffe8-4a0f-9c94-f6f3a60e7741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6f56d87-3671-4570-ad4d-c2f37a2bca62" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ef7f0beb-ffe8-4a0f-9c94-f6f3a60e7741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_609db656-016c-4ce0-87c3-dcb669fc881c" xlink:href="exel-20230331.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6f56d87-3671-4570-ad4d-c2f37a2bca62" xlink:to="loc_exel_IncreaseDecreaseInAccruedCollaborationLiabilities_609db656-016c-4ce0-87c3-dcb669fc881c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8164fc02-5d5b-4849-b5cd-c17a15aa5494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f6f56d87-3671-4570-ad4d-c2f37a2bca62" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8164fc02-5d5b-4849-b5cd-c17a15aa5494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3725d7f-db9b-4bcc-bfd6-72432729be96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_885be6dd-a61d-47ce-b3a0-b691280caa03" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f3725d7f-db9b-4bcc-bfd6-72432729be96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ace68369-34d7-40a1-9163-9b21fc9cf711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_885be6dd-a61d-47ce-b3a0-b691280caa03" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ace68369-34d7-40a1-9163-9b21fc9cf711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f583dcfe-ecdc-45c2-9422-d0289f91a50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ace68369-34d7-40a1-9163-9b21fc9cf711" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f583dcfe-ecdc-45c2-9422-d0289f91a50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_14710a64-3334-4c9d-837d-aa5d031f54bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ace68369-34d7-40a1-9163-9b21fc9cf711" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_14710a64-3334-4c9d-837d-aa5d031f54bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_f2e5529b-d86a-4405-9ffd-f1aaeef3bb33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ace68369-34d7-40a1-9163-9b21fc9cf711" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_f2e5529b-d86a-4405-9ffd-f1aaeef3bb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9df480c8-493e-4437-aba9-0f0dd96cda1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ace68369-34d7-40a1-9163-9b21fc9cf711" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9df480c8-493e-4437-aba9-0f0dd96cda1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_181c0da9-5449-4dad-b8c9-b99b93b6bcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ace68369-34d7-40a1-9163-9b21fc9cf711" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_181c0da9-5449-4dad-b8c9-b99b93b6bcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44d62c17-64a5-4624-a0d0-040a3ae0a23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_885be6dd-a61d-47ce-b3a0-b691280caa03" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44d62c17-64a5-4624-a0d0-040a3ae0a23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c0802a34-15d9-45ba-bfc6-5d3bd2da2d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44d62c17-64a5-4624-a0d0-040a3ae0a23f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c0802a34-15d9-45ba-bfc6-5d3bd2da2d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_eee33e39-9ba9-4e11-a7d1-2270dbb1de6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44d62c17-64a5-4624-a0d0-040a3ae0a23f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_eee33e39-9ba9-4e11-a7d1-2270dbb1de6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b12f150a-2eb3-403a-954d-a952ab1e601d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_44d62c17-64a5-4624-a0d0-040a3ae0a23f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b12f150a-2eb3-403a-954d-a952ab1e601d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fef5421f-b7ab-4905-920e-8f0e07d23291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_885be6dd-a61d-47ce-b3a0-b691280caa03" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fef5421f-b7ab-4905-920e-8f0e07d23291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_368fd1e1-6138-45b2-9d1d-75e15e8c746d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_885be6dd-a61d-47ce-b3a0-b691280caa03" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_368fd1e1-6138-45b2-9d1d-75e15e8c746d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_66ce0b43-b619-46ba-96a9-4bc0c45029e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_885be6dd-a61d-47ce-b3a0-b691280caa03" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_66ce0b43-b619-46ba-96a9-4bc0c45029e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20230331.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60d6a955-728d-4332-a4e2-b5b90f0cf181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f088d157-59a7-415e-9ada-c4689e02c1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60d6a955-728d-4332-a4e2-b5b90f0cf181" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f088d157-59a7-415e-9ada-c4689e02c1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20230331.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_233edb11-a22d-4d46-b408-d1157db1ec75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_496fcaa7-c93b-4bfb-a67c-94b0ca84e8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_233edb11-a22d-4d46-b408-d1157db1ec75" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_496fcaa7-c93b-4bfb-a67c-94b0ca84e8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivities"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4a5f048-0171-43fa-9897-e419fff79048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_11fd3287-166a-4ace-8711-106c7a8d251c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4a5f048-0171-43fa-9897-e419fff79048" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_11fd3287-166a-4ace-8711-106c7a8d251c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestments"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1609630f-1dbe-4605-9187-96de4f8f0668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_d126529b-a501-4514-9671-54c05157121d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1609630f-1dbe-4605-9187-96de4f8f0668" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_d126529b-a501-4514-9671-54c05157121d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a7d05109-9c89-44b5-9de9-8ea860d79194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f6d7cca3-de7b-4a2c-96fa-a4e3721918ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a7d05109-9c89-44b5-9de9-8ea860d79194" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f6d7cca3-de7b-4a2c-96fa-a4e3721918ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20230331.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_aa3c85bb-6a92-44bd-9e25-17e766f9b244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_05e508e0-0cef-4b46-9510-bb7b1abcb27e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_aa3c85bb-6a92-44bd-9e25-17e766f9b244" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_05e508e0-0cef-4b46-9510-bb7b1abcb27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockholdersEquity" xlink:type="simple" xlink:href="exel-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24b46f23-ee44-4a73-9053-8675c54f3022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5126d644-158a-454f-86f1-e836df9c0a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24b46f23-ee44-4a73-9053-8675c54f3022" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5126d644-158a-454f-86f1-e836df9c0a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="simple" xlink:href="exel-20230331.xsd#ProvisionForIncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a40a501c-bea8-4568-819f-b4bc570a921b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_27443187-ed0f-4a80-b3d6-462501abae2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a40a501c-bea8-4568-819f-b4bc570a921b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_27443187-ed0f-4a80-b3d6-462501abae2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20230331.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_06853dfd-7b92-4209-b766-d225bf677ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0de9e26e-f3b0-4e1f-a0bd-0820bbd7d718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_06853dfd-7b92-4209-b766-d225bf677ea6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0de9e26e-f3b0-4e1f-a0bd-0820bbd7d718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_43dd40cd-350a-4f78-9973-71ce06735d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dd01e6e0-5c26-4d2b-9b42-6da890d8356e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_43dd40cd-350a-4f78-9973-71ce06735d88" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dd01e6e0-5c26-4d2b-9b42-6da890d8356e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20230331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3229718d-eb21-431f-8c00-31448277bb38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_cf35a013-be19-4d9b-aa7c-67b38503c3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3229718d-eb21-431f-8c00-31448277bb38" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_cf35a013-be19-4d9b-aa7c-67b38503c3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f86603b2-cdbb-49a7-bcd3-898a5eaae7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3229718d-eb21-431f-8c00-31448277bb38" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f86603b2-cdbb-49a7-bcd3-898a5eaae7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_6b3d2ed1-1c2a-468b-99ee-5e81ece02963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3229718d-eb21-431f-8c00-31448277bb38" xlink:to="loc_us-gaap_FiscalPeriod_6b3d2ed1-1c2a-468b-99ee-5e81ece02963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0b968da7-d76e-43c3-be4d-0848ed684ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3229718d-eb21-431f-8c00-31448277bb38" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0b968da7-d76e-43c3-be4d-0848ed684ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0cff96db-c22c-4e0d-904d-24225b898014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3229718d-eb21-431f-8c00-31448277bb38" xlink:to="loc_us-gaap_UseOfEstimates_0cff96db-c22c-4e0d-904d-24225b898014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_209848ac-5feb-4359-83fb-984120b407be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3229718d-eb21-431f-8c00-31448277bb38" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_209848ac-5feb-4359-83fb-984120b407be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_783d9785-d34e-471b-89c7-7731e4c8b6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3229718d-eb21-431f-8c00-31448277bb38" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_783d9785-d34e-471b-89c7-7731e4c8b6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_78c899dd-2984-474f-b981-73b69e5f20c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_188fdd21-1b8f-441a-b9aa-30f08d5c1d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_78c899dd-2984-474f-b981-73b69e5f20c3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_188fdd21-1b8f-441a-b9aa-30f08d5c1d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d9639be5-649e-4d60-93c0-ab262ae11973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_78c899dd-2984-474f-b981-73b69e5f20c3" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_d9639be5-649e-4d60-93c0-ab262ae11973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_3c354387-ca30-4b43-b087-4d7678616b22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_78c899dd-2984-474f-b981-73b69e5f20c3" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_3c354387-ca30-4b43-b087-4d7678616b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_defa2d4d-f784-4821-9127-511e461e2449" xlink:href="exel-20230331.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_78c899dd-2984-474f-b981-73b69e5f20c3" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_defa2d4d-f784-4821-9127-511e461e2449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_6180a3a8-099f-4f14-ba74-9df555e6632d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_78c899dd-2984-474f-b981-73b69e5f20c3" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_6180a3a8-099f-4f14-ba74-9df555e6632d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4ba8082-b650-4a1c-a4da-cf2943951a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3b556050-c228-47df-8e38-64513d8ccbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4ba8082-b650-4a1c-a4da-cf2943951a0b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3b556050-c228-47df-8e38-64513d8ccbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1aa29baa-fa20-4606-a961-1cb340b527e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ea867f76-0554-4d86-ad92-f138f3a96e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1aa29baa-fa20-4606-a961-1cb340b527e4" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_ea867f76-0554-4d86-ad92-f138f3a96e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4bbc8673-5cbd-445c-91bc-566d4e740768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1aa29baa-fa20-4606-a961-1cb340b527e4" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4bbc8673-5cbd-445c-91bc-566d4e740768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_d3e687a4-0b72-44e4-b581-180bead21308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1aa29baa-fa20-4606-a961-1cb340b527e4" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_d3e687a4-0b72-44e4-b581-180bead21308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_73e67fc3-9f90-4e7c-add8-ca85e311271f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1aa29baa-fa20-4606-a961-1cb340b527e4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_73e67fc3-9f90-4e7c-add8-ca85e311271f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f08cf17e-88cb-42de-996a-daf024e1ecf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1aa29baa-fa20-4606-a961-1cb340b527e4" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f08cf17e-88cb-42de-996a-daf024e1ecf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d17b716e-abd5-4d6f-8a6a-212dc0030411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_555a7956-5809-402e-8be7-eaaa03f5bb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d17b716e-abd5-4d6f-8a6a-212dc0030411" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_555a7956-5809-402e-8be7-eaaa03f5bb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20230331.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_da0b2dab-7b2e-4d77-9e3e-335af3ea7f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9150c4b7-fc6c-4ae5-a7ca-61004fbba2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_da0b2dab-7b2e-4d77-9e3e-335af3ea7f1d" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9150c4b7-fc6c-4ae5-a7ca-61004fbba2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="exel-20230331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9464633-f518-413f-9951-5a35e23e080c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f71ea58f-0265-46f4-b0e2-622e96ceabd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9464633-f518-413f-9951-5a35e23e080c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f71ea58f-0265-46f4-b0e2-622e96ceabd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20230331.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_98879256-0031-49f3-81e0-06fc3fe81cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c865180b-59c6-4ee5-bcf0-5a2b8e478350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98879256-0031-49f3-81e0-06fc3fe81cc2" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c865180b-59c6-4ee5-bcf0-5a2b8e478350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ff0688c0-d2a9-43b9-8e23-313461163a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98879256-0031-49f3-81e0-06fc3fe81cc2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ff0688c0-d2a9-43b9-8e23-313461163a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a979b650-1b30-4f01-8668-e2e571e46787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_327e59cc-af19-4df4-87ee-fbc3286f6ae5" xlink:href="exel-20230331.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a979b650-1b30-4f01-8668-e2e571e46787" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_327e59cc-af19-4df4-87ee-fbc3286f6ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3eab9be2-2dcb-494f-8dca-db36b93f5539" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_327e59cc-af19-4df4-87ee-fbc3286f6ae5" xlink:to="loc_srt_ProductOrServiceAxis_3eab9be2-2dcb-494f-8dca-db36b93f5539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b74591b8-de41-4b0b-94c9-7001a47e0a65" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3eab9be2-2dcb-494f-8dca-db36b93f5539" xlink:to="loc_srt_ProductsAndServicesDomain_b74591b8-de41-4b0b-94c9-7001a47e0a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_196a738d-534f-48ab-bd27-102d63e9b98a" xlink:href="exel-20230331.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b74591b8-de41-4b0b-94c9-7001a47e0a65" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_196a738d-534f-48ab-bd27-102d63e9b98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_c789b9aa-2fd3-4575-a043-8cb245a9072c" xlink:href="exel-20230331.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_327e59cc-af19-4df4-87ee-fbc3286f6ae5" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_c789b9aa-2fd3-4575-a043-8cb245a9072c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_78bd9c82-6bf0-432c-9ffc-f145e19030fe" xlink:href="exel-20230331.xsd#exel_NumberOfCountriesWithDrugApprovalExcludingTheUS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_c789b9aa-2fd3-4575-a043-8cb245a9072c" xlink:to="loc_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS_78bd9c82-6bf0-432c-9ffc-f145e19030fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_eb924d76-8b0b-4636-8420-dca4a9cdb8d6" xlink:href="exel-20230331.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_c789b9aa-2fd3-4575-a043-8cb245a9072c" xlink:to="loc_exel_NumberofProductsinCommercialMarket_eb924d76-8b0b-4636-8420-dca4a9cdb8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_fb1b99f9-505a-4ee4-ad70-9c3116414980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_c789b9aa-2fd3-4575-a043-8cb245a9072c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_fb1b99f9-505a-4ee4-ad70-9c3116414980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_21005cee-f733-4ee9-8dd4-72eb5c1b5aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_d3017c6a-ff2e-4703-a5df-299865a45ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_21005cee-f733-4ee9-8dd4-72eb5c1b5aac" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_d3017c6a-ff2e-4703-a5df-299865a45ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5fef914b-c84e-426e-ac33-e13f3ac2523f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d3017c6a-ff2e-4703-a5df-299865a45ee6" xlink:to="loc_srt_ProductOrServiceAxis_5fef914b-c84e-426e-ac33-e13f3ac2523f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5fef914b-c84e-426e-ac33-e13f3ac2523f" xlink:to="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_8fb5c03f-a136-402d-98c4-e8ebb1bbd471" xlink:href="exel-20230331.xsd#exel_ProductGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_exel_ProductGrossMember_8fb5c03f-a136-402d-98c4-e8ebb1bbd471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_f811b9fe-8800-4c22-9b9d-954a67abafb1" xlink:href="exel-20230331.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_f811b9fe-8800-4c22-9b9d-954a67abafb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d38a1eee-06ae-4ac1-a05f-019bc6edfa76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_us-gaap_ProductMember_d38a1eee-06ae-4ac1-a05f-019bc6edfa76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_67b4ef8f-41fd-4451-b49c-52c1e30df945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_us-gaap_LicenseMember_67b4ef8f-41fd-4451-b49c-52c1e30df945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ac2a659f-721c-4e24-8db8-0fd26a4b6f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_us-gaap_ServiceMember_ac2a659f-721c-4e24-8db8-0fd26a4b6f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_bfaa419e-1d25-4421-9e81-15a292422516" xlink:href="exel-20230331.xsd#exel_CollaborationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ef2d0f4-7ace-41fe-939d-2680522a98ec" xlink:to="loc_exel_CollaborationMember_bfaa419e-1d25-4421-9e81-15a292422516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bff03881-655e-4b9d-b884-2ce06afafdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_d3017c6a-ff2e-4703-a5df-299865a45ee6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_bff03881-655e-4b9d-b884-2ce06afafdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fda55100-aeea-4e0d-8608-ac525b473fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bff03881-655e-4b9d-b884-2ce06afafdf6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fda55100-aeea-4e0d-8608-ac525b473fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f9cf728b-ebaa-45d5-aecf-c394dae670f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_09fc385c-e72c-4547-88df-9b2cfe69b6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f9cf728b-ebaa-45d5-aecf-c394dae670f5" xlink:to="loc_us-gaap_ConcentrationRiskTable_09fc385c-e72c-4547-88df-9b2cfe69b6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ad245fea-5a79-4213-85e5-7e9cab0da5db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_09fc385c-e72c-4547-88df-9b2cfe69b6e2" xlink:to="loc_srt_MajorCustomersAxis_ad245fea-5a79-4213-85e5-7e9cab0da5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ad245fea-5a79-4213-85e5-7e9cab0da5db" xlink:to="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_3363178d-babb-4afe-a4f7-8fbcdf75fdbb" xlink:href="exel-20230331.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_3363178d-babb-4afe-a4f7-8fbcdf75fdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_c7f447b5-747a-42bf-955c-8fd80981a91a" xlink:href="exel-20230331.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_c7f447b5-747a-42bf-955c-8fd80981a91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_67dee3a0-9c9b-494b-b969-5534adc086e9" xlink:href="exel-20230331.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_67dee3a0-9c9b-494b-b969-5534adc086e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_14bf8ad1-3341-44c5-ace4-a4c850d3fb58" xlink:href="exel-20230331.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_AccredoHealthIncorporatedMember_14bf8ad1-3341-44c5-ace4-a4c850d3fb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_6bb71ec7-b5a7-49c9-9588-6f7ce2db6cd9" xlink:href="exel-20230331.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_6bb71ec7-b5a7-49c9-9588-6f7ce2db6cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_98d361f2-4a9f-4a54-badf-829fc0a9817f" xlink:href="exel-20230331.xsd#exel_IpsenMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_IpsenMember_98d361f2-4a9f-4a54-badf-829fc0a9817f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CardinalHealthMember_fe4b08ce-36a2-4478-ac06-c95f5a1d2b0c" xlink:href="exel-20230331.xsd#exel_CardinalHealthMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_68263213-e09f-4e14-939a-33ac9ab83b59" xlink:to="loc_exel_CardinalHealthMember_fe4b08ce-36a2-4478-ac06-c95f5a1d2b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abb0a3b2-c1e6-4434-aea0-0de9eeb94be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_09fc385c-e72c-4547-88df-9b2cfe69b6e2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abb0a3b2-c1e6-4434-aea0-0de9eeb94be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9354e4fb-8113-4b7e-9738-d1fc6621d672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_abb0a3b2-c1e6-4434-aea0-0de9eeb94be3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9354e4fb-8113-4b7e-9738-d1fc6621d672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_115c069a-6b5c-43f5-b3bb-a065c2216c25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9354e4fb-8113-4b7e-9738-d1fc6621d672" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_115c069a-6b5c-43f5-b3bb-a065c2216c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2bbf9b65-6782-4da1-b13d-77b459c2d9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9354e4fb-8113-4b7e-9738-d1fc6621d672" xlink:to="loc_us-gaap_AccountsReceivableMember_2bbf9b65-6782-4da1-b13d-77b459c2d9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_993c7a23-e49d-4ef5-8df7-d53ddd35529e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_09fc385c-e72c-4547-88df-9b2cfe69b6e2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_993c7a23-e49d-4ef5-8df7-d53ddd35529e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_59102456-2d0a-485f-916b-e42d26b70224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_993c7a23-e49d-4ef5-8df7-d53ddd35529e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_59102456-2d0a-485f-916b-e42d26b70224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_370e0474-bace-483b-9679-6ce6d33e9a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_59102456-2d0a-485f-916b-e42d26b70224" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_370e0474-bace-483b-9679-6ce6d33e9a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_d0cd897f-3551-479b-891e-6e6c5350a4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_09fc385c-e72c-4547-88df-9b2cfe69b6e2" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_d0cd897f-3551-479b-891e-6e6c5350a4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9af67907-6b19-463d-810b-3f8d1976180f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d0cd897f-3551-479b-891e-6e6c5350a4e8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9af67907-6b19-463d-810b-3f8d1976180f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10bba732-1d78-49db-a157-dfdcd3aa8e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_903831ef-81de-4a14-b3bf-d5d03d5e1e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10bba732-1d78-49db-a157-dfdcd3aa8e60" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_903831ef-81de-4a14-b3bf-d5d03d5e1e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_389ba217-2f04-4e2b-98af-2d4402c5821f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_903831ef-81de-4a14-b3bf-d5d03d5e1e74" xlink:to="loc_srt_StatementGeographicalAxis_389ba217-2f04-4e2b-98af-2d4402c5821f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0474d0f4-5339-4408-a0b9-456f1d6ac175" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_389ba217-2f04-4e2b-98af-2d4402c5821f" xlink:to="loc_srt_SegmentGeographicalDomain_0474d0f4-5339-4408-a0b9-456f1d6ac175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_bc3519f9-df34-4e2c-8e0a-1866abc1bd31" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0474d0f4-5339-4408-a0b9-456f1d6ac175" xlink:to="loc_country_US_bc3519f9-df34-4e2c-8e0a-1866abc1bd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_50ea287c-6a7c-4181-aace-b18cdc159775" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0474d0f4-5339-4408-a0b9-456f1d6ac175" xlink:to="loc_srt_EuropeMember_50ea287c-6a7c-4181-aace-b18cdc159775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_3207b8d6-8639-4cfc-9351-bb28caf54dea" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0474d0f4-5339-4408-a0b9-456f1d6ac175" xlink:to="loc_country_JP_3207b8d6-8639-4cfc-9351-bb28caf54dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8dbca970-7923-48af-8c14-791cfdd2b35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_903831ef-81de-4a14-b3bf-d5d03d5e1e74" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8dbca970-7923-48af-8c14-791cfdd2b35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e2ca8f0-47b2-4a45-a6e4-abe0715dbdea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8dbca970-7923-48af-8c14-791cfdd2b35e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e2ca8f0-47b2-4a45-a6e4-abe0715dbdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9fb6abcc-0efa-4f1a-aa8e-d3e8b4b9966e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_566f7dc5-8f0b-42f3-8414-354764e7f8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9fb6abcc-0efa-4f1a-aa8e-d3e8b4b9966e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_566f7dc5-8f0b-42f3-8414-354764e7f8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ff8b30d4-4b70-41ed-b61b-1d8278e465a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_566f7dc5-8f0b-42f3-8414-354764e7f8bf" xlink:to="loc_srt_ProductOrServiceAxis_ff8b30d4-4b70-41ed-b61b-1d8278e465a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c59aa42-0c5d-4603-8b6a-4ee3067d05aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ff8b30d4-4b70-41ed-b61b-1d8278e465a9" xlink:to="loc_srt_ProductsAndServicesDomain_5c59aa42-0c5d-4603-8b6a-4ee3067d05aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_25be1425-990f-464b-ad8b-074f98486c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c59aa42-0c5d-4603-8b6a-4ee3067d05aa" xlink:to="loc_us-gaap_ProductMember_25be1425-990f-464b-ad8b-074f98486c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_68f73b45-186c-431c-bc62-da51141a8f69" xlink:href="exel-20230331.xsd#exel_CabometyxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_25be1425-990f-464b-ad8b-074f98486c52" xlink:to="loc_exel_CabometyxMember_68f73b45-186c-431c-bc62-da51141a8f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_05375eff-ad9f-48f3-a32d-7fb382f17185" xlink:href="exel-20230331.xsd#exel_CometriqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_25be1425-990f-464b-ad8b-074f98486c52" xlink:to="loc_exel_CometriqMember_05375eff-ad9f-48f3-a32d-7fb382f17185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0821a24b-3774-4914-964e-88e21ff4e69c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_566f7dc5-8f0b-42f3-8414-354764e7f8bf" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0821a24b-3774-4914-964e-88e21ff4e69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7c21bba-1e65-426c-8014-03c26b649f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0821a24b-3774-4914-964e-88e21ff4e69c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7c21bba-1e65-426c-8014-03c26b649f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_525cc4a8-254e-4422-9707-e740a27633fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b84199d7-1e18-4c07-a2e7-b931732ff5be" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_525cc4a8-254e-4422-9707-e740a27633fd" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b84199d7-1e18-4c07-a2e7-b931732ff5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3b76979-bcf2-46a7-8cdd-b9632d02a384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b84199d7-1e18-4c07-a2e7-b931732ff5be" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3b76979-bcf2-46a7-8cdd-b9632d02a384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_ed50a522-e0db-42a4-8aef-8e3e7a97d75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_f3b76979-bcf2-46a7-8cdd-b9632d02a384" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_ed50a522-e0db-42a4-8aef-8e3e7a97d75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5e5c32e6-61ed-4f82-9043-0dae398632fc" xlink:href="exel-20230331.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ed50a522-e0db-42a4-8aef-8e3e7a97d75a" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5e5c32e6-61ed-4f82-9043-0dae398632fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_9eca8ab6-b91b-4983-a1e6-6aa9a6af0825" xlink:href="exel-20230331.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ed50a522-e0db-42a4-8aef-8e3e7a97d75a" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_9eca8ab6-b91b-4983-a1e6-6aa9a6af0825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_bf45c208-b976-46d8-8c76-6bc7d0b5928b" xlink:href="exel-20230331.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ed50a522-e0db-42a4-8aef-8e3e7a97d75a" xlink:to="loc_exel_AllowanceForProductRebatesMember_bf45c208-b976-46d8-8c76-6bc7d0b5928b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4cc575a9-f462-458f-8129-fd275fe5e550" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_b84199d7-1e18-4c07-a2e7-b931732ff5be" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4cc575a9-f462-458f-8129-fd275fe5e550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c09863e9-6d83-4113-93b0-4352c36c5f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4cc575a9-f462-458f-8129-fd275fe5e550" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c09863e9-6d83-4113-93b0-4352c36c5f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_0f60e3fe-3329-4bd7-8dd6-795ce2e7f3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c09863e9-6d83-4113-93b0-4352c36c5f52" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_0f60e3fe-3329-4bd7-8dd6-795ce2e7f3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_f126757a-41c6-4782-ad76-c0b9c8f0e310" xlink:href="exel-20230331.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c09863e9-6d83-4113-93b0-4352c36c5f52" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_f126757a-41c6-4782-ad76-c0b9c8f0e310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_983c130e-6866-4d8e-bde1-201eb6ff7e12" xlink:href="exel-20230331.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_f126757a-41c6-4782-ad76-c0b9c8f0e310" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_983c130e-6866-4d8e-bde1-201eb6ff7e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_85682307-df51-4001-8265-59c182260415" xlink:href="exel-20230331.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_f126757a-41c6-4782-ad76-c0b9c8f0e310" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_85682307-df51-4001-8265-59c182260415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9fb00f21-9f08-4758-8d94-43cc79c35386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c09863e9-6d83-4113-93b0-4352c36c5f52" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9fb00f21-9f08-4758-8d94-43cc79c35386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_528f0e3f-05a5-44e5-a390-f168847dca0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_c09863e9-6d83-4113-93b0-4352c36c5f52" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_528f0e3f-05a5-44e5-a390-f168847dca0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c8514c0-fcd8-409e-b495-3ae5e6291496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_093ebe09-b757-44bf-bb20-39d0630f095f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c8514c0-fcd8-409e-b495-3ae5e6291496" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_093ebe09-b757-44bf-bb20-39d0630f095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_d83e5b11-d2bd-4b95-9cdf-d9c0021294ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c8514c0-fcd8-409e-b495-3ae5e6291496" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_d83e5b11-d2bd-4b95-9cdf-d9c0021294ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e495aeb1-8e17-4642-9df2-61ab6c7204a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_d83e5b11-d2bd-4b95-9cdf-d9c0021294ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e495aeb1-8e17-4642-9df2-61ab6c7204a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_32e239ef-c050-4bb8-9779-d188acd29622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_d83e5b11-d2bd-4b95-9cdf-d9c0021294ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_32e239ef-c050-4bb8-9779-d188acd29622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_24e2e8d1-52eb-4516-9faf-bc5af4106636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_d83e5b11-d2bd-4b95-9cdf-d9c0021294ea" xlink:to="loc_us-gaap_ContractWithCustomerLiability_24e2e8d1-52eb-4516-9faf-bc5af4106636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_2e794b32-2dc4-4411-8c87-b5426312078d" xlink:href="exel-20230331.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c8514c0-fcd8-409e-b495-3ae5e6291496" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_2e794b32-2dc4-4411-8c87-b5426312078d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_5a9c371a-9e39-4b4b-ae2c-86b45aef2a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c8514c0-fcd8-409e-b495-3ae5e6291496" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_5a9c371a-9e39-4b4b-ae2c-86b45aef2a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_9a29f990-5da9-4ac8-961c-5737c0cdec3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c8514c0-fcd8-409e-b495-3ae5e6291496" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_9a29f990-5da9-4ac8-961c-5737c0cdec3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a60bced0-851c-4f26-9bcc-5a184a3a7615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a933862-08e6-422e-afa8-63ec100ca839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a60bced0-851c-4f26-9bcc-5a184a3a7615" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a933862-08e6-422e-afa8-63ec100ca839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a7a20317-f58a-4682-ae95-41228fb6792d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a933862-08e6-422e-afa8-63ec100ca839" xlink:to="loc_srt_ProductOrServiceAxis_a7a20317-f58a-4682-ae95-41228fb6792d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d369ef09-0e38-475f-82c9-9028b6bd44bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a7a20317-f58a-4682-ae95-41228fb6792d" xlink:to="loc_srt_ProductsAndServicesDomain_d369ef09-0e38-475f-82c9-9028b6bd44bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_bf23294e-3932-4255-9a37-74550105582c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d369ef09-0e38-475f-82c9-9028b6bd44bf" xlink:to="loc_us-gaap_LicenseMember_bf23294e-3932-4255-9a37-74550105582c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ae9e7a9f-2d3f-474f-bf16-8b9e01894c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d369ef09-0e38-475f-82c9-9028b6bd44bf" xlink:to="loc_us-gaap_ServiceMember_ae9e7a9f-2d3f-474f-bf16-8b9e01894c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_250adb3b-df0f-403a-a308-c6097e53d9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a933862-08e6-422e-afa8-63ec100ca839" xlink:to="loc_us-gaap_TypeOfArrangementAxis_250adb3b-df0f-403a-a308-c6097e53d9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28e424c6-a370-40fc-944c-26c462687058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_250adb3b-df0f-403a-a308-c6097e53d9e5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28e424c6-a370-40fc-944c-26c462687058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_a9322b90-efab-4afe-8121-b2cbd6a123bd" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28e424c6-a370-40fc-944c-26c462687058" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_a9322b90-efab-4afe-8121-b2cbd6a123bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90513ec3-450f-4ddc-a1e4-4193b7893a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7a933862-08e6-422e-afa8-63ec100ca839" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90513ec3-450f-4ddc-a1e4-4193b7893a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_276ce98c-c639-4f9a-94ae-3419971f67b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90513ec3-450f-4ddc-a1e4-4193b7893a05" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_276ce98c-c639-4f9a-94ae-3419971f67b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6c93131-48e7-4da6-a601-f350802254cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20d32c44-ebb1-46c2-8632-a89c23c8dc58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6c93131-48e7-4da6-a601-f350802254cd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20d32c44-ebb1-46c2-8632-a89c23c8dc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_de19757e-10f7-41bb-8b3c-701b686ecd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20d32c44-ebb1-46c2-8632-a89c23c8dc58" xlink:to="loc_us-gaap_TypeOfArrangementAxis_de19757e-10f7-41bb-8b3c-701b686ecd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68a92a56-baa8-49ba-b6bf-04b00cbf5ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_de19757e-10f7-41bb-8b3c-701b686ecd9c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68a92a56-baa8-49ba-b6bf-04b00cbf5ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_4ee517e2-a809-4e3c-930e-22368eb28e26" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68a92a56-baa8-49ba-b6bf-04b00cbf5ca4" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_4ee517e2-a809-4e3c-930e-22368eb28e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a825c1-c9d9-4fd6-9ed9-efaa2e65b0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20d32c44-ebb1-46c2-8632-a89c23c8dc58" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a825c1-c9d9-4fd6-9ed9-efaa2e65b0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3ce84dcb-0d3a-4234-9735-8a06b7170239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_12a825c1-c9d9-4fd6-9ed9-efaa2e65b0fb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3ce84dcb-0d3a-4234-9735-8a06b7170239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd8a5b0c-1668-4b74-9770-0ab52e5f189d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95d89f1e-eba0-4eae-9e80-2f5d28f7b77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd8a5b0c-1668-4b74-9770-0ab52e5f189d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95d89f1e-eba0-4eae-9e80-2f5d28f7b77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9d39c701-e6bb-41f5-bdba-c1e2487d7d6d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95d89f1e-eba0-4eae-9e80-2f5d28f7b77e" xlink:to="loc_srt_ProductOrServiceAxis_9d39c701-e6bb-41f5-bdba-c1e2487d7d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9ddadfb5-11ae-42b6-b549-29a345e72698" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9d39c701-e6bb-41f5-bdba-c1e2487d7d6d" xlink:to="loc_srt_ProductsAndServicesDomain_9ddadfb5-11ae-42b6-b549-29a345e72698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_568b7897-e6c5-4f3e-94e0-e14387c4498f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9ddadfb5-11ae-42b6-b549-29a345e72698" xlink:to="loc_us-gaap_LicenseMember_568b7897-e6c5-4f3e-94e0-e14387c4498f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_09adee11-c0c5-43cd-b70a-e147791b3ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9ddadfb5-11ae-42b6-b549-29a345e72698" xlink:to="loc_us-gaap_ServiceMember_09adee11-c0c5-43cd-b70a-e147791b3ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_62740fd8-e1df-465f-a680-05425e53d678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95d89f1e-eba0-4eae-9e80-2f5d28f7b77e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_62740fd8-e1df-465f-a680-05425e53d678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19eb62c3-5fab-43c5-83bd-5a0c6aeaa49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_62740fd8-e1df-465f-a680-05425e53d678" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19eb62c3-5fab-43c5-83bd-5a0c6aeaa49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_23c69ac9-1089-419c-b51c-fce916fa5b69" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_19eb62c3-5fab-43c5-83bd-5a0c6aeaa49f" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_23c69ac9-1089-419c-b51c-fce916fa5b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0c61ab7-d18e-407d-944e-787b8ecb9624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_95d89f1e-eba0-4eae-9e80-2f5d28f7b77e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0c61ab7-d18e-407d-944e-787b8ecb9624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19277997-e307-478b-a515-a0e421fa5809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0c61ab7-d18e-407d-944e-787b8ecb9624" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19277997-e307-478b-a515-a0e421fa5809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9c9f60f6-0287-4607-b5b6-454c5c218f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220bb5d4-8fcb-441b-90a2-4f23fddbb566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9c9f60f6-0287-4607-b5b6-454c5c218f97" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220bb5d4-8fcb-441b-90a2-4f23fddbb566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2efe49d6-7b3a-44f2-b0d1-5f4badaa2aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220bb5d4-8fcb-441b-90a2-4f23fddbb566" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2efe49d6-7b3a-44f2-b0d1-5f4badaa2aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1db76f65-6afb-4b0d-9136-9a4a1f05b41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2efe49d6-7b3a-44f2-b0d1-5f4badaa2aac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1db76f65-6afb-4b0d-9136-9a4a1f05b41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_5436742a-1800-4445-a07e-ba596be3392a" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1db76f65-6afb-4b0d-9136-9a4a1f05b41c" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_5436742a-1800-4445-a07e-ba596be3392a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38553d03-1919-46ba-8845-1137caa999f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220bb5d4-8fcb-441b-90a2-4f23fddbb566" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38553d03-1919-46ba-8845-1137caa999f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_29fa6ca8-4bef-4460-b075-20dcf0b24883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_38553d03-1919-46ba-8845-1137caa999f6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_29fa6ca8-4bef-4460-b075-20dcf0b24883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_955db6d5-3ba3-4c71-a483-c0bdc78e2bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a039cd39-ddc4-487d-9b3e-48cf7a59484f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_955db6d5-3ba3-4c71-a483-c0bdc78e2bba" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a039cd39-ddc4-487d-9b3e-48cf7a59484f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9aa8ada0-f2d2-4a5c-92e4-1e321ecacf84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a039cd39-ddc4-487d-9b3e-48cf7a59484f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9aa8ada0-f2d2-4a5c-92e4-1e321ecacf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d9f7ad8-eb37-4f36-b109-067e3021147e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9aa8ada0-f2d2-4a5c-92e4-1e321ecacf84" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d9f7ad8-eb37-4f36-b109-067e3021147e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_1a29e7fd-59f8-4380-a8f8-08b4f5bccf43" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d9f7ad8-eb37-4f36-b109-067e3021147e" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_1a29e7fd-59f8-4380-a8f8-08b4f5bccf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RoyalPharmaMember_14d15e93-75d9-43cf-b1d5-db754f34b0d9" xlink:href="exel-20230331.xsd#exel_RoyalPharmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4d9f7ad8-eb37-4f36-b109-067e3021147e" xlink:to="loc_exel_RoyalPharmaMember_14d15e93-75d9-43cf-b1d5-db754f34b0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bbacdd05-08bc-421b-b9ee-abc3f453756f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a039cd39-ddc4-487d-9b3e-48cf7a59484f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bbacdd05-08bc-421b-b9ee-abc3f453756f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b96ed93e-8bee-495d-80c5-d5b054510df0" xlink:href="exel-20230331.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bbacdd05-08bc-421b-b9ee-abc3f453756f" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_b96ed93e-8bee-495d-80c5-d5b054510df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_c739b4f2-b021-4d01-a990-b26acd9c8784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bbacdd05-08bc-421b-b9ee-abc3f453756f" xlink:to="loc_us-gaap_RoyaltyExpense_c739b4f2-b021-4d01-a990-b26acd9c8784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_618f9626-4e71-4397-af0e-7797a756a034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_2e1febbf-6a54-4787-ae33-11a1d5c166a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_618f9626-4e71-4397-af0e-7797a756a034" xlink:to="loc_us-gaap_AssetAcquisitionTable_2e1febbf-6a54-4787-ae33-11a1d5c166a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a38ac30d-c872-42ba-b56a-b21b5c02583a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2e1febbf-6a54-4787-ae33-11a1d5c166a3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a38ac30d-c872-42ba-b56a-b21b5c02583a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c493efc4-cf06-4a2c-a817-71d78dca00a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a38ac30d-c872-42ba-b56a-b21b5c02583a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c493efc4-cf06-4a2c-a817-71d78dca00a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_3d2d2a77-48a2-4ea7-a3f6-acf17b27be73" xlink:href="exel-20230331.xsd#exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c493efc4-cf06-4a2c-a817-71d78dca00a9" xlink:to="loc_exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember_3d2d2a77-48a2-4ea7-a3f6-acf17b27be73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2e1febbf-6a54-4787-ae33-11a1d5c166a3" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_51f40a32-040e-484a-8994-2f8fa02bfa1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_51f40a32-040e-484a-8994-2f8fa02bfa1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_ae08eb3b-6100-4df1-be34-038ccd1896c8" xlink:href="exel-20230331.xsd#exel_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:to="loc_exel_IncreaseDecreaseInResearchAndDevelopmentExpense_ae08eb3b-6100-4df1-be34-038ccd1896c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_b2a6ab0d-b8e7-416a-969c-c2f6be9c225c" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_b2a6ab0d-b8e7-416a-969c-c2f6be9c225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_aa638e03-4316-4bc5-8fad-44a68a34009f" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_aa638e03-4316-4bc5-8fad-44a68a34009f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_de7be74b-24cd-4214-a114-fb3015b3822b" xlink:href="exel-20230331.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_a86dcd2c-0d6c-4964-9f31-67878ebc41a9" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments_de7be74b-24cd-4214-a114-fb3015b3822b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_560bd64d-a5a1-4f2c-8067-70e71ea04aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_f30bd359-dd01-406f-a464-1cafc5797191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_560bd64d-a5a1-4f2c-8067-70e71ea04aaf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_f30bd359-dd01-406f-a464-1cafc5797191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8449cc26-ff38-4b6c-871a-5b2cd8e7ebcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f30bd359-dd01-406f-a464-1cafc5797191" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8449cc26-ff38-4b6c-871a-5b2cd8e7ebcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ccd53d50-cd5e-4111-8cbf-55018ee54c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f30bd359-dd01-406f-a464-1cafc5797191" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ccd53d50-cd5e-4111-8cbf-55018ee54c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90621762-0757-4b70-9361-b2519aad9d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f30bd359-dd01-406f-a464-1cafc5797191" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90621762-0757-4b70-9361-b2519aad9d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_daf3310e-55d7-4baa-b234-870c4c53a29a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e73197f-8bc1-4eba-9f8f-7426a97974a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_daf3310e-55d7-4baa-b234-870c4c53a29a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e73197f-8bc1-4eba-9f8f-7426a97974a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e4bbb8dc-6b8b-4992-bba4-55c3fdc2bca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e73197f-8bc1-4eba-9f8f-7426a97974a5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e4bbb8dc-6b8b-4992-bba4-55c3fdc2bca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e4bbb8dc-6b8b-4992-bba4-55c3fdc2bca7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_28f3ed7d-d2b0-42a1-ab95-aa6b88400c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_CommercialPaperMember_28f3ed7d-d2b0-42a1-ab95-aa6b88400c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_ca492d25-c538-430e-b33f-560fe7209b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_ca492d25-c538-430e-b33f-560fe7209b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_688d1467-fadb-4f50-9fa0-7920bd6b5052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_688d1467-fadb-4f50-9fa0-7920bd6b5052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_fdf3c7fe-bee2-4d0d-82aa-014624e454aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_MunicipalBondsMember_fdf3c7fe-bee2-4d0d-82aa-014624e454aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_db775876-2427-47af-8ee2-4b4efb7415e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_CashMember_db775876-2427-47af-8ee2-4b4efb7415e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_921ba444-54a7-42a3-9428-688946213773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_921ba444-54a7-42a3-9428-688946213773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_72f94f1d-2435-4e14-903f-d8339d6ff2cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9b46cce9-1752-4602-b0ee-508af4325f5b" xlink:to="loc_us-gaap_CertificatesOfDepositMember_72f94f1d-2435-4e14-903f-d8339d6ff2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1e73197f-8bc1-4eba-9f8f-7426a97974a5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_de8c9ea0-dba9-4281-bd0e-2bba8d97f542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_de8c9ea0-dba9-4281-bd0e-2bba8d97f542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0286eb0d-d18d-4ad8-84d5-d16a81f6b9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0286eb0d-d18d-4ad8-84d5-d16a81f6b9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6ab93718-11b5-4abb-a434-3aa3d5944bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6ab93718-11b5-4abb-a434-3aa3d5944bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f2528e5-020a-4f2e-a637-b7e6b63a9728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_72b620d4-169a-43e0-ae48-c75b32c5a2bc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f2528e5-020a-4f2e-a637-b7e6b63a9728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_3fbc154b-54c6-406c-8860-6461c48e682e" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_3fbc154b-54c6-406c-8860-6461c48e682e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_815d43fa-a6cb-48c2-bbab-909df5cfb67d" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_815d43fa-a6cb-48c2-bbab-909df5cfb67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_1655ba9c-2d9e-4826-8f13-463384013fdd" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_1655ba9c-2d9e-4826-8f13-463384013fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_3a126834-8407-4127-afc9-e923650e9394" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_23a8362e-77a8-4df6-893b-2cd015767ece" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_3a126834-8407-4127-afc9-e923650e9394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_b7f1c4d7-fad2-45a6-819f-13d30f86e8bf" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_b7f1c4d7-fad2-45a6-819f-13d30f86e8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8eb90db9-79ee-4548-86a4-2b3a5d910cdf" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8eb90db9-79ee-4548-86a4-2b3a5d910cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d20a102d-0355-4201-85e8-1ca9642df964" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d20a102d-0355-4201-85e8-1ca9642df964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_c4fbbff2-ba53-4fb9-980d-53742df533d1" xlink:href="exel-20230331.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fb907948-c916-477c-9f99-57d2a166606d" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_c4fbbff2-ba53-4fb9-980d-53742df533d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_71d1427a-6182-493a-a532-111addfa7623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_df6b10e7-b698-409b-8d76-792d65304af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_71d1427a-6182-493a-a532-111addfa7623" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_df6b10e7-b698-409b-8d76-792d65304af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_53a036d7-9fb5-4111-9cc9-872cc1156c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_df6b10e7-b698-409b-8d76-792d65304af6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_53a036d7-9fb5-4111-9cc9-872cc1156c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc9d5db1-1510-41cf-9a27-05519a2536f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_53a036d7-9fb5-4111-9cc9-872cc1156c22" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc9d5db1-1510-41cf-9a27-05519a2536f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_6be4043f-8670-4502-aeeb-3fc5d1e24e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc9d5db1-1510-41cf-9a27-05519a2536f0" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_6be4043f-8670-4502-aeeb-3fc5d1e24e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_75b93ae2-593e-4d66-bcd1-8662c42e0544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc9d5db1-1510-41cf-9a27-05519a2536f0" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_75b93ae2-593e-4d66-bcd1-8662c42e0544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_503835df-443c-4724-82a0-d6004bdb5bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc9d5db1-1510-41cf-9a27-05519a2536f0" xlink:to="loc_us-gaap_MunicipalBondsMember_503835df-443c-4724-82a0-d6004bdb5bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_df6b10e7-b698-409b-8d76-792d65304af6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_3c8cbf9e-bb5f-4602-a4cf-7bcdc6abe0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_us-gaap_InterestReceivable_3c8cbf9e-bb5f-4602-a4cf-7bcdc6abe0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8405e4d7-0e4c-484a-81ed-db675dee0259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8405e4d7-0e4c-484a-81ed-db675dee0259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberOfBondSecurities_1bf68b58-5ccc-47de-8928-e8370fd03f16" xlink:href="exel-20230331.xsd#exel_NumberOfBondSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_exel_NumberOfBondSecurities_1bf68b58-5ccc-47de-8928-e8370fd03f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_47f19e10-4adc-4172-8ab5-e7103a9885c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_47f19e10-4adc-4172-8ab5-e7103a9885c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82177f83-0eac-42f1-9b24-e477b89fe34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_82177f83-0eac-42f1-9b24-e477b89fe34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_deb8eb6d-c319-4ab1-8540-2110d9b9d560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e90b98bd-9063-4ff7-b1dc-67010db719ca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_deb8eb6d-c319-4ab1-8540-2110d9b9d560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_71c21a65-65eb-49e9-bcf8-a7f0a10fac71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59fcc1d0-34ff-4ed8-b58d-762be26e5838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_71c21a65-65eb-49e9-bcf8-a7f0a10fac71" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59fcc1d0-34ff-4ed8-b58d-762be26e5838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_07ce82e2-4415-4322-af46-3da9c2f5ae56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59fcc1d0-34ff-4ed8-b58d-762be26e5838" xlink:to="loc_us-gaap_FinancialInstrumentAxis_07ce82e2-4415-4322-af46-3da9c2f5ae56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5affe8d7-b2f2-4913-ad59-408c3b0040c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_07ce82e2-4415-4322-af46-3da9c2f5ae56" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5affe8d7-b2f2-4913-ad59-408c3b0040c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_7e2d0d67-cb8c-4e0d-a7e4-b193ce57d2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5affe8d7-b2f2-4913-ad59-408c3b0040c8" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_7e2d0d67-cb8c-4e0d-a7e4-b193ce57d2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_4c731d70-1fa4-4688-9c21-ca8939190f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5affe8d7-b2f2-4913-ad59-408c3b0040c8" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_4c731d70-1fa4-4688-9c21-ca8939190f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_5d2e49e2-1e40-4156-a3a4-405d8659616c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5affe8d7-b2f2-4913-ad59-408c3b0040c8" xlink:to="loc_us-gaap_MunicipalBondsMember_5d2e49e2-1e40-4156-a3a4-405d8659616c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a625bc5-f33e-4f03-ad94-2d7c91f56cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_59fcc1d0-34ff-4ed8-b58d-762be26e5838" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a625bc5-f33e-4f03-ad94-2d7c91f56cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_e42c325e-73b2-4fd1-a27e-e63764ce0849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5a625bc5-f33e-4f03-ad94-2d7c91f56cb1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_e42c325e-73b2-4fd1-a27e-e63764ce0849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f52d3f96-2364-42c8-a4c5-cb26f88f3383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_e42c325e-73b2-4fd1-a27e-e63764ce0849" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f52d3f96-2364-42c8-a4c5-cb26f88f3383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_bfb926ad-1664-4781-a47c-fdbdfbc2238f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_e42c325e-73b2-4fd1-a27e-e63764ce0849" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_bfb926ad-1664-4781-a47c-fdbdfbc2238f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bb6e8785-f588-4632-bbd0-aa278c38d593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_55647f9c-6dbb-4412-8e58-517ca2d9860b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bb6e8785-f588-4632-bbd0-aa278c38d593" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_55647f9c-6dbb-4412-8e58-517ca2d9860b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_eabefa8a-43fd-4e7b-937b-085fcc8f6452" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bb6e8785-f588-4632-bbd0-aa278c38d593" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_eabefa8a-43fd-4e7b-937b-085fcc8f6452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c702ce72-ea1a-421c-95d7-dcc7cad967d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bb6e8785-f588-4632-bbd0-aa278c38d593" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c702ce72-ea1a-421c-95d7-dcc7cad967d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#FairValueMeasurementsFairValueHierarchyDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a3c3715b-5092-4a65-a33e-5b2f44b7c111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6dd15fab-5db9-4751-843e-573d65b10735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a3c3715b-5092-4a65-a33e-5b2f44b7c111" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6dd15fab-5db9-4751-843e-573d65b10735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_38a74309-7e57-46f7-b198-9d76fadd5823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6dd15fab-5db9-4751-843e-573d65b10735" xlink:to="loc_us-gaap_FinancialInstrumentAxis_38a74309-7e57-46f7-b198-9d76fadd5823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_38a74309-7e57-46f7-b198-9d76fadd5823" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c5917d46-cb3f-457c-ad71-f1a2e11e5097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_CommercialPaperMember_c5917d46-cb3f-457c-ad71-f1a2e11e5097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0d4c0f75-5b59-43c7-944f-6f604adbffce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0d4c0f75-5b59-43c7-944f-6f604adbffce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_b724f4e1-ae09-4d46-859f-65bccbbcb4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_b724f4e1-ae09-4d46-859f-65bccbbcb4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_2e231eec-b173-4636-a29f-8d57ff05bf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_MunicipalBondsMember_2e231eec-b173-4636-a29f-8d57ff05bf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2332a7d3-391c-4d4b-ba0d-e17996729f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2332a7d3-391c-4d4b-ba0d-e17996729f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_3b3d5382-6e04-480f-930d-66ea5f2d830e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b18f4953-79cb-4a8e-a0e7-0353c805bcb9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_3b3d5382-6e04-480f-930d-66ea5f2d830e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9765f7a-3366-423d-8afa-804c754052c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6dd15fab-5db9-4751-843e-573d65b10735" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9765f7a-3366-423d-8afa-804c754052c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d24d7d0-1154-4e79-813b-d6f28c24dec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c9765f7a-3366-423d-8afa-804c754052c5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d24d7d0-1154-4e79-813b-d6f28c24dec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_48f76115-07f2-49aa-af3b-3ef23b6582ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d24d7d0-1154-4e79-813b-d6f28c24dec4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_48f76115-07f2-49aa-af3b-3ef23b6582ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_eebfd4c4-35eb-4216-95a0-861b5a2ff12a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d24d7d0-1154-4e79-813b-d6f28c24dec4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_eebfd4c4-35eb-4216-95a0-861b5a2ff12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7567e590-5e41-4ba7-9b32-efb6df53352e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6dd15fab-5db9-4751-843e-573d65b10735" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7567e590-5e41-4ba7-9b32-efb6df53352e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b04359-6d63-468c-9fba-856bb495ce51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7567e590-5e41-4ba7-9b32-efb6df53352e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b04359-6d63-468c-9fba-856bb495ce51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ad826f24-161f-42dd-b70d-186fcc37ddda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b04359-6d63-468c-9fba-856bb495ce51" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ad826f24-161f-42dd-b70d-186fcc37ddda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e6df270-e453-46ea-a026-ad9379d42a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6dd15fab-5db9-4751-843e-573d65b10735" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e6df270-e453-46ea-a026-ad9379d42a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcc0f7d5-35fe-46de-ad88-838c88a336f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e6df270-e453-46ea-a026-ad9379d42a76" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dcc0f7d5-35fe-46de-ad88-838c88a336f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e77f8245-3c1d-4614-a018-0a06a7b45ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e6df270-e453-46ea-a026-ad9379d42a76" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e77f8245-3c1d-4614-a018-0a06a7b45ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_992a9177-be56-4b1b-a9e1-1710b93ba107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e6df270-e453-46ea-a026-ad9379d42a76" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_992a9177-be56-4b1b-a9e1-1710b93ba107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4f1f10e1-f4e4-4b34-8dd2-f3dddc6b859a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8484c966-882e-41ef-b908-6115462484af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4f1f10e1-f4e4-4b34-8dd2-f3dddc6b859a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8484c966-882e-41ef-b908-6115462484af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_95a76b90-580b-45b2-9f63-0be4212319a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8484c966-882e-41ef-b908-6115462484af" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_95a76b90-580b-45b2-9f63-0be4212319a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0760242d-2088-42f5-96a0-18aa89271208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_95a76b90-580b-45b2-9f63-0be4212319a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0760242d-2088-42f5-96a0-18aa89271208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_f7b73479-00ea-44a5-a22c-447746666562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0760242d-2088-42f5-96a0-18aa89271208" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_f7b73479-00ea-44a5-a22c-447746666562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b6ca1ce-6163-41d5-ad96-0ad57a4e70ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8484c966-882e-41ef-b908-6115462484af" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b6ca1ce-6163-41d5-ad96-0ad57a4e70ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_6c417238-ed06-475f-982a-0fe7bbe69b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b6ca1ce-6163-41d5-ad96-0ad57a4e70ba" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_6c417238-ed06-475f-982a-0fe7bbe69b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_a6b5f3c9-134c-48de-a9af-3be8ab94aa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b6ca1ce-6163-41d5-ad96-0ad57a4e70ba" xlink:to="loc_us-gaap_DerivativeNotionalAmount_a6b5f3c9-134c-48de-a9af-3be8ab94aa0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_cd290504-03d8-43ef-996b-c7e621b05624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b6ca1ce-6163-41d5-ad96-0ad57a4e70ba" xlink:to="loc_us-gaap_DerivativeTermOfContract_cd290504-03d8-43ef-996b-c7e621b05624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b9610297-e7f4-4325-b055-db763414922e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_e391109b-a1fa-4ebe-8e94-a616a42fe00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b9610297-e7f4-4325-b055-db763414922e" xlink:to="loc_us-gaap_InventoryCurrentTable_e391109b-a1fa-4ebe-8e94-a616a42fe00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a2ec2ec5-fffa-49d1-ab71-e786ca14d0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_e391109b-a1fa-4ebe-8e94-a616a42fe00b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a2ec2ec5-fffa-49d1-ab71-e786ca14d0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_47517e8b-1600-4c74-962f-171dcc006a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a2ec2ec5-fffa-49d1-ab71-e786ca14d0f7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_47517e8b-1600-4c74-962f-171dcc006a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_16dd611a-5932-41fe-bc86-bcd0cafb87b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47517e8b-1600-4c74-962f-171dcc006a35" xlink:to="loc_us-gaap_InventoriesMember_16dd611a-5932-41fe-bc86-bcd0cafb87b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_bcf81f49-4ed0-4929-b5f7-e1e67c810acc" xlink:href="exel-20230331.xsd#exel_OtherLongtermAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_47517e8b-1600-4c74-962f-171dcc006a35" xlink:to="loc_exel_OtherLongtermAssetsMember_bcf81f49-4ed0-4929-b5f7-e1e67c810acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_e391109b-a1fa-4ebe-8e94-a616a42fe00b" xlink:to="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_5428853c-87d7-44f3-b05a-37d07a2f7528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:to="loc_us-gaap_InventoryRawMaterials_5428853c-87d7-44f3-b05a-37d07a2f7528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_15dc587a-80ba-4b31-b67f-b5880d289fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:to="loc_us-gaap_InventoryWorkInProcess_15dc587a-80ba-4b31-b67f-b5880d289fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_159c3a9c-eb95-43c3-81f0-31dc63d211bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:to="loc_us-gaap_InventoryFinishedGoods_159c3a9c-eb95-43c3-81f0-31dc63d211bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d929a091-e26e-4f8e-9f62-3c6761a50d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_36e9f494-095e-4d24-9c1d-7ff94f61daa3" xlink:to="loc_us-gaap_InventoryGross_d929a091-e26e-4f8e-9f62-3c6761a50d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff01e04e-f622-4421-adf2-6fa3cb90de60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05512dfb-3068-4fe2-855a-e1433c0c77b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff01e04e-f622-4421-adf2-6fa3cb90de60" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05512dfb-3068-4fe2-855a-e1433c0c77b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7e47ade8-cf1b-44e6-abe8-8051a34eb72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05512dfb-3068-4fe2-855a-e1433c0c77b1" xlink:to="loc_us-gaap_AwardTypeAxis_7e47ade8-cf1b-44e6-abe8-8051a34eb72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe7995cd-71cc-4688-a8a5-21f041a4d8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7e47ade8-cf1b-44e6-abe8-8051a34eb72d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe7995cd-71cc-4688-a8a5-21f041a4d8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_750d3aa6-cec5-420d-b885-cfbee52d800a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe7995cd-71cc-4688-a8a5-21f041a4d8e5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_750d3aa6-cec5-420d-b885-cfbee52d800a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5abfffd6-381f-42b6-99c0-083f688ca0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe7995cd-71cc-4688-a8a5-21f041a4d8e5" xlink:to="loc_us-gaap_PerformanceSharesMember_5abfffd6-381f-42b6-99c0-083f688ca0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_PerformanceSharesTargetAchievedOrProbableMember_1de226bf-cf28-450a-a5b8-652074851aa4" xlink:href="exel-20230331.xsd#exel_PerformanceSharesTargetAchievedOrProbableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe7995cd-71cc-4688-a8a5-21f041a4d8e5" xlink:to="loc_exel_PerformanceSharesTargetAchievedOrProbableMember_1de226bf-cf28-450a-a5b8-652074851aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bbc6f902-1adc-4414-a6b2-00400962778f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05512dfb-3068-4fe2-855a-e1433c0c77b1" xlink:to="loc_us-gaap_PlanNameAxis_bbc6f902-1adc-4414-a6b2-00400962778f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8ed9b3d4-32be-46c7-a703-5ff9aa2c4559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_bbc6f902-1adc-4414-a6b2-00400962778f" xlink:to="loc_us-gaap_PlanNameDomain_8ed9b3d4-32be-46c7-a703-5ff9aa2c4559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember_911f59fc-2ff5-469e-8ddf-e970eec2b12d" xlink:href="exel-20230331.xsd#exel_AmendedAndRestated2017EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8ed9b3d4-32be-46c7-a703-5ff9aa2c4559" xlink:to="loc_exel_AmendedAndRestated2017EquityIncentivePlanMember_911f59fc-2ff5-469e-8ddf-e970eec2b12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_05512dfb-3068-4fe2-855a-e1433c0c77b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6c99f103-6797-47da-832a-1ac79da15325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6c99f103-6797-47da-832a-1ac79da15325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_064acc04-0033-4f34-9eb2-06b1bc440939" xlink:href="exel-20230331.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_064acc04-0033-4f34-9eb2-06b1bc440939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_128cd9f3-5e4e-42b2-aed7-f0613e8fb90d" xlink:href="exel-20230331.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_128cd9f3-5e4e-42b2-aed7-f0613e8fb90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b490a3f1-542d-4c3c-b41e-6b130245a87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b490a3f1-542d-4c3c-b41e-6b130245a87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fcccdfeb-f0ad-4b02-a57a-1d4634ef073c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fcccdfeb-f0ad-4b02-a57a-1d4634ef073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7ef445b-bbd7-453e-801c-e7698c2d0017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7ef445b-bbd7-453e-801c-e7698c2d0017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_706dcfe4-c17b-4e30-a22c-e8916768f42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_706dcfe4-c17b-4e30-a22c-e8916768f42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5e6bb0ba-74d0-470c-86d4-7a8d1b432e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5e6bb0ba-74d0-470c-86d4-7a8d1b432e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_bca25d40-4d59-4d43-ba5a-8973b7a8a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_bca25d40-4d59-4d43-ba5a-8973b7a8a9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fd034981-6e2b-4674-aff6-87f8cb487a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3c832dc4-d0a9-4955-b634-b9880547afa9" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_fd034981-6e2b-4674-aff6-87f8cb487a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad6f7005-8938-4ae8-b242-d6e78ff9f3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9adc19b9-39b0-4e1b-9b7d-8cd50036ca06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad6f7005-8938-4ae8-b242-d6e78ff9f3b3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9adc19b9-39b0-4e1b-9b7d-8cd50036ca06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_858d327e-c52c-468d-bd34-c64d69df8056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9adc19b9-39b0-4e1b-9b7d-8cd50036ca06" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_858d327e-c52c-468d-bd34-c64d69df8056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bcdea3ce-88f3-4021-939a-d7241c6d3510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_858d327e-c52c-468d-bd34-c64d69df8056" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bcdea3ce-88f3-4021-939a-d7241c6d3510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b08ebf94-432e-4a1d-a624-3b4a9abb476f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bcdea3ce-88f3-4021-939a-d7241c6d3510" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b08ebf94-432e-4a1d-a624-3b4a9abb476f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9a103e3a-3377-45fe-b354-cb1f2ec8bd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bcdea3ce-88f3-4021-939a-d7241c6d3510" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9a103e3a-3377-45fe-b354-cb1f2ec8bd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_740a009c-4b0a-4d34-81b8-abcf900dcb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9adc19b9-39b0-4e1b-9b7d-8cd50036ca06" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_740a009c-4b0a-4d34-81b8-abcf900dcb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0b0cef8d-8c67-4b31-9eb3-24804738f9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_740a009c-4b0a-4d34-81b8-abcf900dcb84" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0b0cef8d-8c67-4b31-9eb3-24804738f9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bcc15ea5-fb39-4baf-8035-ba18bb2ff8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63a76d27-285f-4b65-87ea-55de66e9c593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bcc15ea5-fb39-4baf-8035-ba18bb2ff8a4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63a76d27-285f-4b65-87ea-55de66e9c593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8ff1f927-0dc8-4c35-9ad6-c4b56ad5e415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63a76d27-285f-4b65-87ea-55de66e9c593" xlink:to="loc_us-gaap_AwardTypeAxis_8ff1f927-0dc8-4c35-9ad6-c4b56ad5e415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8ff1f927-0dc8-4c35-9ad6-c4b56ad5e415" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7558f64e-23ba-495e-8e2b-6983cebd1413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7558f64e-23ba-495e-8e2b-6983cebd1413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0e749e21-3b5c-4061-85ec-ccce4b73872c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0e749e21-3b5c-4061-85ec-ccce4b73872c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f940db62-e9ae-4852-aa00-4042d9dc4404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:to="loc_us-gaap_PerformanceSharesMember_f940db62-e9ae-4852-aa00-4042d9dc4404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_3831fcbb-7adc-4f62-ac39-dd57c7d639c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eb0eb341-8888-44bb-a54f-f40a6df47eec" xlink:to="loc_us-gaap_EmployeeStockMember_3831fcbb-7adc-4f62-ac39-dd57c7d639c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0045e9-4eb7-42f5-8587-516dd62a1fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63a76d27-285f-4b65-87ea-55de66e9c593" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0045e9-4eb7-42f5-8587-516dd62a1fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f290250-3955-4d53-bcb0-89e1e8d8c1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fa0045e9-4eb7-42f5-8587-516dd62a1fcc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6f290250-3955-4d53-bcb0-89e1e8d8c1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#ProvisionForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e147acb2-fd8a-43d8-879b-6540493cc451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ac8435b-3146-4326-a1a3-8973f30a6d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e147acb2-fd8a-43d8-879b-6540493cc451" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4ac8435b-3146-4326-a1a3-8973f30a6d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8cf3c120-a3a0-425d-9d5e-dc2abf8db6de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_631363a6-9f97-4c8e-9647-884610acb4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8cf3c120-a3a0-425d-9d5e-dc2abf8db6de" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_631363a6-9f97-4c8e-9647-884610acb4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c099a66f-73bf-4ea7-8577-70679d955b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_631363a6-9f97-4c8e-9647-884610acb4ff" xlink:to="loc_us-gaap_NetIncomeLoss_c099a66f-73bf-4ea7-8577-70679d955b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7829e3c5-7ae3-4e74-8304-14c8949631f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8cf3c120-a3a0-425d-9d5e-dc2abf8db6de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7829e3c5-7ae3-4e74-8304-14c8949631f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d29e7c6-8128-464d-8a40-2de1487ebd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7829e3c5-7ae3-4e74-8304-14c8949631f9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d29e7c6-8128-464d-8a40-2de1487ebd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b9c84804-a9a0-41dd-b420-fddba0f6a1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7829e3c5-7ae3-4e74-8304-14c8949631f9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b9c84804-a9a0-41dd-b420-fddba0f6a1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49d55774-5d69-42dd-875b-83b02775564a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7829e3c5-7ae3-4e74-8304-14c8949631f9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49d55774-5d69-42dd-875b-83b02775564a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_caf50dce-63ae-4b20-82c5-1c9d79700c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8cf3c120-a3a0-425d-9d5e-dc2abf8db6de" xlink:to="loc_us-gaap_EarningsPerShareBasic_caf50dce-63ae-4b20-82c5-1c9d79700c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0de2569c-289d-496d-ae5c-db2751a17926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8cf3c120-a3a0-425d-9d5e-dc2abf8db6de" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0de2569c-289d-496d-ae5c-db2751a17926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2d82c2be-5198-409d-9ac2-7152aa80329f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3c3ffd74-e26e-444a-b307-fa93363629f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2d82c2be-5198-409d-9ac2-7152aa80329f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3c3ffd74-e26e-444a-b307-fa93363629f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_67b16d77-88d5-4b9b-b5ed-7c898a88fcca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3c3ffd74-e26e-444a-b307-fa93363629f7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_67b16d77-88d5-4b9b-b5ed-7c898a88fcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7df7d22e-a4da-460e-b98d-792ce2bd0314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_67b16d77-88d5-4b9b-b5ed-7c898a88fcca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7df7d22e-a4da-460e-b98d-792ce2bd0314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_d5d1a31d-6b32-48c0-a25e-86ccda50cfed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7df7d22e-a4da-460e-b98d-792ce2bd0314" xlink:to="loc_us-gaap_StockCompensationPlanMember_d5d1a31d-6b32-48c0-a25e-86ccda50cfed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa929935-f9b5-41f7-864b-dc3d4fcba8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3c3ffd74-e26e-444a-b307-fa93363629f7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa929935-f9b5-41f7-864b-dc3d4fcba8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_61b21bcc-f81d-4705-a526-e304a8aeb8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fa929935-f9b5-41f7-864b-dc3d4fcba8ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_61b21bcc-f81d-4705-a526-e304a8aeb8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="exel-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03fe1722-0b0a-4ae5-a998-85f7f2b5a4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_e5921c6c-637f-46df-838f-517cc165f8a8" xlink:href="exel-20230331.xsd#exel_LossContingencyNumberOfLawsuitsConsolidated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03fe1722-0b0a-4ae5-a998-85f7f2b5a4c7" xlink:to="loc_exel_LossContingencyNumberOfLawsuitsConsolidated_e5921c6c-637f-46df-838f-517cc165f8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>exel-20230331_g1.jpg
<TEXT>
begin 644 exel-20230331_g1.jpg
M_]C_X0TO17AI9@  34T *@    @ # $   ,    !#.0   $!  ,    !"?8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D
M,C R,CHP-SHR-2 Q.#HQ,#HR-@      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   $L* #  0    !   !1P         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
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MDI__V?_M%2I0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"!0 617AE;&EX:7-?3&]G;U]21T)?,C R,CA"24T$)0      $.Z*
M+VTF;HFD<OR1I?7(F<@X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  :0!8 #8 .  P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              %'   $
ML    !8 10!X &4 ; !I '@ :0!S %\ 3 !O &< ;P!? %( 1P!" %\ ,@ P
M #( ,@    $                          0             $L    4<
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<
M    4F=H=&QO;F<   2P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   %'     %)G:'1L;VYG   $
ML     -U<FQ415A4     0       &YU;&Q415A4     0       $US9V54
M15A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA4
M34QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU
M;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE
M;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4
M>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U
M='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/
M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "\$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
M   ! #A"24T$!@      !P & 0$  0$ _^$0V&AT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#
M96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B
M93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-RXR+6,P,# @
M-SDN-38V96)C-6(T+" R,#(R+S U+S Y+3 X.C(U.C4U(" @(" @(" B/B \
M<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O
M,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V52968C(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN<SII;&QU
M<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O
M(B!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM
M;&YS.G!D9G@](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F>"\Q+C,O(B!X;6QN
M<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N
M,"\B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@>&UP.D-R96%T;W)4;V]L/2)!
M9&]B92!);&QU<W1R871O<B R-BXS("A-86-I;G1O<V@I(B!X;7 Z0W)E871E
M1&%T93TB,C R,BTP-RTR-50Q.#HP,CHT,"TP-#HP,"(@>&UP.DUE=&%D871A
M1&%T93TB,C R,BTP-RTR-50Q.#HQ,#HR-BTP-#HP,"(@>&UP.DUO9&EF>41A
M=&4](C(P,C(M,#<M,C54,3@Z,3 Z,C8M,#0Z,# B('AM<$U-.E)E;F1I=&EO
M;D-L87-S/2)P<F]O9CIP9&8B('AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#TB
M=75I9#HV-44V,SDP-C@V0T8Q,41"039%,D0X.#=#14%#0C0P-R(@>&UP34TZ
M1&]C=6UE;G1)1#TB>&UP+F1I9#HX93,S83(S92TV.6-E+31C8V(M.#,R82TY
M-F8S-F4V,#AB9#(B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z8S5D,60W
M,&$M-V-D-BTT9F,V+3DY8C@M.6$P8S9D83,S,#DU(B!I;&QU<W1R871O<CI3
M=&%R='5P4')O9FEL93TB5V5B(B!I;&QU<W1R871O<CI#<F5A=&]R4W5B5&]O
M;#TB04E2;V)I;B(@<&1F.E!R;V1U8V5R/2)!9&]B92!01$8@;&EB<F%R>2 Q
M-BXP-R(@<&1F>#I#<F5A=&]R5F5R<VEO;CTB,C$N,"XP(B!P:&]T;W-H;W Z
M0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W Z24-#4')O9FEL93TB<U)'0B!)14,V
M,3DV-BTR+C$B/B \9&,Z=&ET;&4^(#QR9&8Z06QT/B \<F1F.FQI('AM;#IL
M86YG/2)X+61E9F%U;'0B/D5X96QI>&ES7TQO9V]?4D="7S(P,C(\+W)D9CIL
M:3X@/"]R9&8Z06QT/B \+V1C.G1I=&QE/B \>&UP34TZ1&5R:79E9$9R;VT@
M<W12968Z:6YS=&%N8V5)1#TB>&UP+FEI9#IC.3(X83$X,BTY.65A+30Y-#$M
M.3DT8BTW-C5B8C9E.3$X9C B('-T4F5F.F1O8W5M96YT240](GAM<"YD:60Z
M8SDR.&$Q.#(M.3EE82TT.30Q+3DY-&(M-S8U8F(V93DQ.&8P(B!S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240](G5U:60Z-C5%-C,Y,#8X-D-&,3%$0D$V13)$
M.#@W0T5!0T(T,#<B('-T4F5F.G)E;F1I=&EO;D-L87-S/2)P<F]O9CIP9&8B
M+SX@/'AM<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q/B \<F1F.FQI('-T179T.F%C
M=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z.#(Q96,P
M-C@M9&,X,2TT-V9E+3AC93<M8C0T9#-A,S0X.&0R(B!S=$5V=#IW:&5N/2(R
M,#(R+3 W+3(U5#$W.C4V.C4X+3 T.C P(B!S=$5V=#IS;V9T=V%R94%G96YT
M/2)!9&]B92!);&QU<W1R871O<B R-BXS("A-86-I;G1O<V@I(B!S=$5V=#IC
M:&%N9V5D/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%
M=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#IC-60Q9#<P82TW8V0V+31F8S8M.3EB
M."TY83!C-F1A,S,P.34B('-T179T.G=H96X](C(P,C(M,#<M,C54,3@Z,3 Z
M,C8M,#0Z,# B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO
M<" R,RXT("A-86-I;G1O<V@I(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#PO<F1F
M.E-E<3X@/"]X;7!-33I(:7-T;W)Y/B \+W)D9CI$97-C<FEP=&EO;CX@/"]R
M9&8Z4D1&/B \+W@Z>&UP;65T83X@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" \
M/WAP86-K970@96YD/2)W(C\^_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"
M$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-2
M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &1
M 0, $ ," P8               #_VP"$  (" @(" @(" @(# @(" P0# @(#
M! 4$! 0$! 4&!04%!04%!@8'!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P!
M P,#!00%"08&"0T*"0H-#PX.#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_" !$( 4<$L ,!$0 "$0$#$0'_Q $/  $
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M P$! A$#$0   +_
M
M
M                                         #%O'^1Z4Y4Y!QL
M
M#X8^^+]SBOS_ *<F?>X_N],@   !T#X_VZT.BO0-K_H?S3O]L0
M                                                      !COXOW
M:W^D.^\4\>Y)JF.?_9^*?_<72<FN=]>@  #A_P WZJI///I2:7:/4TH>?==
M
M    #C\=ZB_.'I[I?R_J@#7,6F^@/.6:.4<3  &B)K-Z)]!]2^=].U_T/YIU
MS
M       C-P3L&N'I'OGX  28YUP"R#N_H0  0:ZG[BA7U=VS:5W]YSS?ROB
M
M     $,^L.UX)]2]Q@ #,_)^*VH^@O-X $:N#<_K=Z/[\D)S/@]F?>WGP
M
M   1[X9SBLOHGT&0 !*OL+KBPWN?HP 8LX_R.JOS[Z1VF6EM_HWS)D/[7P@
M
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M@  11M6ORU(I6C&J/S/LNPPSG$ROK:>=;YUB0!C:8K0O3M4.()YUOG*)
M%'&F4);5      VAZ@L=^U I0TR@;:H L4K>XW/0  #045:Y0VFH M I>V&F
M@%0&F=;MJ      #T69;9UB0(CVK0IIEJ!E5/I,QV     J?OG5_>GP$MHM?
M7EJ!7]TYW=$GKGLSX 2'YIP>S'O7SZ /QK?\*7WNN( %?737=\3.N^R_I.GM
MKIV9W9_4X \]VN,;Y@"VBFEG-+@ =3*5=<H9374   #X3-K:X&FF5(D59WIW
MX_8Z@<2BTVF@    \UFV.,4      =@/3OCON@<.>>W7'!$P!I+K<])[5N
M*NKTJBOG] )91:^G+7]@#SZ:XQIF      /U/33COW, JWOG5->@&54^DS'8
M    "@77*+$U EM%KZ\M0.'_ #?JJ(\W^H.K?/\ H ?$V6=Y] 2-YMP,   "
M)O779E?'3?=_U'=?J?*MW](>7]YKD!M#RT;8?0"VBFEG-+@#B#S[ZXQ]F
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M"VBFEG-+@8<F/-]KCK +#ZWN0STU             \TVV.-T 6KTO:530
M    #IB/._KEC&8 _0_, &?HGT&Y;<L   >?+7&-<P!8M6]Q>>@      JUO
MG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !MJ:5+^=/3../B?= )GQV_P!+
M3 [*ZM$+>KNV8,]3]Q$#<WI;CZ.\Q]^^Q\0  ; \M6V&L MHII9S2X'#'E[V
MP_, ^&?XF>M;R[K;.$3K           /--MCC= $Q*VEY%@  !VR)GK6P
M$=)CS]:X\<  #M9Z'LMLL1(   \^6N,:Y@"3\6G#6P   W4+%ZW  JUOG51>
M@&54^DS'8    "@/7*+4U EM%KZ\M0  ,+<6Y;5CY_\ 1WQ '*_H_/;KZ/\
M,.*N/\DK-Z)]!:( 2][)ZPGWW!TH  !L#RU;8:P"VBFEG-+@"B33*'-J@ #0
M=R)/UM+F+37K;(<2         /--MCC=      S/$^CK+8    5Z7I3/?/4
M#47NYZS"K8   #SY:XQKF     !S!ZB<=P *M;YU47H!E5/I,QV     H#UR
MBU-0);1:^O+4   5X=+]Z16Z^[& &;N5<1Q3Q[DO#_F_2!S7ZORV_P#I/RYS
M_P"S\0  &P/+5MAK +:*:6<TN ,,3'GKUQZR    :R:-;6P4TS;$@
M#S3;8XW0     ,\Q/HHRV    'YGF^UQQ', "4T6O[RU    'GRUQC7,
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M2J:        8IF//!KCU, Y(V1^0!E)/H?RU[A$@  >?+7&-<P!8M6]Q>>@
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M->0?L_# P=Q/F%7'07HL@#G/U_DMV]'^8.S?O^> !L#RU;8:P"VBFEG-+@
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M*GO/'I;9Y: ;O3.VOT7YER%]KX8V!Y:ML-8-9Z$<MI&Q( ZV53Z9UUVIQP
M !^Y976]L^>FX        *6=,^F3     'TR?$VB4OD6)$/[5KFO0 97B;?\
M]-8   /Q*YKTBG-=C(:2U//21$2*CM,\+S      [Y"SRFF88D 07M2!UZ@
M  #L$+%:WE)6P%36F>"YC<0E)%K**7_4 K^Z<[MB1USV;N;UM'[^\YYHY1Q,
M     8FX[R:(?6W:'7_Q_M S5RGB4R^SNJ1M"B_7+4<O"?5;S(K8  #I$Q!>
MU8BS6/MHQZC9&HY\S=$RVK:P2M\PQ(
M                    Q[\;[E2'G+TYMZ7L)[EZ/EAV)UH
M    !MSB#]CF#Z
M      5H=%^@8[\*YS++L7K2P7N3I
M                                          86XORVJ_S]Z.S5RCB=
MH_?WG/<7H
M                    !IB:I?/7I/JWS_I6P>B/-/9?W?/
M                                                           $
M9^"=@UW]+]Z6I^@O-V5>0\;
M                                   &USTJ(\W^H9U=M=-27YUU^
M
M         !#?K+M7KWXOW3I[:Z<
M                                        &!.(<TSSR[AFJ8
M
M
M                                                       __]H
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MC3+QB;C/,:P5*@C&,8<90ED55\!0*%0D++*BX*3& ("&F?3 PMW8#!G,'Z>
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M5U0ZG%827+'Q%YH3\@^].,B"L'2HMR^(^)H'R%#/LW4&ZAG,._@0XUAQ -V
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M<(JG4>['Z"5F^@E9OH)6:4T%628K'L#=@;L#";?0 =F [ 8&WR]@83L(B/\
MN=?5RI<&=X=X81V:2)7&#)_HV_\ NR>%OW^,:1Y8]Z/[$IN6_A<$ ;-*TN&6
M'[MV5V7V(B.S32M"J1J.DOE2)34YRGP_L2GM;]RA(:&>1#R6T!VCPWL2>O2N
MB+:J=4C),ECX<Z]B=1%K_&ZD66.X^Q0),@WD6   ?\:__]H " $#  $% /\
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M/WPXCO@N*Q$J"?OSOWF@3,8=]4!V8H[X?_1^!W "A^AN=(>=4I=LHANPAME
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M[F:WJ:?+\:$_?'3O7_)W&QC\F\T9"0T?"55IY%4SG+):S4[XJE87*5H-!E
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MR401)^UI-@%YHV\,(+8HZJ"P:[SF3H+N\@19CQ 7DX "LT7=Y-U;->[7L?P
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M0?=IE7*%1ZK#FMQ7Y$T>1-$'0D$9C[5>0VHB2E;M^"+VF]0KUJDL!54  "P
M6 </RTLQER8C)GZ1XN:-1Q\O#Z#&E7#'ZP\B88SI, W:6Q6_:V<#?HC^X2AM
MI 3,UZ+]VPY0PTUW>3:;3<JWL<AZS5?1=WD""K?>QO9LSZA4+.%IBGQ7V4UF
MUNZ/7"D3YAJX*_,,?*Q\Z)O*5PJ8=93SE_+.!HLZ48HX!!R/V@<] JPBI$"#
M80;1QT:4*Y;;2'%3=K6P_??HK*E*6=C  7DT^&(&:T"[8GJCLK=B:]!F0^%+
MV4U"UN\:]4,/J7"D//9_MTTU,299[723O6CM:]$RE_JIM2SVKUU.*M<#0JP@
M141H?,SQX[BH?[:F[WVZ6 V<=#X$L^+/B-4OI'O<T=[T$!T,&4@@X$5@T6?8
MXV7&#CV-SAQB[1&_RAL3#!\GZVI_YHX\*_W#>5V0?#4](CID8#HXFNP5\+3)
MAY*J"2< *R:/O#5 U*.J@YH_/./H)!<^%,V7U7-K4UZHB^E1B-!Y$X11Q _F
M,P:QG1]VFVJ:CUEZ+#(C\J?%G"$B6=KMFY!^XW#,B@ $ *@!8 + ,AH+N$L[
M3P9\EZ*]X[1R Q]!?R4T^)*&SVI>&M/Y=6C*((28A +8RSSAF1:O&+Z+(D+R
M400 _$G$FTG'0?>)O,01.> &;& H^\33M.23[!J J&7H+D#=3"9RK;@.ERNS
MR8QRI5Y%7E'PT:+B^NI6U*:B,P?J!'R</IT?,9WV8-N;4N4O'OGU#/13=Y #
M\A@9NJ^6N=Y-Q@,:+-EGE(X!!Q!L_CGH%''*5@00;P:B*-)-:&M#BALXQ8<Q
MZ"DD=#G.<$%O&;!F:!5$% @!@!4!Q#0^#)/_ +$P5?\ C4],YGH?JN%(FLFA
M_MTTVQ:7KM9./G+G''1*H/&EQ9,^LG>%G: I V^@D3''BSH,<EZ"_N.L8:!G
MO6QJ1>LW^46L>*TT>?.;E.YB3]KA8!<.!9B&#*001<18:+O J:QQ@XMXFYPU
MY:(WV4(2YIV@.C,OXGMUQ^EU><H^>P7$94K:?/JKWCZ@=!]XGGDH@B?8!BQL
M H9\RH6*MR+<!^)-YKT!\0^#,@KY8/W3ZHZ+[O.$4<0.6##-36*/NTT;2&&L
M7$9$5CZE1\A#SI 5DT621XC;3^\>CW15KCPEF(  B2; !:3D*?#E$B1+.R.L
M;W.OHBX9DZ7R<T^+*&SVI?YI9[L,-'YN4/%DBOM2[^-+?=CAZ!CO<P1ER;,Y
MG1_3SCQ<-5#_ &_=FV ?$8=(CH#LJ>=BV0KTDWB4=I#'6+P<B*C1-YD\QQ'4
M;U.:FK1C+'@S(LF6*=W^4CT"+*EB+,0 ,2;*)NJ5\D;1ZSGG'[ZAD!P_*[N?
M'<5D?Z:G][78"NTCR)W*<82YIV8]&9=Q/S3GR=%MW:IK4/5<6<1YIR.5&ES!
M!E)!!N(M'E8?79O[A,%2Q67[W2;NBH9DX</+J,UHB6N)ZQ[*^LU8T:;-8L[&
M))M)/D8B@+GQI<%?/JOWA;V@=$?W&4,%F?@K\?-;.&/U%CYYCH2]VE<YS#5B
M3D!6:)N\H026 ![2<R8DZ^!MYGG96Z]FN5<SZA$FRC;Q.-9L%RK<HR'KMM/D
MUGBM#4XZR&WC%HS%%FRF#(PBI%X^UHN-6@TN8.4C AAB#;]L:/N[5K:IZR&P
M^PY@^6J\I7YIK^@5^;FWZ8-J9%4R3I-WC4,@<>!IDQ@JJ"238 +339B)*5(O
MXL>TWJ%7E82CRI9M1N:<Q>IS''&GC(\MLH./OB#ZJ<Y_T?QISG_1_&G.?]'\
M: 2V;XTNM"5A$'G*3&PVC C/T )NXJ4UL>J@YQ]@S(H$0050 !@!4!P'<MV;
MPD.TP_U&'[5NQ->'H3^-,$)L^!U)T1Q\X\7 =QW<^*P\1AT%/0':8<[!:K35
MZ$E5QX4O:?4+%[QJU1X-BN>XV!U1USD.B+SD#0NY)8F))M)-I]"4!148>*^T
M^LV+W1ZXT;>)UU2K>[7*/:;A1]XGF+,>("X#  5#T)_,S!&5)@?>?HCBYQU#
M&C3IS<E$$6/VM)N%YI\0[,M:D7JKGVFM8\5@'H366@BS$ #$FP43=EA%1%CB
MYYQU"P9"GRV[GP$-O^XW6]T=$<=]7H3;?Y@J393-S:W=!_4<J-_;]V:LU36'
M_&/W_IQ]"J;GNJK)15A%8\L]8\HDP+&))$#2)_PV?__:  @! 0$&/P#_ ,SL
M#7N62LNU<K-;+!1A6J9@NHN=XA8XP=1=B!S#$ZM*G--RR['ERU5=4T678.O:
M>:>"+N7FD)C10"^(7=QQP)Z/[!B2< -9.A@O&>+/23J<&@^%))(IZ"L98@^F
M-$@IN(%I$LAP59I3 #^.4(-$J[=6P5])+_AU5-(LL;>DZ$@_E['59@NS==,?
M>;1:T($M95,"4B3H&K%FV*N)T@@N%4\]US-4];>:Y,=RCH(=<G5@GN4BC[B,
M>N(YR=*"T6RG6EM]LIXZ:BID&"I%$H50/Q#^P7^;WV1IZFI)BL]F@(-363 8
M[J D *NUG.I1V\ 9ENESDM5D<^\9:MTCQ4RKS"9A@\[=);5T*-,(XU0="@#_
M (:8$ @\QT6XY4O558JH,&=:=_>9<->$L#8QR ^R72GRQFB&&RYP=2*-XR12
M7'=&+=3O$E) !B8R3CM4G8.P7+,%[JUH;5:8&J*VJ?8JKS ;26.  &LD@#26
M_7 -1VND5H,OVACJI*;'$L_,99, TA])1J T?.%TIS%?<XQI+3HXP>"VCNH$
MP(!!EQZQO37H_L%N%XN4XIK?:Z>2JK9VV)'$I=C^0:5^:+HSHDY,5GM['%:.
MB5B8H5&S$]\YYV)[7)BGIYI*>HIY%EIJF)BDD<B'>1T8:PRD8@Z0U=P9!F.R
M2? ,PHFH/*J@QU 7F$R8-AS'>'-RWEE=8XXU+22,0%50,223J  T-CL<[#)%
MCGQI67$"XU*8J:EA_IKK$0/M^<84-IJ(RUAM86X9DDYC3QL-R#'5KF?N?:[Q
MYM$CC18XXU"QQJ  JC4  -@ _L%2T02F.7-%R@HIE'JJ>(-42CTCU8!]/EU%
MD+'X+FBUS(T>/<]?1'KHVPZ=PN.76<,LK56$2'J\YW2)M9/_ +"-AL__ &D>
MT]=IJ!U:E51B3T  <YYAI3I<(!'F3,)6X9@)'=1NR^\T_I0H</;%CS_V#9!D
M /5I=*L.>;$TVK'\AY>3!#CBCUCRX?Z8HYM[_B.5_MC+E2#G2]PDK,N!_EU*
MV*FH;V;:Q$.GNCJ&LDLS%B6=V)9F9CB68G622<23MT2]7"#K,O9,>.KJ0PQ2
M>N/=4T)QU$)AUC#M+T_V#W&LI8NMJ\KU,-W15!+&&+%*@ #HB=F_%IB-8.P\
MJ]9JDB)I,MT!I()N;X57$8J/:Q(<?;#DR76=4K+S7%J?+MH+8&HJ,,<6PUB.
M,'><]&K:1I<+Y>JQKA=KK,U17UCZB[MS*-BJHP55&H  :4U%0T[5==731T]#
M2H,6EFE8(B##I8C2TY;AW9*R-347JK7_ #ZV;!IG]('N5]B!_8/-35$2S4]0
MC13PN,5='&#*1S@@X:2T<<,DF5KK(\V6+B02O5GNC2NVSK(=GLEP;IPY%OL5
MDHGN-WNLH@H*--K,=I8[%51K9CJ UZ6_+=/(M56 M4WJX*"/A%9+@97 .L*,
M JCF4#D7',M_JA2VZW1[SX:WD<ZDBB7U3NV"J.G2LS->W*-+C%:[:&WHZ*D!
M)2!.8GG=O5-KV8>A5<0[I3[UOR^[TF7E<=S)7,N$TPQVB%#N@^N8^M_ R+G>
MZ"W%>^%54Q0D?];#18SGO+W6."R)_-*3$@;2!UO-H!19JL]86."B"NIY,2.;
MN7.BO&P=&&*NIQ!':(["23@!K).GP.;.5CBJP=TTKW&F63'HW#)C_=HDL,BR
MQ2*&CE0AE93K!!&H@]DNF<\[7>*RV"TH#45+XL[NYW8X88UQ:221M2HH))TG
MI^%]EHLAV%'(I;A<X4N%UF0:MYT8_!X<1KW0)"/7:-(>+5PC+;4CHK:JCTA\
M$.&GG=N?R.V_--/.[<_D=M^::>=VY_([;\TT\[MS^1VWYIIYW;G\CMOS33SN
MW/Y';?FFGG=N?R.V_--/.[<_D=M^::>=VY_([;\TT\[MS^1VWYIIYW;G\CMO
MS32JD3B]=%>.%V1O@=LU$*2#_!Z97KZV8U%96VFBJ*NH8 &262!&=B%  Q))
MU#T$SWP1SO<[-<<IQ229DRA24]+4+<:#OGG@$\$K">GPW@H.#IO#O@N*R)Q?
MN3HX#(XI+;@0=8(_=-/.[<_D=M^::>=VY_([;\TT21>)1N(0ZX;A;+?,C G$
MAMR"-OR$:4=BXUV"GRZ*EEB3/5FZQZ!&. #5M+(7E@4G:Z,ZCG"C7I35U#4Q
M5M%61)/1UD#K)%+%(H9)(W4E65@000<".PWO.>;;BEJR_E^F:JN-8^L[HU*B
M+M9W8A44:V8@#;I>[WEO.=7DG+M;4$V+*M-3T,HHZ5.YB626:GD9Y6 WI#CA
MO$A0 !IYW;G\CMOS33SNW/Y';?FFGG=N?R.V_--(XHN+%WGFF=8J>GBH;<\D
MDDC!4C1!1XLS,0 !M.E-7<:<Y5F:<\YA9:ZLM\\=-'#:(F7WJBC^#0Q!W4'&
M5SCB^(7N5&/H73,N9KK3V2PV2G>JNMUJW"0PPH,2S$_D &LG4,2=*JW<&;#2
MY>L<;%:?-5]@-37U(!_Q(J(LL4"GF$F^W2J[-&E;BQ70EO\ +@H;:B#TE^"G
M3SNW/Y';?FFGG=N?R.V_--/.[<_D=M^::>=VY_([;\TT\[MS^1VWYIIYW;G\
MCMOS33SNW/Y';?FFGG=N?R.V_--/.[<_D=M^::>=VY_([;\TT\[MS^1VWYII
MYW;G\CMOS33A;F7,=P>[7Z^9;M];=[G*J(\]1+"K22,L:H@+$X]RH')N62^%
M5LI<ZYIMDCTUYS!5.PL]#.AW7A7JB'JI4.(8(RHIU%R<5#S'B1_*E8XK3VRV
M4$,:CF ZR&9C^-CIYW;G\CMOS33AA8+UQ1N-PLU[S1;*&[6]Z6WJD]//.J21
ML4I58!@<,00>WV2MNMUK8+=;+=!)4W"X5,BQ0P0Q*6>21V("JJ@DDG5I56;@
M?8J:>WPLT8SY?8Y"L^&H245 #&VYT/,PQ'^7SZ-4/Q3J:1F_R*.WVZ*(>DII
MG/\ ?IYW;G\CMOS33*V5<Y\1*[,&7:ZW7::KM4]/11I))3TQ>)BT-/&XW6UZ
MF]/T;K3Y,O+6/,\<?76>LW(W1I8SO"&1959=V0#=)YL<>;26"HS?/3U%/(T5
M33R4=('CDC8JZ,.IU%6!!T_K67Y)2>!T_K67Y)2>!T609Q,I7U$M%2,A],"(
M?\=(:/B%9(:FB8A7OMH5DECZ7DI69@XZ>K;'H4Z4=ZLEP@NEJN$8EHZZG8/&
MZGH(V$'40=8.HZ_1K,OYCM\=RM=:!UD#X@JZ][)&XP9'4ZU93B-)ZW)I.<;'
MB6CI<4CN<*\RLAW4FP]<A!/K='IKQ;JNT5$1PDAK8)*=@>CWQ5T$<&-1(=D<
M(,C'TE3$Z1-26"2Q6R3 M>KRK4L04\Z1$=;)^)</9#1Y*+&[9CK(PESS)4J!
M*Z[>JA08B*,'7NC6=K%CAR*FNK9XZ6CHXGFJJF5@J1QQ@L[LQU  #$G111,\
M&3[([K8*,XJ:ASW+5LJ^N<:D![U>VQ]"TY;LT?672]5"TU+B,53'6\K^QC0%
MSVAI9LL6A-VALU,D$;'OI&&MY7]D[$L>V>159PSW=UMEK@80TD"+UM565# E
M*:E@'=2R/@< -0&)8A02)HN'5IMW#VR*Y%-/61)<[I(FS&4O^[QD[=U4?#UY
MT9SQ;N*ESB52CMH4=H#X(<!IYW;G\CMOS33B95\0\UU.:JFRWFBI[5+4Q4T1
M@BEI.L=%%/%$""VO7CV"KM#7A\[9MI-Y)<LY>W*EX9!ZBIJ2RP0''40S[P];
MI-!DJU6?AW;F)$,O5_S6X;AU=U+.J0 ^E"?3T=\T\3<SWE7)/P9[E/! ,=H$
M%,T48':W<--ZJ3X6V..]4$RG'IQ?>TP^!08';[VOYM-]*2&-QL=$56_* #HL
MUBS1>K)*AWD>@N5738'THI5&B_ N*%?>H5P!I+_##<T(QQPWY4$HZ,1)I#2\
M3.'$%?#BJRWG+-08I NQG:BJR03SX+,-(J7)N<J9KXZ[SY7N(:AN:](%-/NF
M3##68RP[?)NV>\VSLEOMX6*CH8<#45U9+B(*2G4D!I)"-7,!BQP4$Z39VS[G
MI>"? >:5A:+=#,88JJ)20#&A>#X5@1@9ZAQ&3CU49 T6CJ>,C5EW;N)*L9CL
MR,\QY^H$)&./-I+Q X%<0JKB-PZMZBMON3:U6F_=5&\\CT2,T<L83;)2]7*H
M[K=90=(LU6!?Y?<Z)UI<T9;DD62:WU90.%WAAOQ2*=Z*0 !EZ&#*.Q560Z:K
M;_:G# )2Q42DA)KO/$LE542#G:)'6),=G=X=]V:M^+R>Y.F3?J.W>+1^C-Q2
MR50!.'F:ZPF_6ZG3!++=*AL=X*NI::J8DKAJ23N=0=>31\%<\W$KE"]3;F0;
MK4-W%LKI6Q_E[LQ[F"H8XQ<R2'=V.,.6\LKK''&I:21B JJ!B22=0 &@RGE2
MM8\+LGU3? 9$)"7BXQXHU<PYXHM:P [=<GJEP]'6< -I.EOX\YZH?W:$L_#"
MRU"=\>]-WD5OQK3@\V,G.AY%AX-6ZI:*QY>I8+[FF!<1\)KZDM\"CDYF2"-3
M(!ZYP?4CL_!C[HVOQ=>16C+U6:+-6>*I<OV2LC.$M,D\;R5=3'JU-' C!3M#
M,I&S18T&ZB#!1M_O.WT>#GWSL_C*=DL? ^S5;06QZ2*^YZ$;$&IWY&6AHY,,
M,4!C:9UV,>KQV<C)GU5?/$SR(N(MGI]VUWZ58,RQ(-4-<1A'48#8)@-UO9@'
MU7)CR]=:HIE'-4ZQ3*[>]T=>^"Q5 QU*LAP23_E8[.2$J((YT!QW)%#C\A!T
MWJ2@IJ5NF&)$.O;WH'*J.'N5ZS>R];Y=W,UPA;N:VIC/\,C#;%$P[OF9M6Q=
M?H5G$JZ0?O-U#T.6%<=Y2*V$]0,1MF==T$>I7V7)S#4&L:3*.2ZRIL>2[>">
MJ2.FD,535[NKWRHE0DL=>X$78.1Q?^O[=XB.5<LWYTO5/8<OVE-^KKISM8ZD
MCC08M)(YU*B@LQU :5V7\GS5?#[APY:(4-/)U=VN<1Q7>K:B,XQ(X/\ @Q-L
MU.[; $C0(@V*HP&O;V&.08K+"P>"925>-QL9&&!4CF(..E+:<V32\4,FQ8(:
M.XS87>EC'_MJ]\3+@-B3X] ==/\ <&0KVM>D)"76T3CJ;A02D8]754S'>0]!
MUJVU68>CPUX U,L@R5DZD2ZYIIHWP$IFB-75DD#4S4ZQ0+CLZQL-NF7*&BHX
M*:AMN:K;%0T*1JL,4<%'5K&BH!@%4   #4-,NW"JLUZANEZM-'6U-RANLXD2
M:HITD=D1]Z(#>8D*4*]K#3CEP!DOTV8\G9"GDER_53,62"2"M>ED$(Q*QK,I
M5F1>Y#JQ4#$Z6JRY?0T7#[CU2,JV>,#J8:BI:5@B*!@HAK(R4Z$F*C5V/B_4
M2ZY),YWH,=9[RLD0;>TH[-EK(]HA-1<<VW.FM<$8V!9W F=CS+'%O.QY@#I1
MV^F!6GH8(Z> '60D2A%Q_$/1NN6\Q6V&[V*]TLE'=;94+O1S02KNNC#;L.HC
M6#K&O2?+E5UU=E.[F2KR)F*37\*I%/=4\K[/A%-B%<>J&Z^QM7HLCC%6&!P.
M!],$:P1S'1>&F>+F)>(^5*4&WU\[827JV18*L^/JIX!@LPVMJDYVPY5;P*R#
M=-VOJXPO$R]4KX&GIY!B+7'(NR292#-AWL9W-KG *H"JHP51J  V #D&ZY@I
M73A=E"H1LRSG%1<ZH /';(F&!*D8-.1WJ8)J+ZH*6E@CIJ6FC6*FIHE"1QQH
M JHBJ %"@8 #9R.*AD<N4JK=&A;7@BVRDP4=H8GLU+:[53O5W6ZSQ45KI(QO
M/+4U#B*%% VEG8#3)>34*G_:]DH;8[)WK/30)&[#M%@3R."J!B$:Y7MF3F)6
MFIL"1VL3R.#GWSL_C*=DXB[[%MRFLRICS*+=#@!^7D9,^JKYXF>1<\OWFG%5
M:[O3O35D)VE7&U3KP93@0>8C'2[Y4NP+5%LE_=JK#!:FE?$P3K[==O0P(YN0
MR,,588,.T=/Y%>*KK<T932.GJW<C?JJ/#=IZGI)P&XY]<,?5=BFR%E:LW,S7
M.$?SNX1-W5NI)!WJD;)I1WOK5[K:5T"J,%48 >A9LJ4N^D5;)UMVJTVT]#%@
M9Y,>G#N5]D1I16NW4Z4E!;H(Z:BID&"QQ1*%11Z0'(K9HSA)#!(Z'MJI(TED
M<[SR2R.['G9G))_&3R.+_P!?V[Q$<FZYCS!<(;58['2RUMUN4[;L<,$*EW=C
MV@-@UG8->C7*9I[=D2R2NN2,K.=T1QZU^&U*#4:F9=9QQZM>X7U1/9*'-N2;
M[4Y;S';C^[W&F(P=,<6AGB;%)HF]5&X(/:.O2XU]QR_-8LS95FAH,RM$CFV5
M$\D>^)**9L<05&+QL=Z/$ E@0QTSK37(B*7,66G%G+?YA>WT,RX$^QII!^(Z
M65I5WXUS?0&1.E12UF(TL^>*KC3+=<BS4EO@2GL16&LM]+5PK\%,TC4<;(@+
M+$71\02#CSZ4&<<EWJ;-MSXCPQ7',F:ZM=R=YH]X&CZHEC$*>1I%922S/O,S
M$D8?]IV7:!MZZT5PBKJK<P)C@:OBD!;;AW-+(=?-V/BY]]+[X_-R!UTR1;W>
M[[!<<.C'3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+
M^?3^+A_:+^?3^+A_:+^?2&RY*R[<<V76H;=CH[7 U1ATF21?>XU'.SLH'3I+
MQ X@O2UW$FXTQIK?;Z9A-362EE ZV..7#"2>79)(O<@=PF(WF;D73).8!\&F
MD_><OWR-0T]NN$8/4U,>.T G!UV.A93MQTO>2,X4'\NS%EZ?J:Z$8F.16&]%
M40,>^BF3!T;H.!U@\BSYHRW<9+1F'+U6E;9KG%WT4T?2-C(P)5U.IE)!VZ4^
M9*)8[?F2ULE%G3+BMBU#7;N)*X]T89AW<3':NKOE;#D);+%-#4\3,W0RQ96H
M7P<4<([B6Y3IZR(G! >_DP76 V%365E3+75U;-)4U]=4.9)IYYF+RRRN=;,[
M$DGIY%LR'E93#+4CX3?+VR;\-LMZ,%EJI1L)U[L:D]VY V8X6+(V4:$4-CL-
M.(:=2=Z65SW4L\S[7DE<EW;G)Y/%;X[0?9E)R 994B#'!2[!<3^/3^+A_:+^
M?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_:+^?3^+A_
M:+^?2"T98M-;F6[53!*>V6JGDK)W8[!N0JQ'IG :4'%;BW3PQYIHE+Y0R8K+
M.ML>12IJZMUQ1ZG=)"*A*QXD[Q?O>1P4^L;YXO3<C@Y]\[/XRG9.(WZBS?9T
M/(R9]57SQ,\D9FL]-UN9\I1O*D:#NZJ@[Z>#MLN'6)VP1ZK174AE8 JPYP=G
M(M.:[9O226]RM=1 X"JI),!/ ?;+K7H8 Z6R_6>I6KMEVITJJ*=?5)(,1CT$
M;".8ZNP?NS1U6;+RCQY>MK:PI&IZJ8<T<6/_ #-@HY\*NX7"JEKKA<)GJ:^N
MF.])--(<7=CTD_F] LQP51BQ.P :/FNZ4_5W_.*1S(CC!Z>WKKIXM8Q!?'K&
M],#FY-R^*S>X.A]N_NCR.+_U_;O$1R;-P,L=64@,<-\S\8V(WU+$T%$^&&HE
M3.XV'"/DQ6BQ6NMOMVGPZJUVVGEJZAL=AZJ%7;#MX8:"6EX47&AC;6#=*FCH
M&P[:3SJX_)HTAX;QRA=J17>VLY](&H'_ !TDDNG"#,P@A&])4T=**Y !VZ1Y
MC_=HU#<Z:>UURG!J*MB>FF!_5RJK?W<FR9 RC$#=+RY:IKY%+04%'&1\(K9\
M/41 ZAZIBJ#6=+%D/*E+U%JLL.Z\[ ==55#]U/53L.^DE<EF/XAJ 'H9%_[H
M>'40DOW#"2%,STZH3C10RM)#52!1BT:=9)%-T1R;VQ3I9&X'T4-[S-2Y@HJK
M,V4:BMIZ6KM;I2U*2QSF=T4@-(-QAJD7NEY\+=D'.%NBJZ.LRW3V7,5L8K(C
M#X*L$R!AB#@0<&'/K&G%*W<5S O *&IFK\H9P-=3/4RUP(6&&GMXEZ]I:Z+#
M>0+JEC+=ZQ;3-_\ W8YSMSVZPP==:N&]NE(*XA#3^]ZL'2E@WD+C4TTDA&.[
MV/BY]]+[X_-R.,AO=DH+R:6X644QKJ:*HZL-3U)8)UJMNXD:\-/Z)L/DVE\'
MI_1-A\FTO@]/Z)L/DVE\'I_1-A\FTO@]/Z)L/DVE\'I_1-A\FTO@]/Z)L/DV
ME\'I_1-A\FTO@]/@MJMU+;*8''X/20I#'C[6,*.6F9LK4Z1\3\G4\C65M2BZ
M4>)>6VRMTL<6A8][)[%VTDBFBDIYX'>*HIY5*2121L5>-T.M65@00=AY%NSQ
M85>LI,!29JR^'W4N=N9MYX<3J$B'NXF/>MJ[UFTL>=,IW!+GE_,%,M5;ZI=1
MP.IHY%VJZ,"KJ=:L"#Z-WSWFB0O3T($-LM<3 5%PK9<1!20 ^JD(UG8J@L=2
MG2^9\S?4BHOM^EWGBC)ZFEITQ$%)3@ZQ%"NH<Y.+'NF/(M5@L-OENU]OE5'0
MV>UP#&2HJ)C@B+T=))U* 2=0TCM1:*XYTO\ U=9G>_H/\:J"X+3PDZQ!3@E(
MQSZW.MCRN*WQV@^S*3D<1Z>]6FCN\$.6Z1X8:V".H1&-80659%8 D<XT_HFP
M^3:7P>G]$V'R;2^#T_HFP^3:7P>G]$V'R;2^#T_HFP^3:7P>G]$V'R;2^#T_
MHFP^3:7P>G]$V'R;2^#T>*S6BBM,4AQDCHJ>.!6/21&J@\K@I]8WSQ>FY'!S
M[YV?QE.R<1OU%F^SH>1DSZJOGB9Y1N%KI^JROFQY*FV*H[BFJN^J*;H Q/6(
M.@D>IY+\-KQ486Z[O)4Y6ED.J*K[Z:FQ/-* 70>N##U7+KLRWMR8J<".BH4(
M$M54OCU<$0/JF//S#$G4-+CFB_S"2X7!L%A0GJJ:!<>KIX0=B(#^,XL=9]&A
MMU3$6R_9]VXYD?U+0HWO=/CJUS.,"/6AM%1%"(@"H@&  &P #DW+XK-[@Z'V
M[^Z/(XO_ %_;O$1R))YG$4,*%Y9&. 55&))/0!IGG/=6<7S1>JJKIEQ)"4JO
MU5+&">98$0<B:S"JGLV3LO)'4YSS# H,L:2D]324Q8%1//NM@2"$4%\#W(,.
M7L@Y9H\O4"*.ODA3&HJ7&V2IJ&QDF<\[.Q/XN0]NS?E>U9GHI%*&FN=)#5*
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M%;*2NJ9*(PPO*&(>0),S8#=YACV*2T%HK=G*Q=969(S Z_P]45P:"8C68)P
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M@RL#@58'80=1'(M69[))U=SL\XF@4DA94V20OAZB5"5/IX\VEHS19I-^BNT
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M0\C)GU5?/$SR:^[W.H6DM]LIY*JMJ7. 2*)2S,?Q#2\9LKPT?\QDW;=2-_\
MQZ./N8(O3"ZVZ6)]%<WYCI=[)]FGPH:20=S<JN(XX$'488B.ZYF;N=@;3 #
M#8.P)GNRTIDOF5XB+K%$I+U-MUL^H;6@.+CV.\.C0%3B",01SCD6[,U-ORT(
M_=;_ $*G^(H9".L&'.T9&^G;&'/I1W.W5*5E!<(4J**JC.*212*&1E/00<>1
M<OBLWN#H?;O[H\CB_P#7]N\1'(CX(T-/5V?+&7(Z:ZW]YXWA-XJIEWZ<Q[P'
M64U/TC4TN/\ ICE*TD:NR:T8@$J>D'FT$>5^)>:+%$-D%-=*DQ#M=5([I_\
M;H$BXN72I"@C>JZ:AG;7TEZ?0QS<7+K3*1@6HZ>AIV_ZDIP=!)G3.=\S81LC
MNM?/4Q#THG<QC\2Z    #  ; !R'D<[J("SMT ;=(KK?:1J7.7$5XKU?:>0
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D%$%P$,8@B50ZQ* JAR1@-8.BHBA$0!411@ !J  &P#_RV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698190608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,636,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698438048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 540,597<span></span>
</td>
<td class="nump">$ 501,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">772,536<span></span>
</td>
<td class="nump">807,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">233,923<span></span>
</td>
<td class="nump">214,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">29,908<span></span>
</td>
<td class="nump">33,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">60,654<span></span>
</td>
<td class="nump">62,211<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,637,618<span></span>
</td>
<td class="nump">1,618,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">806,615<span></span>
</td>
<td class="nump">756,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">116,212<span></span>
</td>
<td class="nump">110,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">229,603<span></span>
</td>
<td class="nump">231,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OperatingLeaseRightOfUseAssetAndOtherAssets', window );">Right-of-use assets and other</a></td>
<td class="nump">289,627<span></span>
</td>
<td class="nump">290,578<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,143,359<span></span>
</td>
<td class="nump">3,071,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">32,621<span></span>
</td>
<td class="nump">32,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">56,551<span></span>
</td>
<td class="nump">77,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">64,210<span></span>
</td>
<td class="nump">65,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">66,405<span></span>
</td>
<td class="nump">50,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">18,324<span></span>
</td>
<td class="nump">20,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">89,486<span></span>
</td>
<td class="nump">78,924<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">327,597<span></span>
</td>
<td class="nump">324,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">6,299<span></span>
</td>
<td class="nump">6,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">186,948<span></span>
</td>
<td class="nump">190,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">67,379<span></span>
</td>
<td class="nump">61,951<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">588,223<span></span>
</td>
<td class="nump">583,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 324,985 and 323,951 at March&#160;31, 2023, and December&#160;31, 2022, respectively</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,558,297<span></span>
</td>
<td class="nump">2,536,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(9,289)<span></span>
</td>
<td class="num">(14,521)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (Accumulated deficit)</a></td>
<td class="nump">5,803<span></span>
</td>
<td class="num">(34,225)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">2,555,136<span></span>
</td>
<td class="nump">2,488,427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 3,143,359<span></span>
</td>
<td class="nump">$ 3,071,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseRightOfUseAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseRightOfUseAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837696171536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">324,985,000<span></span>
</td>
<td class="nump">323,951,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">324,985,000<span></span>
</td>
<td class="nump">323,951,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698485984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 408,788<span></span>
</td>
<td class="nump">$ 355,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">14,315<span></span>
</td>
<td class="nump">13,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">234,246<span></span>
</td>
<td class="nump">156,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">131,397<span></span>
</td>
<td class="nump">102,863<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">379,958<span></span>
</td>
<td class="nump">272,737<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">28,830<span></span>
</td>
<td class="nump">83,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">19,502<span></span>
</td>
<td class="nump">1,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(54)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Income before income taxes</a></td>
<td class="nump">48,278<span></span>
</td>
<td class="nump">85,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">8,250<span></span>
</td>
<td class="nump">16,656<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 40,028<span></span>
</td>
<td class="nump">$ 68,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">324,420<span></span>
</td>
<td class="nump">319,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">326,279<span></span>
</td>
<td class="nump">323,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 363,400<span></span>
</td>
<td class="nump">$ 310,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">38,292<span></span>
</td>
<td class="nump">32,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7,096<span></span>
</td>
<td class="nump">$ 13,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698056384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 40,028<span></span>
</td>
<td class="nump">$ 68,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $(1,507) and $1,656, respectively</a></td>
<td class="nump">5,232<span></span>
</td>
<td class="num">(5,907)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 45,260<span></span>
</td>
<td class="nump">$ 62,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698520816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</a></td>
<td class="num">$ (1,507)<span></span>
</td>
<td class="nump">$ 1,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837693944416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 2,210,615<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">$ 2,427,561<span></span>
</td>
<td class="num">$ (758)<span></span>
</td>
<td class="num">$ (216,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">68,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(5,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan</a></td>
<td class="nump">5,513<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(4,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Apr. 01, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Apr. 01, 2022</a></td>
<td class="nump">$ 2,293,851<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">2,448,130<span></span>
</td>
<td class="num">(6,665)<span></span>
</td>
<td class="num">(147,934)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 30, 2022</a></td>
<td class="nump">323,951<span></span>
</td>
<td class="nump">323,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 30, 2022</a></td>
<td class="nump">$ 2,488,427<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">2,536,849<span></span>
</td>
<td class="num">(14,521)<span></span>
</td>
<td class="num">(34,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">40,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">5,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans and stock purchase plan</a></td>
<td class="nump">7,080<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">7,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(2,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 16,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">324,985<span></span>
</td>
<td class="nump">324,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 2,555,136<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 2,558,297<span></span>
</td>
<td class="num">$ (9,289)<span></span>
</td>
<td class="nump">$ 5,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698348144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 40,028<span></span>
</td>
<td class="nump">$ 68,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">6,855<span></span>
</td>
<td class="nump">4,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">16,661<span></span>
</td>
<td class="nump">19,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">6,731<span></span>
</td>
<td class="nump">1,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development technology</a></td>
<td class="nump">36,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="num">(3,743)<span></span>
</td>
<td class="nump">1,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(19,178)<span></span>
</td>
<td class="nump">91,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(8,370)<span></span>
</td>
<td class="num">(3,520)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">10,372<span></span>
</td>
<td class="num">(3,605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(707)<span></span>
</td>
<td class="num">(1,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_IncreaseDecreaseInAccruedCollaborationLiabilities', window );">Accrued collaboration liabilities</a></td>
<td class="num">(1,864)<span></span>
</td>
<td class="num">(54,261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">1,123<span></span>
</td>
<td class="nump">7,376<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">84,408<span></span>
</td>
<td class="nump">147,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(12,024)<span></span>
</td>
<td class="num">(5,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development technology</a></td>
<td class="num">(36,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(311,837)<span></span>
</td>
<td class="num">(336,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of investments</a></td>
<td class="nump">310,769<span></span>
</td>
<td class="nump">267,615<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(49,592)<span></span>
</td>
<td class="num">(74,539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive plans</a></td>
<td class="nump">7,143<span></span>
</td>
<td class="nump">4,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(2,557)<span></span>
</td>
<td class="num">(4,686)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,586<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash equivalents</a></td>
<td class="nump">39,402<span></span>
</td>
<td class="nump">73,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at beginning of period</a></td>
<td class="nump">502,677<span></span>
</td>
<td class="nump">663,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at end of period</a></td>
<td class="nump">$ 542,079<span></span>
</td>
<td class="nump">$ 737,276<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInAccruedCollaborationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Collaboration Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInAccruedCollaborationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837780344832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. Through the commitment of our drug discovery, development and commercialization resources, we have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib. We continue to evolve our product portfolio, leveraging our investments, expertise and strategic partnerships, to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 67 other countries as of the date of this Quarterly Report on Form 10-Q: as CABOMETYX&#174; (cabozantinib) tablets for advanced renal cell carcinoma (both alone and in combination with Bristol-Myers Squibb Company&#8217;s OPDIVO&#174; (nivolumab)), for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer; and as COMETRIQ&#174; (cabozantinib) capsules for progressive, metastatic medullary thyroid cancer. For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2022, included in Part II, Item 8 of our Annual Report on Form 10-K, filed with the SEC on February&#160;7, 2023 (Fiscal 2022 Form 10-K).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2023, which is a 52-week fiscal year, will end on December&#160;29, 2023 and fiscal year 2022, which was a 52-week fiscal year, ended on December&#160;30, 2022. For convenience, references in this report as of and for the fiscal period ended April 1, 2022, and as of and for the fiscal years ending December&#160;29, 2023 and ended December&#160;30, 2022 are indicated as being as of and for the period ended March&#160;31, 2022, and the years ending December&#160;31, 2023 and ended December&#160;31, 2022, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about sales of products, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies during the three months ended March 31, 2023, as compared to the significant accounting policies disclosed in &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2022 Form 10-K.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since our filing of the Fiscal 2022 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Fiscal 2022 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837801052688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,388&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues are recorded in accordance with ASC Topic 808, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs and the royalties we pay on sales of products containing cabozantinib by our collaboration partners.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:41.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,598)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,150&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,083&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,322&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,555&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contract assets and liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,363&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,070&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, we recognized $2.0&#160;million and $2.4&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we recognized $37.9&#160;million and $31.7&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to our license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023, $69.0&#160;million of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he co</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mbined transaction prices for our Ipsen a</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd Takeda collaborations were allocated to research and development services performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2022 Form 10-K for additional information about the expected timing to satisfy these performance obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837780308544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</a></td>
<td class="text">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading biopharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading biopharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements and Business Development Activities&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2022 Form 10-K, as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Commercial Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Under the collaboration and license agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration and license agreement, as amended, with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,527&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023, $33.9&#160;million of the transaction price for this collaboration and license agreement, as amended, was allocated to our research and development services performance obligation that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Under the collaboration and license agreement, as amended, Takeda received exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration and license agreement, as amended, with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $35.0&#160;million of the transaction price for this collaboration and license agreement, as amended, was allocated to our research and development services performance obligations that have not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib sold by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalty fees earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalty fees earned by Royalty Pharma were $15.4&#160;million and $13.1&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively.<br/><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaborative arrangements with other pharmaceutical or biotechnology companies to develop and commercialize drug candidates or intellectual property. Our research collaborations and in-licensing arrangements are intended to enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Our research collaborations, in-licensing arrangements and other strategic transactions generally include upfront payments, development, regulatory and commercial milestone payments, and royalty payments, in each case contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs or acquire the intellectual property developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent development, manufacturing and commercialization.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2023, we recognized $44.7&#160;million within research and development expenses on the Condensed Consolidated Statements of Income, primarily related to development milestones, research and development funding and other fees, including a $35.0&#160;million development milestone to our partner, Sairopa B.V., upon the effective date of the initial new drug application (IND) for the ADU-1805 program.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March&#160;31, 2023, in conjunction with these collaborative in-licensing arrangements we are subject to potential future development milestones of up to $650.6&#160;million, regulatory milestones of up to $634.4&#160;million and commercial milestones of up to $3.2&#160;billion, each in the aggregate per product or target, as well as royalties on future net sales of products.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837700287088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A reconciliation of cash, cash equivalents and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit agreements and are invested primarily in certificates of deposit with original maturity of 90 days or less. The restricted cash equivalents are classified as other long-term assets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886,976&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,571&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,277)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875,270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,571&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,277)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,085,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066,681&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $10.1 million and $7.3 million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and December&#160;31, 2022, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were immaterial during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,274)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,425&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,277)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,132)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 237 and 285 debt securities available-for-sale in an unrealized loss position as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023 and </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, respectively. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> all securities have been in an unrealized loss position for less than twelve months except for 91 debt securities available-for-sale with an aggregate fair value of $317.1 million and an aggregate $6.3 million unrealized loss. As of December&#160;31, 2022, all securities have been in an unrealized loss position for less than twelve months except for 81 debt securities available-for-sale with an aggregate fair value of $237.6&#160;million and an aggregate $6.1&#160;million unrealized loss. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875,270&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837702621840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,941&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955,225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121,166&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchange rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had one forward contract outstanding to sell &#8364;4.1&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized loss on the forward contract is immaterial as of March&#160;31, 2023. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. The realized loss and gain we recognized on the maturity of our forward contract was immaterial for each of the three months ended March&#160;31, 2023 and 2022, respectively, and are included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837702444976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,877&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837801052688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several equity incentive plans under which we granted stock options and restricted stock units (RSUs), including performance-based restricted stock units (PSUs), to employees and directors. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023, 31,678,788 sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 2 shares for full value awards, including RSUs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,661&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,661&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were 9,738,700 stock options outstanding and $14.0&#160;million of related unrecognized compensation expense. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, we granted 576,960 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $17.08 per share. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were 11,315,085 RSUs outstanding, including RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs), and $172.0&#160;million of related unrecognized compensation expense. Service-based RSUs granted to employees during the three months ended March 31, 2023 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2022 Form 10-K.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;March&#160;31, 2023, there were 4,688,349 PSUs outstanding, of which 1,277,755 PSUs relate to awards that we either achieved the performance goal or determined that attainment of the performance goal was probable. Expense recognition for PSUs commences when it is determined that attainment of the performance goal is probable. As of&#160;March&#160;31, 2023, the remaining unrecognized stock-based compensation expense for the PSUs either achieved or deemed probable of achievement was $9.0&#160;million. The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance goal is probable was $76.2&#160;million. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the &#8220;Notes to Consolidated Financial Statements&#8221; included in Part II, Item 8 of our Fiscal 2022 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, our Board of Directors authorized a share repurchase program to acquire up to $550&#160;million of our outstanding common stock before the end of 2023. The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of our common stock and general market conditions. Share repurchases under the program may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, 10b5-1 trading plans, exchange transactions, or any combination of such methods. The program does not obligate us to acquire any particular amount of our common stock, and the share repurchase program may be modified, suspended or discontinued at any time without prior notice. During the three months ended March 31, 2023, we did not repurchase any shares.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837699485312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">PROVISION FOR INCOME TAXES</a></td>
<td class="text">PROVISION FOR INCOME TAXESThe effective tax rate for the three months ended March&#160;31, 2023, was 17.1%, as compared to 19.5% for the corresponding period in 2022. The effective tax rate for each of the three months ended March&#160;31, 2023 and 2022, differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, partially offset by state taxes.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837700221456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text">NET INCOME PER SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options, unvested RSUs (including TSR-based RSUs), PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837699450000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MSN I ANDA Litigation </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (individually and collectively with certain of its affiliates, including MSN Laboratories Private Limited, referred to as MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The two lawsuits comprising this litigation (collectively referred to as MSN I), numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#8217;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we sought, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and on January 19, 2023, the Delaware District Court issued a ruling rejecting MSN&#8217;s invalidity challenge to U.S. Patent No. 7,759,473. The Delaware District Court also ruled that MSN&#8217;s proposed ANDA product does not infringe U.S. Patent No. 8,877,776 and entered judgment that the effective date of any final FDA approval of MSN&#8217;s ANDA shall not be a date earlier than August 14, 2026, the expiration date of U.S. Patent No. 7,759,473. Final judgment was entered January 30, 2023. This ruling in MSN I does not impact our separate and ongoing MSN II lawsuit (as defined below).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MSN II ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 are invalid and not infringed. On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#8217;s further amendment of its ANDA filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 11,298,349 are invalid and not infringed and amended its challenges to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 to allege that these patents are not enforceable based on equitable grounds. The two lawsuits comprising this litigation (collectively referred to as MSN II), numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#8217;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, if those claims are not found to be invalid, and (ii) upon approval, MSN&#8217;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#8217;s ANDA product prior to the expiration of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032, and equitable relief enjoining MSN from infringing these patents. A bench trial for MSN II has been scheduled for October 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teva ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#8217;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#8217;s counterclaims. On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#8217;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On September 2, 2022, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#8217;s amended ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the two lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cipla ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 6, 2023, we received a notice letter regarding an ANDA submitted to the FDA by Cipla, Ltd. and Cipla USA, Inc. (individually and collectively referred to as Cipla), including a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,039,757 (methods of treatment), 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition), 11,098,015 (methods of treatment) and 11,298,349 (pharmaceutical composition). Cipla&#8217;s notice letter did not provide a Paragraph IV certification against any additional CABOMETYX patents. On March 16, 2023, we filed a complaint in the Delaware District Court for patent infringement against Cipla asserting infringement of U.S. Patents No. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349 arising from Cipla&#8217;s ANDA filing with the FDA. Cipla&#8217;s ANDA requests approval to market a generic version of CABOMETYX tablets prior to the expiration of the aforementioned patents. We are seeking, among other relief, an order that the effective date of any FDA approval of Cipla&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032, and equitable relief enjoining Cipla from infringing these patents. Cipla&#8217;s response to the complaint is due on May 19, 2023. On May 4, 2023, we filed, under seal, a stipulation and proposed order to stay all proceedings, and the Delaware District Court, in a sealed order, granted the proposed order and administratively closed the case.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698078384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2022, included in Part II, Item 8 of our Annual Report on Form 10-K, filed with the SEC on February&#160;7, 2023 (Fiscal 2022 Form 10-K).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span>. Fiscal year 2023, which is a 52-week fiscal year, will end on December&#160;29, 2023 and fiscal year 2022, which was a 52-week fiscal year, ended on December&#160;30, 2022. For convenience, references in this report as of and for the fiscal period ended April 1, 2022, and as of and for the fiscal years ending December&#160;29, 2023 and ended December&#160;30, 2022 are indicated as being as of and for the period ended March&#160;31, 2022, and the years ending December&#160;31, 2023 and ended December&#160;31, 2022, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements adopted by us since our filing of the Fiscal 2022 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Fiscal 2022 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues are recorded in accordance with ASC Topic 808, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs and the royalties we pay on sales of products containing cabozantinib by our collaboration partners.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837695957648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,388&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,682&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration Risks</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues Disaggregated by Geographic Region</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,788&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:41.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,063)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,130)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,598)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,150&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,083&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,322&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,555&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Other Assets and Other Liabilities</a></td>
<td class="text">Contract assets and liabilities were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,363&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,070&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837699514272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration and License Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration and license agreement, as amended, with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,534&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,527&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration and license agreement, as amended, with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698264608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,079&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Investments by Security Type</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886,976&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,571&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,277)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875,270&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,571&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,277)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,085,126&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">589&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066,681&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,274)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,425&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,277)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,132)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,034)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875,270&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837699481888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Financial Assets Measured on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684,917&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,875,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,941&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955,225&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121,166&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,018&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,344&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837699423136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,077&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,877&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,276&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698034560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,661&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,661&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,759&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837701205936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share</a></td>
<td class="text">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:64.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.740%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837696272976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>country </div>
<div>segment </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS', window );">Number of countries with drug approval, excluding the u.s. | country</a></td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products derived from other compounds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberOfCountriesWithDrugApprovalExcludingTheUS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Countries With Drug Approval, Excluding The U.S.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberOfCountriesWithDrugApprovalExcludingTheUS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698352624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 408,788<span></span>
</td>
<td class="nump">$ 355,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">521,322<span></span>
</td>
<td class="nump">448,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(157,922)<span></span>
</td>
<td class="num">(137,939)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">363,400<span></span>
</td>
<td class="nump">310,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">38,292<span></span>
</td>
<td class="nump">32,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7,096<span></span>
</td>
<td class="nump">13,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 45,388<span></span>
</td>
<td class="nump">$ 45,682<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837695905648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Concentration Risks (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember', window );">Affiliates of Optum Specialty Pharmacy | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_CardinalHealthMember', window );">Cardinal Health, Inc. | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_CardinalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_CardinalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698444432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 408,788<span></span>
</td>
<td class="nump">$ 355,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">367,441<span></span>
</td>
<td class="nump">314,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">33,534<span></span>
</td>
<td class="nump">34,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7,813<span></span>
</td>
<td class="nump">$ 7,388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837695829696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 408,788<span></span>
</td>
<td class="nump">$ 355,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">363,400<span></span>
</td>
<td class="nump">310,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">361,773<span></span>
</td>
<td class="nump">302,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 1,627<span></span>
</td>
<td class="nump">$ 7,486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837693759072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2022</a></td>
<td class="nump">$ 77,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">158,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(1,063)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(147,598)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2023</a></td>
<td class="nump">87,555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks, Discounts for Prompt Payment and Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2022</a></td>
<td class="nump">26,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">94,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(100,831)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2023</a></td>
<td class="nump">21,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2022</a></td>
<td class="nump">14,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">14,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(1,117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(13,637)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2023</a></td>
<td class="nump">15,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2022</a></td>
<td class="nump">35,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">49,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(33,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at March&#160;31, 2023</a></td>
<td class="nump">$ 51,322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698371856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 1,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">7,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">6,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,582<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">13,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Contract revenue recognized, including revenue from deferred revenue beginning balance</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">37,900<span></span>
</td>
<td class="nump">$ 31,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698444672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 408,788<span></span>
</td>
<td class="nump">$ 355,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">33,534<span></span>
</td>
<td class="nump">34,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">38,292<span></span>
</td>
<td class="nump">32,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">29,812<span></span>
</td>
<td class="nump">24,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7,096<span></span>
</td>
<td class="nump">13,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,722<span></span>
</td>
<td class="nump">$ 9,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698042432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 69.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 33.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698487872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 408,788<span></span>
</td>
<td class="nump">$ 355,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,223<span></span>
</td>
<td class="nump">6,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">38,292<span></span>
</td>
<td class="nump">32,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,849<span></span>
</td>
<td class="nump">2,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">7,096<span></span>
</td>
<td class="nump">13,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,374<span></span>
</td>
<td class="nump">$ 3,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837701535840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 69.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 35.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698448384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities -Royalty Pharma Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember', window );">Royal Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="nump">$ 13.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_RoyalPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698141728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 234,246<span></span>
</td>
<td class="nump">$ 156,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember', window );">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">44,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Decrease in research and development</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Collaborative arrangement, maximum aggregate development milestone payments</a></td>
<td class="nump">650,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments', window );">Collaborative arrangement, maximum aggregate regulatory milestone payments</a></td>
<td class="nump">634,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments', window );">Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698673520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 540,597<span></span>
</td>
<td class="nump">$ 501,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 542,079<span></span>
</td>
<td class="nump">$ 502,677<span></span>
</td>
<td class="nump">$ 737,276<span></span>
</td>
<td class="nump">$ 663,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837695988336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,886,976<span></span>
</td>
<td class="nump">$ 1,887,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,571<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(14,277)<span></span>
</td>
<td class="num">(19,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,875,270<span></span>
</td>
<td class="nump">1,868,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,132,936<span></span>
</td>
<td class="nump">2,085,126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,571<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(14,277)<span></span>
</td>
<td class="num">(19,034)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,121,230<span></span>
</td>
<td class="nump">2,066,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">684,917<span></span>
</td>
<td class="nump">722,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">684,917<span></span>
</td>
<td class="nump">722,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">823,100<span></span>
</td>
<td class="nump">810,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,105<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10,274)<span></span>
</td>
<td class="num">(13,132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">814,931<span></span>
</td>
<td class="nump">797,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">367,479<span></span>
</td>
<td class="nump">338,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3,859)<span></span>
</td>
<td class="num">(5,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">364,086<span></span>
</td>
<td class="nump">332,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,480<span></span>
</td>
<td class="nump">16,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(144)<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">11,336<span></span>
</td>
<td class="nump">16,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">165,941<span></span>
</td>
<td class="nump">94,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">165,941<span></span>
</td>
<td class="nump">94,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">79,955<span></span>
</td>
<td class="nump">103,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 79,955<span></span>
</td>
<td class="nump">$ 103,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837700463616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>bond </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>USD ($) </div>
<div>investment </div>
<div>bond</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer</a></td>
<td class="nump">$ 317,100,000<span></span>
</td>
<td class="nump">$ 237,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Accumulated loss</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_NumberOfBondSecurities', window );">Number of bond securities | bond</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberOfBondSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Bond Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberOfBondSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837696600160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 845,425<span></span>
</td>
<td class="nump">$ 1,030,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(14,277)<span></span>
</td>
<td class="num">(19,034)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">551,038<span></span>
</td>
<td class="nump">706,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(10,274)<span></span>
</td>
<td class="num">(13,132)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">283,051<span></span>
</td>
<td class="nump">308,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(3,859)<span></span>
</td>
<td class="num">(5,679)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">11,336<span></span>
</td>
<td class="nump">15,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (144)<span></span>
</td>
<td class="num">$ (223)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837693534160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 1,071,653<span></span>
</td>
<td class="nump">$ 1,114,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">803,617<span></span>
</td>
<td class="nump">753,731<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,875,270<span></span>
</td>
<td class="nump">$ 1,868,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837693125584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Fair Value Hierarchy) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,875,270<span></span>
</td>
<td class="nump">$ 1,868,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,875,270<span></span>
</td>
<td class="nump">1,868,615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">2,121,166<span></span>
</td>
<td class="nump">2,066,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">165,941<span></span>
</td>
<td class="nump">94,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,875,270<span></span>
</td>
<td class="nump">1,868,615<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,955,225<span></span>
</td>
<td class="nump">1,972,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">684,917<span></span>
</td>
<td class="nump">722,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">684,917<span></span>
</td>
<td class="nump">722,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">684,917<span></span>
</td>
<td class="nump">722,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">814,931<span></span>
</td>
<td class="nump">797,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">814,931<span></span>
</td>
<td class="nump">797,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">814,931<span></span>
</td>
<td class="nump">797,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">364,086<span></span>
</td>
<td class="nump">332,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">364,086<span></span>
</td>
<td class="nump">332,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">364,086<span></span>
</td>
<td class="nump">332,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">11,336<span></span>
</td>
<td class="nump">16,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">11,336<span></span>
</td>
<td class="nump">16,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">11,336<span></span>
</td>
<td class="nump">16,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">165,941<span></span>
</td>
<td class="nump">94,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">165,941<span></span>
</td>
<td class="nump">94,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">79,955<span></span>
</td>
<td class="nump">103,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 79,955<span></span>
</td>
<td class="nump">$ 103,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698481136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narratives (Details) - Foreign Exchange Forward<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>derivative_instrument</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of contract | derivative_instrument</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount | &#8364;</a></td>
<td class="nump">&#8364; 4.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698765120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 8,777<span></span>
</td>
<td class="nump">$ 8,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">53,610<span></span>
</td>
<td class="nump">43,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">8,490<span></span>
</td>
<td class="nump">10,635<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">70,877<span></span>
</td>
<td class="nump">62,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">29,908<span></span>
</td>
<td class="nump">33,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 40,969<span></span>
</td>
<td class="nump">$ 28,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698683104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">9,738,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense | $</a></td>
<td class="nump">$ 14.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount | $</a></td>
<td class="nump">$ 550.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=exel_AmendedAndRestated2017EquityIncentivePlanMember', window );">Amended And Restated 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">31,678,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="nump">576,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="nump">11,315,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount | $</a></td>
<td class="nump">$ 172.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="nump">4,688,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount | $</a></td>
<td class="nump">$ 9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesTargetAchievedOrProbableMember', window );">Performance Shares, Target Achieved Or Probable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="nump">1,277,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount | $</a></td>
<td class="nump">$ 76.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=exel_AmendedAndRestated2017EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=exel_AmendedAndRestated2017EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesTargetAchievedOrProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesTargetAchievedOrProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698443792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 16,661<span></span>
</td>
<td class="nump">$ 19,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,252<span></span>
</td>
<td class="nump">8,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 13,409<span></span>
</td>
<td class="nump">$ 10,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698744736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Employee Service Share - Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 16,661<span></span>
</td>
<td class="nump">$ 19,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,207<span></span>
</td>
<td class="nump">3,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">12,607<span></span>
</td>
<td class="nump">13,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,053<span></span>
</td>
<td class="nump">$ 1,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837701205184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">17.10%<span></span>
</td>
<td class="nump">19.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837693098016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 40,028<span></span>
</td>
<td class="nump">$ 68,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">324,420<span></span>
</td>
<td class="nump">319,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">1,859<span></span>
</td>
<td class="nump">3,707<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">326,279<span></span>
</td>
<td class="nump">323,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837698180592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities and contingently issuable shares excluded (in shares)</a></td>
<td class="nump">15,592<span></span>
</td>
<td class="nump">16,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139837700303488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_exel_LossContingencyNumberOfLawsuitsConsolidated', window );">Number of lawsuits</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LossContingencyNumberOfLawsuitsConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Lawsuits Consolidated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LossContingencyNumberOfLawsuitsConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>exel-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:exel="http://www.exelixis.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20230331.xsd" xlink:type="simple"/>
    <context id="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie8ad1baf4c4a4f2bb5640105c86601f8_I20230501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="i0a3d041b493744caa9156b79d698c6f6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i47c0db749b524417a3bfe38e87216ea8_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ie6dd521484284a028aab45ea8772360e_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic7906589f9aa479c9565c72719ef21e6_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i9c85c6827b024c629f44a06755732c29_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if392acf72a7a4ae486acfef62c1ccfe2_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ib54ef24bfa5d431b8c16060a36cc40fd_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if94929e9ad634418bfded9c801d3fa56_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="idbadf347b2924c4a9fa6d3b424d3a4c4_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i5cb2995a2816463f841ef310714ba472_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i5df39c1ea61544ecb8c1f7e27e281c22_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ia7e6ca96ef1649d09aee4df309e35b73_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i54f40f89d45a494aa04db7f773107207_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ica0a8eca365b40568b15c0188a145fb2_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icfe186f4510a478e9f6676e77aa16a5d_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i03ef2d0eca0349a592744851911a54b3_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0e2ccc06faab42c1b72c84f6d8fc6554_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9e3410e9e21c40998b84e3d69601d355_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idccb5b94d16a46fdb0cf63047d4d0a35_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ife8714608e344dc7971babe1680ab27e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1508ac4b174b4c78a254a72746c9b9ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied50145a7df5459d92fa66f1d9a3a632_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb2a2cfb158540ca9584fae8239e375c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3118a17fe82743f4a08ef8bc281df1cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i56e9094b4beb4a8fb455ed26efa4b4dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia02620eae926413ab03c9415bcccade7_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i7cf2d5e95a2d4758b7b8e19ee1dc13cd_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i20dd40ea4f824fdc9ef3a7e851b32b65_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i79c3cf115f4f41eda883262bfbc8069a_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i22b9b0ed7a4840709f0a21fddfa8f9b7_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i95578fef614f423aad1a9a09bc7a0471_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i009fe3cdc57c4356822574ede853c0a5_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ia4f89c6cd5174469a45a0fee83e965f9_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i40f7e105971f40d2884d061c483a0023_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i88c7f65af0d44b9ebe6c0bfcbaf1bcc8_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d27cdd49640469c8f242f09214a609a_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ida032638ed6145e19d54c570bc2b9d93_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i595a452dffec43ddacb9c075ff6b480b_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibbe685ef22c941cba593e7a64e54dbf3_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i06debfc85b9342daa487a13cc47e36de_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib55727874d5a4f308e9616357e398771_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="iaa7500ddcb0b4d0db3443cc56170ff61_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iced7a06ad4e4417e870e84a67ede1244_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ibe37fc8620b94da8b2fc78d1941a9030_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id9022e3a517a4086aadbb0f76b987860_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ic354cd8d9401435bb4bef5aa134d8b18_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i145518f569754dcab3e0530961014f83_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i2ac68a66c51c45aaafa439d76a88823b_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iadcb287071b8482091481fd721d6437b_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i887d25b5c3eb476fac598042e121ae9e_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9f6c3de32bb5469faa5988e472ba8294_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i03edf15c3de14b84b45b07e5d3a6783b_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ief8ad52c39a04dbb97764e462472ac81_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i9f99cf5241b6466788f894b2abc4f8ed_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4cd8710c99944d47a9e0d4b3f5b26afc_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i30663220db714d0f884ca85a30e97ed2_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2e8676ff223f403889416c0afd319b61_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ia17b8615b9f449ae815574e6e809f6f7_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibe97f6cf8ca84e36a31f8ac01af69488_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="ia09f023283744b868559533749bfb478_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id32f197bc1034297a1205ca6bff7d001_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="id1dfd4d591884f079548cf36ab7d515a_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i25cc695fcf37474383a6d4d015d235e0_D20220101-20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CardinalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-30</endDate>
        </period>
    </context>
    <context id="i005e52f0aa9441e9b404ce8f42adc3d6_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6c2ff2123a5e43459fdf372396cef270_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i0f1ae657918947af907f5f8fab6b57fe_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id0b5d0c4ace24841940333ae7904c072_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i936cbc93158847ce8d03042dab8d6d3d_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i73abd557fa874e57af0091d9dd6409f3_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i85a5140525004434a113a31a2b6f9fec_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie93c1a4da62d4e91aada27293fc54993_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i2b3ca2a0d827408a96d2c203c0c3d713_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieca193774391470aaad49e0c557cd653_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ie23bc89dd4ed466bb9e19cbc8ccf8e79_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i561a3686c8c54aaa9930ddcb0186d034_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="idb98cc6df0964b9dbc447c72a27d45d2_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="iaf790da88c7f48bebd710b720e67b732_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6803b211b6ba46c0b060c8ef10832fa3_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iab3dde5c402a452ca70d75ca56511047_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i75a9ae3fb4354c558afa5652356fc857_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i37a339e12ecb401f86dd0d2f2d5819d9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iec98443a01d9484790def9f44b69d198_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib2931f6876e343439ec8b11809eebdf1_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i864cb8fb17554a37a8adaea7c33b4efc_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ic1696dcf966747e3b865502c27c29aad_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i021d57f0be044f67974550e7d885e1d1_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i1d81ebf2e8e74fce85e25162934a4d6f_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iff535a866b2c41fdb6f8646e8b488292_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i4acc2ee076ef40faac1edea03e68040c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7033584518df402d9b63ad9da059f49e_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic8c875584853425eba6bda6cacea2afd_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i8956cc8ef7304e6e94df23b6ddff9882_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id6df88e437a14a5e9a085f6a41e74f2a_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i11c0ff70d2a2430fa83299f494f4c105_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iff2c6bd8205a44e2adb86297f4e43f30_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ifa11613f3ae54abb9a1445d4727f95f1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2b291b148d264039a3e055bce29bb22b_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i700fe89825964bcf972c48b666c81680_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iceabd35baaac41af956c98f0f6f9a4c6_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:RoyalPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="if9ade2259f534177966ecdd8ce949ae1_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iffd1fa8ae2c3489f966e69cc776984e3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia307bf0c6b5b4e379b3b2fd963c7ec10_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5231ebc5b9954e8e86f1f3347d082aea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idd8e3d17820d48979b53c203807b119a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9a661a40ef35452e91e33372e447bb37_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia77b0e4b2fe042139d6e224f2fba485d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9d0849b362ce4562bfa01261a0459178_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i0cdebc21ace046518b4cec11c922421e_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="iaaf7287be2844027815aaad0c091426c_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="iee3723a2aa5d463ba5688d589dda3b7d_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i5ed11edd9a934cdead36351f09d723ae_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i5a53bc620960402191b67550fd79e525_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="id2bb0b5859e94e8a936be047b130cf62_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7332d7a5938d414dabe83a5e6080938c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i289d8780126e4649aa6123219a3a320f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6b9c63d0e80744719b3825cef5d5d14b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if7a7c1a85b9741668be6b1244cb03182_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9ff6643a21e3422a80cdf082d9960ef4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1fc468b967af4e86a80786a9c3aa6c5c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i06d5bb9bf05744909898ab9b06c87bd6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i036daf539dfc49c8b73722fa3dae40a1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if87f0d005430404db06bb3f461851a1f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3329a69fdc8a47cba0eb64acea2395f6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie516d60b14c7478095d3f58b37428a68_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i31039ff71e764360b58c4edb8693ba2f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i62ae4221be8d44a8a7c7a3c9e9f180ec_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ide3e32d66598443986f9b93c38b9a643_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie4fae3311f344cb085dfbc49e046ce18_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7acd21d036a3477aac89ae6ccd15d11b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i66f34ea6b40143b8b73529584d025afc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0b40425343ab4840a5a2065cac546d59_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i41e491600bbd4af79605cfbcf83d1913_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i69089dbb95ad41858db9a2acea999f10_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4ed964b6ac9e45588d0755f26b3a0530_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i957abfeaf90a4f888c7d6eb2f35c48b5_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ie92282b3812a4c52a5eb1714922f4607_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i3b5995c0541b401eb07d6d421025aa64_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i65cbedaff73f4c8baa47313cf71881be_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="icd3936dfce8e401ba8d8f7c22abbb987_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="if2074852d3fc4146a552e1020fed749a_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i9899d00466704758b0d0844ee5256ef0_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i456848174e4b411d97e0d18790a81449_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i49a9b1c8da4d4daf938376135d589190_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="idc80802ed0064fbe90e139d4e9f11c0d_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i711f7b4d4689414894669fee3ce78b88_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i6b1713646d824564b9adee7955a921c9_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i4a589a297c4b471ba55f3c7b0af708c3_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i1532e94710824cf39b3266528be43ba1_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="ib6a61c4734ba4ebcb0ef504886ba6de1_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i1eed0c8fb3e145b8afc025317b02b47c_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="id6fb00cb8a194a00aac07f85c0714ec1_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i7b9c7f8a02e440d198176572c5aa2a9b_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="icf6dfcf5d186443cb89d5d13bbf74fcc_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i1777597937c24d058481cbd71160126e_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="id59bda9dff304a61a0e935254d1873e1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6f2a0a5e0af9493ca0f227fed931a4ed_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i64066d08939c412ea45c0e2ce3a1376f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7e165e45ccd64b35b0258752fdd33d0a_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i048b471b1b074d82bde14df2ea6b910d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icc2748b521d641c1bb32f1e95b036970_I20221230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="i2f1f77b69c154581ba20fe6d66b88637_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">exel:AmendedAndRestated2017EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib798adcf0e30410e9cf0c303568c4dd8_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i077b175796d8467ebd7f57f08b70e854_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ie1a8b33f363d4bc0ac9b67d04c777bda_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i453291ae47804d32a67ac7c2f2eefef5_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i5fd484e891fd418a8ed42f45f84ec5bb_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia944468359d74f13b7a8031ab2b2ec81_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i8a18b8eece6d4b23bde7637cca5faffd_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5664ad32e75748ecabb161d218d96696_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i6b8feeeff3a844ed994dd23909d3c10b_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iedfbdcf573f646959d5ef701c8bc3a1f_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="id2ed501ae6df49f8accd5863263afcf6_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8f6f3af4e1e4419cb5a9e743245418f9_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ib0a8da2045b84694bcd4b8144997fa91_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0e6bbea2638d44e18d8bead2fc43515b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6b919b2777644b8ebe2bfda500054c0f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesTargetAchievedOrProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i08af1f4087d548b2a2c27bd855c5a14f_D20221231-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7027abb1b44144f58c42fe80ea5b4fe8_D20220101-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="icb5f735f185d4a9dbe1cc597da942150_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="country">
        <measure>exel:country</measure>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="bond">
        <measure>exel:bond</measure>
    </unit>
    <unit id="derivative_instrument">
        <measure>exel:derivative_instrument</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80L2ZyYWc6ZDk4YmU1MmNiOWU4NGU0MTg5OGZjMDhiMGQ3YTdiOGMvdGFibGU6MzgzMTczZjY1MWI5NDhkOTk1MTgxZmJjODRmMWVlMjgvdGFibGVyYW5nZTozODMxNzNmNjUxYjk0OGQ5OTUxODFmYmM4NGYxZWUyOF8yLTEtMS0xLTExMDk1Mg_7fabae71-998d-49c7-8521-bc695a76b1b6">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80L2ZyYWc6ZDk4YmU1MmNiOWU4NGU0MTg5OGZjMDhiMGQ3YTdiOGMvdGFibGU6MzgzMTczZjY1MWI5NDhkOTk1MTgxZmJjODRmMWVlMjgvdGFibGVyYW5nZTozODMxNzNmNjUxYjk0OGQ5OTUxODFmYmM4NGYxZWUyOF80LTEtMS0xLTExMDk1Mg_1caa9f5d-ca57-43f7-9513-78fa2fdaf4c2">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80L2ZyYWc6ZDk4YmU1MmNiOWU4NGU0MTg5OGZjMDhiMGQ3YTdiOGMvdGFibGU6MzgzMTczZjY1MWI5NDhkOTk1MTgxZmJjODRmMWVlMjgvdGFibGVyYW5nZTozODMxNzNmNjUxYjk0OGQ5OTUxODFmYmM4NGYxZWUyOF81LTEtMS0xLTExMDk1Mg_31dc9ae5-122e-4e5e-bafd-4af2753ca98e">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80L2ZyYWc6ZDk4YmU1MmNiOWU4NGU0MTg5OGZjMDhiMGQ3YTdiOGMvdGFibGU6MzgzMTczZjY1MWI5NDhkOTk1MTgxZmJjODRmMWVlMjgvdGFibGVyYW5nZTozODMxNzNmNjUxYjk0OGQ5OTUxODFmYmM4NGYxZWUyOF82LTEtMS0xLTExMDk1Mg_6bb76e1c-7408-4238-a2d2-e57aeb0cd219">0000939767</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80L2ZyYWc6ZDk4YmU1MmNiOWU4NGU0MTg5OGZjMDhiMGQ3YTdiOGMvdGFibGU6MzgzMTczZjY1MWI5NDhkOTk1MTgxZmJjODRmMWVlMjgvdGFibGVyYW5nZTozODMxNzNmNjUxYjk0OGQ5OTUxODFmYmM4NGYxZWUyOF83LTEtMS0xLTExMDk1Mg_ea078b61-59cd-47e1-adfa-46f257093060">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6MTg5Y2MxN2MyYTY2NDRkZDk2ZjFkZTIyODU0YzNmYzAvdGFibGVyYW5nZToxODljYzE3YzJhNjY0NGRkOTZmMWRlMjI4NTRjM2ZjMF8wLTEtMS0xLTExMDk1Mg_aa57deae-33ac-4309-b7c7-e75fc6da3c12">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6Y2QzNmIwODJiY2UyNGI0ODk5MWQ1YjIxYzVlYWZiNDIvdGFibGVyYW5nZTpjZDM2YjA4MmJjZTI0YjQ4OTkxZDViMjFjNWVhZmI0Ml8wLTAtMS0xLTExMDk1Mg_48acc6c6-d347-45d1-9b27-912b51a4c1a6">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xMTU_6dafdf31-aa9a-4dba-8310-e896878c738f">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6NzAxMmE1NzE1MzdkNGUzMWJiZTkwNjM0NTg2NjgzM2UvdGFibGVyYW5nZTo3MDEyYTU3MTUzN2Q0ZTMxYmJlOTA2MzQ1ODY2ODMzZV8wLTAtMS0xLTExMDk1Mg_67f6139e-6578-4c50-b6a8-63c06ec5d887">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODcy_9145a2b9-a312-4f16-b8a1-17fb0be04766">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6YjNhMDY0OTkzY2Q2NDFkNmI3YjlkODQ2MzM5ZmJiZmIvdGFibGVyYW5nZTpiM2EwNjQ5OTNjZDY0MWQ2YjdiOWQ4NDYzMzlmYmJmYl8xLTAtMS0xLTExMDk1Mg_eaed3404-eafd-4f52-853f-9e7f99d67bc2">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6NDA3MGEyZDk2ZjIyNDhjZjg5OWFjMzFkODJiN2ViZDAvdGFibGVyYW5nZTo0MDcwYTJkOTZmMjI0OGNmODk5YWMzMWQ4MmI3ZWJkMF8wLTAtMS0xLTExMDk1Mg_6965f541-66a7-4c88-b880-e4740ba63600">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6NDA3MGEyZDk2ZjIyNDhjZjg5OWFjMzFkODJiN2ViZDAvdGFibGVyYW5nZTo0MDcwYTJkOTZmMjI0OGNmODk5YWMzMWQ4MmI3ZWJkMF8wLTItMS0xLTExMDk1Mg_9d13fa24-1a1c-4cc9-966a-82b79cb93639">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODcz_794384ea-965e-4f81-94c4-1e63d5a25276">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODc4_b81a8f3e-9770-47f0-92e6-fb46b4db2bf5">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODc5_1e0e5e84-84f0-48a4-be16-cbe58c2301c9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODc0_bb1811f3-64fc-4d0a-99db-fe52e2f4991b">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODgw_35ace888-f8ed-41e7-a3da-4bb9ed904d8f">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODgx_b7f827dd-a9e4-437c-99ee-90a4f08f7b73">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6OWEzY2Y2M2FlNTJkNDVhNzk2MDAyMTAwYTQzODcyNGEvdGFibGVyYW5nZTo5YTNjZjYzYWU1MmQ0NWE3OTYwMDIxMDBhNDM4NzI0YV8xLTAtMS0xLTExMDk1Mg_e347c637-5812-49ce-849b-d313257012ab">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6OWEzY2Y2M2FlNTJkNDVhNzk2MDAyMTAwYTQzODcyNGEvdGFibGVyYW5nZTo5YTNjZjYzYWU1MmQ0NWE3OTYwMDIxMDBhNDM4NzI0YV8xLTEtMS0xLTExMDk1Mg_0e64b942-c5ee-4c13-a2f2-a2ef6132bf5b">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6OWEzY2Y2M2FlNTJkNDVhNzk2MDAyMTAwYTQzODcyNGEvdGFibGVyYW5nZTo5YTNjZjYzYWU1MmQ0NWE3OTYwMDIxMDBhNDM4NzI0YV8xLTItMS0xLTExMDk1Mg_9ca38342-e1e7-4f61-995c-d19c16e30502">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODgy_d661d815-a38d-481a-9d64-663f8bfa8332">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODc3_4e7b1815-d0c3-4bc3-967f-9d3793c5b68d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6ZTdkZjA0Y2JiZWEzNGZhN2JhNjNiZDE3MDRkMDA1YTMvdGFibGVyYW5nZTplN2RmMDRjYmJlYTM0ZmE3YmE2M2JkMTcwNGQwMDVhM18wLTAtMS0xLTExMDk1Mg_17f1d53a-f28d-4177-a949-d898eb6ad169">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6ZTdkZjA0Y2JiZWEzNGZhN2JhNjNiZDE3MDRkMDA1YTMvdGFibGVyYW5nZTplN2RmMDRjYmJlYTM0ZmE3YmE2M2JkMTcwNGQwMDVhM18xLTQtMS0xLTExMDk1Mg_1c0fe38a-ba48-46b6-8762-be84577a6e4e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGFibGU6ZTdkZjA0Y2JiZWEzNGZhN2JhNjNiZDE3MDRkMDA1YTMvdGFibGVyYW5nZTplN2RmMDRjYmJlYTM0ZmE3YmE2M2JkMTcwNGQwMDVhM18yLTQtMS0xLTExMDk1Mg_4aa52a34-80c9-40f9-9c2f-0150d4c67ff5">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODc2_8e62989d-5472-4f7c-afec-28a15cd896b4">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie8ad1baf4c4a4f2bb5640105c86601f8_I20230501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xL2ZyYWc6MTM1ZmIwN2VmNGYzNGY5NDkzN2NmYTQxZjY0YjMyZmMvdGV4dHJlZ2lvbjoxMzVmYjA3ZWY0ZjM0Zjk0OTM3Y2ZhNDFmNjRiMzJmY18xODE3_651e2ce9-9cdd-4ced-84c2-6eff9453ab8f"
      unitRef="shares">325636738</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNy0xLTEtMS0xMTA5NTI_92eaffd2-9602-4da8-98d6-e738e339465b"
      unitRef="usd">540597000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNy0zLTEtMS0xMTA5NTI_c763d141-77c3-45dc-aef0-a3893f31f4a6"
      unitRef="usd">501195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfOC0xLTEtMS0xMTA5NTI_9125f4cd-2b35-4249-bc6a-6c82979c8292"
      unitRef="usd">772536000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfOC0zLTEtMS0xMTA5NTI_58144ea4-d38f-4e5b-b145-701ad10c94d2"
      unitRef="usd">807273000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfOS0xLTEtMS0xMTA5NTI_c54dbddb-63ae-4aa1-b78b-0664aefc8e92"
      unitRef="usd">233923000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfOS0zLTEtMS0xMTA5NTI_90947b63-0e29-41cd-a671-9f9d191d2419"
      unitRef="usd">214784000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTAtMS0xLTEtMTEwOTUy_0534d37e-622d-491e-83d7-51be3f0dd2a8"
      unitRef="usd">29908000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTAtMy0xLTEtMTEwOTUy_94ff8814-aa8a-444f-b173-12068d9f1a3e"
      unitRef="usd">33299000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTItMS0xLTEtMTEwOTUy_f786c400-816c-4a0f-9b45-87af6ec70df2"
      unitRef="usd">60654000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTItMy0xLTEtMTEwOTUy_ce1df59f-dd76-4714-b9a3-5ec1468bc0b8"
      unitRef="usd">62211000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTMtMS0xLTEtMTEwOTUy_32472153-b987-4dbe-adb0-649ca518576a"
      unitRef="usd">1637618000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTMtMy0xLTEtMTEwOTUy_a9bfb43f-0ca8-4580-8722-e31663f8d9aa"
      unitRef="usd">1618762000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTQtMS0xLTEtMTEwOTUy_ec183836-e2fa-48c3-b7e5-c0d755fd4c3b"
      unitRef="usd">806615000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTQtMy0xLTEtMTEwOTUy_7d6e4d86-b21f-418d-8652-8c1d3c10c99b"
      unitRef="usd">756731000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTUtMS0xLTEtMTEwOTUy_5312bd69-d940-4fbb-b324-17d5b8aa16f1"
      unitRef="usd">116212000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTUtMy0xLTEtMTEwOTUy_306681d6-334a-4c50-a20d-eabd02a73b32"
      unitRef="usd">110624000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTYtMS0xLTEtMTEwOTUy_50fb5698-4e8c-43ba-8017-a2a52fc93046"
      unitRef="usd">229603000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTYtMy0xLTEtMTEwOTUy_0887f0f3-0ef3-4f81-9d95-5b75c503047a"
      unitRef="usd">231110000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTctMS0xLTEtMTEwOTUy_97ba3135-ab5b-49b7-b16a-8fb7a0bb161b"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTctMy0xLTEtMTEwOTUy_b2f88a48-4383-4366-8a80-f695badc0f76"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <exel:OperatingLeaseRightOfUseAssetAndOtherAssets
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTgtMS0xLTEtMTEwOTUy_22cd5b30-b472-487f-8fe6-cfc4d2b5f35c"
      unitRef="usd">289627000</exel:OperatingLeaseRightOfUseAssetAndOtherAssets>
    <exel:OperatingLeaseRightOfUseAssetAndOtherAssets
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTgtMy0xLTEtMTEwOTUy_1cfcfe74-3c20-4a02-94d5-77f0d9d73df0"
      unitRef="usd">290578000</exel:OperatingLeaseRightOfUseAssetAndOtherAssets>
    <us-gaap:Assets
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTktMS0xLTEtMTEwOTUy_feb94338-775e-4064-9dbe-32f3607ed0f9"
      unitRef="usd">3143359000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMTktMy0xLTEtMTEwOTUy_e406f7ab-47e1-4581-bb1f-5a8d086946c3"
      unitRef="usd">3071489000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjItMS0xLTEtMTEwOTUy_6db26d95-a4d9-4d72-b366-438935cc446a"
      unitRef="usd">32621000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjItMy0xLTEtMTEwOTUy_ea92cae6-2183-42cc-9554-5fe60df5bdf5"
      unitRef="usd">32667000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjMtMS0xLTEtMTEwOTUy_b96587be-6af4-43d5-be0d-174694bff6d6"
      unitRef="usd">56551000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjMtMy0xLTEtMTEwOTUy_3207dcfe-e4ab-4a11-b7c0-704eb15a4f8e"
      unitRef="usd">77158000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjQtMS0xLTEtMTEwOTUy_4fb8f720-d576-4192-946f-42c1b3850113"
      unitRef="usd">64210000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjQtMy0xLTEtMTEwOTUy_e8529aaa-adc6-40c0-94e5-2c7b0c6f0392"
      unitRef="usd">65072000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjUtMS0xLTEtMTEwOTUy_19db461d-f7e3-4fa6-a762-2ef062b69349"
      unitRef="usd">66405000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjUtMy0xLTEtMTEwOTUy_f5fe4d20-4974-44dc-9a0f-a2998bb62233"
      unitRef="usd">50350000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjYtMS0xLTEtMTEwOTUy_a1a3df6a-58d5-4967-81ea-8f1b384f3c89"
      unitRef="usd">18324000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjYtMy0xLTEtMTEwOTUy_ce18ffaa-1bbf-4419-8676-a39aaf0d4fbd"
      unitRef="usd">20188000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjgtMS0xLTEtMTEwOTUy_91b96a95-2ad9-4be6-aced-56c0b5fe3e77"
      unitRef="usd">89486000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjgtMy0xLTEtMTEwOTUy_8f123792-0e28-4d86-939e-05b422fc52a1"
      unitRef="usd">78924000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjktMS0xLTEtMTEwOTUy_c6f56038-3a03-432e-b750-a03d20474371"
      unitRef="usd">327597000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMjktMy0xLTEtMTEwOTUy_63edb6b3-4e9b-4b83-ad29-48f653c1ed3c"
      unitRef="usd">324359000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzAtMS0xLTEtMTEwOTUy_0755d3bf-447d-443d-97bc-c3962b620d8c"
      unitRef="usd">6299000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzAtMy0xLTEtMTEwOTUy_b1016e33-8dd8-43fc-9629-e1b3ea200b45"
      unitRef="usd">6582000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzEtMS0xLTEtMTEwOTUy_1b8d975d-e9cc-4e85-a69c-81b2d2256021"
      unitRef="usd">186948000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzEtMy0xLTEtMTEwOTUy_7039fa3b-1370-4e03-9c03-c0f199d1b826"
      unitRef="usd">190170000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzItMS0xLTEtMTEwOTUy_f0cb52d3-15de-44c5-8a24-c41f0c7e0611"
      unitRef="usd">67379000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzItMy0xLTEtMTEwOTUy_7b5252cf-fa36-4894-917a-af7805ba80f5"
      unitRef="usd">61951000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzMtMS0xLTEtMTEwOTUy_8f8ddf4c-2f8b-440b-bfc9-61e37b9addc9"
      unitRef="usd">588223000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzMtMy0xLTEtMTEwOTUy_2d70611b-25bd-408c-a670-ce60cc13080f"
      unitRef="usd">583062000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzQtMS0xLTEtMTEwOTUy_1fc3b4bd-053b-4422-b1bb-310a825962cf"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzQtMy0xLTEtMTEwOTUy_0bc5e69d-a784-4b4e-83fd-31b11beff3a2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfMjE_19c015e6-8de3-425a-8685-0d5479d85356"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfMjE_b657e6d9-f91b-4018-9a44-62a9c20c563e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfMzU_1b994aaa-8cff-4b86-9e0a-4f1461440417"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfMzU_5c4105e8-5bf6-4c0c-a0d4-da743450c164"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfNjA_60cf156b-68da-4bf2-ab70-6160ae2f9532"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMC0xLTEtMTEwOTUyL3RleHRyZWdpb246YWQ0OTk3MTU1ZjljNGY3YmEwYzQ3OGY4NDNiNWQxMDRfNjA_d806db59-9f86-47c7-879f-933441e8ecc7"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMS0xLTEtMTEwOTUy_c1ecedbe-9849-457d-adfd-b3aab24b168c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzYtMy0xLTEtMTEwOTUy_7b23eb48-6fb3-4962-8ca9-45fd0bccbf3c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfMTg_55b953ab-cb75-4c00-8f26-2a75d2b5e0fe"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfMTg_b07cd6d3-907a-49ad-955f-c18280afe111"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfMzI_8a0a096b-c5b1-4bf9-bd58-c547e75596a1"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfMzI_e2cb03da-a5bc-4e02-bc5a-4ca8476834ef"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfNzg_64a0bf00-aac1-42a4-9e2b-128a942feea5"
      unitRef="shares">324985000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfNzg_c487a96f-6b55-4e47-8ce1-fc1311b6b7f6"
      unitRef="shares">324985000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfODU_3dc3df6c-e779-4d03-9e8d-f9a42880d330"
      unitRef="shares">323951000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMC0xLTEtMTEwOTUyL3RleHRyZWdpb246NDY1ODVlY2IwNjY3NDk3N2E1OGFlYTliMDUwNmRhY2RfODU_fe19621e-8d67-4241-bf0b-f52d88976c8d"
      unitRef="shares">323951000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMS0xLTEtMTEwOTUy_1ac3f688-ddc4-4b79-8cc4-26271963a51e"
      unitRef="usd">325000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzctMy0xLTEtMTEwOTUy_8d2218da-b13e-4ebf-bca1-6e8fcd1eb96f"
      unitRef="usd">324000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzgtMS0xLTEtMTEwOTUy_3f709bf3-aa75-4976-8a52-28f50a9595a9"
      unitRef="usd">2558297000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzgtMy0xLTEtMTEwOTUy_de15c9fa-4a49-4aeb-8f56-7180d4a98c60"
      unitRef="usd">2536849000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzktMS0xLTEtMTEwOTUy_eb59d8d7-e016-4421-9b59-65ff37dc20c3"
      unitRef="usd">-9289000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfMzktMy0xLTEtMTEwOTUy_9fdbe531-7b5f-43ea-adf8-e7807daa959c"
      unitRef="usd">-14521000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDAtMS0xLTEtMTEwOTUy_4d8aa7e2-755f-43d4-b374-e6b1332c1dbb"
      unitRef="usd">5803000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDAtMy0xLTEtMTEwOTUy_f7602c5c-9eab-465f-8436-5d5fec5bd0a1"
      unitRef="usd">-34225000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDEtMS0xLTEtMTEwOTUy_73308da1-4294-4a3b-913f-f1fb3ee78358"
      unitRef="usd">2555136000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDEtMy0xLTEtMTEwOTUy_49702e56-f937-4eda-bbcf-fffe5eec0abd"
      unitRef="usd">2488427000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDItMS0xLTEtMTEwOTUy_6641144a-01f3-4e9c-aacc-945db49568bf"
      unitRef="usd">3143359000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xNi9mcmFnOjUyYmQ0MzZkNjhkMDQxZTJhNTk3ZGUxNDg5M2M1ZjIxL3RhYmxlOjZhYmUzNzI2Yjc5NzQyZmQ4YTYyYzBkMDk5YzA4M2VjL3RhYmxlcmFuZ2U6NmFiZTM3MjZiNzk3NDJmZDhhNjJjMGQwOTljMDgzZWNfNDItMy0xLTEtMTEwOTUy_59c5055b-f3e4-4d9b-ac78-79764dff508a"
      unitRef="usd">3071489000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6dd521484284a028aab45ea8772360e_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMy0xLTEtMS0xMTA5NTI_4ec3e6d1-6ee9-4e74-a2f0-a9d558f632eb"
      unitRef="usd">363400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7906589f9aa479c9565c72719ef21e6_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMy0zLTEtMS0xMTA5NTI_640d39da-ef04-4e9c-a762-4ad5f1a8a812"
      unitRef="usd">310298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c85c6827b024c629f44a06755732c29_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNC0xLTEtMS0xMTA5NTI_266f3169-da28-46b9-bbad-901fe1555dc0"
      unitRef="usd">38292000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if392acf72a7a4ae486acfef62c1ccfe2_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNC0zLTEtMS0xMTA5NTI_de42ea05-0b72-46d2-86ba-c66eff8b4085"
      unitRef="usd">32067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib54ef24bfa5d431b8c16060a36cc40fd_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNS0xLTEtMS0xMTA5NTI_b10b04a3-6dbc-42f4-be61-98459859d911"
      unitRef="usd">7096000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if94929e9ad634418bfded9c801d3fa56_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNS0zLTEtMS0xMTA5NTI_e8458e8f-d880-491e-8595-bf0a93c9dfb6"
      unitRef="usd">13615000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNi0xLTEtMS0xMTA5NTI_1f4c630e-169a-42af-8a3b-8d0dd5c5ddea"
      unitRef="usd">408788000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfNi0zLTEtMS0xMTA5NTI_de6f39a6-164d-47e6-9264-0ed1e6a834e1"
      unitRef="usd">355980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfOC0xLTEtMS0xMTA5NTI_f572015e-56f6-4aae-b49f-31cd1a29b376"
      unitRef="usd">14315000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfOC0zLTEtMS0xMTA5NTI_46e7f618-9bd8-49da-b593-46c14cd6571b"
      unitRef="usd">13203000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfOS0xLTEtMS0xMTA5NTI_6693420b-9f35-48c5-aa0e-1014e0e6dfd7"
      unitRef="usd">234246000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfOS0zLTEtMS0xMTA5NTI_9fe1f91b-4f6a-471f-b359-b227c54f8342"
      unitRef="usd">156671000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTAtMS0xLTEtMTEwOTUy_55f401c5-e530-43f7-9b36-69728998d67e"
      unitRef="usd">131397000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTAtMy0xLTEtMTEwOTUy_45891aa5-42fa-4506-a9bd-4e49ba33bbc1"
      unitRef="usd">102863000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTEtMS0xLTEtMTEwOTUy_31f5c3ec-4ff1-4693-8ddb-95acf11d39c3"
      unitRef="usd">379958000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTEtMy0xLTEtMTEwOTUy_18495f8a-5c0f-444f-ad11-ee958316579f"
      unitRef="usd">272737000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTItMS0xLTEtMTEwOTUy_bff35fdf-ed81-4cd0-83a7-4f4fd35dd69d"
      unitRef="usd">28830000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTItMy0xLTEtMTEwOTUy_d3bae032-7efc-43ad-b5f1-232dfc7386ab"
      unitRef="usd">83243000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTMtMS0xLTEtMTEwOTUy_603930c5-62a7-4814-b544-c0419a70f133"
      unitRef="usd">19502000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTMtMy0xLTEtMTEwOTUy_87da7e1f-55db-4666-a187-bffd8249be15"
      unitRef="usd">1822000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTQtMS0xLTEtMTEwOTUy_a2409133-476a-4d05-8a76-1530ec6bfce8"
      unitRef="usd">-54000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTQtMy0xLTEtMTEwOTUy_5aabe985-2f6f-4fa8-9dcf-61fa74928df6"
      unitRef="usd">164000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTUtMS0xLTEtMTEwOTUy_4432d986-8873-4cbc-87be-e7debf844366"
      unitRef="usd">48278000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTUtMy0xLTEtMTEwOTUy_5fbc0bff-a69b-4c64-8ea6-c20bcc2714eb"
      unitRef="usd">85229000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTYtMS0xLTEtMTEwOTUy_935e8e59-d734-4f88-950b-2ac136a11c30"
      unitRef="usd">8250000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTYtMy0xLTEtMTEwOTUy_220dc343-9bdd-4a3f-b98c-1c0aa67e72a0"
      unitRef="usd">16656000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTctMS0xLTEtMTEwOTUy_99b3b0e7-afd3-4112-a3b2-aa7f959e400a"
      unitRef="usd">40028000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTctMy0xLTEtMTEwOTUy_05ebc1ae-1b64-4cc0-8e77-e56bfba62097"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTktMS0xLTEtMTEwOTUy_75591a3f-3c0a-41d3-a384-a14c9cb5e104"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMTktMy0xLTEtMTEwOTUy_fcb130aa-716c-4bae-b80e-7523ec23a461"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjAtMS0xLTEtMTEwOTUy_f2a0bb0e-ff77-4fe4-b6e6-772868b144d5"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjAtMy0xLTEtMTEwOTUy_e7c3d43c-eb82-4795-a7eb-6c7af4d96b95"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjItMS0xLTEtMTEwOTUy_48fb676b-7a4f-401b-8c0d-85faf9bfcf0d"
      unitRef="shares">324420000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjItMy0xLTEtMTEwOTUy_a97725bc-811c-44e8-a213-6ee3b05d19e5"
      unitRef="shares">319582000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjMtMS0xLTEtMTEwOTUy_25e10703-be63-48e8-9747-d6521bbbf8ba"
      unitRef="shares">326279000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8xOS9mcmFnOjNkZjQ0ODc3OGM5MTRlNDc4M2I0MjYwYjE5NGU2NmU1L3RhYmxlOjUyMzMyMWIyMGM0ODRlYzg5YTljY2IyZjljNTI1ZmM5L3RhYmxlcmFuZ2U6NTIzMzIxYjIwYzQ4NGVjODlhOWNjYjJmOWM1MjVmYzlfMjMtMy0xLTEtMTEwOTUy_3c043758-ece8-421b-a015-cf6de91c6ccd"
      unitRef="shares">323289000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfMi0xLTEtMS0xMTA5NTI_99b3b0e7-afd3-4112-a3b2-aa7f959e400a"
      unitRef="usd">40028000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfMi0zLTEtMS0xMTA5NTI_aedbe45a-2902-4bab-bc45-01bbb426c8f8"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNC0wLTEtMS0xMTA5NTIvdGV4dHJlZ2lvbjo1YTMxN2E0YzVhNDM0M2U4OGQzY2VmOGNhOTAxMDgyNl81NDk3NTU4MTQ0NjA_86dc483e-8db7-4910-85c8-89689aea3d01"
      unitRef="usd">-1507000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNC0wLTEtMS0xMTA5NTIvdGV4dHJlZ2lvbjo1YTMxN2E0YzVhNDM0M2U4OGQzY2VmOGNhOTAxMDgyNl81NDk3NTU4MTQ0Njk_caca1e35-7255-4bbd-a508-a981d59d348b"
      unitRef="usd">1656000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNC0xLTEtMS0xMTA5NTI_619a7245-4ba4-4b04-8bc1-7f3082e83d52"
      unitRef="usd">5232000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNC0zLTEtMS0xMTA5NTI_88b6f604-7665-4bbb-b2fb-0d2d747b06ad"
      unitRef="usd">-5907000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNi0xLTEtMS0xMTA5NTI_9ba18439-0514-4dc1-9810-4874382a9f0b"
      unitRef="usd">45260000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yMi9mcmFnOmZhZWJlNjE1ZGQwNjQ5MWJhODAyYzA0YjVkZDBjNTZlL3RhYmxlOjMzZjZlNjAxYmJiNTRiYTQ4NWQzNWI0N2Q2YzJiMDQwL3RhYmxlcmFuZ2U6MzNmNmU2MDFiYmI1NGJhNDg1ZDM1YjQ3ZDZjMmIwNDBfNi0zLTEtMS0xMTA5NTI_508b9c6e-83f3-4330-9afa-d312d9626c89"
      unitRef="usd">62666000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idbadf347b2924c4a9fa6d3b424d3a4c4_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy0xLTEtMS0xMTA5NTI_c68947db-295b-4ba8-a4fb-2bda3a34dbf4"
      unitRef="shares">323951000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idbadf347b2924c4a9fa6d3b424d3a4c4_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy0zLTEtMS0xMTA5NTI_fb489127-f17c-40ac-a8a8-c7c5f503e915"
      unitRef="usd">324000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5cb2995a2816463f841ef310714ba472_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy01LTEtMS0xMTA5NTI_fe5bdaa6-92ed-4ac2-86fa-627a0e7e4c12"
      unitRef="usd">2536849000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5df39c1ea61544ecb8c1f7e27e281c22_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy03LTEtMS0xMTA5NTI_e51da0b2-fb9d-4eaf-b58d-fd7402b86d0c"
      unitRef="usd">-14521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7e6ca96ef1649d09aee4df309e35b73_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy05LTEtMS0xMTA5NTI_ec841a74-ad0b-488c-b2f0-ba20fce657d8"
      unitRef="usd">-34225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMy0xMS0xLTEtMTEwOTUy_0529c8c5-d681-4baa-bf1e-e3073fb48169"
      unitRef="usd">2488427000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i54f40f89d45a494aa04db7f773107207_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNC05LTEtMS0xMTA5NTI_12070859-eed7-4ed0-9273-4253d40b89ab"
      unitRef="usd">40028000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNC0xMS0xLTEtMTEwOTUy_cd1d377e-4bae-4ceb-89ce-3460dd6d2f74"
      unitRef="usd">40028000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ica0a8eca365b40568b15c0188a145fb2_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNS03LTEtMS0xMTA5NTI_123162d9-b77d-4bd3-a507-debba80515be"
      unitRef="usd">5232000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNS0xMS0xLTEtMTEwOTUy_cbeb360b-0b1b-4e40-8682-9763c4fab06b"
      unitRef="usd">5232000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="icfe186f4510a478e9f6676e77aa16a5d_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNi0xLTEtMS0xMTA5NTI_41c4c0a7-08d2-4144-8934-4626a80481d0"
      unitRef="shares">1034000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icfe186f4510a478e9f6676e77aa16a5d_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNi0zLTEtMS0xMTA5NTI_4ad2b121-6184-4a44-a063-92a84c3c28b4"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i03ef2d0eca0349a592744851911a54b3_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNi01LTEtMS0xMTA5NTI_f5259ba8-f5d2-4630-868f-4f41b8a9d34a"
      unitRef="usd">7079000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNi0xMS0xLTEtMTEwOTUy_b4dbc783-7492-4531-b326-a3420815af96"
      unitRef="usd">7080000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i03ef2d0eca0349a592744851911a54b3_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNy01LTEtMS0xMTA5NTI_bd0313d0-87a4-4d52-87fa-2cfdfb922ade"
      unitRef="usd">2523000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfNy0xMS0xLTEtMTEwOTUy_1f6ee792-09fe-4c72-ae21-e3be15f80c3f"
      unitRef="usd">2523000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i03ef2d0eca0349a592744851911a54b3_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOC01LTEtMS0xMTA5NTI_f902d693-aab6-4cbc-a7ae-d8d723b0ef0d"
      unitRef="usd">16892000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOC0xMS0xLTEtMTEwOTUy_f5bc2704-65b8-40bb-a8f2-6ae43a923351"
      unitRef="usd">16892000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0e2ccc06faab42c1b72c84f6d8fc6554_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS0xLTEtMS0xMTA5NTI_41f7ecd1-7103-4b6e-8dd6-133406e7e0aa"
      unitRef="shares">324985000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0e2ccc06faab42c1b72c84f6d8fc6554_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS0zLTEtMS0xMTA5NTI_e5e7b4cd-e48d-4ec0-b385-ded65844c3da"
      unitRef="usd">325000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9e3410e9e21c40998b84e3d69601d355_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS01LTEtMS0xMTA5NTI_6ade9ad3-32ff-4c27-b95a-f8b5ba120337"
      unitRef="usd">2558297000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idccb5b94d16a46fdb0cf63047d4d0a35_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS03LTEtMS0xMTA5NTI_7c3f32de-25a1-411d-aab4-e9fd4ecb801f"
      unitRef="usd">-9289000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ife8714608e344dc7971babe1680ab27e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS05LTEtMS0xMTA5NTI_801b6a8b-1bb0-4048-8b49-b61e27e18ed9"
      unitRef="usd">5803000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfOS0xMS0xLTEtMTEwOTUy_88f32bdc-0c14-4504-a200-93515fda8a1d"
      unitRef="usd">2555136000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1508ac4b174b4c78a254a72746c9b9ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtMS0xLTEtMTEwOTUy_cfa6b13d-2e0a-477d-946f-3f8d39d15e22"
      unitRef="shares">318842000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1508ac4b174b4c78a254a72746c9b9ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtMy0xLTEtMTEwOTUy_e7eebc4b-0972-46a2-9f75-dbd4d0d3636a"
      unitRef="usd">319000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied50145a7df5459d92fa66f1d9a3a632_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtNS0xLTEtMTEwOTUy_c55ca9b2-707f-4a1c-b373-728d87df0056"
      unitRef="usd">2427561000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb2a2cfb158540ca9584fae8239e375c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtNy0xLTEtMTEwOTUy_d40deabb-f5cb-4522-a312-5e215a24d943"
      unitRef="usd">-758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3118a17fe82743f4a08ef8bc281df1cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtOS0xLTEtMTEwOTUy_f46b0dc7-6663-40a3-93b5-0452312b113b"
      unitRef="usd">-216507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i56e9094b4beb4a8fb455ed26efa4b4dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTQtMTEtMS0xLTExMDk1Mg_06559ee4-1d24-4d55-be2a-a268ead6b772"
      unitRef="usd">2210615000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia02620eae926413ab03c9415bcccade7_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTUtOS0xLTEtMTEwOTUy_82a5b823-c44a-4912-86bc-5c495cd36fb2"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTUtMTEtMS0xLTExMDk1Mg_2c45c77a-e7a1-4566-9293-3599f06698ff"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7cf2d5e95a2d4758b7b8e19ee1dc13cd_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTYtNy0xLTEtMTEwOTUy_1e6d28a6-08e2-45d3-8b01-df53d64fa7f2"
      unitRef="usd">-5907000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTYtMTEtMS0xLTExMDk1Mg_9abfd654-d265-4965-acfb-405f4a48dfce"
      unitRef="usd">-5907000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i20dd40ea4f824fdc9ef3a7e851b32b65_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTctMS0xLTEtMTEwOTUy_a8fd8dac-a365-4b03-8e7f-b4d9704a7a8b"
      unitRef="shares">1426000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i20dd40ea4f824fdc9ef3a7e851b32b65_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTctMy0xLTEtMTEwOTUy_4e26e2ec-bf32-49de-b925-ca2664af6e2f"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i79c3cf115f4f41eda883262bfbc8069a_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTctNS0xLTEtMTEwOTUy_7ace56cc-9d60-448b-a45c-0c6488447b85"
      unitRef="usd">5512000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTctMTEtMS0xLTExMDk1Mg_b3f4f175-145b-480a-9c55-864cbe0cbd25"
      unitRef="usd">5513000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i79c3cf115f4f41eda883262bfbc8069a_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTgtNS0xLTEtMTEwOTUy_5413b336-ed80-4163-9e60-473557756d9d"
      unitRef="usd">4960000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTgtMTEtMS0xLTExMDk1Mg_2c60693b-0f55-4113-8c65-81d2919cdc44"
      unitRef="usd">4960000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i79c3cf115f4f41eda883262bfbc8069a_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTktNS0xLTEtMTEwOTUy_0e49c5f5-f1d2-41f1-8d73-a21464fbfe88"
      unitRef="usd">20017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMTktMTEtMS0xLTExMDk1Mg_07c5e0b2-bc3c-4355-be3a-40e53c8ce277"
      unitRef="usd">20017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i22b9b0ed7a4840709f0a21fddfa8f9b7_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtMS0xLTEtMTEwOTUy_18b166d9-15ad-4c24-9661-474139dad95a"
      unitRef="shares">320268000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i22b9b0ed7a4840709f0a21fddfa8f9b7_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtMy0xLTEtMTEwOTUy_b354286a-145f-4513-ba41-9fb90b0ee59a"
      unitRef="usd">320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95578fef614f423aad1a9a09bc7a0471_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtNS0xLTEtMTEwOTUy_ee91f2a1-06c1-465d-87cd-27c3325f4d8d"
      unitRef="usd">2448130000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i009fe3cdc57c4356822574ede853c0a5_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtNy0xLTEtMTEwOTUy_27636a78-ad09-4877-867e-5bb90a2a6d87"
      unitRef="usd">-6665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4f89c6cd5174469a45a0fee83e965f9_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtOS0xLTEtMTEwOTUy_bd64011e-25af-42a4-9265-9288bdb7898f"
      unitRef="usd">-147934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40f7e105971f40d2884d061c483a0023_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yNS9mcmFnOjFiMzg3M2Y2MGYwZDQwNGJiZGI4ZjBmOTZlOGYzZmY4L3RhYmxlOmUzZjEwNTZiYTY5YzQwNjRiYTU2M2FlMjJiNmIzM2VmL3RhYmxlcmFuZ2U6ZTNmMTA1NmJhNjljNDA2NGJhNTYzYWUyMmI2YjMzZWZfMjAtMTEtMS0xLTExMDk1Mg_ca270fd6-0017-492e-878e-f2127e4c2316"
      unitRef="usd">2293851000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMi0xLTEtMS0xMTA5NTI_96fa1189-6381-407f-a56c-59e5f551a230"
      unitRef="usd">40028000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMi0zLTEtMS0xMTA5NTI_8a5b6549-1293-4a78-9f6e-ef5f64fb3b50"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNC0xLTEtMS0xMTA5NTI_ffcd914e-33e9-49c8-952c-c7868f6b1f93"
      unitRef="usd">6855000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNC0zLTEtMS0xMTA5NTI_a5632ea3-24a5-472e-8072-2b56df9485ea"
      unitRef="usd">4490000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNS0xLTEtMS0xMTA5NTI_8291b38b-32cc-4ffd-baa1-311444e1aa8d"
      unitRef="usd">16661000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNS0zLTEtMS0xMTA5NTI_6440e8fa-0cc1-4a65-99cd-451dc1de8787"
      unitRef="usd">19759000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNi0xLTEtMS0xMTA5NTI_5388b0e5-1d08-4a4a-b0b5-91093106903d"
      unitRef="usd">6731000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNi0zLTEtMS0xMTA5NTI_79276bb3-6924-4813-8dec-0983c572abfc"
      unitRef="usd">1385000</exel:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNy0xLTEtMS0xMTA5NTI_0d03d4dc-1a46-489f-932b-398ea5d68cdb"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfNy0zLTEtMS0xMTA5NTI_2774983b-8611-4414-af58-524dee3256d2"
      unitRef="usd">-15318000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfOC0xLTEtMS0xMTU3NTU_fdd40b56-c16c-4c28-8958-fa7572f0fc10"
      unitRef="usd">36500000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfOC0zLTEtMS0xMTU3NTg_d3e9926b-252b-45a2-9207-c09921b52303"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfOC0xLTEtMS0xMTA5NTI_5fa7852f-931a-4aff-a335-fb3abf333bf2"
      unitRef="usd">3743000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfOC0zLTEtMS0xMTA5NTI_aa6eaa36-ae3d-4c05-9deb-a95f723f2540"
      unitRef="usd">-1580000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTAtMS0xLTEtMTEwOTUy_243ff06d-11c1-4cea-9cf5-de5da626a5f0"
      unitRef="usd">19178000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTAtMy0xLTEtMTEwOTUy_7c5b88dc-fc32-467f-ba54-5f229f504505"
      unitRef="usd">-91793000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTEtMS0xLTEtMTEwOTUy_e2f16134-897b-4da1-b498-733249866603"
      unitRef="usd">8370000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTEtMy0xLTEtMTEwOTUy_c9292f8f-7a16-4d62-9492-8494ea8b0ad2"
      unitRef="usd">3520000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTMtMS0xLTEtMTEwOTUy_142171e6-92fb-4e8b-ba72-e9e03fe16e90"
      unitRef="usd">-10372000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTMtMy0xLTEtMTEwOTUy_ef3daefd-6bd8-4413-b769-d95329ddd3ed"
      unitRef="usd">3605000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTUtMS0xLTEtMTEwOTUy_3c46604d-85b9-4b52-a50b-39da04462773"
      unitRef="usd">-707000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTUtMy0xLTEtMTEwOTUy_0717a7b1-6305-469e-8aa3-3afb23602ba7"
      unitRef="usd">-1169000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <exel:IncreaseDecreaseInAccruedCollaborationLiabilities
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTYtMS0xLTEtMTEwOTUy_2b3803f1-cfcd-4449-be3c-78a3027fd263"
      unitRef="usd">-1864000</exel:IncreaseDecreaseInAccruedCollaborationLiabilities>
    <exel:IncreaseDecreaseInAccruedCollaborationLiabilities
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTYtMy0xLTEtMTEwOTUy_68b2cf7b-618d-41a2-9165-d4fdfd2f3475"
      unitRef="usd">-54261000</exel:IncreaseDecreaseInAccruedCollaborationLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTctMS0xLTEtMTEwOTUy_c0ce3eaa-5298-42b4-866c-1ba84c6d0749"
      unitRef="usd">1123000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTctMy0xLTEtMTEwOTUy_ff949b0e-03fc-41a9-9299-d4e4d8036465"
      unitRef="usd">7376000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTktMS0xLTEtMTEwOTUy_b665ce27-0882-4388-a5f3-b99909445a50"
      unitRef="usd">84408000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMTktMy0xLTEtMTEwOTUy_53a76b8a-52f9-4425-823b-ce6c4c047535"
      unitRef="usd">147719000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjEtMS0xLTEtMTEwOTUy_fc2d5ca9-6488-4d3a-8216-bc0abdf817d4"
      unitRef="usd">12024000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjEtMy0xLTEtMTEwOTUy_bdbacff9-c6cb-4a5c-9f45-9c134b35771d"
      unitRef="usd">5609000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjItMS0xLTEtMTE1NDU4_13f6417c-43a2-4908-aa76-9cfe6e737876"
      unitRef="usd">36500000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjItMy0xLTEtMTE1NDY1_d880d2a9-72fd-4ce6-8a60-ae0ed8867e9c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjMtMS0xLTEtMTEwOTUy_54379bda-d181-4a30-b04d-56cc3c6b70ff"
      unitRef="usd">311837000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjMtMy0xLTEtMTEwOTUy_4f6f7130-ffb6-4b06-8540-07d23cf33922"
      unitRef="usd">336545000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjQtMS0xLTEtMTEwOTUy_cbc4ab8d-49b5-4750-8688-a23bcb7809e6"
      unitRef="usd">310769000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjQtMy0xLTEtMTEwOTUy_5270b24a-9291-4bb7-bf3b-e04560686c99"
      unitRef="usd">267615000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjUtMS0xLTEtMTEwOTUy_fab996f3-69d0-4f8d-a8f3-87d1048cf7c9"
      unitRef="usd">-49592000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjUtMy0xLTEtMTEwOTUy_64f54853-d65d-4d6d-85a8-b765f849b146"
      unitRef="usd">-74539000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjctMS0xLTEtMTEwOTUy_4138c33e-e6fb-482a-b3e0-d43253a949ab"
      unitRef="usd">7143000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjctMy0xLTEtMTEwOTUy_26653e5b-e0c5-4385-842e-a336c92eedeb"
      unitRef="usd">4891000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjgtMS0xLTEtMTEwOTUy_9eb3fa0d-9d8d-472f-8e4b-3935362bc4ce"
      unitRef="usd">2557000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMjgtMy0xLTEtMTEwOTUy_1f2673ec-7162-4b4f-8012-f4cec436d63d"
      unitRef="usd">4686000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzEtMS0xLTEtMTEwOTUy_5978884d-c084-4e8a-a8c6-8561e3100052"
      unitRef="usd">4586000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzEtMy0xLTEtMTEwOTUy_9c47af53-8652-458c-ba68-965dc3aea08c"
      unitRef="usd">205000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzItMS0xLTEtMTEwOTUy_30f09c68-5a75-46b2-aece-ed6a56234cdc"
      unitRef="usd">39402000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzItMy0xLTEtMTEwOTUy_eb513d6a-0293-4315-a462-ce0838593672"
      unitRef="usd">73385000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzMtMS0xLTEtMTEwOTUy_d0c02b17-85e6-45b7-93a9-31830ba2b07d"
      unitRef="usd">502677000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i56e9094b4beb4a8fb455ed26efa4b4dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzMtMy0xLTEtMTEwOTUy_b6f0fd07-24c1-43f1-83ab-dad35aefc7f5"
      unitRef="usd">663891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzQtMS0xLTEtMTEwOTUy_9d5e0536-9a73-48db-bbfd-71277780260a"
      unitRef="usd">542079000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i40f7e105971f40d2884d061c483a0023_I20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8yOC9mcmFnOjc3MjRlOTE1ZTk4NzQ0ODliY2UxY2VhNDBmMmYzNjZkL3RhYmxlOjEwODIzYzVhODdmYTQxYjA4YWNkMmY1NzNiZjFmYzc1L3RhYmxlcmFuZ2U6MTA4MjNjNWE4N2ZhNDFiMDhhY2QyZjU3M2JmMWZjNzVfMzQtMy0xLTEtMTEwOTUy_685e4efa-2904-418f-9926-89dba35e49c9"
      unitRef="usd">737276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjkxMg_54feda03-31ee-4c02-b674-06de2d018a91">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and combination regimens at the forefront of cancer care. Through the commitment of our drug discovery, development and commercialization resources, we have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib. We continue to evolve our product portfolio, leveraging our investments, expertise and strategic partnerships, to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales related to cabozantinib account for the majority of our revenues. Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and in 67 other countries as of the date of this Quarterly Report on Form 10-Q: as CABOMETYX&#xae; (cabozantinib) tablets for advanced renal cell carcinoma (both alone and in combination with Bristol-Myers Squibb Company&#x2019;s OPDIVO&#xae; (nivolumab)), for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer; and as COMETRIQ&#xae; (cabozantinib) capsules for progressive, metastatic medullary thyroid cancer. For physicians treating these types of cancer, cabozantinib has become or is becoming an important medicine in their selection of effective therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other two products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2022, included in Part II, Item 8 of our Annual Report on Form 10-K, filed with the SEC on February&#160;7, 2023 (Fiscal 2022 Form 10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Fiscal year 2023, which is a 52-week fiscal year, will end on December&#160;29, 2023 and fiscal year 2022, which was a 52-week fiscal year, ended on December&#160;30, 2022. For convenience, references in this report as of and for the fiscal period ended April 1, 2022, and as of and for the fiscal years ending December&#160;29, 2023 and ended December&#160;30, 2022 are indicated as being as of and for the period ended March&#160;31, 2022, and the years ending December&#160;31, 2023 and ended December&#160;31, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about sales of products, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies during the three months ended March 31, 2023, as compared to the significant accounting policies disclosed in &#x201c;Note 1. Organization and Summary of Significant Accounting Policies&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements adopted by us since our filing of the Fiscal 2022 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Fiscal 2022 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberOfCountriesWithDrugApprovalExcludingTheUS
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNTQ5NzU1ODI2MzUy_7b693b43-ca69-41c0-987f-118c14f49860"
      unitRef="country">67</exel:NumberOfCountriesWithDrugApprovalExcludingTheUS>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i88c7f65af0d44b9ebe6c0bfcbaf1bcc8_D20221231-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfMTc0Mg_05a97109-0786-4bf2-afb9-2f767da85d34"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjkxNg_889b8de1-359e-4cb8-a2c4-9ccc11ea2ac7">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjg5MA_163587b5-5a8a-4d2b-a39a-a531598e5eeb">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#160;31, 2022, included in Part II, Item 8 of our Annual Report on Form 10-K, filed with the SEC on February&#160;7, 2023 (Fiscal 2022 Form 10-K).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjkwMQ_1b5805e0-c508-462e-8509-8f868a45e8c8">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;. Fiscal year 2023, which is a 52-week fiscal year, will end on December&#160;29, 2023 and fiscal year 2022, which was a 52-week fiscal year, ended on December&#160;30, 2022. For convenience, references in this report as of and for the fiscal period ended April 1, 2022, and as of and for the fiscal years ending December&#160;29, 2023 and ended December&#160;30, 2022 are indicated as being as of and for the period ended March&#160;31, 2022, and the years ending December&#160;31, 2023 and ended December&#160;31, 2022, respectively.</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjkwOA_1ceb76de-b96a-4654-8b6c-30873b95a890">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNDE1NQ_6da178d4-24f8-407c-9cc7-8fd043fbcb37"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjkxMw_7db2aa47-ab5b-4b34-a108-f34979e4297d">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNC9mcmFnOjY2ZTBhZjliNDFkZTRlZTliMWQzNjU4NGQzZmMxZDA5L3RleHRyZWdpb246NjZlMGFmOWI0MWRlNGVlOWIxZDM2NTg0ZDNmYzFkMDlfNjg5Ng_4201201c-9d0f-4cc8-9a40-9b37f20944e8">&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements adopted by us since our filing of the Fiscal 2022 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Fiscal 2022 Form 10-K, which could have a significant effect on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDk0Mg_cf59775b-7173-4898-be53-76bdbe9595d7">REVENUES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues are recorded in accordance with ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs and the royalties we pay on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Contract assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023 and 2022, we recognized $2.0&#160;million and $2.4&#160;million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, we recognized $37.9&#160;million and $31.7&#160;million, respectively, in revenues for performance obligations satisfied in previous periods. Such revenues were primarily related to royalty payments allocated to our license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023, $69.0&#160;million of t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he co&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mbined transaction prices for our Ipsen a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd Takeda collaborations were allocated to research and development services performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements and Business Development Activities&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2022 Form 10-K for additional information about the expected timing to satisfy these performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDkzNA_75d2e167-b2b4-4497-8fe3-20e00319a938">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(157,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d27cdd49640469c8f242f09214a609a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfMy0xLTEtMS0xMTA5NTI_1088172b-c067-4916-b4f7-dcbfb18d2a8a"
      unitRef="usd">521322000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida032638ed6145e19d54c570bc2b9d93_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfMy0zLTEtMS0xMTA5NTI_434a69d1-5dc6-4131-b9f8-ba9b4e88a970"
      unitRef="usd">448237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i595a452dffec43ddacb9c075ff6b480b_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNC0xLTEtMS0xMTA5NTI_8ce46d98-4f62-42b5-9714-89580ea1bc3d"
      unitRef="usd">-157922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbe685ef22c941cba593e7a64e54dbf3_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNC0zLTEtMS0xMTA5NTI_367fc322-63bb-4b5e-8a9d-103c2f3a9285"
      unitRef="usd">-137939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6dd521484284a028aab45ea8772360e_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNS0xLTEtMS0xMTA5NTI_4ec3e6d1-6ee9-4e74-a2f0-a9d558f632eb"
      unitRef="usd">363400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7906589f9aa479c9565c72719ef21e6_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNS0zLTEtMS0xMTA5NTI_640d39da-ef04-4e9c-a762-4ad5f1a8a812"
      unitRef="usd">310298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c85c6827b024c629f44a06755732c29_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNy0xLTEtMS0xMTA5NTI_266f3169-da28-46b9-bbad-901fe1555dc0"
      unitRef="usd">38292000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if392acf72a7a4ae486acfef62c1ccfe2_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfNy0zLTEtMS0xMTA5NTI_de42ea05-0b72-46d2-86ba-c66eff8b4085"
      unitRef="usd">32067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib54ef24bfa5d431b8c16060a36cc40fd_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfOC0xLTEtMS0xMTA5NTI_b10b04a3-6dbc-42f4-be61-98459859d911"
      unitRef="usd">7096000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if94929e9ad634418bfded9c801d3fa56_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfOC0zLTEtMS0xMTA5NTI_e8458e8f-d880-491e-8595-bf0a93c9dfb6"
      unitRef="usd">13615000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06debfc85b9342daa487a13cc47e36de_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfOS0xLTEtMS0xMTA5NTI_cdcf010c-41f5-4e01-b194-135fd57b822b"
      unitRef="usd">45388000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib55727874d5a4f308e9616357e398771_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfOS0zLTEtMS0xMTA5NTI_e1e3e8db-41da-4ff4-9416-1222118e51bf"
      unitRef="usd">45682000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfMTAtMS0xLTEtMTEwOTUy_1f4c630e-169a-42af-8a3b-8d0dd5c5ddea"
      unitRef="usd">408788000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjI5NWVkN2Q4YmM5YTRmMWM5OGM1MWU4NDg3NmJmODY0L3RhYmxlcmFuZ2U6Mjk1ZWQ3ZDhiYzlhNGYxYzk4YzUxZTg0ODc2YmY4NjRfMTAtMy0xLTEtMTEwOTUy_de6f39a6-164d-47e6-9264-0ed1e6a834e1"
      unitRef="usd">355980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDkzMg_25c3e9db-7025-4a4d-ab3b-a0716de4bad5">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaa7500ddcb0b4d0db3443cc56170ff61_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfMi0xLTEtMS0xMTA5NTI_540c95cf-bccb-4cf7-90d4-daf1f4f0216e"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iced7a06ad4e4417e870e84a67ede1244_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfMi0zLTEtMS0xMTA5NTI_823654bd-67bf-4e33-9c1c-db042db12a1f"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibe37fc8620b94da8b2fc78d1941a9030_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfMy0xLTEtMS0xMTA5NTI_c35b1fea-50dd-456f-a471-ef5aff2f07c7"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id9022e3a517a4086aadbb0f76b987860_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfMy0zLTEtMS0xMTA5NTI_8460454c-c5d4-47ac-805d-68cb070d1ec1"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic354cd8d9401435bb4bef5aa134d8b18_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNC0xLTEtMS0xMTA5NTI_9e51545e-a33f-467d-99a0-70d98c1ae45d"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i145518f569754dcab3e0530961014f83_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNC0zLTEtMS0xMTA5NTI_a432a148-e499-41cb-bba1-80d0d281bea1"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2ac68a66c51c45aaafa439d76a88823b_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0xLTEtMS0xMjE1MzY_a91870da-07b0-4962-8356-c9cf2fe79c36"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iadcb287071b8482091481fd721d6437b_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0zLTEtMS0xMjE1MzY_0d5fe927-1ec9-4983-9544-549db57e78d1"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i887d25b5c3eb476fac598042e121ae9e_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0xLTEtMS0xMjEzMjc_57a14c28-1e29-4b6c-8d49-e023d7cb76ec"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9f6c3de32bb5469faa5988e472ba8294_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0zLTEtMS0xMjEzMjc_fbff282f-c412-43b4-b9b3-720ecb42f29c"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i03edf15c3de14b84b45b07e5d3a6783b_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0xLTEtMS0xMTA5NTI_8d78ba1c-04b5-402e-873a-4690edbe23b9"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ief8ad52c39a04dbb97764e462472ac81_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjUwZGJjYTNmMTM0ZTRmZDU5ZjAwYTliMDI4ZDJkODFkL3RhYmxlcmFuZ2U6NTBkYmNhM2YxMzRlNGZkNTlmMDBhOWIwMjhkMmQ4MWRfNS0zLTEtMS0xMTA5NTI_e66c569f-6df3-4e2f-99f0-e6ffa8a8f471"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9f99cf5241b6466788f894b2abc4f8ed_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMS0xLTEtMS0xMTA5NTI_041e8edf-3825-471b-824e-b4d02897653c"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4cd8710c99944d47a9e0d4b3f5b26afc_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMS0zLTEtMS0xMTA5NTI_b2e4fcf4-dc8d-47e8-b9da-4bdfdca813c7"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i30663220db714d0f884ca85a30e97ed2_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMi0xLTEtMS0xMjEzMzk_7090e063-62b1-4dfc-b8c9-9fce88e6c3a3"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2e8676ff223f403889416c0afd319b61_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMi0zLTEtMS0xMjEzMzk_3363d9ff-3dd0-4f9a-b04d-1ee2f312d5aa"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia17b8615b9f449ae815574e6e809f6f7_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMi0xLTEtMS0xMTA5NTI_26aa70fa-4539-4a5e-8541-b21522b12482"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibe97f6cf8ca84e36a31f8ac01af69488_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfMi0zLTEtMS0xMTA5NTI_3cb54bac-1245-46e9-94d7-4a494872c9c1"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia09f023283744b868559533749bfb478_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfNC0xLTEtMS0xMTA5NTI_edb6661f-dc08-4505-8279-faa451eb633f"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id32f197bc1034297a1205ca6bff7d001_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfNC0zLTEtMS0xMTA5NTI_b92e6bda-ffd3-4b36-ba64-175df9759a87"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id1dfd4d591884f079548cf36ab7d515a_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfNS0xLTEtMS0xMTA5NTI_ec7371bd-e7c8-4be2-8e24-b0b81f2df19b"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i25cc695fcf37474383a6d4d015d235e0_D20220101-20221230"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjQ0NjhlY2ZjN2JiYzQwNGQ4N2JmZWVlZjk0MTNhNmI2L3RhYmxlcmFuZ2U6NDQ2OGVjZmM3YmJjNDA0ZDg3YmZlZWVmOTQxM2E2YjZfNS0zLTEtMS0xMTA5NTI_b449b19a-4ce0-479d-8d5e-d7c6135318a3"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDk0NA_cee5dcb9-f30c-4cb3-8885-c55ef71e5036">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i005e52f0aa9441e9b404ce8f42adc3d6_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfMi0xLTEtMS0xMTA5NTI_2750046f-e86c-407e-9ef7-7550edaadeaf"
      unitRef="usd">367441000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c2ff2123a5e43459fdf372396cef270_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfMi0zLTEtMS0xMTA5NTI_6454dc1f-601a-4028-8b7d-0e0351db12bd"
      unitRef="usd">314065000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f1ae657918947af907f5f8fab6b57fe_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfMy0xLTEtMS0xMTA5NTI_c4bf5767-61e7-4765-a69d-24ce74cbe682"
      unitRef="usd">33534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0b5d0c4ace24841940333ae7904c072_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfMy0zLTEtMS0xMTA5NTI_1230c07d-fb9d-4a89-96e5-96a3341b2b35"
      unitRef="usd">34527000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i936cbc93158847ce8d03042dab8d6d3d_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfNC0xLTEtMS0xMTA5NTI_2f985df0-3699-4ac8-97ce-595288acc259"
      unitRef="usd">7813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73abd557fa874e57af0091d9dd6409f3_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfNC0zLTEtMS0xMTA5NTI_073b5a9b-8533-40c4-92dc-a09570f397e8"
      unitRef="usd">7388000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfNS0xLTEtMS0xMTA5NTI_2dad2680-415e-4c89-9091-f3a6cb7e3fab"
      unitRef="usd">408788000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg5ZTIxMDAzNzlhODRhZWQ5NzlkNThhNzkzNWQ5MGJhL3RhYmxlcmFuZ2U6ODllMjEwMDM3OWE4NGFlZDk3OWQ1OGE3OTM1ZDkwYmFfNS0zLTEtMS0xMTA5NTI_82a43de1-3b3d-4e19-a494-88fa5735c288"
      unitRef="usd">355980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDkyOA_e17cb73e-7cfe-4c27-9baf-2a8c610baded">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with Accounting Standards Codification (ASC) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues are recorded in accordance with ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs and the royalties we pay on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net, and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets are primarily related to Ipsen Pharma SAS (Ipsen) and contract liabilities are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda).&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85a5140525004434a113a31a2b6f9fec_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfMi0xLTEtMS0xMTA5NTI_c193014d-6367-4378-9917-4637ab445b0c"
      unitRef="usd">361773000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie93c1a4da62d4e91aada27293fc54993_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfMi0zLTEtMS0xMTA5NTI_09b0dabb-cda3-417b-8f7c-d2cb1c3a18e8"
      unitRef="usd">302812000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b3ca2a0d827408a96d2c203c0c3d713_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfMy0xLTEtMS0xMTA5NTI_0ffb76d0-09fb-4344-9545-baaab637a732"
      unitRef="usd">1627000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieca193774391470aaad49e0c557cd653_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfMy0zLTEtMS0xMTA5NTI_9d504c5f-671b-4294-b798-19f4ad298243"
      unitRef="usd">7486000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6dd521484284a028aab45ea8772360e_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfNC0xLTEtMS0xMTA5NTI_39d6c2c2-a067-4598-84ea-2350b425381c"
      unitRef="usd">363400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7906589f9aa479c9565c72719ef21e6_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjc2YWE0YTMwYzFkNzRlOWE4NDAwNmQ3YWNmOGJmZjk2L3RhYmxlcmFuZ2U6NzZhYTRhMzBjMWQ3NGU5YTg0MDA2ZDdhY2Y4YmZmOTZfNC0zLTEtMS0xMTA5NTI_6377cc84-a013-4d9d-9609-f0de3a2921c0"
      unitRef="usd">310298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDk1NA_a356603f-35d4-4801-bb32-fd42f3246662">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie23bc89dd4ed466bb9e19cbc8ccf8e79_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMS0xLTEtMS0xMTA5NTI_5d584701-58f5-4adb-97c9-e85eacf6e3bf"
      unitRef="usd">26881000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i561a3686c8c54aaa9930ddcb0186d034_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMS0zLTEtMS0xMTA5NTI_8587631f-1210-4a0e-a573-e23e5508afed"
      unitRef="usd">14924000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="idb98cc6df0964b9dbc447c72a27d45d2_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMS01LTEtMS0xMTA5NTI_64062327-8c78-4df0-acb8-6d6798a586b5"
      unitRef="usd">35426000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMS05LTEtMS0xMTA5NTI_63a30203-df64-4ac9-b460-09a8de9ffe9d"
      unitRef="usd">77231000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="iaf790da88c7f48bebd710b720e67b732_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMy0xLTEtMS0xMTA5NTI_89aee9e0-52bc-4699-900c-662d03ad255c"
      unitRef="usd">94959000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i6803b211b6ba46c0b060c8ef10832fa3_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMy0zLTEtMS0xMTA5NTI_2a83bc42-bacf-48ba-b3fe-a0181751ad26"
      unitRef="usd">14913000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="iab3dde5c402a452ca70d75ca56511047_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMy01LTEtMS0xMTA5NTI_75fa53c3-d74a-4558-9699-b05cf458fbb9"
      unitRef="usd">49113000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfMy05LTEtMS0xMTA5NTI_332d7d73-1a5a-4fb0-8a77-a9bc7ccb26f0"
      unitRef="usd">158985000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="iaf790da88c7f48bebd710b720e67b732_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNC0xLTEtMS0xMTA5NTI_861eafbb-7e3d-493a-903a-26484b6e4f36"
      unitRef="usd">141000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i6803b211b6ba46c0b060c8ef10832fa3_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNC0zLTEtMS0xMTA5NTI_a1a501bb-6a17-4759-a3ec-9372205053ec"
      unitRef="usd">-1117000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="iab3dde5c402a452ca70d75ca56511047_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNC01LTEtMS0xMTA5NTI_296e5ac8-9efd-410e-a73d-fb75f0884c61"
      unitRef="usd">-87000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNC05LTEtMS0xMTA5NTI_177a0456-6e60-4afc-a17a-542da93acdfa"
      unitRef="usd">-1063000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iaf790da88c7f48bebd710b720e67b732_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNS0xLTEtMS0xMTA5NTI_f7ba2096-19ca-4381-8ba4-741d85d50660"
      unitRef="usd">100831000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i6803b211b6ba46c0b060c8ef10832fa3_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNS0zLTEtMS0xMTA5NTI_e252b95a-e629-4308-8dd1-98fb85799be2"
      unitRef="usd">13637000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iab3dde5c402a452ca70d75ca56511047_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNS01LTEtMS0xMTA5NTI_f6178d70-ab39-4545-9402-67710c803893"
      unitRef="usd">33130000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNS05LTEtMS0xMTA5NTI_788afa03-ac15-4ca8-9972-e941d77badb1"
      unitRef="usd">147598000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i75a9ae3fb4354c558afa5652356fc857_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNi0xLTEtMS0xMTA5NTI_05d65785-3716-4498-a000-3338c5cb01ec"
      unitRef="usd">21150000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i37a339e12ecb401f86dd0d2f2d5819d9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNi0zLTEtMS0xMTA5NTI_e06cbde6-c549-4817-b02c-12de29d53441"
      unitRef="usd">15083000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iec98443a01d9484790def9f44b69d198_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNi01LTEtMS0xMTA5NTI_3ac818eb-0a8f-4354-aa63-eb6387afa51d"
      unitRef="usd">51322000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOjg1NDhjOGM5YWNkYTQxYmZhYWZmYTI1ZmY2MmIzMzdjL3RhYmxlcmFuZ2U6ODU0OGM4YzlhY2RhNDFiZmFhZmZhMjVmZjYyYjMzN2NfNi05LTEtMS0xMTA5NTI_8473d677-91cd-4259-be30-b0b6d9d7f93b"
      unitRef="usd">87555000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNDk0MA_96e1dfd3-3d52-4bd3-b3de-e4f722ce2baa">Contract assets and liabilities were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfNC0xLTEtMS0xMTA5NTI_1bb61a90-6a06-4b7f-a45c-0ac26de7c7ee"
      unitRef="usd">1387000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfNC0zLTEtMS0xMTA5NTI_3b8d1dde-b296-444a-a6d1-86fd4ad803e0"
      unitRef="usd">1659000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfNy0xLTEtMS0xMTA5NTI_21871696-a9da-4d62-a612-ac9d32723c9e"
      unitRef="usd">7064000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfNy0zLTEtMS0xMTA5NTI_547f0a68-c3c0-42d2-b697-1c2ded0406c5"
      unitRef="usd">7488000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfOC0xLTEtMS0xMTA5NTI_5bebeb47-3ef7-4b32-8031-09706813b16e"
      unitRef="usd">6299000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfOC0zLTEtMS0xMTA5NTI_feba945e-90e8-41d2-8c2f-f8dc65823514"
      unitRef="usd">6582000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfOS0xLTEtMS0xMTA5NTI_cfd04d81-c955-49f8-8035-b50e967824b0"
      unitRef="usd">13363000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RhYmxlOmU1M2NmMzg4MmQ5MzQxNTZiOWE0MjAxZjMxY2NhYWNhL3RhYmxlcmFuZ2U6ZTUzY2YzODgyZDkzNDE1NmI5YTQyMDFmMzFjY2FhY2FfOS0zLTEtMS0xMTA5NTI_0beee80c-f715-46a6-90a6-190fa8c7818c"
      unitRef="usd">14070000</us-gaap:ContractWithCustomerLiability>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNzE0NjgyNTU4NjYyOA_8c33556f-a6dc-4dbd-ade7-69b67a60d617"
      unitRef="usd">2000000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNTQ5NzU1ODE4OTY2_f46bab7c-c1e6-440e-8efa-ec09193433f1"
      unitRef="usd">2400000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNzE0NjgyNTU4NjY1Nw_3ce6bbab-f8cb-46c2-9c15-45af2193c4a5"
      unitRef="usd">37900000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNTQ5NzU1ODE5MDgx_f56f6ef0-820a-4323-b2e1-0dbc4fa700db"
      unitRef="usd">31700000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV8zNy9mcmFnOjkxNTIxMDViODcwNDQxYmFhN2ExOGM4NzI5NzNhN2E2L3RleHRyZWdpb246OTE1MjEwNWI4NzA0NDFiYWE3YTE4Yzg3Mjk3M2E3YTZfNzE0NjgyNTU4NjY4Ng_b9651e54-e016-4ffb-be7c-96a624f2ab0f"
      unitRef="usd">69000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNzM3NQ_d7967e20-10ab-49b4-8846-bddf56672984">COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established multiple collaborations with leading biopharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have made considerable progress under our existing research collaboration and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Historically, we also entered into other collaborations with leading biopharmaceutical companies pursuant to which we out-licensed other compounds and programs in our portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Note 3. Collaboration Agreements and Business Development Activities&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2022 Form 10-K, as further described below, for additional information on certain of our collaboration agreements and in-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Commercial Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Under the collaboration and license agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration and license agreement, as amended, with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023, $33.9&#160;million of the transaction price for this collaboration and license agreement, as amended, was allocated to our research and development services performance obligation that has not yet been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Under the collaboration and license agreement, as amended, Takeda received exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration and license agreement, as amended, with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $35.0&#160;million of the transaction price for this collaboration and license agreement, as amended, was allocated to our research and development services performance obligations that have not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Pharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GlaxoSmithKline (GSK), that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib sold by us and our collaboration partners. Effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalty fees earned by Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalty fees earned by Royalty Pharma were $15.4&#160;million and $13.1&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research Collaborations, In-Licensing Arrangements and Other Business Development Activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into collaborative arrangements with other pharmaceutical or biotechnology companies to develop and commercialize drug candidates or intellectual property. Our research collaborations and in-licensing arrangements are intended to enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. Our research collaborations, in-licensing arrangements and other strategic transactions generally include upfront payments, development, regulatory and commercial milestone payments, and royalty payments, in each case contingent upon the occurrence of certain future events linked to the success of the asset in development. Certain of our research collaborations provide us exclusive options that give us the right to license programs or acquire the intellectual property developed under the research collaborations for further discovery and development. When we decide to exercise the options, we are required to pay an exercise fee and then assume the responsibilities for all subsequent development, manufacturing and commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March 31, 2023, we recognized $44.7&#160;million within research and development expenses on the Condensed Consolidated Statements of Income, primarily related to development milestones, research and development funding and other fees, including a $35.0&#160;million development milestone to our partner, Sairopa B.V., upon the effective date of the initial new drug application (IND) for the ADU-1805 program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of March&#160;31, 2023, in conjunction with these collaborative in-licensing arrangements we are subject to potential future development milestones of up to $650.6&#160;million, regulatory milestones of up to $634.4&#160;million and commercial milestones of up to $3.2&#160;billion, each in the aggregate per product or target, as well as royalties on future net sales of products.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNzM3Nw_92b8e55a-bdd4-45b2-b309-177066986cd4">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration and license agreement, as amended, with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration and license agreement, as amended, with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2931f6876e343439ec8b11809eebdf1_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfMi0xLTEtMS0xMTA5NTI_04407593-9575-4521-a6a4-dd4c6902ce42"
      unitRef="usd">29812000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i864cb8fb17554a37a8adaea7c33b4efc_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfMi0zLTEtMS0xMTA5NTI_d50c28da-15b5-4ccf-80f5-19267320248e"
      unitRef="usd">24614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1696dcf966747e3b865502c27c29aad_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfMy0xLTEtMS0xMTA5NTI_28e35767-e2a3-4106-ab08-974dd7d7d9be"
      unitRef="usd">3722000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i021d57f0be044f67974550e7d885e1d1_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfMy0zLTEtMS0xMTA5NTI_1e6eaf5e-bfa9-4ea9-bcc4-99883d0cad29"
      unitRef="usd">9913000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d81ebf2e8e74fce85e25162934a4d6f_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfNC0xLTEtMS0xMTA5NTI_68ba6824-6a29-4327-aadd-38ec3f58ecaa"
      unitRef="usd">33534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff535a866b2c41fdb6f8646e8b488292_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmViMTZjOWRkNzUyZjRlNjBhYjAzOTM4ZDAyNDM2MGI0L3RhYmxlcmFuZ2U6ZWIxNmM5ZGQ3NTJmNGU2MGFiMDM5MzhkMDI0MzYwYjRfNC0zLTEtMS0xMTA5NTI_1c49e364-f3d9-4d2c-9b37-b14d8c8238da"
      unitRef="usd">34527000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i4acc2ee076ef40faac1edea03e68040c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNDM5ODA0NjUyODIwOA_a3420906-7ca8-4314-a45c-48914bb3739e"
      unitRef="usd">33900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7033584518df402d9b63ad9da059f49e_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfMi0xLTEtMS0xMTA5NTI_1f5e50a8-8121-4f4f-9f2b-b271e350118d"
      unitRef="usd">2849000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8c875584853425eba6bda6cacea2afd_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfMi0zLTEtMS0xMTA5NTI_55c620f2-3b8f-49dd-b554-353c77066112"
      unitRef="usd">2365000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8956cc8ef7304e6e94df23b6ddff9882_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfMy0xLTEtMS0xMTA5NTI_daf2b9a6-8462-4231-9346-3cfa2eb1f344"
      unitRef="usd">3374000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6df88e437a14a5e9a085f6a41e74f2a_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfMy0zLTEtMS0xMTA5NTI_3bf92c46-7eac-49ff-81c9-b447a98a5aef"
      unitRef="usd">3702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11c0ff70d2a2430fa83299f494f4c105_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfNC0xLTEtMS0xMTA5NTI_93328f29-7824-4ba3-b192-4a2f3427d7db"
      unitRef="usd">6223000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff2c6bd8205a44e2adb86297f4e43f30_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RhYmxlOmYwOWZhMGI4N2U5MjQ5OTliY2U1MDQ1MTM5YzkzNDIzL3RhYmxlcmFuZ2U6ZjA5ZmEwYjg3ZTkyNDk5OWJjZTUwNDUxMzljOTM0MjNfNC0zLTEtMS0xMTA5NTI_d9daac67-df05-44da-b518-80052a07358f"
      unitRef="usd">6067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ifa11613f3ae54abb9a1445d4727f95f1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNDM5ODA0NjUyODIyMg_cdce9828-7d9b-4382-b65b-7eb1409d4a5c"
      unitRef="usd">35000000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="i2b291b148d264039a3e055bce29bb22b_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfMTY0OTI2NzQ1NTg5MA_6df22343-8b35-4442-b467-3a3afd6d9a38"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="i700fe89825964bcf972c48b666c81680_D20221231-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNzE0NjgyNTU5NzYzNA_fb80e389-34cb-4037-a9ad-718c7bf019ce"
      unitRef="usd">15400000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="iceabd35baaac41af956c98f0f6f9a4c6_D20220101-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfMjE5OTAyMzI2Mzc3Mw_a03c152e-f22c-4327-972d-20369e4bdf1f"
      unitRef="usd">13100000</us-gaap:RoyaltyExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if9ade2259f534177966ecdd8ce949ae1_D20221231-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNzE0NjgyNTU5NzYwNQ_727344e2-e7d9-4ce7-8613-71448ae7dc46"
      unitRef="usd">44700000</us-gaap:ResearchAndDevelopmentExpense>
    <exel:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="if9ade2259f534177966ecdd8ce949ae1_D20221231-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNTQ5NzU1ODI4MDQx_3ba31677-6596-4326-8d2d-26476b5555e8"
      unitRef="usd">35000000</exel:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="iffd1fa8ae2c3489f966e69cc776984e3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNjA0NzMxMzk2OTczMw_6fc324a4-53e3-4c8b-bb69-5785455277e9"
      unitRef="usd">650600000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
      contextRef="iffd1fa8ae2c3489f966e69cc776984e3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfNjA0NzMxMzk2OTczNA_089dac67-b495-4d5a-b197-d792f11e74fc"
      unitRef="usd">634400000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments
      contextRef="iffd1fa8ae2c3489f966e69cc776984e3_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80MC9mcmFnOjI5Nzg3NWIwZjQ5NTQyMWM5ZTQxNjhhYTIxNDA2Mjk3L3RleHRyZWdpb246Mjk3ODc1YjBmNDk1NDIxYzllNDE2OGFhMjE0MDYyOTdfMTY0OTI2NzQ2MDM0NA_9296f638-1829-4234-bb63-e2b1dab53d9f"
      unitRef="usd">3200000000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjg3Mw_3069b4bb-d28a-4d2b-a461-df79e7d05854">CASH AND INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A reconciliation of cash, cash equivalents and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents are used to collateralize letters of credit agreements and are invested primarily in certificates of deposit with original maturity of 90 days or less. The restricted cash equivalents are classified as other long-term assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,085,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable was $10.1 million and $7.3 million as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and December&#160;31, 2022, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were immaterial during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were 237 and 285 debt securities available-for-sale in an unrealized loss position as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022, respectively. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; all securities have been in an unrealized loss position for less than twelve months except for 91 debt securities available-for-sale with an aggregate fair value of $317.1 million and an aggregate $6.3 million unrealized loss. As of December&#160;31, 2022, all securities have been in an unrealized loss position for less than twelve months except for 81 debt securities available-for-sale with an aggregate fair value of $237.6&#160;million and an aggregate $6.1&#160;million unrealized loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjg4Mg_ed29aee4-4979-441a-b8a9-5b2dead7cf65">A reconciliation of cash, cash equivalents and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjg4NA_2a5b8448-c738-473c-aece-d99f1de07ee6">A reconciliation of cash, cash equivalents and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfMS0xLTEtMS0xMTA5NTI_35fd8062-5a6d-4949-8bbd-72b6bebe818f"
      unitRef="usd">540597000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfMS0zLTEtMS0xMTA5NTI_cdb99e51-a08b-4448-a87b-63cb93aae738"
      unitRef="usd">501195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfMy0xLTEtMS0xMTA5NTI_7934ebf2-7f3c-4659-a34f-c8c9a9777ad7"
      unitRef="usd">1482000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfMy0zLTEtMS0xMTA5NTI_4370f171-2907-4ca4-babb-829eafb84614"
      unitRef="usd">1482000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfNC0xLTEtMS0xMTA5NTI_18f94f12-dff9-4ef9-8fce-c1e82c88f4e8"
      unitRef="usd">542079000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjI5ZmEzZjcwMTgwZjQwMGZiYWU0ZWNlNjQ3YmI5NWM5L3RhYmxlcmFuZ2U6MjlmYTNmNzAxODBmNDAwZmJhZTRlY2U2NDdiYjk1YzlfNC0zLTEtMS0xMTA5NTI_2dc15d8b-5be7-4d19-b548-cdd8d334bc06"
      unitRef="usd">502677000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjg3Nw_f73140c7-4a10-4589-981f-0ace132fda0c">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,085,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia307bf0c6b5b4e379b3b2fd963c7ec10_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMy0xLTEtMS0xMTA5NTI_13b89343-52fc-41af-9e34-8061c807df28"
      unitRef="usd">684917000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia307bf0c6b5b4e379b3b2fd963c7ec10_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMy0zLTEtMS0xMTA5NTI_eae3a747-996d-42c3-8413-7d6047358244"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia307bf0c6b5b4e379b3b2fd963c7ec10_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMy01LTEtMS0xMTA5NTI_ba75ce66-ce35-462d-b07e-b7ade5e88a9b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia307bf0c6b5b4e379b3b2fd963c7ec10_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMy03LTEtMS0xMTA5NTI_006881a2-9175-4402-9374-653d3910b398"
      unitRef="usd">684917000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNC0xLTEtMS0xMTA5NTI_d19ad82b-3002-4ce8-94ad-73771313e596"
      unitRef="usd">823100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNC0zLTEtMS0xMTA5NTI_0a29fb2f-9012-435a-be05-54728b4e3fce"
      unitRef="usd">2105000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNC01LTEtMS0xMTA5NTI_e2c555b8-4d10-405c-9432-76732997d805"
      unitRef="usd">10274000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNC03LTEtMS0xMTA5NTI_dfe12fb1-c571-4e08-9f39-33d14bc4e0ee"
      unitRef="usd">814931000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNS0xLTEtMS0xMTA5NTI_d50e5531-bf98-43ef-a796-99a3985bd0c0"
      unitRef="usd">367479000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNS0zLTEtMS0xMTA5NTI_6e3d5750-87f3-4f8a-bf43-e9f5fc073035"
      unitRef="usd">466000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNS01LTEtMS0xMTA5NTI_0f628791-7428-4137-b431-7d0286b9e61b"
      unitRef="usd">3859000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNS03LTEtMS0xMTA5NTI_657c88af-5736-4408-b405-fa3484d2ef31"
      unitRef="usd">364086000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNi0xLTEtMS0xMTA5NTI_3c7c5693-b465-4c25-9057-fb0d8a9cdf39"
      unitRef="usd">11480000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNi0zLTEtMS0xMTA5NTI_af107c8c-d4ac-4bad-9c38-da38cf7d9930"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNi01LTEtMS0xMTA5NTI_bc63af92-88a4-4d5e-81d9-c017c6a1be78"
      unitRef="usd">144000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNi03LTEtMS0xMTA5NTI_a642b7f3-0a59-4412-80fc-2780e81dc0f4"
      unitRef="usd">11336000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNy0xLTEtMS0xMTA5NTI_5177164d-1d53-4bf1-a1b3-35eecce5bdd6"
      unitRef="usd">1886976000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNy0zLTEtMS0xMTA5NTI_04892f4c-8d49-49db-aa2e-a9dcef418c31"
      unitRef="usd">2571000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNy01LTEtMS0xMTA5NTI_2f635f28-ea4f-4ba9-90e6-f9d7c4ba96e7"
      unitRef="usd">14277000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfNy03LTEtMS0xMTA5NTI_95fcec5e-2f07-4ab6-bf4d-3d5d13510edc"
      unitRef="usd">1875270000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="idd8e3d17820d48979b53c203807b119a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOC0xLTEtMS0xMTA5NTI_a99dce0c-3a1a-4c22-99da-98ba70af3a8c"
      unitRef="usd">64000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="idd8e3d17820d48979b53c203807b119a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOC0zLTEtMS0xMTA5NTI_5e08c6bf-128d-431e-9bde-f7ddb9fca5c4"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="idd8e3d17820d48979b53c203807b119a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOC01LTEtMS0xMTA5NTI_9e6940c4-62b7-42ae-ab9d-10f53f58762c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="idd8e3d17820d48979b53c203807b119a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOC03LTEtMS0xMTA5NTI_d1f4d5fc-4d09-4834-b642-1412ae8738ac"
      unitRef="usd">64000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i9a661a40ef35452e91e33372e447bb37_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOS0xLTEtMS0xMTA5NTI_c692ca31-031a-42ef-afff-e45efb4f2f10"
      unitRef="usd">165941000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i9a661a40ef35452e91e33372e447bb37_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOS0zLTEtMS0xMTA5NTI_040c405d-4b92-4ba3-99de-a9cb7f53072c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i9a661a40ef35452e91e33372e447bb37_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOS01LTEtMS0xMTA5NTI_40d8558a-d31b-44ba-aef5-efe1d128fba1"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i9a661a40ef35452e91e33372e447bb37_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfOS03LTEtMS0xMTA5NTI_9c1429b4-48e2-475d-ac8e-a19bf189f3e6"
      unitRef="usd">165941000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ia77b0e4b2fe042139d6e224f2fba485d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTAtMS0xLTEtMTEwOTUy_478128dc-46f0-4594-b30b-87d14e3ef35d"
      unitRef="usd">79955000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ia77b0e4b2fe042139d6e224f2fba485d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTAtMy0xLTEtMTEwOTUy_30e05793-65aa-41de-ad0c-8ae329c1814c"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ia77b0e4b2fe042139d6e224f2fba485d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTAtNS0xLTEtMTEwOTUy_ae6a3487-7ce2-47df-bfe5-c458e07fcfd0"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ia77b0e4b2fe042139d6e224f2fba485d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTAtNy0xLTEtMTEwOTUy_ad00e96d-377f-47be-ab84-9f93d099ed52"
      unitRef="usd">79955000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTEtMS0xLTEtMTEwOTUy_f85171b1-9ae7-43db-aaf0-048c4345c428"
      unitRef="usd">2132936000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTEtMy0xLTEtMTEwOTUy_5b12dd0a-ebf8-4de2-bd68-87d410c3adcd"
      unitRef="usd">2571000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTEtNS0xLTEtMTEwOTUy_e0272a0d-dede-4ee1-a420-dace19560fc0"
      unitRef="usd">14277000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjY1NjQwN2M2OWE1MTQ3MjJiZjRjYTMyNmY2M2I0Yjc0L3RhYmxlcmFuZ2U6NjU2NDA3YzY5YTUxNDcyMmJmNGNhMzI2ZjYzYjRiNzRfMTEtNy0xLTEtMTEwOTUy_df4e17bc-ae55-4b8a-9b75-1263b32697be"
      unitRef="usd">2121230000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9d0849b362ce4562bfa01261a0459178_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMy0xLTEtMS0xMTA5NTI_92e7ab33-1340-49ce-9838-d729bc05d3b0"
      unitRef="usd">722018000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9d0849b362ce4562bfa01261a0459178_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMy0zLTEtMS0xMTA5NTI_de8a4289-6998-4955-90a3-22a92d4def23"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9d0849b362ce4562bfa01261a0459178_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMy01LTEtMS0xMTA5NTI_93d8ad40-a619-4861-91f7-7a47e12a3427"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9d0849b362ce4562bfa01261a0459178_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMy03LTEtMS0xMTA5NTI_690c85f9-4b8e-49ce-94f9-49819eb2346c"
      unitRef="usd">722018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNC0xLTEtMS0xMTA5NTI_6301c4b9-a028-45d2-b4ea-b167650b5685"
      unitRef="usd">810439000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNC0zLTEtMS0xMTA5NTI_ce5fdc0b-0265-4c87-9b21-ed63681ffbf6"
      unitRef="usd">541000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNC01LTEtMS0xMTA5NTI_10d52ad8-8cb5-4772-9352-b61436ca77de"
      unitRef="usd">13132000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNC03LTEtMS0xMTA5NTI_164679e6-81bf-4f46-8794-853561ffc2f4"
      unitRef="usd">797848000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNS0xLTEtMS0xMTA5NTI_e166ff23-fa4d-448d-9e32-71065e848d36"
      unitRef="usd">338218000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNS0zLTEtMS0xMTA5NTI_aa3d6130-f6ef-440f-97bb-3bb62f85917d"
      unitRef="usd">48000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNS01LTEtMS0xMTA5NTI_8a88d572-9126-43c4-aac4-433b9617807b"
      unitRef="usd">5679000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNS03LTEtMS0xMTA5NTI_1311fe69-7349-4420-8dc5-2b90310c741f"
      unitRef="usd">332587000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaaf7287be2844027815aaad0c091426c_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNi0xLTEtMS0xMTA5NTI_919aa278-b581-4465-b034-dd5d9ddb7d3c"
      unitRef="usd">16385000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaaf7287be2844027815aaad0c091426c_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNi0zLTEtMS0xMTA5NTI_1a824968-5a91-4129-b3fd-936e67a95bd2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaaf7287be2844027815aaad0c091426c_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNi01LTEtMS0xMTA5NTI_c68e2d28-bfed-4977-9fd5-7b870ddffe02"
      unitRef="usd">223000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaaf7287be2844027815aaad0c091426c_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNi03LTEtMS0xMTA5NTI_5376fa13-6a9b-4a25-84fb-19f5cf808d8f"
      unitRef="usd">16162000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNy0xLTEtMS0xMTA5NTI_275d3ca3-e644-4294-a2fb-d2b3443b30f3"
      unitRef="usd">1887060000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNy0zLTEtMS0xMTA5NTI_48e5c619-4ff3-4237-829e-7f8ee374310c"
      unitRef="usd">589000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNy01LTEtMS0xMTA5NTI_3a5c6db3-8811-486d-99d3-965243c1e507"
      unitRef="usd">19034000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfNy03LTEtMS0xMTA5NTI_c55c9d7f-ecac-4ffa-b762-b0a0f6996624"
      unitRef="usd">1868615000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="iee3723a2aa5d463ba5688d589dda3b7d_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOC0xLTEtMS0xMTA5NTI_a162f9db-8954-4166-89ee-02c98bfd68be"
      unitRef="usd">41000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="iee3723a2aa5d463ba5688d589dda3b7d_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOC0zLTEtMS0xMTA5NTI_a69cca42-e1d2-4487-8873-633d4e79a6cc"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="iee3723a2aa5d463ba5688d589dda3b7d_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOC01LTEtMS0xMTA5NTI_4da1119a-ab73-4bde-9cdb-199e81114f88"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="iee3723a2aa5d463ba5688d589dda3b7d_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOC03LTEtMS0xMTA5NTI_8a4ace60-d8a2-4694-aff8-adafc576a2cb"
      unitRef="usd">41000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i5ed11edd9a934cdead36351f09d723ae_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOS0xLTEtMS0xMTA5NTI_e8695ecc-28ce-49ff-8847-0241f9d23159"
      unitRef="usd">94344000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i5ed11edd9a934cdead36351f09d723ae_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOS0zLTEtMS0xMTA5NTI_fab29d81-050d-44f0-824c-6e5423cc1ac9"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i5ed11edd9a934cdead36351f09d723ae_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOS01LTEtMS0xMTA5NTI_3314e16d-69c7-4730-b75e-8e5a729080f7"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i5ed11edd9a934cdead36351f09d723ae_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfOS03LTEtMS0xMTA5NTI_d918904f-5028-4204-b1c3-aeb906c42cfc"
      unitRef="usd">94344000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i5a53bc620960402191b67550fd79e525_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTAtMS0xLTEtMTEwOTUy_c33c3cad-db3f-4fd0-bc74-50ecd565a613"
      unitRef="usd">103681000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i5a53bc620960402191b67550fd79e525_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTAtMy0xLTEtMTEwOTUy_2c6d3973-d96a-47f2-aa08-668109d50e9a"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i5a53bc620960402191b67550fd79e525_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTAtNS0xLTEtMTEwOTUy_9f40fd8f-5465-4572-a350-b4182d32a833"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i5a53bc620960402191b67550fd79e525_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTAtNy0xLTEtMTEwOTUy_bedaf7fb-e431-4199-9063-59137e9d94a5"
      unitRef="usd">103681000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTEtMS0xLTEtMTEwOTUy_50c85dd2-6bb8-4f2e-b263-c73af57c2460"
      unitRef="usd">2085126000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTEtMy0xLTEtMTEwOTUy_b1b79094-2da0-46ea-a3e9-ddbb4636c027"
      unitRef="usd">589000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTEtNS0xLTEtMTEwOTUy_cfb7e409-f1a9-431c-af71-484dbfec6ed1"
      unitRef="usd">19034000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjFlMGQ5OTgyYzYyMDRhNWFhMDkxMjdhMDhkYTQzNDUzL3RhYmxlcmFuZ2U6MWUwZDk5ODJjNjIwNGE1YWEwOTEyN2EwOGRhNDM0NTNfMTEtNy0xLTEtMTEwOTUy_07d5ab16-7557-4b93-a964-ebca09a6c012"
      unitRef="usd">2066681000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMTIyOQ_759c236a-730c-4beb-9b7e-cba7de516be4"
      unitRef="usd">10100000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMTIzNg_549ad1e9-f932-4033-a24e-a21081e21b6c"
      unitRef="usd">7300000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjkwMg_cf05a11c-fe8a-4ed7-82cf-b2bac96bb200">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,274)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,030,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfMi05LTEtMS0xMTA5NTI_3d11324c-0286-4db5-bae3-e68b52d9919c"
      unitRef="usd">551038000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfMi0xMS0xLTEtMTEwOTUy_80adcafa-a273-4561-98f6-96e8c876352a"
      unitRef="usd">10274000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfNC05LTEtMS0xMTA5NTI_dcfea0ab-c670-423b-a98b-08d71f0660a9"
      unitRef="usd">283051000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iba81ba4971aa4d8fbb90a1de6a5f8752_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfNC0xMS0xLTEtMTEwOTUy_32e0bdfa-aac7-4ab8-8731-50d8275eef3d"
      unitRef="usd">3859000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfNi05LTEtMS0xMTA5NTI_32fe4344-f3ec-4d31-99b1-4188e02883b0"
      unitRef="usd">11336000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i94d9cbf940494410ba3c5f1c0ad88c1c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfNi0xMS0xLTEtMTEwOTUy_0bc3c637-384e-4672-af2a-90d4836f942e"
      unitRef="usd">144000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfOC05LTEtMS0xMTA5NTI_125506b0-1169-49ec-9c5a-4e8824920998"
      unitRef="usd">845425000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjVmYTBmYjFlMzA4OTQyYjU4NmUwMjg4NjNjZDNmYTNjL3RhYmxlcmFuZ2U6NWZhMGZiMWUzMDg5NDJiNTg2ZTAyODg2M2NkM2ZhM2NfOC0xMS0xLTEtMTEwOTUy_1fe0d65d-9594-45a4-96bd-108cdb85d782"
      unitRef="usd">14277000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfMi05LTEtMS0xMTA5NTI_d02848d2-96ad-4fe2-bfec-5337ac8b468b"
      unitRef="usd">706711000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfMi0xMS0xLTEtMTEwOTUy_74f7f3bf-3c01-4dd3-b911-ac6ec20dfc79"
      unitRef="usd">13132000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNC05LTEtMS0xMTA5NTI_9ac20843-cc92-4200-b8dc-7ea68586aeb5"
      unitRef="usd">308307000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i7f3adc8ded9a48ab927951f9b5956ed1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNC0xMS0xLTEtMTEwOTUy_b476ef97-74bb-46a8-9166-1de5a2dd7cb4"
      unitRef="usd">5679000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="iaaf7287be2844027815aaad0c091426c_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNS05LTEtMS0xMTA5NTI_cfddb7ea-de84-4442-b291-f62bfca90f54"
      unitRef="usd">15792000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="iaaf7287be2844027815aaad0c091426c_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNS0xMS0xLTEtMTEwOTUy_432bfd6a-0f17-49a0-8603-1f403dac1429"
      unitRef="usd">223000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNi05LTEtMS0xMTA5NTI_4449ef30-ed1e-47bb-a461-4c4b7b05248a"
      unitRef="usd">1030810000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjYyZWZjM2JkMDRhNzQzMmI5YmY3ZDA1OTYwODg0YmM1L3RhYmxlcmFuZ2U6NjJlZmMzYmQwNGE3NDMyYjliZjdkMDU5NjA4ODRiYzVfNi0xMS0xLTEtMTEwOTUy_f48750a0-ac02-4e65-bacf-d556fd4f65ce"
      unitRef="usd">19034000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMTY0OTI2NzQ0ODQ2Ng_b17b5643-f4b3-4375-85a0-4ca6b499fcd8"
      unitRef="investment">237</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNzI5OQ_71f1c6be-f473-46d6-91ff-0b8bc8039d85"
      unitRef="investment">285</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <exel:NumberOfBondSecurities
      contextRef="i5231ebc5b9954e8e86f1f3347d082aea_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMzI5ODUzNDg5MDkwNw_73ace392-7f8b-4bda-9941-51312a7f5231"
      unitRef="bond">91</exel:NumberOfBondSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNTQ5NzU1ODE5NTk3_70bc4bde-ee0c-434c-a1de-4d34dd988d88"
      unitRef="usd">317100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNTQ5NzU1ODE5NjA0_a9e4fc55-b46d-462b-93be-7038b85a4f9e"
      unitRef="usd">6300000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <exel:NumberOfBondSecurities
      contextRef="i0cdebc21ace046518b4cec11c922421e_I20221230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNTQ5NzU1ODIwNTMy_dce7e626-9818-426d-983b-a1bacd529a56"
      unitRef="bond">81</exel:NumberOfBondSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNTQ5NzU1ODIwNjMx_eaaa77dc-14b6-4d64-a0eb-bd96b938fef7"
      unitRef="usd">237600000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfNTQ5NzU1ODIwNjQ5_3309cb66-a25a-4674-8112-72de729dc466"
      unitRef="usd">6100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjI0Nw_d68ab2c7-36d7-47bb-a7bf-8d2a8ef7ab1b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RleHRyZWdpb246ODA4OWM2YzAxOTkwNGY5YTkyNTJhMDRmODNhZmY2MGRfMjg5NQ_b9e03ae8-4348-48a9-8579-43fa167ea500">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMS0xLTEtMS0xMTA5NTI_1f62d054-eb21-46dc-a71d-ab3ee2cfc527"
      unitRef="usd">1071653000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMS0zLTEtMS0xMTA5NTI_38c36d37-cc4d-4409-a89f-5e5b0a3e5652"
      unitRef="usd">1114884000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMi0xLTEtMS0xMTA5NTI_efd520f1-0922-48f7-95b0-cbf7772f91ad"
      unitRef="usd">803617000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMi0zLTEtMS0xMTA5NTI_9208941e-230d-42c0-90ce-749ae2e77813"
      unitRef="usd">753731000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMy0xLTEtMS0xMTA5NTI_07a49bf6-ae9f-4ad4-9f2e-9539cbd9de95"
      unitRef="usd">1875270000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80My9mcmFnOjgwODljNmMwMTk5MDRmOWE5MjUyYTA0ZjgzYWZmNjBkL3RhYmxlOjEwMTk2NmY1MWE1YTQ0ZDBhYWM3ZWUzNWVmYTIzMTA1L3RhYmxlcmFuZ2U6MTAxOTY2ZjUxYTVhNDRkMGFhYzdlZTM1ZWZhMjMxMDVfMy0zLTEtMS0xMTA5NTI_4ab03518-2c7d-4208-b22f-367de329daa2"
      unitRef="usd">1868615000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RleHRyZWdpb246Y2I5OTc1MDVhMDU5NGUxMmEwNjNmZmU5ZjhjYjUzZGNfMjQ1Nw_a225782d-828a-4354-b699-ac9034aace65">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,955,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Forward Foreign Currency Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchange rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we had one forward contract outstanding to sell &#x20ac;4.1&#160;million. The forward contract with a maturity of three months is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized loss on the forward contract is immaterial as of March&#160;31, 2023. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. The realized loss and gain we recognized on the maturity of our forward contract was immaterial for each of the three months ended March&#160;31, 2023 and 2022, respectively, and are included in other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RleHRyZWdpb246Y2I5OTc1MDVhMDU5NGUxMmEwNjNmZmU5ZjhjYjUzZGNfMjQ1MA_d3e67dac-65d5-4966-8269-b5888748d1e8">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,875,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,955,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,121,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id2bb0b5859e94e8a936be047b130cf62_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMi0xLTEtMS0xMTA5NTI_a6245f96-0fd4-4f18-a205-d11591c2c621"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7332d7a5938d414dabe83a5e6080938c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMi0zLTEtMS0xMTA5NTI_619332eb-51a2-4473-81e9-f383a6a8c2be"
      unitRef="usd">684917000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i289d8780126e4649aa6123219a3a320f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMi01LTEtMS0xMTA5NTI_41c3efa8-d7c2-4d59-94c1-433b7c1d0e3c"
      unitRef="usd">684917000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b9c63d0e80744719b3825cef5d5d14b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMy0xLTEtMS0xMTA5NTI_f2ed08dc-07c1-4222-b1dd-d8503aef9ebb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if7a7c1a85b9741668be6b1244cb03182_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMy0zLTEtMS0xMTA5NTI_d665c7c5-26e2-4685-99c6-4598e8791b5e"
      unitRef="usd">814931000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ff6643a21e3422a80cdf082d9960ef4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfMy01LTEtMS0xMTA5NTI_cade9844-32cb-4a61-81fc-d47a00a4793b"
      unitRef="usd">814931000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1fc468b967af4e86a80786a9c3aa6c5c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNC0xLTEtMS0xMTA5NTI_78b0d77c-9bff-4367-b0cc-4d3dbbc08d84"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06d5bb9bf05744909898ab9b06c87bd6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNC0zLTEtMS0xMTA5NTI_6efe591b-8332-4d74-ab1b-df24d37bebfc"
      unitRef="usd">364086000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i036daf539dfc49c8b73722fa3dae40a1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNC01LTEtMS0xMTA5NTI_580d535b-f0d4-44ab-ad2b-5a631c693df3"
      unitRef="usd">364086000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if87f0d005430404db06bb3f461851a1f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNS0xLTEtMS0xMTA5NTI_a0e0b407-fd74-47f9-94db-61ab57a586f9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3329a69fdc8a47cba0eb64acea2395f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNS0zLTEtMS0xMTA5NTI_905c3875-9168-46b8-8395-42a1a0cfec3d"
      unitRef="usd">11336000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie516d60b14c7478095d3f58b37428a68_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNS01LTEtMS0xMTA5NTI_fb76ffe2-ec4f-404d-ae76-5b4e7bd6c752"
      unitRef="usd">11336000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31039ff71e764360b58c4edb8693ba2f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNi0xLTEtMS0xMTA5NTI_8d3746c7-33b3-4399-be7a-de56f8f2583d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62ae4221be8d44a8a7c7a3c9e9f180ec_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNi0zLTEtMS0xMTA5NTI_88204163-eca7-4d30-b0cb-aac6e955a5f3"
      unitRef="usd">1875270000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide3e32d66598443986f9b93c38b9a643_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNi01LTEtMS0xMTA5NTI_ddf03602-844a-4abf-9fcf-4bb2ff613245"
      unitRef="usd">1875270000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie4fae3311f344cb085dfbc49e046ce18_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNy0xLTEtMS0xMTA5NTI_11903239-53c7-44b9-a945-7f2ff7dd770f"
      unitRef="usd">165941000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7acd21d036a3477aac89ae6ccd15d11b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNy0zLTEtMS0xMTA5NTI_a6d51ca1-5e28-43ac-979a-d87abc2fd6bc"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i66f34ea6b40143b8b73529584d025afc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfNy01LTEtMS0xMTA5NTI_b0a4b949-bfb7-46c3-8906-58e25bff386d"
      unitRef="usd">165941000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0b40425343ab4840a5a2065cac546d59_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOC0xLTEtMS0xMTA5NTI_5a085826-efbc-4906-8cae-021a070541c4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i41e491600bbd4af79605cfbcf83d1913_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOC0zLTEtMS0xMTA5NTI_85f11a2f-7564-44da-9e88-ebbe5d7f0b82"
      unitRef="usd">79955000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i69089dbb95ad41858db9a2acea999f10_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOC01LTEtMS0xMTA5NTI_b19bcf8f-129d-40e7-b1ff-05a3d2e13e74"
      unitRef="usd">79955000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i31039ff71e764360b58c4edb8693ba2f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOS0xLTEtMS0xMTA5NTI_26ebbe97-00e7-4ab1-a7cf-f659a4ec6a4b"
      unitRef="usd">165941000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i62ae4221be8d44a8a7c7a3c9e9f180ec_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOS0zLTEtMS0xMTA5NTI_eb35c52e-09b3-4219-a3b4-c96f85bda2c7"
      unitRef="usd">1955225000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ide3e32d66598443986f9b93c38b9a643_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjAwODE3OTE5OTZkMjQwZTlhMTkxMzIzNjY3ZWVlNzg3L3RhYmxlcmFuZ2U6MDA4MTc5MTk5NmQyNDBlOWExOTEzMjM2NjdlZWU3ODdfOS01LTEtMS0xMTA5NTI_fe13e463-870e-4118-8ba9-e270c454868c"
      unitRef="usd">2121166000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4ed964b6ac9e45588d0755f26b3a0530_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMi0xLTEtMS0xMTA5NTI_258448b5-8687-45c7-a306-682bb51de541"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i957abfeaf90a4f888c7d6eb2f35c48b5_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMi0zLTEtMS0xMTA5NTI_434a0505-e4d3-4783-8a4c-98869d912ee2"
      unitRef="usd">722018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie92282b3812a4c52a5eb1714922f4607_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMi01LTEtMS0xMTA5NTI_5fee1961-ce26-4c52-b07f-491797eac8d6"
      unitRef="usd">722018000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3b5995c0541b401eb07d6d421025aa64_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMy0xLTEtMS0xMTA5NTI_9377043e-72f0-43ee-ad32-0e3e32acf4bc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i65cbedaff73f4c8baa47313cf71881be_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMy0zLTEtMS0xMTA5NTI_d2a96d31-643d-4d52-b0dd-772f5c21a5dd"
      unitRef="usd">797848000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd3936dfce8e401ba8d8f7c22abbb987_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfMy01LTEtMS0xMTA5NTI_ad090a5f-4736-4fe5-9702-e17d9900f406"
      unitRef="usd">797848000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2074852d3fc4146a552e1020fed749a_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNC0xLTEtMS0xMTA5NTI_ed12ec25-52a6-49aa-8e48-f654e2d00ed2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9899d00466704758b0d0844ee5256ef0_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNC0zLTEtMS0xMTA5NTI_0e298185-f391-4036-a199-0447569110ee"
      unitRef="usd">332587000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i456848174e4b411d97e0d18790a81449_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNC01LTEtMS0xMTA5NTI_80fc2b42-977f-4b13-8679-2b3df15de655"
      unitRef="usd">332587000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49a9b1c8da4d4daf938376135d589190_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNS0xLTEtMS0xMTA5NTI_b1f21361-ccbb-4bc7-8be7-cd3e378a671e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idc80802ed0064fbe90e139d4e9f11c0d_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNS0zLTEtMS0xMTA5NTI_c41ae773-9152-43a2-b7f8-600bee184c37"
      unitRef="usd">16162000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i711f7b4d4689414894669fee3ce78b88_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNS01LTEtMS0xMTA5NTI_c3d60002-dea2-43da-8935-2bc9cbfdfc5a"
      unitRef="usd">16162000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b1713646d824564b9adee7955a921c9_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNi0xLTEtMS0xMTA5NTI_4c70d077-6688-429e-aecf-ae4611e03ea3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a589a297c4b471ba55f3c7b0af708c3_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNi0zLTEtMS0xMTA5NTI_2b2b9717-025e-4ada-b1bd-05e3a44bda2c"
      unitRef="usd">1868615000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1532e94710824cf39b3266528be43ba1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNi01LTEtMS0xMTA5NTI_c90c0893-c0eb-4e19-af44-4111dba6728f"
      unitRef="usd">1868615000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib6a61c4734ba4ebcb0ef504886ba6de1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNy0xLTEtMS0xMTA5NTI_7cb85957-86ae-4bfe-acc1-791455a85763"
      unitRef="usd">94344000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1eed0c8fb3e145b8afc025317b02b47c_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNy0zLTEtMS0xMTA5NTI_c5028a46-5866-403c-8601-a25b9b3db2a6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id6fb00cb8a194a00aac07f85c0714ec1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfNy01LTEtMS0xMTA5NTI_63e8a7df-137b-4ddd-8c2b-84ca34e44b69"
      unitRef="usd">94344000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7b9c7f8a02e440d198176572c5aa2a9b_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOC0xLTEtMS0xMTA5NTI_25d7ba92-d833-4465-ade8-5a05ff39f860"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icf6dfcf5d186443cb89d5d13bbf74fcc_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOC0zLTEtMS0xMTA5NTI_8b821ab2-af39-4271-99a8-1535c90438fe"
      unitRef="usd">103681000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1777597937c24d058481cbd71160126e_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOC01LTEtMS0xMTA5NTI_43446709-529a-49e3-a667-0933ccdb4a77"
      unitRef="usd">103681000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6b1713646d824564b9adee7955a921c9_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOS0xLTEtMS0xMTA5NTI_8d891966-970d-4c82-923d-52e212677574"
      unitRef="usd">94344000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4a589a297c4b471ba55f3c7b0af708c3_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOS0zLTEtMS0xMTA5NTI_8f7a0c4c-b866-404a-bec9-d5faadee45fe"
      unitRef="usd">1972296000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1532e94710824cf39b3266528be43ba1_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RhYmxlOjVkMDM4NjVlZjA1MjQ3Yzk4ZjhkYTFmYjk1ZDk1OTVmL3RhYmxlcmFuZ2U6NWQwMzg2NWVmMDUyNDdjOThmOGRhMWZiOTVkOTU5NWZfOS01LTEtMS0xMTA5NTI_6e96ff49-72b9-4bae-9714-368ac528666d"
      unitRef="usd">2066640000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="id59bda9dff304a61a0e935254d1873e1_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RleHRyZWdpb246Y2I5OTc1MDVhMDU5NGUxMmEwNjNmZmU5ZjhjYjUzZGNfMTgxNw_ac3eee5b-3abd-4bf8-b179-3fd2496365d7"
      unitRef="derivative_instrument">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id59bda9dff304a61a0e935254d1873e1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RleHRyZWdpb246Y2I5OTc1MDVhMDU5NGUxMmEwNjNmZmU5ZjhjYjUzZGNfNzE0NjgyNTU4MzE5NQ_7188ff15-058b-4ca6-baff-449ce145b3e4"
      unitRef="eur">4100000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="i6f2a0a5e0af9493ca0f227fed931a4ed_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80Ni9mcmFnOmNiOTk3NTA1YTA1OTRlMTJhMDYzZmZlOWY4Y2I1M2RjL3RleHRyZWdpb246Y2I5OTc1MDVhMDU5NGUxMmEwNjNmZmU5ZjhjYjUzZGNfMTkwMQ_d3acd4cd-bfca-4aa3-9e6f-6bb82302e280">P3M</us-gaap:DerivativeTermOfContract>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RleHRyZWdpb246NDQ3N2FlZDU0NTRmNGZiYWFhMmJjYWI3NmQ0YWM5ZjJfODk_c6280ea9-97a1-4d9b-955b-20a5baf15a4e">INVENTORY&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RleHRyZWdpb246NDQ3N2FlZDU0NTRmNGZiYWFhMmJjYWI3NmQ0YWM5ZjJfODc_20b96b6c-9433-463e-bb0a-588f5e0e7a0a">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMS0xLTEtMS0xMTA5NTI_27b3a34f-5a11-4ecf-b53e-5a78f325c793"
      unitRef="usd">8777000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMS0zLTEtMS0xMTA5NTI_540a9412-6834-4eea-a217-272274291280"
      unitRef="usd">8077000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMi0xLTEtMS0xMTA5NTI_78b85983-686b-43ae-b151-9bbe6ed4e94c"
      unitRef="usd">53610000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMi0zLTEtMS0xMTA5NTI_0eb15f99-c7d2-42ba-a0a6-e2c067d36a4d"
      unitRef="usd">43564000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMy0xLTEtMS0xMTA5NTI_f0df5279-fac7-4f52-b910-0567bd25ed7c"
      unitRef="usd">8490000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfMy0zLTEtMS0xMTA5NTI_b63143ea-a169-4fc3-a6d7-4f3e92f021c5"
      unitRef="usd">10635000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfNC0xLTEtMS0xMTA5NTI_d4c1deef-b593-4f96-9f8f-309c31448811"
      unitRef="usd">70877000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfNC0zLTEtMS0xMTA5NTI_c7254f71-d419-49f3-9440-e2dd28b3b680"
      unitRef="usd">62276000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i64066d08939c412ea45c0e2ce3a1376f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfNy0xLTEtMS0xMTA5NTI_57ab1d18-3dfb-4e26-8382-90b05a25f589"
      unitRef="usd">29908000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i7e165e45ccd64b35b0258752fdd33d0a_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfNy0zLTEtMS0xMTA5NTI_424a2fe2-3829-4809-a60c-5629cf9dcb48"
      unitRef="usd">33299000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i048b471b1b074d82bde14df2ea6b910d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfOC0xLTEtMS0xMTA5NTI_ea6f2a5f-647b-4686-a093-a776ffa4a9ee"
      unitRef="usd">40969000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="icc2748b521d641c1bb32f1e95b036970_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfOC0zLTEtMS0xMTA5NTI_51e5b164-5810-48ee-a78f-54bdaa06caef"
      unitRef="usd">28977000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="icc2748b521d641c1bb32f1e95b036970_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfOC0zLTEtMS0xMTA5NTI_6aaf5c70-2721-4a95-b858-34ea44226861"
      unitRef="usd">28977000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfOS0xLTEtMS0xMTA5NTI_25c5c26a-04a4-4e78-8bd3-8e4924967892"
      unitRef="usd">70877000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i47c0db749b524417a3bfe38e87216ea8_I20221230"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV80OS9mcmFnOjQ0NzdhZWQ1NDU0ZjRmYmFhYTJiY2FiNzZkNGFjOWYyL3RhYmxlOjY1NGU3NGE5N2ZmOTQ4OGQ5MDQ4ZmYwYjAzZWQ3MTljL3RhYmxlcmFuZ2U6NjU0ZTc0YTk3ZmY5NDg4ZDkwNDhmZjBiMDNlZDcxOWNfOS0zLTEtMS0xMTA5NTI_83b3e473-ebe6-4357-83a7-ff4b7062c069"
      unitRef="usd">62276000</us-gaap:InventoryGross>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfMzgxOQ_0db38291-2e73-4c40-867e-289adc6e0fab">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several equity incentive plans under which we granted stock options and restricted stock units (RSUs), including performance-based restricted stock units (PSUs), to employees and directors. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023, 31,678,788 sh&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 2 shares for full value awards, including RSUs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were 9,738,700 stock options outstanding and $14.0&#160;million of related unrecognized compensation expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, we granted 576,960 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $17.08 per share. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were 11,315,085 RSUs outstanding, including RSUs that are subject to a total shareholder return (TSR) market condition (the TSR-based RSUs), and $172.0&#160;million of related unrecognized compensation expense. Service-based RSUs granted to employees during the three months ended March 31, 2023 have vesting conditions and contractual lives of a similar nature to those described in &#x201c;Note 8. Employee Benefit Plans&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;March&#160;31, 2023, there were 4,688,349 PSUs outstanding, of which 1,277,755 PSUs relate to awards that we either achieved the performance goal or determined that attainment of the performance goal was probable. Expense recognition for PSUs commences when it is determined that attainment of the performance goal is probable. As of&#160;March&#160;31, 2023, the remaining unrecognized stock-based compensation expense for the PSUs either achieved or deemed probable of achievement was $9.0&#160;million. The total unrecognized compensation expense for the PSUs for which we have not yet determined that attainment of the performance goal is probable was $76.2&#160;million. For more information about our PSUs, see &#x201c;Note 8. Employee Benefit Plans&#x201d; of the &#x201c;Notes to Consolidated Financial Statements&#x201d; included in Part II, Item 8 of our Fiscal 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, our Board of Directors authorized a share repurchase program to acquire up to $550&#160;million of our outstanding common stock before the end of 2023. The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of our common stock and general market conditions. Share repurchases under the program may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, 10b5-1 trading plans, exchange transactions, or any combination of such methods. The program does not obligate us to acquire any particular amount of our common stock, and the share repurchase program may be modified, suspended or discontinued at any time without prior notice. During the three months ended March 31, 2023, we did not repurchase any shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i2f1f77b69c154581ba20fe6d66b88637_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNTQ5NzU1ODMzODk1_07ead383-8e6a-4670-99b8-43f1b9d56821"
      unitRef="shares">31678788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNTQ5NzU1ODMzOTAy_acb32676-9977-4970-b1cf-9451314b180d"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNTQ5NzU1ODMzOTA3_0f42168d-65e6-45be-8d26-383fd37c5c3c"
      unitRef="shares">2</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfMzgzNQ_b9ca5b8f-228b-4693-b250-e524614ba7f4">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib798adcf0e30410e9cf0c303568c4dd8_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfMy0xLTEtMS0xMTA5NTI_946c6341-324d-4d62-8b83-be58e9046c36"
      unitRef="usd">3252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i077b175796d8467ebd7f57f08b70e854_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfMy0zLTEtMS0xMTA5NTI_34829000-dc2c-4ca1-b641-9918ec768577"
      unitRef="usd">8899000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie1a8b33f363d4bc0ac9b67d04c777bda_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfNC0xLTEtMS0xMTA5NTI_1b3793c6-63b1-452b-8b8b-13d9de0a1d03"
      unitRef="usd">13409000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i453291ae47804d32a67ac7c2f2eefef5_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfNC0zLTEtMS0xMTA5NTI_e0fe74fd-e33c-4b8f-952d-f393e0777275"
      unitRef="usd">10860000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfNS0xLTEtMS0xMTA5NTI_87326b8f-21a4-4c07-854c-90df6f7af3c4"
      unitRef="usd">16661000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjc3N2VmZTRjNDU2MTQ1ODU5ZDEzNTlkNWFmMGE4MjQ3L3RhYmxlcmFuZ2U6Nzc3ZWZlNGM0NTYxNDU4NTlkMTM1OWQ1YWYwYTgyNDdfNS0zLTEtMS0xMTA5NTI_d487923b-2647-4841-b1a4-42de055c7e41"
      unitRef="usd">19759000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5fd484e891fd418a8ed42f45f84ec5bb_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfMi0xLTEtMS0xMTA5NTI_a2cb8e3d-7a65-431e-a830-0badf94662f8"
      unitRef="usd">2207000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia944468359d74f13b7a8031ab2b2ec81_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfMi0zLTEtMS0xMTA5NTI_e4021e23-a5ea-4dee-bd46-b046076302eb"
      unitRef="usd">3678000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8a18b8eece6d4b23bde7637cca5faffd_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfMy0xLTEtMS0xMTA5NTI_3c832f02-35c4-48c5-a48a-5e3a9da3775a"
      unitRef="usd">12607000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5664ad32e75748ecabb161d218d96696_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfMy0zLTEtMS0xMTA5NTI_14a543a5-1a1e-43de-b4e6-d84b9dce35ad"
      unitRef="usd">13073000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6b8feeeff3a844ed994dd23909d3c10b_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNC0xLTEtMS0xMTA5NTI_39156876-33b7-4f22-ba07-048066757b5b"
      unitRef="usd">794000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iedfbdcf573f646959d5ef701c8bc3a1f_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNC0zLTEtMS0xMTA5NTI_20f3ea86-232f-4cd7-9bc0-34c791986537"
      unitRef="usd">1709000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2ed501ae6df49f8accd5863263afcf6_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNS0xLTEtMS0xMTA5NTI_c06e9ed8-4d4e-4d07-9965-468f2cca5421"
      unitRef="usd">1053000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8f6f3af4e1e4419cb5a9e743245418f9_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNS0zLTEtMS0xMTA5NTI_5e221734-719d-4454-853e-4afdf0a41d74"
      unitRef="usd">1299000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNi0xLTEtMS0xMTA5NTI_fdfc4afe-1791-445c-97dd-280280388b80"
      unitRef="usd">16661000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RhYmxlOjA2ZGFiODBkMjk3YzQ5MTliMmUwOTQ2MTI0NDJmNzM4L3RhYmxlcmFuZ2U6MDZkYWI4MGQyOTdjNDkxOWIyZTA5NDYxMjQ0MmY3MzhfNi0zLTEtMS0xMTA5NTI_fbab00de-0b20-47bc-8b9b-9f3010da8059"
      unitRef="usd">19759000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNzE0NjgyNTU5NTIwOQ_09742957-87a4-4eda-a568-f04f0274929f"
      unitRef="shares">9738700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNzE0NjgyNTU5NTIxMw_8d03fe66-148d-471f-b09b-69979b599beb"
      unitRef="usd">14000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8a18b8eece6d4b23bde7637cca5faffd_D20221231-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNjA0NzMxMzk2MzI2OQ_1c8bf62d-447c-45f8-8b85-5e37942ad2b0"
      unitRef="shares">576960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8a18b8eece6d4b23bde7637cca5faffd_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNjA0NzMxMzk2MzI3MA_f7391932-4cff-412b-a1b7-fba89f874b78"
      unitRef="usdPerShare">17.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib0a8da2045b84694bcd4b8144997fa91_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNjA0NzMxMzk2MzI3MQ_075423a7-35c1-4662-b128-5a816596e26f"
      unitRef="shares">11315085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ib0a8da2045b84694bcd4b8144997fa91_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNjA0NzMxMzk2MzI3Mg_a4b3b7fc-cd54-4eb0-87f1-3306a05038ae"
      unitRef="usd">172000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0e6bbea2638d44e18d8bead2fc43515b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNzE0NjgyNTU5NTI1NQ_f8fa61e6-f21a-455d-940e-0badbcd4fb95"
      unitRef="shares">4688349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6b919b2777644b8ebe2bfda500054c0f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNzE0NjgyNTU5NTI0OA_c9c6b222-d041-43e9-832e-db520a4afb54"
      unitRef="shares">1277755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i0e6bbea2638d44e18d8bead2fc43515b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNjA0NzMxMzk2MzI3NQ_de935d31-80d5-4897-b764-5e8c95cebd86"
      unitRef="usd">9000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i6b919b2777644b8ebe2bfda500054c0f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNTQ5NzU1ODM0NjAx_c97106e8-3f41-440c-a766-7a482a067154"
      unitRef="usd">76200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i0a3d041b493744caa9156b79d698c6f6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81Mi9mcmFnOjRjNmI2MGVhN2YyZTQ5ZGU5OTRmMjMxYWVjMjY4OGZiL3RleHRyZWdpb246NGM2YjYwZWE3ZjJlNDlkZTk5NGYyMzFhZWMyNjg4ZmJfNTQ5NzU1ODI4NTEy_3091e775-ca8e-4fa6-b249-3d0f53a6f58a"
      unitRef="usd">550000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81NS9mcmFnOjllYWViOTU5MGJiMjQ1NjM5MWQ3OWIyMTExMzYzN2QxL3RleHRyZWdpb246OWVhZWI5NTkwYmIyNDU2MzkxZDc5YjIxMTEzNjM3ZDFfNzgw_840b9a60-de3e-4c04-aa39-b5422479655d">PROVISION FOR INCOME TAXESThe effective tax rate for the three months ended March&#160;31, 2023, was 17.1%, as compared to 19.5% for the corresponding period in 2022. The effective tax rate for each of the three months ended March&#160;31, 2023 and 2022, differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, partially offset by state taxes.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81NS9mcmFnOjllYWViOTU5MGJiMjQ1NjM5MWQ3OWIyMTExMzYzN2QxL3RleHRyZWdpb246OWVhZWI5NTkwYmIyNDU2MzkxZDc5YjIxMTEzNjM3ZDFfNzE0NjgyNTU4MTcxMw_f7097034-5d84-4e8c-a232-b93f1f3abe61"
      unitRef="number">0.171</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81NS9mcmFnOjllYWViOTU5MGJiMjQ1NjM5MWQ3OWIyMTExMzYzN2QxL3RleHRyZWdpb246OWVhZWI5NTkwYmIyNDU2MzkxZDc5YjIxMTEzNjM3ZDFfMTY0OTI2NzQ0MjgwOA_fca6bff0-b1fb-4bae-af6a-e50aa2bda01c"
      unitRef="number">0.195</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RleHRyZWdpb246YzY1M2UzOTM2NjkxNGVkNDk4MzcwMmFhM2E5N2E0MDZfNzQ0_1d7ec239-4f17-4d9d-9857-15a0a24f9f8c">NET INCOME PER SHARE&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities included outstanding stock options, unvested RSUs (including TSR-based RSUs), PSUs and ESPP contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RleHRyZWdpb246YzY1M2UzOTM2NjkxNGVkNDk4MzcwMmFhM2E5N2E0MDZfNzQ3_c718c09d-918c-45e9-8e89-26bf16ab8a8e">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfMy0xLTEtMS0xMTA5NTI_99b3b0e7-afd3-4112-a3b2-aa7f959e400a"
      unitRef="usd">40028000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfMy0zLTEtMS0xMTA5NTI_4cad5fab-d9c2-4e2c-9cec-2497e6050fa9"
      unitRef="usd">68573000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNS0xLTEtMS0xMTA5NTI_48fb676b-7a4f-401b-8c0d-85faf9bfcf0d"
      unitRef="shares">324420000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNS0zLTEtMS0xMTA5NTI_a97725bc-811c-44e8-a213-6ee3b05d19e5"
      unitRef="shares">319582000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNi0xLTEtMS0xMTA5NTI_521204c9-d39c-4236-9f5c-172b5ffc7dc3"
      unitRef="shares">1859000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNi0zLTEtMS0xMTA5NTI_a6a103de-3fd9-47ac-b91c-e560dcf19f3d"
      unitRef="shares">3707000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNy0xLTEtMS0xMTA5NTI_25e10703-be63-48e8-9747-d6521bbbf8ba"
      unitRef="shares">326279000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfNy0zLTEtMS0xMTA5NTI_3c043758-ece8-421b-a015-cf6de91c6ccd"
      unitRef="shares">323289000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfOS0xLTEtMS0xMTA5NTI_75591a3f-3c0a-41d3-a384-a14c9cb5e104"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfOS0zLTEtMS0xMTA5NTI_fdc7a084-1e40-47c0-ac40-a724bfdbfd2a"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfMTAtMS0xLTEtMTEwOTUy_f2a0bb0e-ff77-4fe4-b6e6-772868b144d5"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ice1209c2131a48b9a09dbfa3aa88291c_D20220101-20220401"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmZmMTgxYWVlZjZlNDRhNGFiNzVhMDI4MTAxYjQxMDg3L3RhYmxlcmFuZ2U6ZmYxODFhZWVmNmU0NGE0YWI3NWEwMjgxMDFiNDEwODdfMTAtMy0xLTEtMTEwOTUy_25f515d5-f419-42ac-a1bd-f01404951aeb"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RleHRyZWdpb246YzY1M2UzOTM2NjkxNGVkNDk4MzcwMmFhM2E5N2E0MDZfNzU3_9132bdc3-2342-429d-94fa-ecb5654f7c51">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i08af1f4087d548b2a2c27bd855c5a14f_D20221231-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmIxNTBlMmQ3NjE2YzQzMjFhNTc3NGVlODExZGE4MWM0L3RhYmxlcmFuZ2U6YjE1MGUyZDc2MTZjNDMyMWE1Nzc0ZWU4MTFkYTgxYzRfMi0xLTEtMS0xMTA5NTI_d479d3c8-2afa-45c4-80a4-00dbdf08a73c"
      unitRef="shares">15592000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7027abb1b44144f58c42fe80ea5b4fe8_D20220101-20220401"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV81OC9mcmFnOmM2NTNlMzkzNjY5MTRlZDQ5ODM3MDJhYTNhOTdhNDA2L3RhYmxlOmIxNTBlMmQ3NjE2YzQzMjFhNTc3NGVlODExZGE4MWM0L3RhYmxlcmFuZ2U6YjE1MGUyZDc2MTZjNDMyMWE1Nzc0ZWU4MTFkYTgxYzRfMi0zLTEtMS0xMTA5NTI_8628ab36-93e3-41e0-9596-10a0aa42a1a3"
      unitRef="shares">16522000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV82MS9mcmFnOjJlZjc1ZWY4ZTNlMzQwNGE5ZTczMGU5MmQwOGU3NTkxL3RleHRyZWdpb246MmVmNzVlZjhlM2UzNDA0YTllNzMwZTkyZDA4ZTc1OTFfMTM1NjY_f50b825e-066d-4a6d-9ee1-68ffbdd6c09b">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MSN I ANDA Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (individually and collectively with certain of its affiliates, including MSN Laboratories Private Limited, referred to as MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, for CABOMETYX. MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patents No. 7,579,473 (composition of matter) or 8,497,284 (methods of treatment), each of which is listed in the Orange Book. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting infringement of U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 8,877,776 are invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to include additional Paragraph IV certifications. In particular, the May 5, 2020 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of two previously unasserted CABOMETYX patents: U.S. Patents No. 7,579,473 and 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 7,579,473 and 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. Neither of our complaints have alleged infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 7,579,473 and 8,497,284 are invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patent No. 9,809,549 (salt and polymorphic forms) is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. U.S. Patent No. 9,809,549 is not listed in the Orange Book. On April 7, 2021, we filed our response to MSN&#x2019;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. The two lawsuits comprising this litigation (collectively referred to as MSN I), numbered Civil Action Nos. 19-02017 and 20-00633, were consolidated in April 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#x2019;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 7,579,473 and 8,497,284, if those claims are not found to be invalid, and (ii) upon approval, MSN&#x2019;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#x2019;s ANDA product prior to the expiration of U.S. Patents No. 7,579,473 and 8,497,284 would also infringe certain claims of each patent, if those claims are not found to be invalid. Then, on October 12, 2021, pursuant to a separate stipulation between us and MSN, the Delaware District Court entered an order dismissing MSN&#x2019;s counterclaims with respect to U.S. Patent No. 9,809,549. In our MSN I complaints, we sought, among other relief, an order that the effective date of any FDA approval of MSN&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 7,579,473, 8,497,284 and 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. In an effort to streamline the case, the parties narrowed their assertions. On April 8, 2022, MSN withdrew its validity challenge to U.S. Patent No. 8,877,776. On April 14, 2022, we agreed not to assert U.S. Patent No. 8,497,284 at trial and MSN, correspondingly, agreed to withdraw its validity challenges to U.S. Patent No. 8,497,284, as well as claims 1-4 and 6-7 of U.S. Patent No. 7,579,473. As a result of this narrowing, the trial addressed two issues: (1) infringement of claim 1 of the U.S. Patent No. 8,877,776; and (2) validity of claim 5 of the U.S. Patent No. 7,579,473. A bench trial for MSN I occurred in May 2022, and on January 19, 2023, the Delaware District Court issued a ruling rejecting MSN&#x2019;s invalidity challenge to U.S. Patent No. 7,759,473. The Delaware District Court also ruled that MSN&#x2019;s proposed ANDA product does not infringe U.S. Patent No. 8,877,776 and entered judgment that the effective date of any final FDA approval of MSN&#x2019;s ANDA shall not be a date earlier than August 14, 2026, the expiration date of U.S. Patent No. 7,759,473. Final judgment was entered January 30, 2023. This ruling in MSN I does not impact our separate and ongoing MSN II lawsuit (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MSN II ANDA Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2022, we received notice from MSN that it had further amended its ANDA to assert additional Paragraph IV certifications. In particular, the January 11, 2022 amended ANDA requested approval to market a generic version of CABOMETYX tablets prior to expiration of three previously-unasserted CABOMETYX patents that are now listed in the Orange Book: U.S. Patents No. 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition) and 11,098,015 (methods of treatment). On February 23, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 arising from MSN&#x2019;s further amendment of its ANDA filing with the FDA. On February 25, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 are invalid and not infringed. On June 7, 2022, we received notice from MSN that it had further amended its ANDA to assert an additional Paragraph IV certification. As currently amended, MSN&#x2019;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On July 18, 2022, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting infringement of U.S. Patent No. 11,298,349 arising from MSN&#x2019;s further amendment of its ANDA filing with the FDA. On August 9, 2022, MSN filed its response to the complaint, alleging that the asserted claims of U.S. Patent No. 11,298,349 are invalid and not infringed and amended its challenges to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 to allege that these patents are not enforceable based on equitable grounds. The two lawsuits comprising this litigation (collectively referred to as MSN II), numbered Civil Action Nos. 22-00228 and 22-00945, were consolidated in October 2022 and involve Exelixis patents that are different from those asserted in the MSN I litigation described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 21, 2022, pursuant to a stipulation between us and MSN, the Delaware District Court entered an order that (i) MSN&#x2019;s submission of its ANDA constitutes infringement of certain claims relating to U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, if those claims are not found to be invalid, and (ii) upon approval, MSN&#x2019;s commercial manufacture, use, sale or offer for sale within the U.S., and importation into the U.S., of MSN&#x2019;s ANDA product prior to the expiration of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015 would also infringe certain claims of each patent, if those claims are not found to be invalid. In our MSN II complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#x2019;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032, and equitable relief enjoining MSN from infringing these patents. A bench trial for MSN II has been scheduled for October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Teva ANDA Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received notice letters from Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#x2019;s notice letters included a Paragraph IV certification with respect to our U.S. Patents No. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book. Teva&#x2019;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva asserting infringement of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 arising from Teva&#x2019;s ANDA filing with the FDA. On August 27, 2021, Teva filed its answer and counterclaims to the complaint, alleging that the asserted claims of U.S. Patents No. 9,724,342, 10,034,873 and 10,039,757 are invalid and not infringed. On September 17, 2021, we filed an answer to Teva&#x2019;s counterclaims. On July 29, 2022, we received notice from Teva that it had amended its ANDA to assert an additional Paragraph IV certification. As amended, Teva&#x2019;s ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of a previously-unasserted CABOMETYX patent that is now listed in the Orange Book: U.S. Patent No. 11,298,349 (pharmaceutical composition). On September 2, 2022, we filed a complaint in the Delaware District Court for patent infringement against Teva, asserting infringement of U.S. Patent No. 11,298,349 arising from Teva&#x2019;s amended ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA be a date no earlier than the expiration of all of U.S. Patents No. 9,724,342, 10,034,873, 10,039,757 and 11,298,349, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva from infringing these patents. On September 30, 2022, the parties filed a stipulation to consolidate the two lawsuits, numbered Civil Action Nos. 21-00871 and 22-01168, and to stay all proceedings, which was granted by the Delaware District Court on October 3, 2022. Following a similar order granted by the Delaware District Court on February 9, 2022 to stay all proceedings with respect to Civil Action No. 21-00871, this case remained administratively closed, and Civil Action No. 22-01168 was administratively closed on October 3, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cipla ANDA Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 6, 2023, we received a notice letter regarding an ANDA submitted to the FDA by Cipla, Ltd. and Cipla USA, Inc. (individually and collectively referred to as Cipla), including a Paragraph IV certification with respect to our U.S. Patents No. 8,877,776 (salt and polymorphic forms), 9,724,342 (formulations), 10,039,757 (methods of treatment), 11,091,439 (crystalline salt forms), 11,091,440 (pharmaceutical composition), 11,098,015 (methods of treatment) and 11,298,349 (pharmaceutical composition). Cipla&#x2019;s notice letter did not provide a Paragraph IV certification against any additional CABOMETYX patents. On March 16, 2023, we filed a complaint in the Delaware District Court for patent infringement against Cipla asserting infringement of U.S. Patents No. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349 arising from Cipla&#x2019;s ANDA filing with the FDA. Cipla&#x2019;s ANDA requests approval to market a generic version of CABOMETYX tablets prior to the expiration of the aforementioned patents. We are seeking, among other relief, an order that the effective date of any FDA approval of Cipla&#x2019;s ANDA would be a date no earlier than the expiration of all of U.S. Patents No. 8,877,776, 11,091,439, 11,091,440, 11,098,015 and 11,298,349, the latest of which expires on February 10, 2032, and equitable relief enjoining Cipla from infringing these patents. Cipla&#x2019;s response to the complaint is due on May 19, 2023. On May 4, 2023, we filed, under seal, a stipulation and proposed order to stay all proceedings, and the Delaware District Court, in a sealed order, granted the proposed order and administratively closed the case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <exel:LossContingencyNumberOfLawsuitsConsolidated
      contextRef="icb5f735f185d4a9dbe1cc597da942150_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA0MGRkNGMzMzMzMzQ4MGJhMWU4ZDk0ZTU1ODk4NGYxL3NlYzowNDBkZDRjMzMzMzM0ODBiYTFlOGQ5NGU1NTg5ODRmMV82MS9mcmFnOjJlZjc1ZWY4ZTNlMzQwNGE5ZTczMGU5MmQwOGU3NTkxL3RleHRyZWdpb246MmVmNzVlZjhlM2UzNDA0YTllNzMwZTkyZDA4ZTc1OTFfNTQ5NzU1ODE5NTA0NA_64e8ad5f-df3f-488e-a0a8-5be6ee5eda87"
      unitRef="segment">2</exel:LossContingencyNumberOfLawsuitsConsolidated>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M22VD66G,PQ#FI9GD[C/Z^=2VL1IJT5<:) RM894W4TM@;14T89YPX9ZPV?:
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M[#]J]3=:[+OO0ANAH37J+G>< 7 C ,^W KAYN#&?F@Z?%M?_ 5!+ P04
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M0NL6P5%*@&8MP:SEP'[7[3D."M47PZIL8!4MLHH6/YN0+@U'Z0":M8/_)>G
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MU1R2:VXXW=:'NCY2SFE17VX(%JNW-!#?KRGEWV[D.;'#4<7%?U!+ P04
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M8^R3W/4Y0J^SB#NO6# YCUQW-_UAM^]263O*[JB"60!8'(X; /6\=-3$4@+
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M!7J,$4$0DL*D#YO#$$X$!>_@6IU2YK2HTW-8BW[LC+8MYFMJ!Y'7(_3_D"A
M5A&\$J\#FKZ5&MU+ V:KA[5IRW0@WFMT6"S9WUYP,!)GTFEV\19+HX0A,.;M
ME"!@=5DX9</O\+"3R@6$Y01L$9U/:"D(:^USXU2+ZZO<4/,QJPHR79,XG6EI
MV]3%.BIJC^<(.&+>5)SQ!&F-13S2-55,A\L9)0+J<0*XTXBG;6E-(@M*I*@#
MVJ23:>B&S!D8Z:%E2<FILM%31S251/?PP1%?[9*-<, :JD$QUI)@FY$^(5?E
M9ERH+;Q(I>)$8%[D'_R.7 E[.U,I6]A$78IY=[:NPNC9<O"ZL:XA^$"2=,V$
M?YE0)J(DCX\H&G=J$2F/F U_;M-VAI9O.0"\Y>(QS9E@G!-S<YR2^[.+<Z33
MA$V"!06R#EN!R@;5X;ND( X1I7ZJX]P8CZ7,#]!F;.BU;.0.'^QV%GF#HH4&
MJ'KN<%TH1H"!0']KH!<-+*21S#XVD7D1N*'*'$LV5<'DHR)%"RI69!M#\F;#
M@> -0"!H5:&<G:/6P-U7S*7F5K8U #&1W*%;5_DH=;0WUVZD=MDE4'0D<O.F
M9D9.=(^!?+/?YU8!;,+8J&AL%!CZ0&O;J8_Y+86EU5<7ZXX;+E4;H5:NSX'*
MI43Y*.:EJ>_!U%JA?ZO .]]"'(-K=Q 6L2=0>_/&-[8U;D=I_9&"HGRYYERA
MMJ:0U2XW39&1AG3-$J@,&&G B0W7_3.B6TOG:(Y8VQH, 9_:.QYT\2$-;JGO
M3:=H/1 NOF]C/ZFJ!G*>TCNTS;DNL)?5Y<J[..<%*K$-9=6+Z-;]RZ +G;G9
M?L#S!^>*S$PH$_%\/*0H/#\9KI1ZV#*BIDN)=0@O#')T%)UZ:>$@S((%,-HQ
M9O0,1<(*,)V>&-)H$ <G@G<Z\M.S\+M&H2D:#:J-N/'?VH0D -B6.6YEKN3O
M"@UAZ$L\.0J1"&0,.8"10:-!@,*!*U+O3GD*"&3;AA@$*MY2SUZL0[+&8R8
MFD)TD8Z$<O=&4L\]*8LM<S]-H:@XUV:LQ4"?$L60\^2H+>6V"CQJUY;G4T4V
M0+!#D4X&ZK\.1*988W93"V8CTQYN(]T,PQ#S49HCDH;&+>= @L)RSJZY21N:
MOF*"_:'9GO!7K7K7#F0_D7V-0=0/O1D&VAA8-1#^ANH\UXHI1]HPHMW0<N+<
M,M"$E'\W'81FH)S4R(:E?*!EI:SD(O8[= B3RM"8XC4#U43H(O%6A$V3>.V)
MD_1!)B&&-6+@05<A,V-U(_WZIX9.9@B/PP7-[Y@@V)'](T XJ>.J8>ORW3R
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M>8'708M(H'.A'(97#2ZWJ*.I^_"Y5FI-FKC01>A $> W*VVIQ3J1R3Q&@E2
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MP1%N.H#_UQKEN'D@ =W7HJO_ E!+ P04    " #G@:E6F;Q[>]0"   5!@
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MMP3O>Q/13JF6J%>^(1FZEUK:IFK;:-OS3II2?TUO&B9=T(I+ P*7!(V/![T
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M6:L*=YD)2$73 CQ?*Q3&YH8V:+\97OP/4$L#!!0    ( .>!J5; 53_U_ (
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M46_B.!#^*Z/L:G4KI20XT%(6D&C+:?O0'H+N[L/I'DPR(583.V<[I?WW-W:
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M^?+8:G91N2QUTJCEH=]6N+"7L9/1IO2&FL6'I/5%2\MHPB"WW]X-JLRGV<+
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MQWO"^-]7^B].3_DWC4/MG,[YXT1)F#T]@/LC#?V'+[1 _2/7\_\ 4$L#!!0
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MX5_>T"(_UQ7XC(@M-0V)((CDF42.B@)PDGH67>KHC&G)#QW7'I.X^;IT8$U
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M]F9)3R%JMX'65TK9[< %Z!_7V4]02P,$%     @ YX&I5JT:VF1!!@  ]Q4
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M9WIW3M&&$HD$=/!4J3HVL8NCT+?O+I N28+=(C*'V._6Z:44U6*)YFQ52Z"
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M("8Q5JT"/B ^N,DEL>:78#OM0/QXSG8;.I95$Q)\2?QV=\_SW/D\VRI]:RH
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M".I*OB6)F/I%VR+6T- R8YS$!5AD$(=)?L4/12$. (*G'F 5 .L8T'D&8!<
M53D]STS)FF*.O0$E6T1EM&"3 U4;A19JPD1NXPVGXFXH<-R;PP:2#!AZC[X(
MT\PH\;,E1^7R-&0X""@$F(./%H]EQ.D4. XC=B:0=S=3='IRADY0F*#;-<D8
M3GPVT+E(4#Y&7Q;)C/-DK&>2L=$U2?B:H<O$![^*UX6P4IVU4S>V&@FO,3U'
MMOD.689EU^0S:8:/4@$W<KC5D(Y=%MM6?/8S? ?%E!8FJUV=T>_/(A1=<8C9
MG[JZY;R=>E[YJE^P%"]AJ(EWF0'=@.:]?6,ZQH<ZT2V154K0*4O0:6+WI,G2
MPD*T,%F=X)S%42SRKVCC=0RWY[H#?7,HY6F8W>WV7:,,JR39+9/LMI)D(\M+
M=Z4ELHI@IQ3LO)(QG39+T!)9I02]L@2]5O8\9^D>.LZQ.X9Q9,R:,-.P^FZ]
M,=TR2;<QR<EH_/7Z\O;7S[K,&J$OW8J6R"HJ^Z7*_BNYL=]F"5HBJY3 -/;?
M9:,5/Q8T54.:O9Y]9,BZ.,-R3:O>D>9! V$V>U(Z<G[UK3:Y1NA+-Z0MMJI0
M:R_4>B5;%L1ME:$EMFH9]CV,V=@?_+\Q[2??9M.Q>L>V?!K5Z[C.D2GU@P8W
M!AJHOI^A)<D2GG>#Y6IYMABICOIH?2S/'*IQWM/D!Q;1*@9APE $*T%IG/?$
MFT+S,T ^X215;?2"<-&4J^%:G)N R@!Q?T4(WTWD \J3F/</4$L#!!0    (
M .>!J58T_C)-WP0  +46   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;,U876_;-A3]*X16#"T01R)IV7)F&TB<%MU#L<!>NX=A#XQ$VT0ET2-IN_GW
M(R5%E&>)7H0&W8NMKWOON4>7Y]B<'KGX*K>4*O M2W,Y\[9*[6Y\7\9;FA%Y
MS7<TUW?67&1$Z5.Q\>5.4)(405GJHR 8^1EAN3>?%M<>Q'S*]RIE.7T00.ZS
MC(BG.YKRX\R#WO.%)=MLE;G@SZ<[LJ$KJC[O'H0^\^LL"<MH+AG/@:#KF7<+
M;^XP-@'%$U\8/<K&,3"M/'+^U9S\FLR\P""B*8V524'TUX$N:)J:3!K'WU52
MKZYI IO'S]D_%,WK9AZ)I N>_L$2M9UYD0<2NB;[5"WY\2.M&@I-OIBGLO@$
MQ^K9P /Q7BJ>5<$:0<;R\IM\JXAH!"#4$8"J %3@+@L5*.^)(O.IX$<@S-,Z
MFSDH6BVB-3B6F[>R4D+?93I.S9?T0/,]E6  ;@U!3#%]0O($O,\3EF_ DDHJ
M#A3<D93DL;ZG)P&LV"9G:Q:37($%473#A0GC:W#/9,SWN2ISW*;ZK9=A;^^I
M(BR5[\ ;P'+P^Y;OI7Y$3GVEVS!@_+B"?%="1AV0,?C$<[65!B%-3N-]W7[-
M 7KFX XY$WXBXAI@> 50@##XO+H';]^\<^3%-;>XR(L[\J[>+\!*+Z-DG](K
M -$@F%QI[ >JIUH9$KZ0=$^*X6P097BK2)?@SR5/4Z#G[TA$\E<;5R6$83L$
MLZ9OY([$=.;I15LD]>8__P1'P2^.!H=U@T-7]GDU$X H<$]CFCU24>:NR$1M
M@,N4HR*ET8S#?#Q&&$[]0PN2L$82.JE^$/S *J5(]4 F0'$@2:HIS$A"-=DW
M;5C"5R!O5$,>.<E;[(4P<["C@O&D#5T9'S:8@F$TB<)VJL9UW;&S[H,N)ZJJ
MK:MO?%9V (,1;J\:U54C=U7R9*:^'.]2UZ@ L: )TQ>9E/M_+^423-0"9C@.
M)U$[G$D-9_)?)U>O_GA[,K:X#<CD#$@T#L..=P$#*[^!>PJV1&SH(XF_RJN&
M>!J1U3.=[12HF"N(^TUMJ6A53&>5GI,,&R8"?[S251B^<X_(]HB^O]A5.9MC
M@T91U*%VT#H+=%M+3[V#K^$6T-H%=/O%9<FK$C3YF@PGX:2#+VL/T"GEET6O
MBC\1VV'7:[(2#]T:WU?UX+GT:PT.HBZ;A%;\H5O]7RY\\-P/$(1AT('$&@)T
M.T*A96#Q3,JB),7_0"ME6/#!CCR!6RF95 9S*SAGC;X#;5T$3OX'NN>TLIX]
M(NM0R.U0O72ORGFZG"9HV#XTR!H-<AM-3]U#KV$=R%H'<EO'9=U#YSZA^8(=
M/[J0]0GD5/3+NE?%GRH-A...PE;JD5OJ^RH?.C>  <0CW 7(.@!R.\#+A0^U
M6$*H-;@#B34%Y#:%I?ZYIVC[VW!&]IU3:PYH_./E##D-JF^/UG:0VW;ZR=GY
MWQ <#M&H8Q2L?R"W?_25L]=P!&P= 5_XSW)1SO"Y_&LUZY(S;.4?.X7ZLIQ5
M\2?R$75H![;ZC=WZW5?,\+FJ#S"&N..W$VYL++EE_>5B5B5L;KN$$)MI/T'B
M-W82=8^;8K]4@N)?:;FI6%^M]V1ORYU(^WBYH:N!;5@N04K7.C2X'FL:1+E'
M6IXHOBOV)1^YTH06AUNJIUZ8!_3]->?J^<04J'>JY_\ 4$L#!!0    ( .>!
MJ586$Z^\R0,  %\.   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;*U7
MVX[;-A#]%4(-B@1(5E?+E]H&O':+%DB Q6[2/A1]H*6Q340B79*VTWQ]AI16
MOHBKQH%?;)&:<X;G\*+A^"#D9[4!T.1+67 U\39:;T>^K[(-E%3=B2UP?+,2
MLJ0:FW+MJZT$FEM06?A1$*1^21GWIF/;]R"G8['3!>/P((G:E265_]U#(0X3
M+_2>.Q[9>J--AS\=;^D:GD!_VCY(;/D-2\Y*X(H)3B2L)MXL'"U""[ 1?S(X
MJ)-G8J0LA?AL&G_D$R\P(X(",FTH*/[M80Y%89AP'/_6I%Z3TP!/GY_9?[/B
M4<R2*IB+XB^6Z\W$&W@DAQ7=%?I1''Z'6E#/\&6B4/:7'.K8P"/93FE1UF <
M0<EX]4^_U$:< )#'#8AJ0'0)2%X Q#4@_EY 4@,2ZTPEQ?JPH)I.QU(<B#31
MR&8>K)D6C?(9-_/^I"6^98C3TT?8 ]^!(N_(7' M<1[(3"G0BE">D_>,+EG!
M-,.(UPO0E!7J#<9^>EJ0UZ_>D%>$<?)Q(W8*H]78US@D0^QG=?K[*GWT0OJ8
M?,"L&T5^Y3GDYW@?I31ZHF<]]U$GX0<J[T@<OB51$,6.\<R[X;,MPH,*'CG@
MBV[X C+,'KC@9VKB9G9BRQ=WSPY925$>Y^? ](;,[=H 2?Z>+97M_\=E?\6?
MN/G-H3)26YK!Q,-30X'<@S?]^:<P#7YQ>7=+LL6-R,Y\31I?DR[V:6,EM4O=
M95Q%D%H"<WCNIV$\Z(_]_:DAG5FN-<21,>T-FXQG0GN-T%[G FJ$%L>-/'+)
M[=URG=R2;'$CLC/[TL:^M'N=[*0$KLE62/.5<AE7$?1.9JT?I,G%.NG,<JTA
MCHS)8.!>)_U&:+]3Z'O!U^\TR+)+:K^5.(V&PPNIG7FNE>K(V!M$;JF#1NJ@
M4^I'H6E!,L?&<&D>M$80QG$:7XCNS'BMZ$'['$B"?N!6/6Q4#[_OQ)/U)T5"
M)M:<?87\+7[#LV*7,[YNWMH/#I9/@.L_;WJ7L&:<F[@E+2C/P.78L.48UJ#!
MA6'#EL8HN0Q:="KZP9T?!L?"*.ATK*F,CDX1K+/)%J0MMU$^$<N"K:G9+XHH
M_%<KAE%8$N&(]@RK(A/-Q N54=!R*NX/6U;58:=>Q6&_95:WFA]UZZ2,#/_'
M+7/),$O#[8_3@+"E+!VVUTIWYFMWUZW8*I_\D\H;B[&UO<$H/%UV7%=%:]/;
MW))F]FYPT7\?CN;57>=(4UV]L*+%7:=( 2ND#.[ZN&!D=9NI&EIL;7V_%!HK
M0ONXP1L@2!. [U="Z.>&2=#<*:?? %!+ P04    " #G@:E6@J48:>L#  !U
M%   &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6S%6&UOHT80_BLK>JKN
MI#:PO!E2VY*=M&JDBQHE=^V'JA\V9FS0P2[=7>RKU!_?72!@;,S%#9*_Q.SN
MS,/,,X_7DYGN&/\B8@")OF8I%3,CEC*_-DVQBB$CXHKE0-7)FO&,2+7D&U/D
M'$A4.F6I:5N6;V8DH<9\6NX]\/F4%3)-*#QP)(HL(_R?):1L-S.P\;+QF&QB
MJ3?,^30G&W@"^3E_X&IE-BA1D@$5":.(PWIF+/#U#0ZU0VGQ>P([L?>,="K/
MC'W1B[MH9E@Z(DAA)34$41];N($TU4@JCK]K4*-YIW;<?WY!_Z5,7B7S3 3<
ML/2/))+QS @,%,&:%*E\9+M?H4[(TW@KEHKR+]K5MI:!5H60+*N=50190JM/
M\K4F8L]!X?0[V+6#?>C@GG!P:@>G3+2*K$SKED@RGW*V0UQ;*S3]4')3>JML
M$JK+^"2Y.DV4GYRK]%/RS#@I25UL.( JDA1H02.T+(0R%P+=PE85/-<G:*&)
M3V0" OV(NNZ/RHP6ZJ"@$7 D8T G\%66,D9WN0"*WM^")$DJ/BB\ST^WZ/V[
M#^@=2BCZ%+-"$!J)J2E5JCI@<U6GM:S2LD^DY:![1F4LT,\JDJCK;RJ*&I[L
M%YZ6]B#@/>%7R,$_(-NRG9YX;H;=%[ERMRIW>R <IRF;4^(YWR[;%M""<T(W
M%;&*K\[Z-U4%70I"4=?ISX\*$]U)R,1??017 ;C] >C;Y5KD9 4S0UT? O@6
MC/GWWV'?^JF/G9' .ERY#5?N$/K\$Y,D55=.I<V^5"M_O_37]]YV[EK!) BF
MYG8_B6,SQ_/"P&K,.N%Y37C>8'BG2]E^1_J"'D0]MSXC@74(\!L"_$MKV1^3
MJY' .EQ-&JXF;]1RY>_MB]3Q'/= RCU6KF=/^I4<-,$%@\%]3%;J]QT&PQM$
M.+<2(X%UD@V;9,-+JS8<DZN1P#I<8:OM,JPWZK8&Z$@RL$/[0+A]9K;EGU N
MWFN#\%G:1?^B_WLQ#[_IW+J-A=;EQ6YYL2\M\SJ"L?@:":W+5]N7X<%6YC5"
M=XX4;(<!/A)ZCYGK8_>$T-MF" ]W0]V&7!.@E"^&(QY$/+M (Z%U\V^[+>Q=
M7-"CMF9CH77Y:ILS/-C/O$;0_I%2)U;H'^KYV H[/O9.Z+EMB/!P1_0-/;_E
M'A]\\=EE' FM2U/;FN'@XK(?M;<;"ZW+5]O=X<&&Z#6R#X__'9S81]?XL548
M8N= ]>;> "<#OBGG6@*M6$%E-:-H=IO9V:*<&!WL+_5,K1P,M3#50.Z>\$U"
M!4IAK2"MJXGZ)O)JQE4M),O+,=$SDY)EY6,,) *N#=3YFC'YLM O:":-\_\
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MYTAU^O>3P$0?.63LOSZ"ZP!&_0'(Z^62%7@),T/<'PSH!HSP[2^V9_W6Q\Y
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MCE^09MT-RLZPJO'#::DLC3J_K.C?@MHYT/E**7MON'DW_*VR'U!+ P04
M" #G@:E6E<*\- 8#   $"@  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6S%5FM/VS 4_2M7&9I &DV:M,!8&ZF%/=#&5H'8/DS[8-+;)L*Q,]M]\.]W
M[82L12&(J=*^M'Z=XWN.;^P[6$EUIU-$ ^N<"SWT4F.*4]_728HYTQU9H*"9
MF50Y,]15<U\7"MG4@7+NAT%PY.<L$UX\<&,3%0_DPO!,X$2!7N0Y4_=CY'(U
M]+K>P\!5-D^-'?#C0<'F>(WFII@HZODURS3+4>A,"E X&WJC[NG9B5WO%GS/
M<*4WVF"5W$IY9SL7TZ$7V("08V(L Z._)9XAYY:(POA=<7KUEA:XV7Y@_^"T
MDY9;IO%,\A_9U*1#[\2#*<[8@ILKN?J$E9Z^Y4LDU^X75M7:P(-DH8W,*S!%
MD&>B_&?KRH<- /$T \(*$#X&])X 1!4@<D++R)RL<V98/%!R!<JN)C;;<-XX
M-*G)A#W%:Z-H-B.<B4D^9[=2,6?J:*X0Z8R,AI&8PGBA:;G6<(Y+.N_"SL#(
M&I^9##4<7LE[QLT]3%)&EL)7IBS1$F'_' W+N#Z 0[BY/H?]O0/8@TS 9<8Y
M[:0'OJ'H;0Q^4D4Z+B,-GX@T@DLI3*KAO9CB=!OOD^I:>O@@?1RV$EXRU8&H
M^P;"((P:XCEKAX\*@@<E/&P))ZI/(G)\O9>=!.6#2>$C9VMYG5/SL\4UN=?*
M;B^#4UVP!(<>?>T:U1*]^/6K[E'PKDGZCLBVC.C51O0<>_2\$91)(THI,2^M
M8)23F_UO)D4%)F4"MD$_OQ G7!C,]:\FKWJ[]&I'9%M>]6NO^JU),T&56"?D
M#%3U+5+R"+K]->.-:5+RO75\]HI?QD$GH/1?;DIJW?0?)1W5DHY:);D[I;I1
MF@2THE]Z=CLBVQ)Z7 L]_M]Y?KQ+KW9$MN752>W5R?-)0<F-:RI?=&-BEP3=
M8".SN_U.[U%F-ZV*.MUZ51F=O_&@YJCFKL[0D,B%,.4#4X_6I<S(O>"/QL=4
MXI05R5^:LCZBUV>>"0T<9T09=([IFU-ES5%VC"S<LWTK#14!KIE2F8;*+J#Y
MF93FH6,WJ N_^ ]02P,$%     @ YX&I5EE;+BJ- P  & T  !D   !X;"]W
M;W)K<VAE971S+W-H965T,SDN>&ULK5=M;]LV$/XKA%84+9!&KY:3U!9@QRL6
MH-V"9&T_#/M 2V>)J"2J)&4W_WY'2E;DV-$2PU\DD;Q[>,_#(WF:;+CX(3,
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M:&5E=#0S+GAM;,U878_:.!3]*U9:K5II('&^F85(4T;=K=1*H]+I/E1],,&
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M6O!QJL&]N_]5'>=?3+LP:Y[O@6U1MCXG-72:)R=*?9R',]6&91(E= TP:QQ
MHN)P0CXL%,_+0^:2*SBREI=;2E94Z "XO^9</2WTN;7^/T7T'U!+ P04
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M+@H#^?XB3?/')\7]_P[W>YS^#U!+ P04    " #G@:E64,VU#;H"  !I!@
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MN7[@Z=7YG3I_5-TY+K&LJ@RL*-5GOC_8-O+B?6W#(-L*7%^O+>BT!:/:;JF
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MT"34MWR9Y-K]DDT3&W@D6VDCRP:,"DHFZBM];(S8 2!/-R!J -$AH/<"(&X
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M1C!Y-Y)Y8K81U+\+:1P XV]>C6SL?42KWWDDCN@#VDC3!'D,B.[0*LEB>@1
M&V#WD2^O(6$@@Q92Q  M:2*=Q8G>F]6#&@-Z>P."1#%_)\.^;V[0V]?OT&L4
MI>A;2'-.TH!/3"&+4%1,OR2\* C;3Q!VT%>:BI"C51I T,PW9?&5 O:C @N[
M$_ K85?(P>^1;=E."Y]E=_H\D^E6D6YWT'&J#7$TGO/4ABA9/VPO19TS1M(]
MR+^00-LCJL>MR5$OSP^$!>CG/Q(2?1&0\%]M^A;/'[0_7[TVKGE&?)@:\KW
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M')^@; #N5U*:HV$/Z =R_@]02P,$%     @ YX&I5K&0OSU1 P  I@H  !D
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MT/=5-%L_R&!#@#^OC<&S$YIK_C44?P%02P,$%     @ YX&I5DTT^C!/ P
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M<SR%C]M+J<NE$^W'\3E:7K1=[TVC]8>X[8OYQ\KJ](++Z>6<=_\!4$L#!!0
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M2P$"% ,4    " #G@:E6!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .>!J58Q["IT[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M .>!J5:97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ YX&I5MT-FPO4!0  U1X  !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M .>!J5;][E^Q[P8  &8<   8              " @1@.  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " #G@:E6JHB.E-0"   2"@  &
M            @($]%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ YX&I5NHAVTQR!0  91D  !@              ("!1Q@  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .>!J5:8F;B $ ,  ' (
M   8              " @>\=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " #G@:E68YZT$*("   @!@  &               @($U(0
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ YX&I5C:D9U-L
M!@  MB@  !@              ("!#20  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( .>!J5; J[=LF08  $(;   8              "
M@:\J  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #G@:E6
M#^!X<(H,  !H'P  &               @(%^,0  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ YX&I5O0&.'+,"@   QX  !D
M     ("!/CX  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M" #G@:E6+PK*/9(*  #>'@  &0              @(%!20  >&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .>!J58GEE-M: @  +08   9
M              " @0I4  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!
M A0#%     @ YX&I5JGF1VQE!P  .1(  !D              ("!J5P  'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #G@:E6F;Q[>]0"
M   5!@  &0              @(%%9   >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;%!+ 0(4 Q0    ( .>!J597 ME:U@<  #\4   9              "
M@5!G  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ YX&I
M5L!5/_7\ @  C@8  !D              ("!76\  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " #G@:E6WJVSC>H#  !L"0  &0
M        @(&0<@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( .>!J58T9!IAJ@X  / Z   9              " @;%V  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ YX&I5D0(C6 X"P  H1\
M !D              ("!DH4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " #G@:E6K@DPWJ\&  "Y$@  &0              @($!D0
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .>!J5;$KZ1C
M  ,  &@'   9              " @>>7  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ YX&I5JT:VF1!!@  ]Q4  !D
M ("!'IL  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #G
M@:E6_E+N'= #  !1"0  &0              @(&6H0  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .>!J5:!5^%,V@(  " &   9
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M970R."YX;6Q02P$"% ,4    " #G@:E6'7$\_X,%  #&+   &0
M    @($RMP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M .>!J5:,7 7?-P,  &,-   9              " @>R\  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ YX&I5J#8]W\X P  E0T  !D
M             ("!6L   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " #G@:E6-/XR3=\$  "U%@  &0              @(')PP  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .>!J586$Z^\R0,
M %\.   9              " @=_(  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ YX&I5H*E&&GK P  =10  !D              ("!
MW\P  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #G@:E6
M:;BZSW4"  "Z!@  &0              @($!T0  >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( .>!J5:.=2U Z@,  '44   9
M      " @:W3  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ YX&I5I>D:^IR @  N08  !D              ("!SM<  'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #G@:E6E<*\- 8#   $"@
M&0              @(%WV@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( .>!J5996RXJC0,  !@-   9              " @;3=  !X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ YX&I5E31:+(>
M P  ,0H  !D              ("!>.$  'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " #G@:E6EL,E)+0&  "G*@  &0
M@('-Y   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .>!
MJ59"<I3G3@,  !(+   9              " @;CK  !X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ YX&I5FI^\A_, P  LQ   !D
M         ("!/>\  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
M    " #G@:E6<Q:/$<,"  #A!@  &0              @(% \P  >&PO=V]R
M:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( .>!J58.3_VAA @  /M1
M   9              " @3KV  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL
M4$L! A0#%     @ YX&I5E#-M0VZ @  :08  !D              ("!]?X
M 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #G@:E6 3#@
ML!P#  #B"P  &0              @('F 0$ >&PO=V]R:W-H965T<R]S:&5E
M=#0W+GAM;%!+ 0(4 Q0    ( .>!J585T+*>Z@0  !D4   9
M  " @3D% 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
MYX&I5L%R="Q; P  %0P  !D              ("!6@H! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " #G@:E69&$%#+P#  !X$0  &0
M            @('L#0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( .>!J59_6C+P3P(  )P%   9              " @=\1 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ YX&I5K&0OSU1 P
MI@H  !D              ("!910! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " #G@:E6QMT'_^ "  !Y!P  &0              @('M
M%P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .>!J591
M.;8?^@$  "8$   9              " @00; 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ YX&I5DTT^C!/ P  2A0   T
M     ( !-1T! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #G@:E6EXJ[',
M   3 @  "P              @ &O( $ 7W)E;',O+G)E;'-02P$"% ,4
M" #G@:E6''H1J$H$   @)   #P              @ &8(0$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ YX&I5@^45$C: 0  62   !H
M ( !#R8! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
MYX&I5B%=IR;- 0  )"   !,              ( !(2@! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     #X /@#I$   'RH!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>185</ContextCount>
  <ElementCount>213</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome</Role>
      <ShortName>Condensed Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Collaboration Agreements And Business Development Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</Role>
      <ShortName>Collaboration Agreements And Business Development Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Provision For Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxes</Role>
      <ShortName>Provision For Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables</Role>
      <ShortName>Collaboration Agreements And Business Development Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Concentration Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenues - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Collaboration Agreements And Business Development Activities -Royalty Pharma Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities -Royalty Pharma Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails</Role>
      <ShortName>Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Fair Value Measurements (Fair Value Hierarchy) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails</Role>
      <ShortName>Fair Value Measurements (Fair Value Hierarchy) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Fair Value Measurements - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails</Role>
      <ShortName>Fair Value Measurements - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Stockholders??? Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders??? Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Stockholders??? Equity - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders??? Equity - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stockholders??? Equity - Schedule of Employee Service Share - Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders??? Equity - Schedule of Employee Service Share - Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Provision For Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails</Role>
      <ShortName>Provision For Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForIncomeTaxes</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CommitmentsandContingencies</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ResearchAndDevelopmentInProcess in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. exel-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="exel-20230331.htm">exel-20230331.htm</File>
    <File>exel-20230331.xsd</File>
    <File>exel-20230331_cal.xml</File>
    <File>exel-20230331_def.xml</File>
    <File>exel-20230331_lab.xml</File>
    <File>exel-20230331_pre.xml</File>
    <File>exel20230331exhibit31110q.htm</File>
    <File>exel20230331exhibit31210q.htm</File>
    <File>exel20230331exhibit32110q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="518">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 518,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 185,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exel-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 368,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 28,
   "keyStandard": 185,
   "memberCustom": 24,
   "memberStandard": 32,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Revenues",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Collaboration Agreements And Business Development Activities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities",
     "shortName": "Collaboration Agreements And Business Development Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Cash and Investments",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.exelixis.com/role/CashandInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Inventory",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stockholders\u2019 Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.exelixis.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Provision For Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxes",
     "shortName": "Provision For Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Net Income Per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.exelixis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Revenues (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Collaboration Agreements And Business Development Activities (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables",
     "shortName": "Collaboration Agreements And Business Development Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Cash and Investments (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.exelixis.com/role/CashandInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Inventory (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.exelixis.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Net Income Per Share (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:NumberOfCountriesWithDrugApprovalExcludingTheUS",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i8d27cdd49640469c8f242f09214a609a_D20221231-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "iaa7500ddcb0b4d0db3443cc56170ff61_D20221231-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Revenues - Revenues Disaggregated by Concentration Risks (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails",
     "shortName": "Revenues - Revenues Disaggregated by Concentration Risks (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "iaa7500ddcb0b4d0db3443cc56170ff61_D20221231-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i005e52f0aa9441e9b404ce8f42adc3d6_D20221231-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i85a5140525004434a113a31a2b6f9fec_D20221231-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i47c0db749b524417a3bfe38e87216ea8_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i47c0db749b524417a3bfe38e87216ea8_I20221230",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Revenues - Contract Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
     "shortName": "Revenues - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i1d81ebf2e8e74fce85e25162934a4d6f_D20221231-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i4acc2ee076ef40faac1edea03e68040c_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i11c0ff70d2a2430fa83299f494f4c105_D20221231-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "ifa11613f3ae54abb9a1445d4727f95f1_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i2b291b148d264039a3e055bce29bb22b_D20221231-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Collaboration Agreements And Business Development Activities -Royalty Pharma Narrative (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities -Royalty Pharma Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i2b291b148d264039a3e055bce29bb22b_D20221231-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
     "shortName": "Collaboration Agreements And Business Development Activities - Research Collaborations and In-Licensing Arrangements Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if9ade2259f534177966ecdd8ce949ae1_D20221231-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Income",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
     "shortName": "Condensed Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Cash and Investments - Narrative (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Fair Value Measurements (Fair Value Hierarchy) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails",
     "shortName": "Fair Value Measurements (Fair Value Hierarchy) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "ide3e32d66598443986f9b93c38b9a643_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "id59bda9dff304a61a0e935254d1873e1_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "derivative_instrument",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Fair Value Measurements - Narratives (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails",
     "shortName": "Fair Value Measurements - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "id59bda9dff304a61a0e935254d1873e1_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "derivative_instrument",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Inventory (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i0a3d041b493744caa9156b79d698c6f6_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Stockholders\u2019 Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders\u2019 Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Stockholders\u2019 Equity - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders\u2019 Equity - Schedule of Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "ib798adcf0e30410e9cf0c303568c4dd8_D20221231-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stockholders\u2019 Equity - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails",
     "shortName": "Stockholders\u2019 Equity - Schedule of Employee Service Share - Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i5fd484e891fd418a8ed42f45f84ec5bb_D20221231-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Provision For Income Taxes (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails",
     "shortName": "Provision For Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i08af1f4087d548b2a2c27bd855c5a14f_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i08af1f4087d548b2a2c27bd855c5a14f_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "icb5f735f185d4a9dbe1cc597da942150_I20210430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:LossContingencyNumberOfLawsuitsConsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.exelixis.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "icb5f735f185d4a9dbe1cc597da942150_I20210430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "exel:LossContingencyNumberOfLawsuitsConsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i1508ac4b174b4c78a254a72746c9b9ca_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "i1508ac4b174b4c78a254a72746c9b9ca_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20230331.htm",
      "contextRef": "if8e59070b253456ab9e3ca2ff9431c6a_D20221231-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 56,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_AccredoHealthIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accredo Health, Incorporated",
        "label": "Accredo Health, Incorporated [Member]",
        "terseLabel": "Accredo Health, Incorporated"
       }
      }
     },
     "localname": "AccredoHealthIncorporatedMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofOptumSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of Optum Specialty Pharmacy [Member]",
        "label": "Affiliates of Optum Specialty Pharmacy [Member]",
        "terseLabel": "Affiliates of Optum Specialty Pharmacy"
       }
      }
     },
     "localname": "AffiliatesofOptumSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AmendedAndRestated2017EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended And Restated 2017 Equity Incentive Plan",
        "label": "Amended And Restated 2017 Equity Incentive Plan [Member]",
        "terseLabel": "Amended And Restated 2017 Equity Incentive Plan"
       }
      }
     },
     "localname": "AmendedAndRestated2017EquityIncentivePlanMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CardinalHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health",
        "label": "Cardinal Health [Member]",
        "terseLabel": "Cardinal Health, Inc."
       }
      }
     },
     "localname": "CardinalHealthMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks, Discounts for Prompt Payment and Other"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commercial Milestone Payments",
        "terseLabel": "Collaborative arrangement, rights and obligations, maximum aggregate commercial milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateCommercialMilestonePayments",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate development milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaboration Agreement with GlaxoSmithKline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative Arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "label": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "terseLabel": "Contract revenue recognized, including revenue from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInAccruedCollaborationLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Collaboration Liabilities",
        "label": "Increase (Decrease) In Accrued Collaboration Liabilities",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedCollaborationLiabilities",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Research And Development Expense",
        "label": "Increase (Decrease) In Research And Development Expense",
        "terseLabel": "Decrease in research and development"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpense",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen Pharma SAS"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LossContingencyNumberOfLawsuitsConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Lawsuits Consolidated",
        "label": "Loss Contingency, Number Of Lawsuits Consolidated",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuitsConsolidated",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NumberOfBondSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Bond Securities",
        "label": "Number Of Bond Securities",
        "terseLabel": "Number of bond securities"
       }
      }
     },
     "localname": "NumberOfBondSecurities",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NumberOfCountriesWithDrugApprovalExcludingTheUS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "label": "Number Of Countries With Drug Approval, Excluding The U.S.",
        "terseLabel": "Number of countries with drug approval, excluding the u.s."
       }
      }
     },
     "localname": "NumberOfCountriesWithDrugApprovalExcludingTheUS",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OperatingLeaseRightOfUseAssetAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset And Other Assets",
        "label": "Operating Lease, Right-Of-Use Asset And Other Assets",
        "verboseLabel": "Right-of-use assets and other"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAndOtherAssets",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PerformanceSharesTargetAchievedOrProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Shares, Target Achieved Or Probable",
        "label": "Performance Shares, Target Achieved Or Probable [Member]",
        "terseLabel": "Performance Shares, Target Achieved Or Probable"
       }
      }
     },
     "localname": "PerformanceSharesTargetAchievedOrProbableMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products derived from other compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities",
        "label": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities [Member]",
        "terseLabel": "Research Collaborations, In-Licensing Arrangements and Other Business Development Activities"
       }
      }
     },
     "localname": "ResearchCollaborationsInLicensingArrangementsAndOtherBusinessDevelopmentActivitiesMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RoyalPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royal Pharma",
        "label": "Royal Pharma [Member]",
        "terseLabel": "Royal Pharma"
       }
      }
     },
     "localname": "RoyalPharmaMember",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20230331",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r200",
      "r442",
      "r494",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r200",
      "r442",
      "r494",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r197",
      "r395",
      "r440",
      "r452",
      "r488",
      "r489",
      "r494",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r197",
      "r395",
      "r440",
      "r452",
      "r488",
      "r489",
      "r494",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r198",
      "r199",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r441",
      "r453",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r198",
      "r199",
      "r415",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r441",
      "r453",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Abstract]",
        "terseLabel": "Contract liabilities:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r451"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r22",
      "r23",
      "r122",
      "r404",
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r19",
      "r23",
      "r79",
      "r363",
      "r408",
      "r409",
      "r468",
      "r469",
      "r470",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r4",
      "r451"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r474",
      "r475",
      "r476",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r71",
      "r72",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "netLabel": "Total stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r104",
      "r121",
      "r140",
      "r182",
      "r191",
      "r195",
      "r214",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r340",
      "r342",
      "r355",
      "r451",
      "r491",
      "r492",
      "r530"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r116",
      "r124",
      "r140",
      "r214",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r340",
      "r342",
      "r355",
      "r451",
      "r491",
      "r492",
      "r530"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r202",
      "r221"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Debt securities available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r60",
      "r205",
      "r402"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r60",
      "r204",
      "r401"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r57",
      "r201",
      "r221",
      "r397"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r83",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r42",
      "r118",
      "r428"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r37",
      "r42",
      "r43"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash equivalents as reported within the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r37",
      "r94"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r100",
      "r110"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r235",
      "r236",
      "r418",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r474",
      "r475",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r451"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 324,985 and 323,951 at March\u00a031, 2023, and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r24",
      "r130",
      "r132",
      "r136",
      "r398",
      "r405"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r48",
      "r49",
      "r91",
      "r92",
      "r200",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r48",
      "r49",
      "r91",
      "r92",
      "r200",
      "r414",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r48",
      "r49",
      "r91",
      "r92",
      "r200",
      "r417",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r48",
      "r49",
      "r91",
      "r92",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r50",
      "r91",
      "r93",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r48",
      "r49",
      "r91",
      "r92",
      "r200",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Other Assets and Other Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r251",
      "r253",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r251",
      "r252",
      "r274"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r251",
      "r252",
      "r274"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r251",
      "r252",
      "r274"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenue",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r27",
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r47",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r203",
      "r221",
      "r228",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r212",
      "r226",
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r212",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "Accumulated loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r209",
      "r222",
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r210",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r208",
      "r436",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r211",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r321",
      "r322"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r40",
      "r180"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r84",
      "r85",
      "r87",
      "r88",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of contract"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r273",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r286",
      "r314",
      "r315",
      "r316",
      "r320",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r137",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r161",
      "r163",
      "r165",
      "r166",
      "r167",
      "r171",
      "r346",
      "r347",
      "r399",
      "r406",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r137",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r163",
      "r165",
      "r166",
      "r167",
      "r171",
      "r346",
      "r347",
      "r399",
      "r406",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based payment arrangement, nonvested award, excluding option, cost not yet recognized, amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r64",
      "r114",
      "r133",
      "r134",
      "r135",
      "r148",
      "r149",
      "r150",
      "r152",
      "r158",
      "r160",
      "r173",
      "r215",
      "r250",
      "r317",
      "r318",
      "r319",
      "r328",
      "r329",
      "r345",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r348",
      "r349",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets Measured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r246",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r349",
      "r367",
      "r368",
      "r369",
      "r438",
      "r439",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r348",
      "r349",
      "r350",
      "r351",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r246",
      "r277",
      "r282",
      "r349",
      "r367",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r246",
      "r277",
      "r282",
      "r349",
      "r368",
      "r438",
      "r439",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r246",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r367",
      "r368",
      "r369",
      "r438",
      "r439",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r225",
      "r227",
      "r230",
      "r247",
      "r249",
      "r344",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r436",
      "r481",
      "r482",
      "r483",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r120",
      "r232",
      "r396",
      "r437",
      "r451",
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r28",
      "r135"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r325",
      "r326",
      "r327",
      "r330",
      "r332",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "PROVISION FOR INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r142",
      "r159",
      "r160",
      "r181",
      "r323",
      "r331",
      "r333",
      "r407"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r394",
      "r471"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r123",
      "r429",
      "r451"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r464"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r140",
      "r214",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r341",
      "r342",
      "r343",
      "r355",
      "r434",
      "r491",
      "r530",
      "r531"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r97",
      "r107",
      "r451",
      "r473",
      "r484",
      "r529"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r117",
      "r140",
      "r214",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r341",
      "r342",
      "r343",
      "r355",
      "r451",
      "r491",
      "r530",
      "r531"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "netLabel": "License revenues",
        "terseLabel": "License revenues",
        "verboseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r37",
      "r38",
      "r41"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r41",
      "r101",
      "r111",
      "r115",
      "r128",
      "r131",
      "r135",
      "r140",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r164",
      "r182",
      "r190",
      "r194",
      "r196",
      "r214",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r347",
      "r355",
      "r435",
      "r491"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r182",
      "r190",
      "r194",
      "r196",
      "r435"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r44",
      "r54",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r75",
      "r76",
      "r78",
      "r129",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r125",
      "r127"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of $(1,507) and $1,656, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r21",
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development technology"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r451"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r36",
      "r69"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "netLabel": "Net product revenues",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r61",
      "r109",
      "r403",
      "r451"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r108",
      "r112",
      "r451"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r73",
      "r113",
      "r532"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development technology"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r416",
      "r460",
      "r472"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash equivalents included in other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r65",
      "r106",
      "r411",
      "r413",
      "r451"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (Accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r114",
      "r148",
      "r149",
      "r150",
      "r152",
      "r158",
      "r160",
      "r215",
      "r317",
      "r318",
      "r319",
      "r328",
      "r329",
      "r345",
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r178",
      "r179",
      "r189",
      "r192",
      "r193",
      "r197",
      "r198",
      "r200",
      "r272",
      "r273",
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r200",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyConcentrationRisksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r276",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r262",
      "r263",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues Disaggregated by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "verboseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration and License Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r67",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r9",
      "r10",
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r43",
      "r95",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r283",
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r50",
      "r91",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration Risks"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityScheduleofAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "netLabel": "Collaboration services revenues",
        "terseLabel": "Collaboration services revenues",
        "verboseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails",
      "http://www.exelixis.com/role/StockholdersEquityScheduleofEmployeeServiceShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r98",
      "r99",
      "r103",
      "r466"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r64",
      "r114",
      "r133",
      "r134",
      "r135",
      "r148",
      "r149",
      "r150",
      "r152",
      "r158",
      "r160",
      "r173",
      "r215",
      "r250",
      "r317",
      "r318",
      "r319",
      "r328",
      "r329",
      "r345",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r173",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Share-based Payment Arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r2",
      "r3",
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive plans and stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r2",
      "r3",
      "r65",
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive plans and stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r56",
      "r451",
      "r473",
      "r484",
      "r529"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r247",
      "r249",
      "r344",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r481",
      "r482",
      "r483",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesResearchCollaborationsandInLicensingArrangementsNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesRoyaltyPharmaNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r400",
      "r447",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises",
        "verboseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r174",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r143",
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at March\u00a031, 2023",
        "periodStartLabel": "Balance at December\u00a031, 2022"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r146"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r162",
      "r167"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r161",
      "r167"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL108322424-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r455": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r456": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r457": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r458": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r459": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5291-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0000939767-23-000048-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-23-000048-xbrl.zip
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MC\(Y<1+CS.3RWHC'1DHK.<\EJI,3>H'6##[Z\MA*NV<.T(&S1*UVGA(NF-5
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M7 ;G9XLXY$7+/0410+$@HJ4  9AFEB<OA5V$]*2/)[Y9[,-UW ,#$G(],F+
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M+IM"%/$F)DH,9PG*0%'+"KFS%SXX'D*47A"6:RAXT"1HZ4$J22D195A?._=
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MLC%-2(K&&B;S6ER?K&9>&*>4\H8J4X9ZSO<1\U;W'%JC^B6+*$5TXUW@T@&
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MXI,J0VP/FKV\%SX^/Z^/WCHW\+(7_SF-'7]^79FN3O[BU%S9X+37:W8.)K6
M^8M'NOKUW_B2>=[E_'6>0_G*4VUT3DX'_>$9=&(/,T^^SP2W9W#.@@9IN0F"
MB@ NFEP"0!&#2F;*$/.<0\6=K*X\JL&PDB@N0Q)KM,D1E"B4L  *QV<<NH$#
M9R15BCM[Q9T775'.>L4#B89H(32UCALF?4PRR$"%*X&N3"? 4VI=?01V,"\*
MG#1H3\%(9[6@2AD7E:-,".\(IZ8,]+)2X%]YM+8I*24X,!JY8 P,\2$1PX)%
MCSLF42GP_"CPO.@,35X@TEFE(:%/K5!I-/ZTGB/7\[)R3>9UU)R<395[/1%1
M03IG72(2::<EUM@\>>6(\D:[H"H%GM-1LU+@L0)S%2!);@-"L?7&::Y9SIX=
M( H")=CI-H\*O-@ZDXQ.)! B!2>"B(!HYQQ/0E$C*= J+C,5G?FAV>FY(@OS
MHK><,PO*IN -".T=D.B4&.:7X5:F:K#^Q?2V+)YUE%0%11P57@MMB)6!)VD<
MUX(94"7(P+WP>CLOJL(IX38E3:-6@JL\7^U%S*DI+'? JJ&Y&B._,X_"D/<S
M1ETT00@PH+T&[FVTB1H2JXA,-5A]9R=/Y)&SH)0<EHVP1B7K+/?<."1?H@1[
M@G^],&P4"2)*A"8^G&\R,B3G<\50H7RD%<&8UU%C@FRGG/NA-/C :"!< 1=:
M WAC(2KO Y6!TC),^\^AYDY86:IQ\BZBI1!L(ZA<&DMPEP.ODEEI1"!,0JJ(
MUCQH[KPH"T$M$4QRP<$)(PA(8$1)#UX*%60)2JG-H[*4:H N\[980:.P5!'B
M7!"Y4J\BTB/#3(8':FGE$\SK8%FI[W"HML38X)R5$ 0UT@1T95F>-[#6IE+D
M0YI#]5UDC1$QY%25"KR-0DIC M%2)J8<!R(Y*<%FLSG4F'*-UZ7,DV"E!I<B
M)$M )&.,UT%%QQ*7.>5J&79)SJ'B5GN%IK\-WC)FF..&,A!>,I#144T%?IV$
M(KI2W-DK[KSH"G?26NF)%#1'7Z(C"')!,)HC+Z!$"73EEUFI/E?L8%X46$GO
M8H"4-$_"&P<@-*?<)TV-H6X1LDQ4"KS(H[4/W'(5<B76B CLP 23M&<,'+K9
MI@RC]2^CP/.B,XD1+8QD@2<OJ% @)8LX9),4@Q;C%*'SK3.+"3J+O5=H@KZU
ML380(I321&AI',G9(D7,V8=43%50:%Y'S4J!QU%-J8PP5(LHG* T6!U)H$9;
M H8*82L%KG3FELY8L(YZ$T $@2Z+Y89K1;G,*0JIK4!O]FO7YXHLS(O>!F^(
M(2SB@*U$<M&2F+-MB[P.FGI2AK2:E=[^@IZUIC1IAUBKC$4O"7\H95.,W$=M
MG"E#!O)%U]MY4165)TBX$BH8AM1.N%S:+6HK)5A&?47GJC'R.]P.D,,!L]JC
M/Z"I RD3]]H12)H8SRL%J@:K;Z?_D9Q%BZI#$(%\XM9QII1DQD7!'90AZ?\O
M%X9U"A3U0G/A0$3G'8E)$F&,<J!"K&0VKZ/&!-E..3/ TXC>G#?)\4B%= :2
M)TQRB@,6P_&K#!4LYE!SJ[U"CQ",4,D1XE%EJ15 "( G.AF)/ZF(OL+<>=#<
M>5$6[:Q'Y0"2R_610*VA6DG-O 1@8%VE+ L_0)>L$,CUI2$IKPM),E"CA. (
M>C9G\.;.)2V2KT;I>1TL*_4=DDRMM;3:<NV9"$3F"5/O@J94#>L85.I;:<P-
M<B>M"V!#2IP(R+5"H^6229&GUGDL00;.-7S9CS!H?HR?Y;/5[!_?4)5N+S8/
M.NMG_A Z!Q$_?H)>F*J0'K2AZZJ.5+AZO0_-J_>[N[#4G:=>MG^OHE7QM'>K
MZ6:_*QC5S]9WM^[3UO4@?V) 0$8"R0K+/9#$F$XQ6$Y!Q/!A;8Q'M*C4[$?4
M#%6I-UA#P/F,!E>*]OG854^&RU-OZ.3ED9^9OQ%$J4 ,]K07E$40Z!!&YB,'
MRK4J0:ZWY]!"7(_;AS$.7G<1O?'H=6EN=#YBD]W>M O93C C3:1*1A2%#THX
M+AUATFC)4@B<!U*"9:KS(Y4)UG\69CA%11W1(ACF0J0B))83L%A*2E W_>M2
M&8X\FX/#V'O=[1P,8J^]VN_'05D,QGNF\]921M%@J*?.<99HM&@Y7%E=@A5B
M<R::R5D-RB%I[93U5 IIJ(.\VEX%I9PQBNOYMYHW*)D&M.,7XEC%DT(,JYVP
M%;%G!C$P0O7Z/Z?XW!LHQDYF&/FZDMB/T]9 \(E$]!\H.@_XJT>A2&6\",&4
MB.%A]W?;<3L+)5]Y]^"#4HLY;H$"7,MQB>Y)/G?][ 1;BXO(\PB:(-526Q6,
M4#JZH)/4B1BG2312C 1,*!D*F!%!*@'_O("Q%\F]!(RGBB].?8" (P7C.$]<
M\2"<)^"M4SH0X36*/L"B6?!V;+6:G8-7L1-[T$(QKX9VL]-$GV[HW8TE/85!
M<O:V+"1GED+,:=Q%X R4!J\]0R8:4TQRT6QY7D0] ZN6*0@CHK$TY:Q18&(0
M+ F9\$LOG2N15:_F$,K.^4F\+MSU]DFK>QY1![K^>/,D2W\1;1:L$$(9+FW0
M(E'N-!C"*3CF6/2&ELAFYTB0,[!( ]0X$Z-'%T8XQEV(&KT8[T$F2*E,L="O
M"#)[-+VF1Y]F*,K=3G/0W]K>742KE$H)P!$T(C,6)GIPCBH:&#7!*F55^:UR
M5L*<@64J9U)$!I0XY!W1P5KT7!FWQ ;N*5F L?)-[*5NKSV*$T%O,=EM#,D%
MC\XI3THHBP.FC$D3ZHWS/!>&*[U-/KX89V"-@<4@"7HI*B1ADP'O@S2*,\4A
M^:3*;XW7",\B6J))"K$TB4BC$-1Z)\%&+3@3$GV19,MOB8\KPAE8H2-@ J!H
MI#,(IL)Y)*W#/ M6)[ E6!<R:UXSG53\43D7 ;$P%\B*2#<-?@PL><$EE26H
M.#*[H6TZV;F=I=8QK;42:"#11>92 $ER@5I/2K ,XH9 AK-4MZ2Q [V#.%CU
MA\WX,8;-WIM>UX%K32$@/AVS,9!H$L3H((5Q#)AGV@4CI9= 12H3I\ 60K-U
MF@.8GQ.[K9_YUFF(X66OVW[1;9^<#H;AT,VT#KU.LW/01XD.)?G\_.X&;@1.
M,S3F=O#NPX:F,R,Y>Z:B"=/9=W?(4X1(N5XE2]&0"-()_*5,3&5Q%6,&_ <Y
M:])<)FID$&"#B]1[:74 *QB5HW4AE(CIKPOY,<RDN0=^?/G%T^;9,X3Y[FG/
MQ_[HXR'RBN']0_/CRI_XXW(M$PE!>)[_"$,<T&B"%5%*8XU(]$,VD,_7] ?G
M+7SU=K-3',;FP>'@F2!/Y,G@CT_-,#A\1@GY_Y>NGXDC#9X\Z)X\LWA:?KP"
M6LV#SK.\."+F]:F#//)<GN^Z/7S,PG=;+3CIQV>7O_P1FOV3%IQC%[2:G5@,
M+_ICW+KK#@;=]K/\'!_SXFT/K?%-AO<;'?[\B$_(Z#$'V!V#<'GG\>$GPT-/
M!^'V,<Z>,,Z_>I@\H5\]-JMFQ;V:?3KLB5%O8(?W3P"!B"]=7G "(2"V/&,G
M9S5Z78BMF&[U^:B[OZH&%,6$!_--+H_B/;N]9__*AI/2'PFUN$C0;K;.G_W/
M"VS3]9K_L]R'3K_HH[Z/3^@W+^(S@T\S_/3I4AG)'T/U&"MGUL?1XX;H<P)5
MA+AGIQW4L'P6/@7,^A%JA[V8_EKZU_<-42^M[ PMI9MJ+[*A=P;]/Y\"2B]W
MY:617LKZ&V(D68A+/W[J4$N>#@WOZFXW@>$N^_Z*I+&??J";J;C1S_IF/[-L
M"KN-C9WUM=KVSNK.^O;UGIFCI]Q>?[&[M;&SL;Y=6VVLU=;_\^+?JXU7Z[47
MF_7ZQO;VQF9C!H_.[O7H[Z%_B)HQZ':6:VM/7CRI,72,[%<?]Q[P/[K2]9ZN
M_-!+/_*H8>T328:V\)51XYI)73MH]1,MOW[XF]=.K.$QQ%^>,98I&YGWW2 P
M[M1Q-^&9M7ZWU0RU2^4:'Q]B^JV#WQ@S>OG6-[N\W0RA%1_9#E]N;M6OE.[K
M:#BMCKAK\)Q)/_R)_+#3[31.VWB]KXUIY%8>F)K)1&F))BY7C)0*G(W< TO)
M"DZ]NG,]6:T#F2"'V'RVUO7#O34Y(K$TGA'@[\[=6O?C:[;U<8_73\/1^L?]
M5_9H\VB5U%]M'3=>U2]&_[T5]5=_'];?[XK]M6.RO[-+-]>.1>/5WMEKWFCM
M770_-=:>'^^O;1V-KR";:\^;>SLO6YNOWLK&JUW:V#F0FVM;[?H[<_::[9_O
MO?>JOE.G^^V-3PWVKHUM7>!?V5@[OFBP1GMOY^W9_M$>V3NJG^^WZQ_#JY=-
M]VH7KSF0>ZQ^UF#U\[V=/=98V\+['K/]HY?'^SL;YYMKNP1;:N]=K(ZO>8?W
MDIW]G>[9YEKK:.]BG>]=_'W8P+8;^(Z;.]CZ^ZU6_6A#-';P^;&E^DOSZ?7.
M^J"^3<[PW[/ZVC&M'WP D#I$B 7GX OT4&SAM-=%U#)Y%8![RI96*"G>#GG^
M9SFN7%/M.T;OB>/TW)%]2022_9^#;4HN+YTP; O[ RW?C=O9KK^*V]] G)$8
MODK8)X,YY'N,^+$PY^TI]/!U6^=;\:3;&RS5AD'0 =[@;/ L-<]B* :]TS+#
MTAY[BZ"S\6ES[>_F'ML];[S:P'L=R_K[MW3O:.-L[^)=:^_]?K.QMG$#EDZ.
M]M?J;.]H5=3;?Q\AA&';;\7FSO'9_MJ[9OWHY5'C_;M#?!Y2;V586KT)2R+/
MY"JOBL"%+H0,M,B!\\)2YB0%X2FHI97__I?50OWQ360JLQ;_][^H(G]\^?/M
M[NK6SOK6Z[W:UOJ;S:V=VIO=K>W=U<9.;6>SAL1_!]E]C?+:YE:-RM_"[[7-
ME[6=?Z_7OO )KOR!U1<[^3"U7/P ED_-1; _V26CGR^[O=K@,-;^N;3*VBAZ
M51ONH*D] AZ\&=YO?11%O(X& ;\IVGC/PWQ9$>"\.(_0*V*GE.CP3H1__]W:
M9ZV/[JA[5K]XUT9+Y_OO]PC2#/Q[3#9WZGR/[1\VUEZV&T=;S?K%W^T]:L[J
M.[L?D%2DD+ S 2P4(C@H#$>"$8U51ANON4E+*_6\K:+&Z7(M]_E7+7S.M+/;
MJ]A+Q5[*P%YV>OA\S1PN_#I]2=#JEYF_-"Y6S^KM==JX6*?UBX#/N'M1?_]W
M<W_G^%,#D0KOPQI'!Q=UMGO3K>+UM75TQ78Y(A;>XRV^1_ULK_UW:W-GE>$[
MXCOML<VU^L7^NSOYB]))46YCH:0VA?"2%$Z!*13W1$4O@S%ZS%_$K\1?=K96
M&]L;0Y8R40)3FT<&<W<X)!<B;?;S=&SM91/Q'J7N8N_9U1L\XG U19Q9'\Y
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MO[=VC9*HA+."%5ZB8R \Y07V/\,?,:][SG$S-UIM4VGG3P+L957 T9*PFZL
M\F!6^@4 CZ? MR=(/7##48%C#CP(5%KT<:4O K6>JLB)) PI$[HR#>@'^&<,
MPJ,2Z[77KU],9C>TN%3O9B=/KR'Q_U;VFFEX>1N=,*Q%6W/G-7\8\1WQ\8Z1
M(,7A/&EVYCZ[M\]JO]'?1^[>(?1KJ=E"CQ!:+3PE[R')CN(_I\WL)J)WZ.+X
M!&SYNJ?(\P3K:'7_V%_\PM>\U/OL0^;#P]7]X337Z!V>>M*+/@Z)+&6UX9ZZ
M?NTW; \MI-8_15;7/^SF)6F7^_\&AS"X\1JU3W#]4?-SCBX>O\COHQ# ;^R+
MMW5H;'B2.\)WR1<-S\<K\Z.,&QN6%!X^R?!)H3^H65(+<-[__<F7NR!JHW^F
M'IM^<=KKX2.-=OCD(6\ @]-^*1'C03&M\P]!*1H,E06:?2B$H5#8H$2A%$_&
M)3"<H[WOQ?Y-N_Y2;#^X(/\]]GA6U/X#-[RB!OPQB]TAC>Y/O?9JKPFMVFZG
MF>-CM?KV ]]^O$/J!V))Y<#26L84A)-V<S! %(HMA)5>MY-I3>N\%I'BG-<V
M,ML!/XP>KL$ 1AN&;H#LYS:^C,UMG>*9@L@,H5OQX+0U6K:Q7>Q,&TQ'SW,%
MC_$&]ETSJ.FOK;SJP-Q_8SS\Y0#0\P\BZCQ!)XM /"^$PQ]6Z80HR+7E7CIE
M0@6 %0 ^(@ V^S6HM7*NZ!IXCP#8RQ5.AYC1R_SKSF]KJ)K%G0?Z;41.O$OO
MDNT@GK3QW<^7,]W$YI">Y;XZJ!WTNI\&AY>'GR#[C,-G"S$U.\,]T?T,FWDR
MA^%K?N4)AX?I'Y>G??>$KS_?Y8F9<HY/_LJS7I[9[ P!_G+FQ15L].N83G_)
MH9^49Q[&D">,F)^:AZ%/-#>3GS!Y8LGD9W<8?R*UG$9&5CJ%I^5/J+IWJW=$
M<RZ5 ^TV/GQVZ9L981]MSN&1=D[W7B":''1[YW?$?X8G#7'&CT\J=2AH?R<<
M[^/S[;&_F_OOU_$:Y#$L9[1K-/?7UGE];>NXOK9*]W;J-W<.MAH,[X_/F-,S
MX'&RWU[G>^UU5F=_']=W_*?&J[>?ZFOO#NOTSKT@5"<:)(<BL>P:4JT+L,(6
MP5@3G8* ^K^T\OKN46 >4S=,BG^0*_ZA_GBT%?#S8N"KGR4]&EK'XEY$\8K[
MB'<Q<;QQ%YO\A:6\6$:\/:+<(P.^XMVCCV-&O7"RGCHS&7;J\],^WKG?7\2T
M48_$19"#O+W%13Q)D1LH' A3".548;1BA8M&2*U!11$?DC;J 2#^LWG]?P6<
M6;_;6Z^PY4>QY;(C7PW[\<6H&RN,^6F,.;\#8P2 9,!%88BWA2#)%M:S5! J
M21!>Z90W/4T!8THR(9Z^$2O,:\#O#'$VTUW3.\-)'625G>YP3N:T/XHSXON-
MLM(.KI(P7DZPY(F7?*_6>;[YIR;>&F];Z\1/.8C9BQ^;_2%+[4#'9\-&[IJ3
M1>23<^VF +V0%Y]W/S;#W8NU:Y3_!G?-N^=080W_S"C&3Y6Y5Y!;S5Y!?CS(
MW3^,K=:E#M5^0\T8AII':72&,W7#&&[MCO#MUR?/]F+_ 7,STYRD>%35*='$
MT&1>>/H$/VOK0HZ]#YI#91],5,P:&PHI=,[GJ'T!*?J"&:#2!V.5$Y?SE3^S
M+6KV$WBKPXFO.IS7QHFWES,@]6+M4_XQUKR7PQEU'$I..\V1WO6'95^7KNMB
M-!"H@R2\ )&8<U()0HGT1BE"DQD7NY4$53!$WT2WLO_7TD;CY1WKF(8+H8=+
M\$859C=/!\/A#HWINH9V3MM%Z [W ^0&D90@=<:VR"^GK^O\@Y(T,A\SOPNA
M$!YMUPC/"A4S($@.+F^QY$PN*ZZ6-3>72GLIX97:2+*7 ],=&]W\:(UZ?[@\
MLOM9+$^^GDKT>FG'D^Z( 3WKQ;Q&Y6/\:K''\50B^7P)N'ZW=3KX^B7?,"ZN
MKHSKKI0C-RO0W:^<I5ZZO.:P]]G%.XB%ZT4X1K1 C^X9M#[!>3]GS[R[YJ44
M]ZMX^:BE#MGL2QU^^Q$F7NIPWC:CW\Q=.:=[YF]5*-ELU'(EM-JHAM2</O5&
M8VW]/^59*?& ,K/FB9&37WR@I[,1-C^LFN2&U<F&)B>>\'6ZF;[NWLOR!L>G
M[^]_M#\;CQUMSODY4_^Q >1>>W>F/(@]]!GN/XI1@J)#J*UMU(K:RXW&:N/%
MQNIK'!LRV*[N#*N\WEF^=[*3MM/<>W5W$'IC$-OCA6]/'A9A_Z:Z3DLI9U!$
M^J'/\ -*R9=67EX%)X=YJ]H_74EZ @ S+ 8[-7Q9>%'RAT'(Y"?W;LEZ?'V1
M3WY&Z655ATK>/RYOE3><9]\XSS#@;T,J,UP4\QQ::-&QMGT8XZ!?^VVW Z>A
MB4=^K^RZE'(NFUVSRJA_4MCVJT;]>7#.<9"<A+X=*],NO;1%R4R[&K)_7MZ,
MW=.Z\V1>+Q[B>7DG:67K"R+[RM9_(7G+>]KZ<);TL-O"6_3'LW2U]7].FX/S
MRN)+KP&RLOA?1][FOJ,[] ]K+UO=3Y5K7GZ)J\K"?QEY<YJ7$@YB/Z_/_8JI
MWQ5-K\R\]&+7"S\YQZK)N3G3.Z675NK0@8,ABERMX%MK]OWIJ!Y]3D"RVH'6
M>;\Y9!:?P2>CTVBC0CYG*_9/6R/RL7D21X]4S?&54R,867@HXA44S9GB&;:T
M\C;O3&H.AFM^AZB"7[0N/V=0:G7[IWGQ\:KKG@XN4Z]N-?O'%=*44N#\@?'*
M$B"-J)!FWA1O%#<=]% .0Y1YT^OZ&#*P5#!22FG^&(Q4ZU;G;-VJ,9?K5O/"
MU<V=?Z]O_2*+5FO5>M5YPQ-+EU9>QP-T<(?#PC 5<C4NE%.._(&A\[G&CO&"
M]]4*0>9-\\322O9):R_!#[J]"CS**<*\]WEAP:-6Q>+G3N?TTLINYXNZJMO0
M&NVS'Z_5^2(S3_9:=_O#[<ICEE*A3#DE+A8YUEZKPNSSIG/8T-+*6DPPG*W;
M/<D%8&*GV>U] 2\5E)13K((N,I94@?3Y4SJ^M%+':Y"JI(@,Y8LIN@I#RBG.
MQ<8066'(W"F=6EK9'*;)W.B,TK9A4Q5ZE%.0"XT>HX"KJB!D[C3/+JVLGQTV
M7;-**U)6^?T8<E13^',VA4\I6UK9WGC56-W9W5K?_I8LOYKS_<M<EX^> O1^
M*C#IL668:)!-(LUHSOU5Y1FM\HQ.)17F]Y+*??GP/Z"R?.F+BQ[WC6KCU3=W
M;J;ZZ1=22W<(+Q=G+%" .8'RL_YI&\WH_!$QI]298U]L-M;6&]OK:S7\;7OS
M]<;:Z@Y^>+[Z&M5PO;;][_7UG>VY??K?FIW:X+![BFV$_G(MGOEX,LAE/48Y
MM&L!!O#[_#[]Z1<["K_RC'.7!=?:)T;2GTF"J\03Q=C$T]52^42+KQ_^5K/?
M/L;M_;+@_O##WJ\/)NO0MYLAM.)W?."'53>X.]/M]:(=#W$8[\[>>_5BC_-.
M0\.M0\\?UOBX7,.C57B<GPY8BSZV'<+LN _8M3[XCN;>5:MJMF=6#[S(O>'
M'Q_TNNA-%&.S\#Y&]%]^%D(?B2.,2B)O;W])P+Z1%OUK;SEF!$.G\JO)TN^3
M=_U[W?B0-G[\(7]8Z&GX9\Z$?G<L_,5IKX=87X-^/P[ZSWY*^C=>]Z>$,^TV
M)F2XM>&_;)@493[EF9,%Y16%/O\2_SEM?H36-3_X.AF\UXN3VDR*L][SE?_K
M0:_VQ\VX_UR\TU=+<9WVPXTZ7 1X(((Z8;D6P@-8*I73-BAKO$IJ7(=K6 KN
M<QVN@E^6X3KM%P< )\^RYJQV0OYG_;/:K Y>0*^7JU6^@]9IO%\U+C[C:ER-
MIFW[]LO.YM'N^5[[+:E?[!\WC@Z/ZVMOS_9W_CYL[!SS_5>[9XVU UEG=;I_
MM('WV3K<:Y^U-H_V\=_=B\;%!ML[\K)Q\?9\O_U6[.WLG>]=/,<VCN7>Q:JH
MLW='E]?@O4[WV:YJM%\V]W?JO'ZTWVQ<'//&VM_M_;7#P\;1WT?U5V\_;>ZT
MCNIK!Q?[[QNI<3ZLVCJLWEK?696-G8T/ED5(*;#"*L(*$< 4U@151,U-Y-P*
M)=W2BA1D65I]JYC7#??G)XSA$N!^P"@F.8I7D+0@D"2T)\%I89UD0E -W.6R
MY]%H1E6$46G 7*:25) T7Y!T<1.2O%8\4$$+K3TOA R^@)A( =Q8GCA- A1"
M$J'+U,HY@J0)<?:YYWO;A]W>H!C$7KO6['R,_4'[+K)WU0/LQWK@3I0M)21-
MBB4-^WL'NWOC<V]7"#0I!-I\<0<IHDPFX4/!')>%8,(6SBLHE#?,:IM_LJ45
MK=FRS%N$'X9 WT"!:9&B^WJ^OZSI3HI-5*8[9=.]11ZDH4)$$$7@)A4B2E<X
M*F2A"85 B;<BH.D:HI>9YG-DNK]*L&BG!R%7??81N;5KQ?YRK1,'/T4>[NNB
ME1*!)D4>MC[W=",.QJ'7"H(F!D';M]F#ER*X$%RA.,1" -#":>,*HI1 1\:;
MF-D#XWS9L@=#T/R%5"K;G11[J&QWVK9[BSY88H5VBA<D,EL(BCX *$T+FVR@
ME@8F<D4L1L6R-F*.;/=7B3UD'MT9='OG5;AA6HSAJHL1<RJPF138(, ,@68(
M.#OK>&SW_ .17 2N8Z$8"X6P-!:&!UU(ZB)/) 0&!M'&+EMBYLA7J<(,<T84
M*I.=FLF>WS!9*U(RAHH"P$ AA$B%HYH7E!%E@DT4.(Z)R.V9M7-DLK_JJK>Y
M)S1O>O$$FJ$6STYRJ9Y1:J[N<#^[O[9.J@J13(OPC$6P/I+ :B<,TPFL#GN]
M<KHF#JH;MWE0TD9YU(?"4.4+ 205U@E9& U)1:])2&QI19%E)>?)Z:H")G/&
M@RI+?FQ+ODF/?*0A29N*$+0JA$:BY"SP0D9/A3+.$Y<K$K)E1ND<6?(DPR=,
M/M'W8!LSL<F=[@!:DR 6X_>_U\+VQ<*J2;&."I6FA$KUV_R",X$CB>2(1487
M(KA80'"D4,)ZD-1(K6!IA2XKKI<5G52HY=[&4:(XS"]H\),B)Y7!3\_@;](0
ML"XYP5-!/)A"2(.NA6:LB)PJQ9,)%D8&3\VR5JPL!K\86P'OMLC7W<[!9!:5
M+K2K-"GZD;N[6I@V-4QZ>YN$H =DN.&JB"Q!(8Q'.J*C+'!TT5*FG!G&Y95I
M"E%IGI:U5U&..2,2E>E.VW1OT@D=5!3!J,(QF@I!32B,DJPPG@;N\ZI2BZ:K
MI5K6? '#&G/)%][TNB?X&.?#"9.\Z?@D6\+/KR9=Z(GFR4V5C#K]30LZ@]5.
M6+_L]VKB>:(8M'N;/DA.F4-Y%<$*4HCD7.$X$P7503H#0%6BZ-)0M8Q#R!S-
M/%>+1>:,/E0V_&@V?)-'<**4H4$5G MT ;PD!3 2B@@N$ ::HT5G&R;+BCUX
MHG/^-J?,)8]8BRGV<KFT 9R-9T2J+2E3)1&7/;[1\=UVW(&S462T@I^)PL_>
M'12")"=16(6(QA>".R@,H1HQ""1+WG(BU-(*8W99D6ICR@):\*0H1&7!CV3!
M-PD$,48GDO+V%/PADJ&%#586TFF); (-6$/>6D:7D43,D04O<B#B5;<;/C5;
MK2KJ,"W"<-G#%;A,#ES\;7I@M0-.N2S 25?@(*$+1Q5RA.0T$(>_4[>THOBR
M>OC6MRK ,'_F.BEV4)GK5,SU)A=P+!D# MD\-\@%N%*% 4.*I*QT$#Q)6LVA
MN2YR+&$K_UYT4W':C^-8PN?]'%5 8=+\()[%UK/-DY@+ZG0.7D?HQZ$$-M-N
M/PY=DNM+P"M FAP@'=SF#XSY(!TGA1.:%0(]%:0.414^>1&8DXE+C\Z)L<N*
M+6 JT<J>'TH@*GN>J3W?)!@4#3=%+0KN&<F[LEAA19"%UHD$&S0/B>3=Z619
MZ@>OF9Z_8$-)-G/<O8ECNNNXYZ8+[I_T^(??N_1H/-F-*A763@YKC^_8 1N=
M%9P;!%<9"T&4*&S>IL)9XHKH&$BR2RM\F0J^S.6D,@N498=*A6:_/)I-=A=.
MA6831;.;S#$B@"4-KA ZTKS]AA;.T51(,($8987R/*,9T719F-*@V6*$KNZN
MQ/5Z8_7YQNN-G8WU[=IJ8ZVVO;/YXG__O?EZ;7UK^[__91C5?]36W^YN[.Q-
MJ%H71R&$[FDN[CG'Y;KN^Y2+/,%Y6:^KU037;#4'S5@5[2I]WJ%5[_$M!OW:
M"9SG#*-5K:X%+8PS,3=PK#!O1OI2[6.>-)$ZNB,QD@J.J;S !T2PA0B:%2Y/
M](E<"D=Z+T1.7,#9LF+SM.^H*LY58=!4G+<*@Z:/0;><.;#,0U0%HWF= ?.^
ML%**0J:H2$C2X=\1!JEYFM7[53)BHTWT3F-^QW;.>@9#6\R+#ESLQ-2L"G--
ME1+EKE]OG[2ZYS$^'W=X!4L3AZ4[<CHYJZ31+A8*DD!"%&3A(@D%U4)9X5)2
M(5<)5,M2/I@:5:L5Y\^()\@I*B-^+".^M2&2$1U\BD44.5H,-)?*\:301$1'
M)8AD8BZTMTSE/"7 _X6"1"-N@8?RL]0&O2;^_"(06"UJG,JBQG''OQCW^^O/
M'5[ATL1QZ8Y<32(YDS0C19 YC2VU>>F32MG[H8X;22CE2RM*++.YVF95K62<
M$W)1&?$,C/A6X,)(9@&@@.#1B GR"BNB+)C7CB 4$Y[K\"FY3/2#$Z94@8L?
MWRP1'0S&!2]2Q%_"::P-NC5_VL?>B+TJ<#&UP,6+<1=CJ]AUE\!T7L'2Q&'I
MCD1.U 8G% U%TC'OX095@%:L8#$1Q9RR7%B$);4LR(/30%:!B_DSXDD%+BHC
M?D0COLDMDDQ1A+PMPFI1"!%\87/9&F#6&N<48QP=!$F6N7RP@U %+AXP*=)J
M@>OV1K,B5=SBL>(67W9[A4S30Z8[DCP!14$F!84T02(\*5T8&G,6AQRY$(E[
M@_2"FF7^\!1S5>AB_NQXHJ&+RHX?S8[OJ*1E4@(HJ',)&0:UA5$:?05N 1()
M(KFPM,+(,C4EVGRY (5&'QYNF0F$;%ZK*?I0*K30'MJDPBRCK>HC**VBO]/$
MSSNR45CJK (K"P9YZ:R+")T^AD(J3QQZ;SQJO;1B[+(P:HX\M"K,,B<\J#+B
M&1CQ31*$3@OCVK*"1&:*80D.RVTLB'2"L>0E [JTHLVR7<1\V27)0#$I3G%[
M]]VO4F)P8D6]*GR:(C[=D;8!A2,5X:;@0'(./A8+IW-6?\(#(T(+KFE>&Z^7
MI9W4XOBY2=HPP5#,+VCS$ZL&5MG\=&W^)B=1/ :G')I[M X="\,+" Q=#).4
MY)[&P'VV>3&)1"V/9?.+O'_]<V71DVYO:);=A"8U+OO1BQ]CY_36_N?*@9K8
M8A-L--_N?7-P>#EG?15+;G0[OD*M":/6Q>IMID*TE($/(\DZX \>"JN=+SRW
M>=$)(\$@:JEE9B>5CJ6*ALR1,4]LT4EES#,PYENIORE!J7%>F!!R_N_D"[1B
M6T3J> 1&B!,R&[,T\U0)<#'2)_T Q^A>IK*MM7(NVVK]R:-,NES+'UQATU2Q
M:?V.Y:W.!*ME**+U/E<:DP4HZPM#'0N,2458KE-JU+(5\S1Q72U F3.J41GR
MXQKRK:+GA-N$PBLHUP0-F?#">OSA2:+6!K1SIM"0+5FF>IXVP2UR*&.TB*-U
M13:J91R/M8SCBS!KA4#30* [LI\EXG$,";R@,L0"12@+ TP47E \I"-1%*F$
MTLM<5T&+!33@B2[AJ QX^@9\BT*@X"3S"36(JT(8*PJ+8BP@:4.D T-RZC!%
ME^U<Y>CYM99O5,LV9DTPOH"F"I F!TAW) TSR820A"]8,@X9!7&%2]X6BD:N
MG44M]79I11JSS-BD*J!7ZS46PMBGL%ZC,O:)&OM-]L&"SAZ"*YATH1#$^ *4
M)H6/BGA/.4'ZD8V=+Q,UJ00@U4*-AQ0:Z+;;S4$[=L9E4[/]X3/'CD=CJ?W6
MZ YBC9+?'U)[X%[RN43&Z3"!LW[S6:?9^FMIT#N-M^=7K[I@M1->?-D!%2#\
M$"#<D=6+)L^=0"P@DN?1G['"4><*3@D8)JU"5R7;V0TDF%F!BBDIZX^,9)6R
M/I:RWAR]B/,R*AL*T$84PHE8&)X"*JO#,0W'&@[LJ\KZ2%/M,^%LVX.N/S[L
MMM T^O]3B_^<-@?G/U>/9H(E@Z;6QF./]Z'Y\;+M<1-%/O\9I<.MK8\LZS>]
MRV6:_2SUY=I_?0OGWL3>]B'TXD28^T;CY4V\NWJ:H0J^@=YF;WL @QC>0>LT
M?K[[&/I(!7WW@+Z]0?W%=>C#]EKQWUOG^^_#B6-"[;U_2S;Q6>O8'_M'K2/L
M#[[77O^T=_&6;[[:$XVU1K/Q_NU9?6TKU8_6/U#K"47L+$S(";:8A,(H(PL2
MI$!*9B27ZML#YE<4Z>?B/94BE561G)(ZJF"+9-&+%(2:PH(0A6)@/2->*HZ0
M29X0<CMZ?>N+V@GT:A^S?)=K7]6]?I9[_W'P:ZAC_=73P6&WAY <JFC$W.KB
MQ>X'ZJP5.9FI\2GE72>JL)% (1(5B@J!N*2_ 6IW*M:4\*Q2K#(IEO2"$AE-
M(5U2A?#$%T""* )HP84DGBJQM$+),C*\>Z#<2-%J<"7]821GCO1RH]\_O:&3
MR$Y]ULM/Z&_W8Z=2R1FJ9.-H]8,B/F6)%\H$1#B76 %.DT)112"R9"5G/XIU
M4QU$*YV:>YT*AJC@I"ULPJ$3M4$71MM46,Y1':*)WN/XV>G>'^*:0Z%?!1[0
M<:[6[DQ^;ORZN0W]H^M\(C7/8B@N8J];V=B/VMBM= 8T^AA<+*P1MA!2AP)"
M"H7C &ATCJJ\27!8#IS],4<+=JH5=W,VR5U9[12M]O8J.\:C$Z90*6<EL(JA
MDPC9?E,@SGN7^%Q:[6-/4LQ7:#M/GG4[<Q'7'CU*%8N<G)7Z[_+7QMH>]L.[
MUA[;^-0XVL/VL$VV3C=?O6SM[;2:];7=3XTV/@-#-WWGX(.4#MT><(5W6F8W
MG10F,54PT#(P)R-)<;9![4J+YE^+'-$^J, +2S1ZUA9"KN6<"D\-,P12I'E'
MQ0]'M/^8543["YVKHHZE4<2+C0\&"!"K$,ZDHSG$8PL7I,&/0D<MI54YL>.,
MPH:55I54JR+SCO  !4B7]YX35C@O$>@\&*&5X2*FI17D8S\;S/YC'/49!K6[
MIX/^ '_)7/11(MQWI6.YH:EW1"(K+9TC+6U<''Q0 HA+2.  /&(? U'8R%Q!
MF0$K6(H1Y.-@WST4:O.SDE=:-<]:Y8718%4JE)/H($2A"^,C+9*GG%*'RI#4
M*"VA-;?KRMW&OA^?MIM<CJD*U$JE?IMKNQ]X\+GLD"^BUK80(6>+B"84R8)@
MQI# 4>R/,F=7@=KB:!4ZI%8Q&@L3E,:A4M "1TY7),F",58K;T(&-7[G#N([
M0&U0JT//'XZ"GIPNU_*PN#P$N[7H8]O%WK5C;+F&^G(2\?J/L77^@-F^A<[Y
M,P7Z,9XTJ SPQPSPUIX7\#PI8XH0?-Y&@.!L//[&%--H6QPDC=F"'EQJMDK%
M-7]F.84!M#++GS++6X5- O9[7MWD*(_(UETJG =:J&B2#S0Z9/)#MCY'9OFK
M%*9?Q<?-70VMV@DT0]'LU#R<- ?0JG)L36O@_]SG;[#+-SHO1AU>L?/)H= =
M-=)XTL2ZQ N /*F(?+HP(%G!3)($K+02[-(*6Y;2++.'%S"I5OS,GP%/BB)4
M!OP8!GR31H1(I;<)"@%YP1Y$5Z#IJD)30X* C,%D:,!<+1LQ3TGR?J%*]*?M
MTU9>"E'KCDJP=MLGO7@8._WFQUAK=?N_2C+PWQZ%5_3Q_?"W6_CT60[#=( O
MOI3"1@>%$E^C*!IQL)EVX*S"K<GAUAUUTZ*3-IB@BTBHRIDX:&'SXGPE4^(Z
MY,V5?&G%+C-S&[-NY7^I0A)ELNR?)QR59<^A9=]D)#8%%R6GA78R%8)'R%L(
M3!&U(3I =BK\T@H5RY+=#MC/Q+1_E;#&UO]C[UN;VDB2=O]*!_O&.3,1*D_=
M+YX-(AC L\P9A&WP>/$71UU!MI!X)6$;__J3U9(P(&&#$=""FMC% K5:U565
M3SYYJ<PXLO#'4$4[Z,' A]4OY\E)B*GC.Z.KJVL]61-I43Z.Z0)L3N;_W.QO
MC">_8-.BL*F],:<'&@_:6A4I4J+&IL"1@R5%43K"&/4D.+>R*EH:W[KV9W%U
M/ 7J423ZGB7Z,MM(2F+JA4<F6H<XF ](<R:1"")%+US .8V8\1:=$^"\/MMH
MJ-^C^;7%AW-JM94BXP_"/LZ7S=NL%Z)@T^*P:4XC-,48UL'F#%_#$<^=E QA
M"262'(M@#S&AQ\$5T2),+DL!XE)M?)G",D7J[UCJ+S,2;A2F44B4 *\1CSG%
MP^4.*"E%$:/'UH4L]5SK%J>W#JDN6=GQ):$MYUJBU*FAUZ$QURSF/'ZJYPSF
M(O1/7#>>+=/M4*XQ,_@_#S@Q2P_[=]!19JT7BA*X2R4PIW&=E)P0SBW")#%0
M L;GLUY@I7(18&V%U"YG][4(9RTF%A667YP@/;"KJD!I@=+&,.@"I?<*I9?Y
MM#!>8"$<2BR"%1V,0]8KC911DH>4!-8V0RE6!#CUXX'2FG#_-K+PI=/C1N?J
M%QW9P4&G5W^]N0A>/H(,#.Y/+&G-F@]C!?JM?P3?>0I/7O7ZHTR=!_#G7M6!
M$1T,ZFSJP:CJIVIT&(>Q6N_W0NP-8\BOZ@FLXY O.CW;\QVXO"X@4W<7>59=
M/'AU;B8FXQ <!GK<']8YB,\'L6OS@:W?/W?"Z'"*'><^-5E8_.TCUL$03D97
M?R07]$0PSWEC/1^>',$2G/[>L'5@E\ZGG?N9GZ1&(,QQ"-RS_!_7V%D2=3 \
M"J&-YHF\)V9E^J'#P;>"60<1N4&T'Y%-\&#/;?>S/1VN_'9Q6\)<G%^0J^;R
MW+21[U;>2NDFLZ2O,4GC-0)X[N?F\K#P(/QQD*^"4=B''D)U.,C*ZU\_7B4%
M4I?!(<M3[KR3Q>3?O]G5>3O@W,S?WPY5<W?HYG\W_][Z[]9NJ]IJKS^[4JH?
M>ICK.^V-S?;NYD8%KW9W_M[:6-N#7W;WX)_MS?;>;K7S(C_!SO9F8Y_AETX/
MD+9_ O<(PU85O_@(NN@X#L9E32J 6_MK<T=_TK,GH0,:X>HQ7@-]:P7Z#?5K
MI0U#[]KC87P^??%[Z R/N_;T>:=7#Z3^T!3;)ZHB.ZPN*>SZ^\9O3Y#.F&=:
MD QV$U?9Y(LG./BLQL%+'&3\GN3/)*57OHV?D2O?^]YMB7BF^-5O?^^VWW^/
M&7DW@[WV',PQ-*?+"/PO/MXK?^"*_4YUS+%4W*TA9ZXEW?-9^=G3F.5ZFCW0
MVK':ANL.A]4F*/,PKC)0,=*Z1F.RLAU^L!W.N9(NV&6SEM=-S+)F3D7V[UY_
M(J[7&O*I3RB]<R%<EBOOJ>3R ^4W?XJ]DSB\52_(A<G573:*7-0@F[<_&['G
MES2_OQW!NAOTPXD?58.)+-PFP_&1Q48>5W0CRA $)5QSJKG%5%OKN(A6*T69
MQ/']QB2Z0=!U#R?4.^;%H'^4W4EY"&\[H\/UDR',0QQL?O'=DSQ_:\-AA/^%
MI3E)M;,[C7RT/[[[\ JN]6SGSVVQO?>ZV][P?)MNX>T/^Y_W/VSFS]+VT1OR
M+?+QYA3N?[K]=NMT^\_\/:_A^P_$_E[WPS[=.JT;#^UMD7='VV(F\K&W!6/;
M^K+_82LW)8+Q__-A9Z-[N/.V_6'_PU]'.V^WR?:'?X[VOW;36=1C%W_9WEL3
M\-GW/'H&JYQ+PD2#>%0<69HPLB8(H9-D-+J55299B\^I9;OTQQ4*4CT2I/+*
M8"FT2<9:KHPW0@JO<O&QF"B)<HQ4F. :J2CFN"!5HY'JZV6DDAP'9H)%,6$^
MR791DB)N@TC$:JL)!:0BN$6-;CQ2-8_ -H(4+VGYC;\[/L>8KR3$C_1 _@WP
MV7@MO-14.4RYE]0D#H12*B$4HYZ:PB27"9_;Z[-,DDJ9&)$&!4LUXM(9Y%SN
M_())BD0($3P&?,XEOFB#R@V6DAL+DO#$#+4^*6J5Y39R+>&WF"3UQ,,+6AC8
MDDGX# ,+D=-HL4#8*>!=,E"DI;/(2PG;6CN.M<C51%N ZXV7\.:1I480L"7U
M2J[G' LWR72JX":?@)$-;\?'EJ]*P0W0V@D.AC%WR8K &7':@WA*;)GTGN,4
M"A];*K3>G>5CCF"'N65(AMREBB:.7)0D-UT61@L33&["IUK8W/I0<//\>D7
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M+X$ELL8%Q",WSC+FG"<@UIBVM"S.K69<^0 -8!XP0;(_$SV_C7/K"69#W4E
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M8KFG;PW&F(FX[=;<X:7M!-3IU:_7[7%G!'\ODWKC2?7^Y.BD6UOOX\,#%^.
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M(F=-9I)DC JL96Q2/L6A*+*1$A29BT0DC3U+C=*1CSE3I;:6D<LB4)_BF,K
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M9SLSQ5&X=#AXA:24#'%L&3+,"80!V@#7'"', 1LCLB7P[*FW@FD%TY8!TVX
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MNYL;%;S:W?E[:V-M#W[9W8-_MC?;>[O5SHMJ?6WW/]6+OW?>[E:-?9!?.CT
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MCG;,*3'$"=.>L8BBS(U3-+7(L8A1X RVAS7<6)=+DA#^L+U.QQ*U7"'R1J/
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MX _;F^V]W<8^S"\G/7L2.@"CO\Z.\9J8P%=^J*8>8(DJ\JR:../;)T=P'[^
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MA]7.RXVM?W:FP^EU (E/CJS[]==6/8IC$--._V0(SS0"*S\+^F$\MJ-^'@_
M_N#<F/(XYG^F!5 ;.OVZWD^L.OV0L20K/?A+?S"#IZ-#$/1.F.C"W^L;Y\G+
M4_=ZZ]7\N0-*-\R(.QE"_P"4W1"^K@6:>&2'F8W[K)1/NC#JTTO?D:4?/G5X
M.@2=#9 X'G@&EK'W::P:SM3S174VP168_YCI0F?R2UWA"*#L*&\%N/2,$>3%
M@MMV!M4P3IK>U750ZR.3>8+&R@ VVK)H@NS1&\O(E= XT>N7H%%KKY(4-N'
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M<G6N"=.KTDFO!NO,)4\&@#?^-%.5,_,G9* #(K0&/#/'X 93'X>SW0R4DS&
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MS-)KOENVV"J:KU&:#[1=K?5J[;>W^7EG[\WI>Y*XEPQ'1*0!U4=M0MHRAW3
M(0@O0H@65!_6+75[7KQP$7M@_V<!V0*RMT\YCH1BXREAQ'+MC,4FN/_/WI<V
MM9DLZ?X5!7/G1G>$BE/[TCU!!&WL'GJ.1-O&[8N_.&H%82$QDC"&7W^S7DEL
M$F83\ JJSPQFD5[5ED\NE?EDLLQ:K:DAOK@72P>R)U= -D29F+'@4$@>$%=1
M(D,E1S@&$J75C$>RLL:$:!K]X&J$FH-L_;R%1_- _E5QL:[=B0E\\LS7V@Q2
MEV:0K[$9Y(V4WU<HI97AG%NCK=""6ZZ<%S9$!GX*UL$;NO+HC:/]7@Q'W3C<
M2C#A+"J#*5EX9_CMCY/\]1W@=_\U<].?MG:_4N%9!(,&*4P%@KT*R#KP+RQ6
M1(;(G0TS;:'K2P"^/6XYG_<;,*@B_[X4A<DM2Z:-%!O'>_VJB?WW3CB:MG7+
M5"JQ:E\_UNH$_^?XF]P7K#^(T^Y#5QY;-<*PPPG-^+"PBA=6\<(J7EC%"ZOX
MLY-D%U;QPBI>"E=GXE_K*3?A&G=K38V6_Y\X'(*Q_Z8_.)PX&@])%G_Q20B]
MHP,'QMIEM\5:)3!X8MYAQP,.CG'.O!>2*' ,);GA-H9>]6$N.2[98?G[S+(E
M9S$_1)?3;YD$_3X=?_GSK_V=[?9!:[L%8_EP\&7CD_BROWZ\DUM2;FS"&/_Z
MMK7Q[MO5H%][^X]O.P?MO1;=^=$ZS:THOWQK;W</6AM_[&U]WCQN[>]]:QW
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M;904S*^L4?[8C!XO+(#S/$Q!+Q=4<DF@(M@;8S@/7%D3<>".)>&HM.EJJP)
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M4DA,4? =?4Q4W=2^N@!@W0!P)DPL>>Y$21*2F-C,A:N1=BH@'#$3)#A"70
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M\$OXW>J="LV>;ZO:<_?DPJ*>_W)0-13,T!Y@2ZL>A(-@>SXVCD'\&^OCGH0
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M<TJIE2H:'!WUUAILP\HUG\.HHC1*'+2'3U'"@9>GB.26L.B#MG7V%N::H !
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MZE\?$\/3)X,#5FYMK./V_J>3K8W-XZWUKY9QB@V62'FKP?(D'%DN/.+:$.X
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MJ2B-]TI)HWED-]U.7@W>?X\7_-,/52@61/W\@G+8LC\Z!T<'Z[N[8#3#P;F
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M1/)8P4:"1\'E=9U6BRC7393O$CIX;EDNH8/'$O29T %.DFIE"%*<@MXF+/?
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ML9&88TH,<5()@5-0)@HJ2N1A28$*P*D"J0JLMO-K/IU\]8QYYFU P;%,31O
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M=<<ST0;_-\>'C]\]%^HOY?#2X6IQ#$A0M#J@^_#47.L?^!I,3;Y^N-^/L>C
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MN&]GC_?>[[WTD#MWMO2AWZN<LOE!;6-&4=[ /0F @,@)PP!@C40FZ808-AY
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M$!O=?-C\X@+DXE'V)W,#_ED6F5N[U ?A<NG'A:W[-R,N^:*ATN4HF"N%CFN
M5.-V7N,FOK]==#>9ZD)=-CW+%00W/__]=XEE_98;C?N,+$EI_7>38L]'O5QD
M-G>ANAHM5)9$C#\GLU:6HBZ[?-AV;OYQ5O/Y^.XA1V?S<ODE;_3BG_KM)T[?
MK#$]]://',W"16]'@_-VFO#/27'<&[7#N(/>O@T@8O"_80N%,XD>UQO/'7FZ
MLWS9WMEM8METY;S2]V0YRE7\^[Q%^Z3J92[8N@<RT#XI6H/!J"Q&>5;A^_Q3
M?U(.*/=,<3'"9($(#'+CEMR=Y5)'HG&#S-R[YZ)D^I.7!KZH\+H.PSV;K,_G
MVK\Y$>/W\/[ORBJ?I0!/%X1]N\5?O[#OAC#J@F>(,D[!N.<RL#Q9%+T34O"D
MO"!3'4K /XK),1R!E06I33!4!L6$L@Q6U%PO%IMKYD]AQDT0]&OT*:7WIE*M
MN2#K(SJ>7"O0.KL+R6VOOE85=JT*N[ZV*ZO"KE5AUZJPZW),6%78]2T<:JU?
M<1 NN;R9P\]F]]?XU6.2=M]FA#?6-I'$L59!<.VHI9XJ%[007EC"T[VS/Q[I
MMXS[];Z%N.^MGXWF7^UZYR-K'&S2G=./I_6#]_N-IF?@W[2W-S9_[G[8Y/5O
M=7Q]\W/G8)/4/WPYV=WPM-[</6ALU$_JWS9)X]3CW6^Y==S[PYV\L7KZ*=5G
MY/<&KDQ@7B-JP2GBPG.DL>4(X^!" HE0+'<4$S5AYGP\]/(I(7/,_GV;@*$P
M5=8YXC@GG">A/:<I:ARM<!Q^N'=*2 48BP884Z%/6E)M72X#P&(N:ALQ,L)(
M1+#%UG)JB<T% 61-T"4'C,4C?$]_)#+=MO#1S:)S3])%[.U&\)/OX )8=5IE
M\8+!>C>\.]]U!DQ;N/[1M'[>WO1?[=T#3W:_[?#=$I@^'C<^;(K=IC\%X!
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M*3527P,Z0W-,>WAV"CZ)>3^"<P9:0DSGB.IM> O7XI@IZG,"&GGWJ 6:1/>
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M"<YZ1CA+A"@(5%AAA_^&B?(V8VR]K+GCW2DK&18GV;GZ]6R7HV7_?M?I$)#
M 5U.8BE(S\0P*A;!D1X9^,Z'W;;S#H6R'8GC?:8<P-(<Z-9YP +DK@SS,**@
M!NO(" S1BR<=.$37E08T8C0R0M<Z7&14[S/U-@HR:(P(1S(3/Y<1$_05H&VF
MR%>ZEYB\*3S!M8;DBT=>&*%;"=0G[D&(EX C)83U\D&G2!6++U [?)G58=3$
M U*'I7LO3 .-$-7)DI(^ C'&'%@J.2,0R41A!&M"6>[[%/.\ND,XM3>>R) Z
M:6%J3Z7L>/?O5K<'C#>":Q:);P_J+=AO[ZWC'9X//B"G:_7;%<V?,:S%ONNK
M3\_B3H']! GD(7;-*UU@]&:D&;+FEA_!83D3$!YP/B6;Q]GY<GJR2Y2@8+$G
MLV$* ]N=%$#IE'_=9=J'/X(%"P<I_UPHZP2$/T7%3!VC@U(R9BL=+<OXAH)-
MI)+#_A'W0*U)+@;7<@.KC!0F :4D>N7LRPB'DH09Z&DI<H(SPPO8LB3C$57=
MC(7S\>GOK>YA9V]^GR0N46(?X)U#8>\:4'?B1W0[E-6HC'K>K4LOA"5[SKOV
M_X#*('_;+3*>R[.++__YCZ/!WELN0H 0+C\2'@(PY3?T!IZ5[J3NA[)S]OET
M5V'=0KM^"J&4)MZM5'*=.V_&5DDL98*69FH;#!*?FZP,852P_SP?&&QF677&
M!G>++G&[6SR)7E32A!Z?%:H"5V?57RDN9R=G=5*)-\4DVTK!AQ2H&7B9J,]R
M5FKX'P@UB:62]8E8""<LI(=TSUK);)$]"=9D2,YJ.FRM=X.Q:Q>:12"JU(CB
M\DAHHJ\SEO+7XG 'E(.ORE-Q%A/2HYD_Z/4BXGIJY%9B?5=%D)@KDFNH_)HY
M<YQM;#LE@3WIN''F?=(J*6GE6D&K&IB,R3&FT8$ZX7\%5D8/:G4&KL<NEY>4
M:%]< <S297U>K;TK,98&$EHXR$IEL;C38/E7'2U]E@'C& E6R-0!AL4N3VKS
M-YF %^0*#0Y6M(?(1S,ID/X8H6#]5#+G)$*3K4$.E)$#W08YT" 'GH34B!U$
M"3O:-=>$RVWYXTZO3I2QF&FG'3%#E8G%)E+!"=QB#8F1RB1KJ#?!34*FT,7Q
MF>U@1(=<#/KB-6)C:Z0\+)>VB5(7Y^(_HH0J5DY1Q.YF82"L&CHJ,J2*%5&)
M'>G-X>J[8\/3SR89<&I.Y7<NCR]!G.!?V,-[Y7T5P5SM .G]4<X?L(WIL5VR
M2C7V/)%#$^ #UY@Q*'G1\@J^$[4HNQHN?H6\4SHE4$[O3A00[QN_3'F]I'W/
MT[:63T8V^HO2< @LW\3@9:Z4QF737V3F@*K6=ATE0S265X;VY%(+,QLI;9%"
M]S2>T:0M+Q+O".S#79)^93B_ZE<(7QJC9X!=%L;-TG9^)ZM,-1X"O02#@'AU
MBB$YL"^  X79#5.22&-E;.A@*OM+.88ZQ2FX<A/Q=NNN*9PA+7S<PH0Q^/.[
M@.ZYK-A,ST5J9I"+3(2SYJIR6]AE%7EY[/-$+;M$I&DH^S!6T)6=QR9A2.]S
M,+($7/O?8XH9O?]]ES47V<GN5W@V(- DW$,O]@)*>@8]V*@NA3@/:HPJ8/(+
M:X^DUV3$O&045ZM5%-FJUJT*6I[+A9ZI!17I5H9PWWVZ7+I;!HKU_J2XV4LT
M6UZBI1$75[M8*7<E6V<3V$I)JSQ'I0;:L]#4;Y_E4,P2Z3Q]_WO;^92 GHV+
M1JR96RR"C=6VXCC):48D=WBO[KE'E3;/ M6UN"W+Q:*[5(B1T%023X7^E> ,
MI/,NE6 M%I_9+ /M&^2MG*@R3O1Y>'%IO;\(+X)Y,E476H#TF*9U@C3.QK @
MX/VE-,\IU04&MHI\ASF$JSBJWO=/NHX<1\WP+XJ7'&N2@&E0MT!](GK<3QS;
M)8\03]VEQJLY9SK](:(1]9'\],O'/W9+J3G%"SMG[/BYSH_*8U@7 LJ'7./.
M4F34U5XU6F$(Y %XB-;Y\:DI[ CP;$5;=.5541$N*"*E$KSU/$[FA7.;$WU=
MY +2=;.&^)%X"RT,W<T.R9P-;G5QIU>QE"(?6;[9VZ+)E:QQ!DH8'E-Y!"HR
M:M5+U.$A%7Z2&<"!&K08F52@&=K(%%V3R:@% CD*5K_=J :Z.B$I/E0\,]0)
MJ';L"M]2T%=,_&?.Z0="EA/I\!,N F%%H\QEN4DD^+7H98W%*-352\-,Q]1U
M)$2J&;)FIN#^O?.*WAPAHF\1/T#PB_3QZFB$#-O1JK#_"::&4M(#.3[5U;<(
MU/<4T 2X>!922A4>&6$U-;AA?'+QY02C22S %KU.YH L.&$Y&11T@9@((G0K
M1$.0&:FW$AQ+#BXWA@-$A9-CH!J^\221&BV<XP7<15(Q"%!C<9%C94<X.R<7
MQPBJT4C(STI!/.$%GZFRI]J1+#^XDN+3=%O&]LP4Y=KY?'+6.KEZ_V77Y,*8
MM:G5XSV@$H\[9Y=7NRI$UG80H$@Y?:Z"\GC:*DJ&4RZEH3@6:==F[)89NWPR
M]/T;$4VH$,<M)\%@;-/:%Q6FTVI,M3X_1.@APA (>YT/,\PVAZ^3.[(E,,^.
M2)E>;*NH)^>7G\Y.6GTLM4^A1!EBGH2WR51-=>$Q8TQZE6^VI(. G'=YKUAW
M8!?8K4'Q8\"1X1BXWJ&'Z&FU^@^GQR9Z@*C8$SN8(,5[05C@-^&5J,^E F/%
MKCPC.D2*(NH43G(A.K14JN9L[^G<N6C#HA!HV!9Y\@[#Q[2NN!@WMQE(,L2S
MD,R9V,AZ[ \W%/82= Y!BBUF*Y##N37!#&*"4\GPCHAOPS2)N1S@'=Z<4$*X
M,L)11)H0LRD0+)?S5K8PQY>$/- JK Y'O-AGKN/LUD@R JAI#[WL)^@4_X0,
MMG7T_@)C=BOO1-F^F,O9ENH)H81EX9,,^S%67"(=EG 7.;O(!.+ 8>GJ<(V*
MPOS7O4YNX2ZA3@9ZUZK+=2_C;DZ7+4="BN$58Y%R+-567:5Y0%IU$<-@23E5
MG .-6)BD9GC]M8\6_@B&_[1\Q/9E<!T-@E06L]*53ZX^'K<&>#. [T["*!SC
M4RZ5%<BS*MHI#F6^0Y12V+K*<);>3W*OC"G.(5I(1),$Y!'"-DCUI0TS9FPR
MX9,J$I/>+3H9JKVG^T"5XS$]O,&8LRFT\XRXK(2U?T$=)I JW.6,BM7D8^?L
M[$P]06-H;\EEXH=BRM;P)]3/X&OGRD=TDL1DZS@[YHN7G\[UWW=EQ7TZ3[@\
MJAOV&"D+U!N*>KD6@H0$I\DO0[PEB@,514/YR3DO1CTB8*J"_U.A)# -WYU=
MG.RV$*!"AIA&D((.-\+F,EF>WH9HX>Q\^7"YJU:N9J;SA8P+8([VVL[QE*L!
M2@"B.NIP//]]!B_8BR:@-?'6R)K,^>6NNY#85;T@&V_C%79+:M0Z6 <"/TF%
MW?CL+HRB L:?%'>0@F;.F,M^Z<IL:Y/%QTL ;2D:X2.J)Q46ZQ@A?< 68^Z,
M%%?F>_*]7J;RSY!52D\=)U@7!^!-H^KL6/$'2V!<DUPJ@0\J0:&Y3CO$9"^0
M,,"0WJG$\Y$0P=#SOQJKEJK.PFT)$EDK$XP3*1:PY!;N+EAH$9$?+ )1?@2=
MD9 )QIYGGU%/KG)PJ:BP3GVG!TS/EELOC&3IA:FGO;T*RRASV)#&M,EEV7M6
M.P*[ZA'H<\H];VH3Z$,^OS3G3%Q:3<$U-BAE7NI\T%1;J>&R9A&O-@+;:R*P
MKS4"^]S6PU5!!U=5+4IP+XL?9<8X8&<0=\A0JKX)K2QW*E2IFQ_:SB_):#0&
M1:;UT9,H>2I,N$,_[QIL&RI@\+Z_DRC\FU6P(=9#CF6DAII8TYA2Z2$54P&G
M65'L#IFWES5$*4@XCAB!;)68MJH@'+EWK6E4 '3L3^=T/@_^"005$!+\BA7!
M<<KV97M+&D0BQKI C.(5(Q3A/D]>KH.T-C+X"KAKLR_LNJ#($I;D2W,IIV"R
MUWD8*(-96Y*VY2QS\F;S[KY%!J5QRFD)5C:^UM[@$"V SU?')U<M0FHOL #F
M?'2H[F* L37*20\<SIC63 @$0=-46:YX7.2=,S$6VK-%H"?,SHI!-XN<FR0=
MD\]+A81V/O]RM2M5=CC4<$(>0"PGQXYS$:=@\FBOMUFC3$,G-=]*[5>DJ11/
M4$:-@%ZJ>&&^)X>.B]D(QL^E]D9ZAEO4RX;_G@,#T'/K%C<OJ-@\0\64ND*)
M"93@%N7$'=@#^OGRY./)[IJ;#&P2B(H-:.J*E(];LK@0<1PK6"++X*KY]E?.
M-XS)U4EJS8I;>7%RLB+R9L KQG@NK(#5T7 L33QRY% E+Q.?4YK[6(BI3!8S
M1O.</00W[11F2(GHHS#FHF#RZJLSXR9BQLJ3!HRVVC[BP4B'K#;2[,BRK"<=
MK'A1GRV&8>E=GBI=,986(:X,OEXCQ]N&>-XO*EGX6$=,MF MU8K!_[-]H?59
MQ4I(,GL(J8"N;+M%*KV5FF3=1@Z^M:3^(K6=<CZ2R3_2J@7<U_52C:Y^/2M"
M^(NYRZZ5U?SI_865,*[SG\=L);))REQ2ZT'7:7(WY0!,-L%B)!02#@29\["\
MTAQ1"&(HAX+PG'5$/=VDQB<3C62,N^ 12X7BJ2;*+[/NE<D.[#02TM6"#WX5
MU/L;8P4"LY%#OQ"L(('%\6FL,B.0CZ)T:D7A"*LC))1E;1!K1L7DHO'P;J/(
ME:,QI-C-;< ;YQ)32H\O6IT.>R#-[[UVX<,PT^K$W/"VPE+:8,[,+D- %B5I
MVXH-J0,,S;- 502'P' LR=P@X?*/8,PYXVO2#>B%[.%HD8>C(E>B^)=5$]$>
M!)J,U$JP6I%12A"C)$LM9%P<]29)JY ^E)K",IY%9!C-16-I6/.]<'[@K&)D
MU""*H[M2SQ(M=;F,3QV-9N0),E&;U3A9RART'!]U1:5_G%Q@_-6F!>PX8BD@
MION/02OAR;0$EFE1Y6)YXLOC"O-'597[A<XF[CS:DNQS1/][^]C,%,X_4A1!
M2DHA7>F32/VOSJ\_>\>N<PK7&*@VF+K.SR*EFE6XFB\C>%M*.=!P-?*I3/A3
MFT,$!K3K2R6/.*X$!+:?)0ONCP+8SN@J9$.12F/3A=3N@,JF5,R9W&A9T?]M
MN['G?>Q*!\UN"'%5I <$2%I.6J+!" NJ42W84G+LS'#EA.6-]J#.<7.3?=Q5
M> 7/E$NQ+4Q6[O#,N-ZCJZQ6RAOE/KE%OVL)A6A/61NG9C=9)!=XQ#Q7*6V[
MF0-JRK&4Y:U\0I/'@B/(>Z<WF5O</<R;IYJV,LC&M;S)_;US?G%!"+#^X#],
MF:N<?-PWJMP6?!\>PZ?V.NJIA*N%&W@*L@I4T9<:+7/5<C2(6+G3A\:LY\M6
MH PM_<F@IUA'T7DNS:'8\D%;<7*9.H6D+=$]5#DGG\CZ%$H9APG)HGDN5XB>
M$1 FE9"[OLTD>_<3F)7"2%9(UH&S<CC.CKL1ZG 4?A-!*TBR%<$W*XY'/F48
MY=YR=_4RK/G; G4HKO-82CWB'AL*/NNZX+!5<O 7_ ^9T:P8_I5CH>ZL7$P&
M"SQ@^3H:1@ OW[D\.?GELPRVE24:PY\JES[5E3XJHRD8#))%$;3G99D&4(PC
M%]@1O&R!I$5C%T-Y$@8QK5B!KEW+=V'9C.,":2,$0D[R@4Z(%!#7 3,;)A%1
M87=U+/;QN0XH(ZRGXLF04CSDKA_DKD8,&8=F38\6DXQ@)0Y,5?$8UW(_H,Q6
MQS>_+JX5SIF.)3TE(QO !-48LVX C3@@J@N5((XM,23_F'-L4Q6;*O]BMAE[
M4Z!";B]E#%8:R]6$UR</E9=9,PA5\W+=W'W#5Q<<J1*R  >C,@CFW=,EE]TX
M1&T!1@'6-17D+9;.\1:FV2,WYL>RL3>E\-_$"]-6($#PXZA$SE5^,@IG,3>G
M:JCL=Z=ZHZX=[G2(XKTT8,@&5]%3P6'5*5%>58*Y?*-ZWB"Y]H%UF[4AZI4<
M[[3*(/')YXVHE>-+*IZ9DQI7'*+;/P"RQVH6G+>#,)4KR^MJM N8G'6,>$PV
M[)3NF]*%5%"AZ-4N@^XNT7\6M#!_'K5DQ,JR5)'-&;+*+[7&^90(1WZ%G7!$
MUJA@R/D$Q57HF=D0@])J,+#/S4*T 33W-5V[%+W1+JE.I$SF)JBDE;"=TW/0
MOR; UB[4GRS8YTD:4F5R8LLD#:Y8&NQ<O#\A;.=MV^FVNY3701%_:HN&;$H!
M-V0).!O**5$'[!6?NWN#BKMGY8[?\_X9=41>OI6XL452<5ZHP'IJ93PNNI9-
M[+\<^^\WL?_7&OO_H2:7M2CH>D==PW?FQ>!!9TX,/H>S9JG0RHI2:T!Z!8=%
M Y)%)&Q(?#BWJX5'K3@K@A*?8\-MB5FM*9!JH'-7;*7!*_P^D/!PA9-3V&_$
M\',J[HAZ<LWLPDKKJ]P<=:\NRJS<7:4*>C(.69E 72.39<,(WKMB/<#ZK&/I
MK#\A<K"R"K9Q=EH(#?6I\B^PCH2_J;9<Y;*(2S+15)LO^$-+!@0LVYF[2>"
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M8J<^2J?P4W;@6FT\WEJS4-O';\"_?_[UY]XQ7%>JP41E@V [,.5.1]9(+GA
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MM)M&6A^;CC"++Q)FL64X]9_3),OF,"(N)_WENE(@XM6]6!7:B:N*EC?@=M&
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M$K>([S6O<L9BZF53&-WG2?YR<D)O.;TZL586(5;1]R98TQ)^=/DP(I$!E3E
ML/ ,?. <SA^.!ZS(NQ9$1YF((GGDOBCL=WM+ZGS^(? R_ E;"XOSX,3SM/J&
MC+V9V0IU75(Q]G#N1*OWOQXX7!;"JN!O^((DSIPX01KPALFMV**]3(6?7,?P
MG?D-Q%V%75I80)6V'TD]$)F?AD-8/5 <WNI>Y^UGV T6K]TV_WN>7GOP(G.+
M+O,Q;,<,WW$)(C(<@;@$0C_VZ76X\U] (_)#D=&8W;=X/'#</)SUG@P_.($S
M0 6*;N('N*VQ'P)+N82+)? "J4'XVT 841[PC+\@1S@[<YTS>-(YQ/D@47V
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MW4T(_/+.U/RDO7V8&I[,S&3Y4_A"2N.]<<1X$B4S(32KI"16N-FPX=E;ATO
M6FP4S]2N)DO59</,3T"/G^'$KU-O#%],DYD7 7N8>#->=L+T8)-7!D0*C^(0
M^%'$]7!EH==0;%=UXRN0!">YO,W_2H:9<^Q/X?Z!LBAPXV'O(N\.MT&Q%0</
MHM?I'KAP%4 DAH(E#<J4*1SY5-6O75C*USXK$'JP(S$C8[G(+?+C-;Z(M!##
M[)+X6FB>@G)54,5>O(##'%&MV50 VQOG<'V'P(W&P%E@DP*4TG!-0>K=XOU%
M]0 AM$SI03(&IA/ZQ5?"!]T]ZRF\[+!1A8?:#G!G3\)MB>E:/-%3X%DEB$U
MU(E";\BE@GDCF)GCT#X530:25-_&J8V)M"V!CGO)4%^!E,EWC)@RW4<XF0B6
M35.C#6*- "EXU628C\EUPYVE>\JRDS=R[?,RFT]< 5XTR5.P:VH%'5Z;22JM
M ;=1<T86:JEXPS^A^!&^E"2H-OI A[#+:8$]S;&7)^2J;^<G:LV,&2)P-0>.
M.%:Z;ZEP=U'&>FF*V"SFGW?A],8YFV0B=H'7?!6!QXP31:=DHO/[E*3$P6$>
MX7B8IYD<BXP84UY^-,?5%1^?WSRL*@WFT$/O'=?[ALN('Z%VCDN1*K?:JT7[
ME)G%:VDC)6X@P1*M* 2#/>.ZU(6O*J\!3C*?P'M@]?PP+ _$HAK1-9=SE/,*
M<#[A5'Y:L<UNP=Y@"\/,4!^>PT6SKVG?U:=9CEP@*QP*7#[@5TEL)D6G<8LW
MB#9(;BFR./II6U@!JKM1EH!2C7T-YA0FZQ))9EGDAU:5>;+;(B_&^V6JBB-U
MZU+U7,Z>Q62AF+W1.UA>P QHWXGS*_(G71RN VZ\+'9.I)/A?$C8@QSW/52,
MQEBD/]/$# \AX= 4RPJ4H6Q9[YR_-4S^1I$7AT-MA18*^8\D 2F&!^\-PH"L
M<JE]3\()=1)QK67#F'_#BWC@MG.&'0:"D+M0W G*4XEYLZWUP88K-2V)?:[T
MKUZK7H(N@"2_OF%NDN;7EF(H1G 1\4J8>:BW>I&Y6L7+Z19O;H$=FNM#E>]!
M]_%!:0(B]"3OHY,B7QVSSL+4>79F+UW9,N$Z!U)#QT/Q5(C>0-YF@O:+_1K,
MYW#8=XF7DJ)P"C3KP_=A>OD4#"\2T,P@03S[-QZS@GR"6_KCWEX'[W1D*1#X
MRD3Y)(8"U:)Y1<3BE%3_GPB-\Y% E-Z@>F#>IY@]CE+^3+%YEHB@TG%C$I0\
MR%5",:5&)G Q<$WVV8&JF-#[,WA#)A7\D:W/@"06@?ZCNGVPSQ$8>3&S7"OQ
M*:'[F\?2$L+O<$<4U!%\VK7WWX#*OH79?_[CL-<]>%O<*]P(U11!?M%'0<--
M+K:$#WX(8R_VI?\)CL?8AK"8/ +5&P@]90]3"+)5=H6("KX8M?^I]L7@7Y%?
M2:8JK70X3!+Z0^P( BH\BBGK2B*ORO2-QO,(LRS'Y#0\"QQI.FL['_(4[R H
MH\!BT"- .5#7I#$,X;C@3^PM@7^S7';\F,K!R1"VO!C4/(4U9*,%(C?/7,UR
M;Q+0<1]H^H;<YR@&QS1\A=K[!,J/42-JHI'6S\W[**93U)?1#4T^R_JL9)5^
M0!24#%%?%1AY!%H!&RTR"V(G;-E302X%^!Z( 5M5+/15LC]%DORQJP*>BCE[
M]_ 2ULEWL2&97%I\X_>,S;(35&&:7,=7G3ZX59-]WES'S<!0+R7_:"LR9HI!
MR8?-G=F*#=#N9R6JGGD/-'4_X1XL2'[<\KRDA]W)-;%3?R3I5W;7DMW1)".]
MDHP.M]_MN)W>IEC1+4OJ:,CWI9)O[VC@#CK?UVN^]N3[(#E)6X56?N#S_-[#
MK!N*>2M*N3^+'G/R_<"M[P'(OQ3Y4+6T>EZ7GMOM@1CH;YK!6+]*Z0V=U9O.
M.OO[[O[A8V55-17YO_. 'JL<?WU6^$2:09.O4\[7Z37Y.DV^3EWB>@L\=4\U
MJ>HK\N:1IK'TI4ZYLO!=<6L61WSG@(T+<T0*=8-EBA+E-7BW0)M(71+"(4/5
MB%S52(@L$P1\0^@SSDMC1?$I1A=7IQL9V _,'Q'=<ZD?;O&928I8"XD=T9@W
MC3=+A1_!; C4IH%I,GR.@\:$EIHFUKMX\@24HO42HH.!4N5M1DC'4&T$["<L
M .&-#!I" "8CCQ"-P;'Z"BA2 09DX9X81*10>+0>C2YE5"N"H1#FA(>QO:".
M![!;G^<.GBQ*6K+N#2%OLJD&40:"=(',N1%1@,E$8^]/((ZA%W\E#*X&[$T\
MH&K,JXC%3,%[&!-D 0<%W#>&5S%"$!2V,":RG*H/CCI. +(8*3 2648I%0NW
ME<$G!GM2!J=XUZFPX(M(?WP*,)A9,^8DFJ0MO&Q\^_B^RAW ZV70JY4;1M@H
M:XTZY:LU2M(6@N/;S@=,R3*HJ3"&C\8JP>O:2QGLAQBM[Z<R%R8C'$3O]3IO
M/R>P48.V(0)K.2X]TWVK0*S65PBY!B(Y0'QV@#^1JXX@/Q(]!\NXQ)Q+&LJ,
MA.R"\G"<+\ VG3/7.8-GG"XSFS!S?LOA[Z JS."("4L,>P#; X]T6K^UYR3&
M VP(TF\Y1;9:N#@KY J]"0Z/*I(;U#RRTU(*'LH1RHM0B%,)XLUT%M9:V0C5
MPJ>4NZ%1ZHBJ4GEFK:H\,[?T!0O1O5Z^67D 2GRHPHKCUQD4IIZM$U!K*<.D
MJX)';.-"Y\K1OSYHUOZ@O=] LV"R:^_!%L&=2D.T\/DW^^V#I9;MLT&A7FKI
M]-<)9WL1U:&;<MJ/4$Z[08,M[-DI9#4*:J$32"6THMI!@Q-['4";0T39?%]+
MSMJC;!K:?9FTVQT<N ?=>S9<?";B;0 ^*T53GK$CB%TQ]Q1+#;2B!FO:&1RY
M>T>]W2W&5#0$5FL".QBX>_VC&A%88WIL9'J,=$K]_4V/EW@%JY96SRL(%_"^
M;<RWR$1H:.Q9(9J=34N</SJ%O:@NWQMB@LZUO^AXGFD_^V)6!^E6^;Z<$ M[
MI>$M/^(%?^9LAQ01/A3%Q)[G)-6LQN=3,;8KA(U$2O%BK%SH,A"FQ:5-,)8L
MXLSCXDZ!F*3"#^5O>F .AU*4%&NH(""#LF*YB)29/F.2*( J:QI:14M3,8JH
M/A9C;&2!9VQE[@S%]$Z(6,&)1#CA**X,P&IL![P@P=G!O F.4:CFA%^XN^%1
M9@Z7,?*3ZY@J+$F<P )<@$$#X*NX(_G6!'W7]J=N4(=;E>\+UJG2EX8P+A:L
ME#7E*@IO\[=4U4$J1.7\"(RUW2F649FK7\=P!*IIR"5%@.3#-)LZ?S$60Y:\
MZC%:)I[#7\ X(5?XTQ5=],Y(>C;U'Q$W48%9J!J6J/262P-5@B6V 2U634]G
MVN?QX*QUH3'TV'<$H3D6R_(53D+"7:K</!81,QXE4X1L0(*,&F,0A$%1637+
MY' SN$;^7WG(&'4B?U\6GX3- Y*ALO0+2[M.A7\3<U4ZNWQ7L1+N>;X SU*)
M_+(Q1J7:?08*1'>*)ZIX.Y7,&W%)KP( 9^'DS8X^U)5X-BI:RSVHN>QS("97
M<O:J23W;?CZXF*D4 'B[L,X@W70+MXF$JEEW 7.'9&\JV,) !3AT :^HBM^F
M8AW141IGHYMOES@M5N5=7+NV ,C;7HEDBAZ^&HE4Y92:DTA4QK= WKI4/V/=
M=8UFPK93V7+2ATK5L+GH)Y#L-!)*WY;U#[T[+PU>$.=>Y?AKN/?ZW%MQMD?B
MWIJRM:ZM6P'9A3H+R1T+Z?35IA?V2UBV)KWPU:07UH7Y<G5IU%2D4(%;#@O"
M\LY4NK="X4+OSDT2$>M@N96*<3BU^G1=([H_)FFU0IIEZXBS-;ML[?^PZ:X_
MW.8NR.V")U*07SF8?>>F3&U]=+U56E J6'V.$UV[6BM&23[%JLJJ1'B"R4;4
M,2G!#@KX9ZMFOTQ-,=M1J.F[L#ZO%"I8,QJ31J(D,^["#_ '&(@<3"K1YU=.
MB<)ZUH5D*%"Z<S:%/PI.+M06M6[A4#&S^92G;J<-=U[WC9!UYF7_!Q]T%"OW
MZ3'SGL[6RWMB.ZJ\ANZ::Y G6[&.^\Y>3?]0F4?5AWAO%G!4/Q: !BTN\=CW
M,945F>87V#U?6;GO90NC+>(*H/T)4"=U0O$2YWT5>2"QX=4D8O+,MH#."8].
MT.B7K0" J.%S,9DR#>E&DRIF0=XO[*(2>VQ'<_NZK\+Y,P^N51,7M<$LRD [
M'4_L%A/4$U-U>8 +) *[]P>[UMQBS(0%EEOLKZ<\UK(5!8L]R;5D/ZRXL%RD
M@AG&DE1]>A:30U#/%=&$(X>*HLN%>H4!U,+DE\9>8'> L-;)W \>I7Q67C4P
M2.RA!3N<Q\IE(=L4PJBR:X5Z09C1Z,PU84XJ/#2U-I>&11TAB:F9&'<\H+KO
M0PP?Y62+H*_?&-:4X3V_(&N.UH!1^%5$E*N>^-@[@$T5W"9L)[JLP<(&M-EV
MSF/<9M4@ _8SA .W*$S<>E'./5J 0LR4=4:[2]W6X@3[$ &/I4-](X68W4^*
M:4?%P3BH9]+B X'IPV&LNIG&'C56*.;!8V0P&WDZ;@-;0C*/K"];C+'KJC@B
M%>'W(HSG9"**Y UDNVWI0"KGOMA700<T4S'$#7'QH--K@9HM"E)RYJ4"5A';
M[CT/\QX]"C1ZF X94?$&'6K*"D)DL?_L;:%: /7<J[J:1ML% W84<B 3[F=&
MBBEY&U2.]ULZ&=!C5?\WZ5VDB@EO%>FFJ#'8$2R+3]B]<O!)#.C"-M/%GI(J
M93W\UF&ZXNX5)9V8?=I -.H,Q9(PL55:0=UK'H2BLLHGGN7#/V4_/9E>#UOQ
M4Y(6CMXTU'BK*TI8>VR'KA?$EZW9,(=E^M=K->=/;9J&U.XA3ZU[!<^ F@.;
M3OM&C7Q"#$RS!A<3-29Y)A4Y7DL+&PUCUKWBQ7!IN2Q'D?=;74Z8AVIV(ZRV
M.WZ8^OD8KXNORE)P98_,U*+ +>-..<@PB") #N&RM222;)A[[*3I##_$?1"6
MG)G;/LT(D9_ [ )TR7@3=.:H^*LLAL!-'SC4E(DXI!EHKG6#2 .017F6B;E.
M5*CFJNBORL]FH65*>9@#X> ^C'"<8U$$UB2G0C>UG>^FU$;7<,X];6C;F%FS
M%+%YMJ7NZ_?5R#.^JLF)HB6R=90(+TO\4*BF=7@G%LH!R6C<,LN0/&<)4$26
M*5 =+.EU$MR!79FPSYW=YVRQ>J0":=/OUOBVY0S9XC4Z"YB]]E;9N)I51TQB
M1V^MU99\I1^YVF&[P;ML0UG:;I\T)Y#=MS*XG<0-%,$<QUXT0]8%IVN.\$0)
M 'KFPG"]<QV(7FWL':PP]H;I3__D_SRJ6[_:/KL0U$C ML[2)$Y0*2[6A*TW
MY5(A&.#I&1#*1-U2TN&I;2X>B]2'1^2RI]B_97G92Z[P>H!82:^]6'4W1&*X
MS,?4^Q4&O+3N2(69:[E$%K@3GKP<S'T=#(>]%0Z&Y3[U1Z%@6GB_C2N&?9]R
M:SX\(?A#I'X_-7:H<TQZR"?6^B["[.N6T#AJ-E)736'6R_R&Q,)196*67>CL
M6=0S^,H,F99P*WFD@^/'\5 =[M64@+"6$SI!DXCER1<,\ 5(+_6ACH7(A.IU
MO3=6!AHK1JGU[85.]$+;SQ%6=MXICPUQZ\*4J7;2RFD[.XPB#KE/O7.1HUW=
M[7NM[MZ.V.5>[8'ZA:7"I0'$O?_&=P1U=/RX>]0?D KBC4D[(9\-?L=^<-<T
M:![.BF\<VF\<ZC?:W^9B@B<WH:"NH'Y.+.H<VTN"/8"KX\^,"%"?-2'D<@AY
MT(20FQ#RDY :=_=.E.K%G@G=(5AV."9;D=N8D_.,&01I9.Q==]?E:A1W%.2<
M)X5&N>BU@P9-U93<5!&Z,FID8VXHISZBFUAY_J0<4.NF\"D!:7B7GD=&':OW
M.]DL VW!E0%AQ/C?)'?DMFTA:3 4B#QS$RYBB)7]8H7L@N41/DZ=H4LZFN*Y
MKG6D1%T45B8W)0QK&E07ID+.L;&8MIUWPO=R#CR'\0V')R)K:T-R-I:^GM%2
MBF)74Z0]<S7)\ASM(1'YA!["D%IYN^0I"SF<8%M/QK^ [EPTSMID-E&U3HQE
MK'E#<.6@OH+L83^!FNIW[&_UFTM;C?,@#0%QM-@6_@9=F[>R1K",XI&O5HGV
MQ!+MYO.1%N_J\R*+<4TT"V8:IO8QW8?QT)KOQWTJ=_=[MY/>@:2[M9SKQ#C$
MPICZPIO+@(=@'3$? A!X^UG0FT4L2\F1M_;<)0GY5.<[4%X]'(+<JM*Q,F*+
M425!T7>(LBU/-T>=I7:],- Y]P5WL_DN29-[M0KSWF*%>0,S_O"'1LM^'5KV
M$U+L@EZWQQ=7SME9VSF_^N7]A7/V^</YQ:?CJ[/SS_=U0AUU:^J$ZK:=C^(:
M.-@7AI<#"]M>]].GR\_.F7/\^?38^0B\DB$4]5G-BC13YQ)A5U2\O-?I'KD8
M*]=8?P_URI L+[(!3*UYF"*M.,N'14CP!_@C*&2P*2[YCE1JW@3U*HQN&AP"
MH[]"WP&IEDF=_.3XW?FG]U?_^V^',CH1J -#Z6!6B(%3&*4X+1TF\#!*X%VG
MWN3&.?L?JR8_CD[Q;,R&$*:9!Z',OGC$,9S/2=LY= \/#MR#@WUG)_,BF0"?
M1+-QDDYN8*J$9]MUG2/WH#=P^X.>LX-_RB,V/N 3[+;;'\ P?6<'E+Z;)& 5
M%N0%X3!W:4QZ"@;9.UCPE&LUOXC"S$+&G1,:QGF7)%]= B#H/5MGKX(P(&-!
MVSO+MLR[]L(8%)ZY;3IP]PZ.W &N$2.8B<FI96N1?(.'[N#HP.T=#A8N47BP
M0HVM !5^X4H)KW7N3Q,BU"/7$.LHC.CD<1X13'>JOGT*2LX=;M]IR*7^03;D
M*5DRSH36@M!AU.P8.J$6B_<941JL"18>@:E:6U$B&"\-,]T#QCX(NB@P3?Q0
M@RK@GM":/H-.)V^?6A1.@%<5<G.928(5'W1*CURGBS:IN-;J*H%V:-X$0/+"
M<;9JPM37PL."ATB32!9JN0%-[I,W<_8HU-(I,@9)4VJI/($0U=] ^9-I\K1T
MF+B\H78/B\5DQSUI*)/3AXN5,A3'FHM^!0TON0P2P7V9C,R,XASLT, ?IG=H
M#XI;!!X1@E+OKQF"22E[L^R2X.[JVZ!WMMNUMO;YR'CI9!=3=>$,*JG[LP@)
MLB0-9+VRC*TDHEZZ["NFIGEM@;D6N:C>5.R]P9OZ:-=HU8:MOE4( T$ "$RT
M6Y[H!ZJL<:QV-\[N5*SD_V_OVIK:QK+U7U'UJ9HB5<9@&P@D=4X5@:2;F>Y.
M)J2GYU58,M;$ECR2!;A__=G?6FO?)/E"8L 0/\PT 5O:>]WO"_GV.)<C[1#\
M><R,IE_! J/*@<4KRO1_I9K5<)S!E27$(&IUC6)/M/V,4/:#)5&ZD(W!414?
M)ZWC_9/6X<')0@4)6>X"X98*P0"*J]A"0PP%KGXN5N-47J1!C*Y#/T)N\T^J
M#L-ENHN4RZF"X4AA59!B6%+F*ACB<7E@-5QAHD\ZFPO])6!V()GE<P#):V\@
MK92L*,IDRH5%PKHD/<E('1G[M!6D)=0.1%ERDXRHJ3N#.E+2MW.RJZBF\YJN
MTMW?W=\_ZO5:#/J^6[N1:+ !9AL4WEI<7F -B8[&]J3,T<Q*=B$<WV0B%IV9
MBE1RZ)#LVD5BF3Q'BHT'-%B8T;N3O/((A\SF0E.YT90 [C29EEQG[HM%7>0K
M_.^6%JXJFRABS>40\A1=<3I 1Z+4Q@JU<0WX3J).7DY@"XIR;7D7<;80C<.T
M1(TZ;9$KBYAKP6DG'-5_0F'1;R1<KKL\I-M@C%@6PUQ)Y<SY,VH_JN:43/BQ
MBEMJH!SEO;+$9IX*1T5F@%Z%-@JU8:NRPKT7'(DW%;]E#MEUY] =UU[&ZR7
M*"F(UA2M^)ASU4G5.9HKC\@V@TQDB6*5.HG,(BL5H_ER+D>U[*!5X0@O^Q5
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M^")_&/PKTM,W@N<+JP$MHEPJL@I<7IMM(KP\R75:7I=*S@A?B?!Q1)E^YP+
M?:"CF(-CD)Z^C8/=WCYC%X!&SI2Q!WH@"K'PLFUU1BTQH7##''W\0MN;&V3[
M?4OT]KF&;S\Z7-MQ)/)*<1H]0*XI7B-"_#O"-=5S/5[,AOHN;-1F=U'4QNV[
MNIWO(#8$=]2]]D\ZK8.><H3[^:Q0]$9ZFIQB'276'SK8#W8FPS ?A_VXY/X.
M)VPJ$6%\]KBUWSF<$RXE]?LAOLH)KA(^Z'YW\&B;.:YFCH^VI98_:A+XD4EM
M'8%;*X@\>5,1*7/#N)X6T"\QJF!>UL**H4/7NWC <.NJUUP6?/U[J83TZX?0
ME>EJZI(<"S+#J47%5-_7;$9H)-&3Q?K59+BBBA0P%/=0D!I?7864'@+%"U2?
MX$0!HG.\)H6VAJ2><_@U,X[8^2</SC7U>RS@#&X)=FA[KH-]'V8$;U".QYS9
MQCI,Q"S&B)A^3)+;E(':* K/2BM6#'"O'.'N=G?W%?R/.<*-?YP<',Z)<)NL
MLYYPKL"8C6[0ZA*/DKNDJ!N3=FZ*TX%F\"6D7 W).RUJ5&:[03[54B<$0K5K
M/) 7%DU?B=I_\-CZ:A+AH2/M;FBZ%IOF@80-:="U!ZCYFNL(4S>#M>69/ QB
MD?-+H];&<NM0(*C774?<>DZ\\8+&D5 '1-$?QA$%[O!71Z3V-DC,W3-T]"6^
M"9]IX.C"Q'\[C48P%XO)/&NZ9[WTCW[=5/^WKL(_O, P5N5@:RSYVXQ2OL77
M_::J/<@JQR6I!;^L/]2IESVLT?;&Q5KW<6E7*?CQ#7,/=JL8X%US8R)C:X*'
MMHC#SY"NRY%=\7++_%A;MMN$O%3?0YW:@XUWI^86G2<;4:P]P>[),O><<+:L
MYO!;_'+CC=<)ZGF[XT_1B^5XGQM%9TOC$4Y)?#4F\21MN4\CBQ=&0CS^6%H*
MNE'H?Q)>^/,!_8^ZK%J'Z]&HIUJ>DKJ?YT&RG40[B@F7.!VXTY9JEKA=GJB2
MQ'[7+Q#2QIP;A,'R(AOCXD(6)[*V.'#6V=W?/W[=,8&S3N?HF+%)]4K*J0!!
M36Q?E[O83VG>=&K+=N<),:>X2K*<&/>. :+D401%HF <YL(MJS_4^+YB8,P[
M<LUOJ,#!@J'%94$HS,)RA)!F\X01IN^JEU.F%".2:4P?0ZG^* $B 6C.5YL@
MLCF>YGV;R1.ERIZIW^RFOHYTF=1Z.N8(+.Y4WXUI9EOLVZZS$**UO JBHG66
M))<(J,U.]0/ZU-S@T7$)9.U.-7/1/9QJI[#UWE%%W_;S@3K?VV[XW#H=J+HI
M0RZX AP!0?TNCBQ:MF4NU3*7U]LREVV9R[-W?AJ$S/K2+]\C,Q\@$\,R?XE3
MX -D;D4![;8O,:F+>U%/=%FP]%$>5)572R;E%S'RE+Y'(4.5N/Y:T#C/&]#[
M!>8HOA;-[Z*WZ&>UC(G/$\J]]U#EPARK6?=,;)"MO(Q/Q@2R(I/" =K0DO%_
MKV(:]1Z2;S=#[M?9[>!O1QC1< W7HZ%XMG0C2ENNB3&J)]F(HTU6)+P%;KIX
MYU<[N,2IS/X ]Z74YBO5$N+^X'ZZ?D*ODB\YK:WC[+J(PKF=^A%K&6B<@5EC
M8_8'X_#R.^*;*!PKK?7M"^9.#C9U;(HRJC#'.?@0TKZ%^4;-YOB <_./VHK6
MDLE=XV8W6,2C(KZEF5Y:;O!(:#N2[BH>9;=,2\X,N%E6!L60%$%?$=.@'-%
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M+6>:?]_;P>EL'G9"7MLT=BV-?;Q-8_^H:>RGCH&=3B4P0S(?RZEL[)%L"4F
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M>'+$BD4Y0?C")"_M\2WQ,EJI9\H489#=H*_3H$TY5"33SZMW$UD D;$+AIK
M/;7CQW21+5E'B&KK B]ZK-"RJ3\B/].DE**L7]J,FLVX)DZ!G:T?XF1(Q3S4
MHDM;D$NN2F#4@Z;MR'H<7L;3G^?A8!K\K(\(4KDPY/:1 :-/<YX5""JI5_Y2
M*I5*%2+]/.'PQ+FIMWB7X#AT3%VK:=)^7W2;(KF/?/"DCPZ'F.-8G&1CHT69
MSHF+5D1+)/&FCT2H@^:AHYGW%$ZM@:0+#>BJ,#7M<F(P22MJ5?H:24W_H/H>
MZRMQ82^.\%QLA\^TH1FK)!*.S5&OBX("SZ4"\^9A4MBN<:W .99M$.!V&J&!
M=_27>HUR88P$BABU).M;:QT1<-0^7"487\_U  6[/?HV)4H554B"!LJ<4P5/
M,LW B2)[08%&8>^4PTL-KN74L-^/1Q0&<^;'3\+I\#:$40)50\%C[WE*&63]
M4!<"Z$A;.W@//>PTE296SY %.(R5<>/P,@F"T^@F*6!/HHX;;@CRG^1SL*#D
M_H7&@S(7:\LI'21H>B";E10HWQLACQM .8D=L2B50>W@$C%A79KL5[M*9KY%
M9V>+@/L#$']-J7A+[U2A?*LM,*MDNVV@Q&Q;(TG@74I15((6H FO%1%F:F 3
MF$*<P$#,9,8@_N67R^ CM"9)W8N42G,4<'Z6^"RN(,,B287H)B(*MI/_R:ZF
M_($ZFHI"R]^A)+I)'6AM5"PEH(J9?"D&5J_;V3>!KRSC4E"J!ODX5L9IB1@B
MV8RG7 %.94VH"\[R29:'SIPFJNPXQ5L5U0F(U9=>215KM,()3T?(?E\/V7!P
MDTFZJ9V-=9W"22.E=5FT-SQ7"<GIO))I\C4* T?H$:H<842;N%8A/$4?C]BJ
ML&XX4_;;8!+GXV3J/<TZJWI\9"&UY"2)U6TM;]KS@H%XT&FH*UGZ>'H"O""_
M:S[[UM[!*%HG(<,%8YP):S@SES9!+Z095:M)B5+G>%]Y:\K/\5_&]0V*P&?V
M$U0EP!]3[*=<5_>F81Y;$GY+E<52#ZB<7*3)U%&W&?]JQO]DF_'_43/^CTQJ
MVH]:+-C8XH"!&2GO[CI.^[9;T6%D-L#=FK?(R!\E/X;)54)2N8]&#?),8Z67
M1X5;G&C\0D0*!S02R=N25E'/UGSEQ7)WDSA*'+W])Y4")Z8<FTK'./4/#QI=
MQZ)%B]@KV.) E(FJN2X>U:N%T@F%'.0H3'5Z6_EDS>>C1$Q*64QJM/$+\+R,
MC&2)K9O#V=)M<D;1*]FRB<W.D2_G1*FUV4W5UV%:CWYJ6Z^H9&0JZ/'=0XH9
MFB_2YP9+TFJVRL(+\7'W%,\WI[('31]2&TXI<1A[5-J/K[OE?-7:%BY\I5,B
MADD.>,5BH5>-PBNX1=<MV.WJ"5<EFWZ2QY?S.]DJ?2,9$CN*I-6@7LM:D1<2
M??&F/#E-M&Y6N1;TEQD5[#CXX3Z_^X*J]ND93@6!9,[\H!SL:&5I%V*FNW4&
M?BV!2PS5I-R2J"Q3VJQ*,NW@@Y6,V@2J@LL#IY-T1@-FEJ9BF9/T=>Q F] B
M88B&/4AD$X&$6!M1JD<:P35!.'W9-D?(^'4@/'**2;A:))/8>4L#/'?K=355
MBL'<D != EW-I_5\D1=ECUVGK:V\D7I&L^^,WV>"U1T6?A5,2]I]$)7/J05-
MF:T*B)9O!A7DS?1 ,O-2%W<NO5OGDZN@A),$9Z8ZJ&6BWI*(XRD17!+E%0ES
M_Z>4J.$-(OB:2A'JI0P2PB7IHBN3S>/CZ,?,_*]8*8/Z&/HG;C%,)F((?1DF
M.3>5*)K;G+O=LR+F3]!:_RO+MMO4Z4HPB0-'6:"=RI3\*UD'ZD*HA76,FZ[4
M-%18(]!M1W-2>5Z9!<_7U _Q7N^7>O'3FJ+!DE-SMHJ@V<%6TF'<$!?/T2R-
M/+)#1$W8N=!-BZ9QD&^GY0C-@=@\@IX[;B?*R.YE9HP-LK7L^?FW3Q7$4U6@
M@W?U%XUU NXP'B><7:@3C"[@W3G[[>R5'Z@WF&[-3^8ZB'-,DAHEZIHFDS5T
MPWK0PLUYE&(:AQ%GA952([U% S\,:HDD=GGV$-T$DJ\*G.LP%<7FY:&8>*S(
M,Q(S'H:C ;?S ?3V ^Y@@>M<#WC!4T*H7K/0A5-\/  15:Z8R?C;F0=<,7BH
M!(?"2"4OR,4;461!7TKCZ6V6?VWI[DA^O6P$4C:59A+SA3IZD<_C?"EU1='S
MU)DY&^J8>4L R<,,-$8S*>J@AR?4UOPE<SJHN. @I<055O6Z9S"1+[_KQ55.
M"%YS:IJL$Z2OQ"A)2T5L\_!>DK7J2GY-W\"9@A1-<%2<9HMC?8F">NQR-("K
MZ%3MLB5GN\CGF!-._).*&))4&J0]5X#ZI"4:KUB*=NTA/*>;YD#=I,5C";AZ
MPC:OZS6QWQ0IZ.*1"L")*$6BD,7 +S9\C]=)!^0F:_\YDV_+? 7*-?6:5[:_
M3BLM-I,3 ,$84A!@;)#/."81^ V ]I-.=:&H3;2.PUO1\>V"XL)B$_\7^\?P
M5_-Q#!J-8XE)-,K8^=6*BIWC2'K=[TF>)ITSB]DY4V)(T;KG4KCRW%;A%''L
M$S6/0])#,6KL'E;WU<?!V<=_79SO=DX"R"^EF?J!)*KU%N_/95%DNW]\S5&%
MJ(CI3_0O9"NA>I&0$K/97M<2/,&9KB@96;:R!F1!]1,>;&?8MZ45+,_THQB8
MS1<.@746/[6[%UR-2+;V]2B[0A'<#3LC;M62N^;<!:;R -VN>A0WT=03/CH/
M+%#WS\N)*86G7 L_PX2O5E;ET,&#=4!>Y(^K/^50I<@QSUK,YOKLFBT'H0*Q
M;E-*%XEKS9"5X*#O"8)%!UQ32DB\30J.DC+>==F<ZU6*R+0M'3)"C)MD<!U/
M&?MA'%<UN]-#3 &<D=:ZY@FMM'&D+3KXGE?4(%KI7.%3>?%=#69+6CBWT$$9
MF1RQBW_76M>8D"?5HDD\-HWP)Y$;GYB).LU3JN),/.AZ""+&5",Q$!^X?=5+
MK6K;:#6J9TL7)9+BA.@D7LZX="E>I_<*N@05KC6P7! 6GGJHT!QG=R\9%V<D
M%2YC956#Q)'DW3F_/+L\Y3:RA#%$ 0<\\49Y5C2BAD<7&AZY!Y>3A&F\KBF!
M-15D,$P%B=/,@X1[)SKOHN-Z9>Y.T(4JWO(LI21KE% 'N\_5PDN8"ZB'CYH)
M,1GL?!,&@[]+C?;Q:*0GH1D9^,T3.U]OZ,3.;COX(\V1..$]II=ZO,![3/F=
M:8+25N<?W)GUB6>H%G_[G\[1_MOZ_S\3D_'W;.J2_C:178'/P?[\1/;JM*^N
M^=,V_?T#I+^?2H;UVL%Y/ A)G?^!1H#+.$5%CI5=+T4>K<IPO0W5-@?MX#>L
M7KGDJO-STV[_PV'H:$,Q=*A'0E_8:=<_&FY.FG"C3M7?51>$'?RF*,?J[K.W
M&X"PHW;P_HY*<^['0Q6S@N>J&<L%*<M=RL5/BOB-_N&M\ELGRH-[DZ1T&OJ2
M!H*8.PU5W?0^_K,H\).3]O%A!SI\FJO_1?K%HM[;I-[WIE'];Z_;QP>=N7_=
M;W_KWPX/#K_IFXO.>M!I'W>?RV&/VH?[\_^Z66<];K_N'3V3LSXG@GU>9^T>
MKD:O>R1CC..A1>@!R>LI B\CR,W__:GW4Y!GM_QS]Z>*,!3QUIE, UI,&6BY
M/D&\*+U^TYW<!1U?NH[B0;W%A9[C>R\/YN>=+-,CQ/*B/^:JCR<^WN^T[+/B
MA@C2E^!.XV8?F/EIY:_],"A7?I/I('P8 '<[M<\^7ZA=F&89F=/Q.1[$F$@4
M+P?>PU'D"R#'#^[F\DV3/[\H%",\W8#C9M72ZS:IEE4P*7\D?^(%2AUL_%F9
M4U:"Q2(VV@*<^"I857]NX;YN];JWJ2+M=$+3=NXV]7SWUZM;JEV+M$#"\SR<
M?J<](VKQNW#5 $:&22VZE$T>N[^SW3'P^3Y+[SL!TD17# Y"VUI28,MALK]J
M#LP+H<8L(M\^V<$D,S:<3B?%F[V]V]O;MCI?^SJ[V3O-^T.T"N[%T768[Z'(
M8>^D=_+ZZ/4>SLD_=COX^?717GP7CS"G:?^P>Q3?]3HH)$ '0C]N#Z=C"#/^
M=W!F%K;+. '7FT#*73THN4N*%J7=?G2P!5LHC,GE;#=D81]6[#P'(=S9W_WG
M(TGAYP .]=3=WGZW=[B%R1/HZ>< C>.]PSU(FL<&R7TLPV< QEZ[NUX(;NV[
M35;1W>,]N4FO$XYI-%Z81J*E646?\J_UW'6V]=[-N!'8L>J"A]3ESX!SCG?_
M\6B<LREW?B"U_ QNOG;E^QSNO-=[ !7[4A5IYQ$I9*M)OU^3BJO:V^_U.D8G
M=CK[_V4U:*,;$L[XE"=I/YF$(ZA F87!PQ3SX!-&+87<)_C^3F8!HF?E,XV"
M[O3"W<[!3LB]*_A=T#F,^%</K4&W'WV8CVZP*/JW)X=>A&C=.BG/7K1V5Q&M
M'TQ[XU:T_K ?W6!1].)$:[?=P32Z[N';K81]YA*V.\=X+999K[23?D41W#FF
MC5AG;3.HN],[W-]*VN?YT0V63"]-TG;V.^V+WR\W0,H^TJVI!N??[S[_2L/.
M:(#)N6RL60<0NJ^?$_:QXHQ@D6A8Z.T]ZH>8AT&'DPFF0<MDFPL<G(9DQ2AA
M"@,J?KR*>>T7!DK0\Z;A-8^UC\=7<13)6DCS#)R$/ZC?UWZ!?'5Y]LL&\-4B
MZ^5!F,M%[Y?P+DNS\4RI=UICB+9Q#$<,ZTRWU<_/YJ,;S'<O43^?G?ZZE2,U
M.:+>T=?+?']-TJ_8:K65*L_XHQO,A2]1JIR__["5*C6I<AX/:(O)5JB\C(]N
M,!.^1*'RZ^F[K5"I"95?L5FFV J4E_#1#6; ERA0/GU^OQ4H-8&"G=0*25OG
MY\5\=(/9\*6)E74FEI]1SN,+=CGVO1H7K$73BRQHU>,_RS"?8O%Y\#GFD=)I
M@'$2 ?K 6GH]9!1C,GHPP#@1.R;[\OT9#Y7F#_'V7F_Q\15FF4O+.?:T9#Q<
MFONA:S7\,M>='FW'(\M:Y<Y)KT=CJJ5;H*4W&C@?]<IR^#L'[G>"G=MA3%,8
MQV&$',: 5D[FLLT73XNDB70Y<%XIZ.1**D]XJP@OBI\%U[+".O&Z4$?J6"5V
MM6!$=Z@P12/U:=4A0Z,A&[)'8P#_KSY$X-'&)B^;S;@1LY0[%>7W;;.4.]V?
M]+>VLY1?\"SEQR79YOFBEQ<__W[ZY8_/[R_]<V_L!%BW[L;9Q..MYUPJAOF+
MU[1K,L7F#2R"D0TK6,, @<M;D4638 ,.5DJEE&3FC6%Z02<1CWR %JV74"[T
M/%EU^U<<M5<?FG_HDT6.RS=!_7''N;[NM ^ZQ]\RSK5[U#[:/WZ(X9"]WC-Y
MZN%!^["[VC33%2W<3709EHW >5R+TWCN:WGI4K7"E3WO?[WX]\5E*UCKNU?U
MVI_@PK^?M1O\_3G36 \7C,S;&+I^T Z\<1)%H_B17:_?PEEPT@I0&?NDP2PC
M"A[S\N]F;^YQZ941^21WV2OV@K-AKJR6; +'\>^H-TY39^[?"C2[WL%<3T+0
MWO"RQY83&SO8K"JPF^>_?3?];(R@WF2I8]L)_H6E:0B8)Y%>@7<V3.(!NP.F
MK8#_J7L+7C(^'B3T2$]J6JO>C)Z=<SAGI\8Y6]KT@=^?]OM9F=+F1/GXJTV,
MDVU:2*P[/R2V=Y5%,_6?X70\^K__!U!+ P04    " #G@:E6KWI?(240  "V
MK@  $0   &5X96PM,C R,S S,S$N>'-D[5UK<]LV%OV>7X'5SNRV,U5D6?$C
MWC@=68Y33YW88SMMOV4@$I(P)@D5(&VKOWYQ 9(B15(@];#94IU)+8FX#]QS
MB,<%0'[X^=EUT"/A@C+OM-5]N]="Q+.83;WQ:>O;_47[N/7SQS=O/ORKW?[C
M[/8*G3,K<(GGHP$GV"<V>J+^!/UN$_& 1IRYZ'?&'^@C;K<_*J$!F\XX'4]\
MM+^WWUN\RD]&0ZMGCT;OV@>]@_?M=]WN0?OXZ,AJ6_;QWJAK]XX.CP]_&I^\
M'[T[(/8Q;G</NONR&#YL#WO#;GO4LX\.]P_W]M\=]I329W$BK EQ,9(5\\3)
MLSAM37Q_>M+I/#T]O7WJO65\W-G?V^MV_OAR=:>*ML*R#O4>4J6?A]R)RO<Z
M<'F(!8F*DV?BI(K##_29BK<6<SM0W;U>KQN5!EUTB7;J"1][5JS=]GG;GTV)
MR)>1ESMP&>SLM?>Z[?V4)=N/Q9)F#CKZ8@MAW^=T&/CD@G'WG(QPX$B1P/LS
MP X=46)+'C@$D$X52%SV,1\3_RMVB9ABBY2(Q,<W" % U)TR[B,O(SK"8JA<
M%=P'L?T6TF!>,0O[BJ%04D2URI3O$,<7\*T-W]X^"[O5*6\U$.TQQM-*EI,R
MVGKX2Q4/$LSLOG__OO,,5,OW()<[JGP;/K;EW='K5C!;1,+RMN6W=B2W"1_F
MMUDU'R*Y-7W(O;&*N&"25-]%23?R;]2208@$H/8'50P*8KT=L\>.Q0+/Y[,R
MY,\3B;Y4H7U*F4UH%=M1<?B08Q-['O.5//P2_C:=4F_$] _R)R#,2<2:6S**
MFL],-Y!S:ZH_)YA;G#F&^[@SY6Q*N$^)2'8A2L&$D]%I"UK+=M1*?G?P\*WT
M)"J2,9"F/ESN2!'B7,UK$LD"^TY;0@+@$!V;.E=\RDG5BDL1(;LH!?3?OOX6
M=JK67XI8@?//J+Y-1E6K+T6H1U>H/4C?R^N(VJ>M 9/CWQL\EM[![]]N+XO'
M,LKL7"#2&NF=._1Q3_W71>WYD+F-E"0"T0^=18$%58$@]K7W47U>I'DH'!99
M(KC C])RZ<#FBH4_1I%<&E_/)IX4EA\$<Z@-\X8S[," X6Y"B"_*!]ZHR8C(
MOH3A3H:2Q)"$.E%2*0JU(JUVAU8BQC>8R^I-B$^EPYN#+JW6B&-O%1S1#RDK
M/S8=USB @HTNY;3?K= &EE-GQ/%=.1SGJA$;(:U\A]X\W /FRAI.9!GZ2#8,
M99YN(ZX'J^":LK1#N0P2FVN-*QDRXG^X*?QW;78Q3'<^LQXFS+$)%Y_^#*@_
MVQ@#<E0;,3]:!?.DH?\B;6J'<>)6Q&)RX;"G]4;)^1J-B!ZO=!=+_4@9:!".
MUWR,/?J7\@)[]EW@NIC/Y'U$QQX=R9;+\_N62I)1;WPC(V?)B7%92%=3;D3W
M/<Q.J; <)@).Y)>D'20-H="2ND_GMM#<&(JL-0CJ6_)(O* \>G%Y$R#=O45
M(M$&17? ' </&5=N],><Z(:E[]EG@: >$>)<!L5A4_BY;_GTD?H5;J55U1NQ
MZRYBE[*$YJ:0M(4B8RAA#<W--0EOV5O(IN;2>R3"5P$J#656THC2?@8EZ*R@
MJ4NH:5#T+S#EOV$G(%\(AHA4 B!?V(A!;Q$#T(.4(I34U" 8@'R>SWCI\?M<
MP!CN=XOACF4;%.#59THK3(2Z!XLA3RKYS[^/][M'_VO>5.>&LT<*&XTN&-=S
M^WO\7+[G+A(WHG&XB$:L"4E549I!*6L0&E^)'R9V"+^;8%XZ7Y@5-")PM(B
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M_!R!(7AOJ*51K@ZU*^KGXO.DJW63&?&:U36QZ5U.JN'Y*]>C\/S"M2=GW-"
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MY99]]4F>.JHJK EQ\<<W_P=02P,$%     @ YX&I5@MG>*I0&@  8 @! !4
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M=Z\G &G7!A2^G)SISL4QT>\F[^!S38D?G]5@OYQ,;ZA,R@%))RE2@QHXTTD
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MFI2[OO#W/_'QJ[T/T;;./;S^.,?U9N-=EH87039'76F]9BV&.GU?D.O* AU
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M2Q"UYTPH;4!D%D Y32\$-Y$0BRQ,M*37]M?>#$R-[K9H[\SH(O8^&'%NW=R
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MAY;HS0Q!+99O4P&F0[VH!#4$Z1D4;IQ3-J? 6O<Y;6&H]Q,56"4NHU/<>S*
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MX&+UJ\ /*#Y56#(\1 N9.P3%;*Z!8P3K;'28HC<]7*!^</&I3H7-W MKB5B
M=>*,LBY"T%Q#8*@$+T'33OBM6GU 7K:H5N^BU,<1R?(Z.U\XDH\:&)W, <&C
M8R"*SL(5&ZUM/2#F6R1K9^[NF0C[CF3=68'IL_2)_!I 0UZ.XD5#S&3-)D[G
MN[/99O.M6KTM%1ZJ5N^BDL'JE3<!]8RJU3OI:*/"Y6T$/*#V<\@E:N"<J*U$
M;9S7RH/P02J-5AB_4?;FL+3>M5J]#Z5O+M?>J]6U<;7GBTPUDS2H(FD34\@
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M;*)FNG5?Q+V GC&+VBFJASKTW\XF))B/X:12?,WLDHM,MA"?$46]*B*#$R$
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MM.V.WXPL/41';D=VR4/;!%]/B:Z'L.TI:74H9-B(I#MJ<A^,L[G8+ 1"4#F
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MR$?)URCH*?@IE"B,*5PH3E/$46125%&T4PQ3K%$R4 I2JE!:4)ZB/$.92/F
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MUO&D4ZNSJ4N_J[7[6/>;'LN>OE[[WH]]+GUC;SW>SK[S>[?6'_Z>]'W4 /U
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MD\VY;]EB@U^]D7I75G1T4&)GJOZ?2G,=^Y3%Q=LUBN59DX*5@:HV?H*VOQ'
MWW^FZQNA2_NWI &D)_&.:<@ZRE&IUN+ CB=!US/_/;Z_%CC+Y_6R_/6-L<GN
M%H4[=Y>6;B_M_3=5^*NDQ.2L^=[,U?+V5:LG8W$RWQT'YNO_*TDD;A_OG#NQ
M(?XA(6=,7![EH-GTW\F!]ZH<//!J,_W.B=).,\<[OLO_E12 ?O!^M75AJ/B
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MI4H)@Z$8% V>2ARLKXX#@,6SF?\&\2_81V510'7&C:I%9INV_XWPSUG^"7
M QB;>DF?8KX'-;QKXB.<>ZS<-(%XN"<XT@MG))=I:\A') ;Q)4@RJ:O<Y0T:
M?;G^H*]V?.KGR[:==,9Q?'*"ZEHQ[2SPS6PE/EUS(_$%:JGT8CD!<.8@QG-&
MR%K'I8\/#E21"$ 8C615N(D@%J'\-L<Y6>T4S&$=N!!0E>5K-? '8&Q8^P>
MGQ?>Y6U0CMNT)$A^5MYE9W]<JTOST>H6\4HR(B6T<\34G^(D<F7<Z9>!Z:\G
M7IO?(U[:YRGEKR+/7]0)8 IC*GQH\AC^DH<"NWV#48/#A7RBF1\3>DP96_ !
M83,/GT"LA.1#5J P:5RY?"S<D!,N8G:GG6-"I1AL2YIA&X-? 03>S@^&[F6M
MU,\5;Y7,G66DB+GV\OF2P0U'%/<97#25]+42#&!B7:YDRU)O\DT*MF%-W\)A
MJEY"#9[=1][T%_Q;>E1'<461?!PE97$YC9OPCM6T;#J9&A-%_WQNQ0GE5>R
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MFSRNGOQSE-"@NZ%/L?U3/E/8XY^:NT_L(,D+,[PEB?72:H:X!"PP1#],JSO
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M$GE0557UWR);X0C//_-'Z%I/Z0:C-(N13:6MWGE22Q<.DO8[]S*:JK)>T4K
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M$6$>>35JRLCB,RRQN64]2KU9$&_ST$ZI9C--(C59DI!9IY_ F_(WYJC>?70
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MY 04;FL$34U//((<%SW><_SS$4]?BF\3/B%\$S>7"R"J!7L52;@P#4'5C>^
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MMYGM:09_I$]2/Z\OU7J!(\[=Y:!/,U?TZD63I1;JC[(P2:^3Y3[DO."Q1ZR
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MG7T%]09<$A.U=:4'+2\-%'9[-V"J;*C,=CXY,SU"=DM+#>/9C;'5DT1;W?H
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M!&+J>T$L."5I:L73 P@Y-?;NZ A6.2A:+8&RF!6C:SWU]_H34YJ"QT950%]
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MAVD42X:].,9S=3?-C?/,344W&V+I:C@<KZP+ ;=EF.^TT(#KS62IQ*Z]^&>
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M)TPD\U6^(HN)C>E&INF-I_8A?LP+_:..+F_V\@G3^:K)\D6_Q&_S)5=KQ>H
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M0Q_K3%MQRF!*>)6(4#!"(V5U,1M/HZW6I^8YI -TLTHZN[=_&[(@H)'T4ZF
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MQ[S,5LTV9^J%<4("#P9!A""*4E][>!%(0L8#IJP-[%MM]9SH:VI615=4O9W
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M HAV-R4O:>JR2B"E3@;?\2NYD95GR8O^[P?"U$.RL96H3Q,6(0%9$%!=X"B
M5! /DB#V4T\$(?%[5?BPD&%RQ+I5N6/7A\KR<*;/F)C1Y,!(#TV3K?3[**LO
MM.PSG5&V\EJKM1BE6$8/,!T7P;"1X%6*6_2 Z%C1BCY-]=@2NF*L>!+\K?H]
M8V319MG(Q#K+0QK2D'E1"K&G\\&''E+FI9J[$U^** Z"* R,S$NS[J9&>(W
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M5QFD@1G3T?A8TZ=S+!WQJSNY1B5@YW#N,K3[#GKZC]DNG9$?1HB$ >02![I
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M"N@QPB */ EQA$*81,I"Q0$*HI3:%6&]%,=Q:JVZ1])LEK@4G8'9?P-+)=\
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M8A-*.>6I.7,88Y*E9D.1:0+-^SE,TE0C@2+BZRUI[F=L)J46J[S-DY;[>%D
M<^2K;O8\+_:.09O'.>=42LAS$MO:5"EDB&<P3Q,B;.$[C#SI( . .TP"XE>U
M6ON<-J@"".0 J#NZH,Y'LF]_4RVA=2=5-Y(7H)8RH&>I'890;J0CO0SK,VI7
M]<!!=.+QK@3=WXV-7RQ?OVP"1<V^CJ*((4B5#1E&.8$4&2NL4*PE39'DF5?
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M=WBQ&V)2;=;K7TKM*W)P5?S<6_SP<$,6,%NA=Y$'3WX8:A":<BD&Z[OS'OC
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MZMXS?N$-8&[3MSL,/4_=2C#P^UJTD#0=C3J'BK?=;WS8$-I&Q0ZB8IN?ZK@
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M7!5VM<<_SW@G]P%Q\U@$!GF@2*E::!OU4(L-;C<@EY)?E AOA \82^4-6*A
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MU'SQ-)U;0_H^0^6V%@X/?\]KXUHA4&L$MM7H*J7 CE;6568,^70VK<Z"?12
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M^X=W/W_W:A%//^7Y^KN7RXSKG+[[?;K^^-U_I+SZ^W=EN?CTW7\LEG^??D&
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MET^FE0GS]:_X*4^89,QSAI!2L5 5'&!&!B*I%%0FC69T P3<7G4K%)C>47
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MP3-72ARF\6\MMYW@.PY;[L^\3@[]CW_$CS@_R9MX:U BTW8MZ.))50GR<'Q
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M.CFM?B*VOL=9_@77=5C,V6:$S6R68Y7BJ@ZVN=ZD3T618>- >9EID]("!O3
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M5'!V7N(^,4$FD1,''@76@5MDHOB<06?',QE$PIO6C3UOKC]N3X[Q$;:W+#K
MT?M\4AGQ+G]>+!\_'"QXXQ(=B63)PU>DHDEYJ^K<*Y>3<2IBZQ*=K0@;MUOG
M^,AK+[T.(/G;*K\I/Z[6TT_$J]6$Q5*\20&B$!%49@D\(^J%JO$J4L^,M\Y#
MN4W!N+T-QP?9 ?+8&TU?\C(LFK6^^OW&Y;]<S.G+>,Z?A\^+8)Y.!D;0)9,I
M(+4')POI<:>X8$$Q&UI':G:E<=Q^/^-C<E"9=J #GZE)O+L[ZV3RUFE(4I&&
MMSR0W1HM6"MY5M$%$UL_[>Q&X;C->\;'ZX#R[#7F>%E;_J&.XCJHUOWB$YI6
MO#]$U9'KWJV+SOM$-R<I(1*R*A"\XV!E,#[K(EAL[;4=J>[]U72%)R?+VL-R
M<ZHNEMWP_$:)GW,E)3I*/+@"2G&D_2."9(6YI"-/LG7,;BO"OHZ*]UW0\T F
M6F/Y='!EOH\?<SJE0UVSZS:=B9>7VYNN_O[#6?WS)^+<XD9%?R)GW(>LP2A/
M>C89!EY&!AB$$9@Y][;U$=R#S'$C>,< Y-"RZP">-]CX(]TSRSG.+EFX^N'L
M;WEQLL3/'Z?Q1>U2>><DDL>NE706(DI6L^/)@6?T5T4.O76&F] \*_H <L<-
M!QX#KL>2Y=BSEM_E2*=Q.IM>',8Z(V;S1EX=+[*=7\QFB]]K6_C-$*WEE_P#
MSC9_O;/GE N*.M:UV,IK)^HL$&%!<[)F#<]"*?^<,=B2H''#AD,B=#2Q=:!A
M'V3F:I7KEJ]FG=_9HN&NMN%VP+PG&Z=P!0&M I^*UCH;(T7S)KB[DSEN!/(8
M&G5HV?7J)._9IFA_G_JP!<=LS32@Q]XF/A150,><@& TW>S((Z"JK0F+\$IZ
MS9&U]F>[2,RY--ZK[?YP@Y\JVU_I2GKDQQ_HJQ6>#YN[:RT%K0TC=D8A'.F4
M5,!EZ<CFUUPF%V,H0SEH VSG6T@+V@7EC[EY8R.EV]O@7DNF Q3]8Y\U4/.H
M =7S+@UX$(4/B$"6*ZL-> R@-S49(TC%@A8V#]&TX#@MI&X<GP?; -TY$;67
MARW6 -.:[+'DB!?)"RA<NB*)+5FU?L;<C<*Q2^P&0=43.J^UT#KPN:YW=Z_Y
M_]U]7K=1#2'2)B7H&!(HI2.YE2&"-B:I;!6SS=N\[4'FN$'7HX-S&/%U@-#K
MWFBU(5KMA_9F?O?:NA'RD-DXBPI8L+7!22:?4I,/2ZYFR)@$EZPU-G<B<-S8
MZI%0.9S(.L!C9=P-?GW!Z:SNI\X;I)-VO?6Z[;>+U;3*]JKEUIVM6]JZ+5&"
M+[[67%JRQ5-R$-'I+#D7MOE(]8;DCQN%/1*6QQ)W!TB_P>&7,URMIF5:9QA>
MAOI.<78Y;_X5>9EW]EJ8BX7;#,[% $JD#-X;A(2%"95YCJ7UY.!#Z!TW0GLD
M+!]-H+WZYP]V]=S?17_JXX;K0CJ@H_YDS\G$;;#<9,"0='VO+^"0 ""X2)$D
MR!1O/7;I*+U(-\\4JPL.IS?S=_70+:?SDTWAT8WV35JC]=J =LR#8H*.0L@6
M,M8Q:T6'T'P0]*XT=MRQ=!?T/-JQ= A1]:JKKMHM[J^?[GY$VX:F P<,'VMA
MF9 %D3" #:*F#5D+/LL,4FHL,J,M@[1('ZBMZ;4#?[7(2X)T#97?OGX]URRJ
M8*%$$T%AUH V(AC.F"HAH,BMM>^VM(T?!FR!E<=#*PTETZNRN=]<='^M\^AG
M#=0&=4 ]=&"S2?3**",E%,T=*"X+F<R:@T:ILY"9.=:Z(]ZXS5"OS\R/A)3%
M6<[O\_++-.;KMI@WB:IY3/$JA3DN3N;5DSZOP]U0>L/[L#RC=@68,&0^F*(@
ML"S ")&]B9FLBM8%,H-MYJMNH+H+IA]7J6/"HV%-X]"]#_=7PH]]U#!]$ =4
MP8]VP?/.62_(QB?Y<%"^2'"\-B W)<J2'8^Q=4[U4-T0;YR+.RM4OR:^F*=7
MT]DI'<X[ED=T1M<H.6@?#:A,ED>(A=%9%,%E99W4;#BEN NIG792W 5#3RBS
MP83601#X>ILOYNMIJEN:?LG7@<D?_XBS4SKFY]FEGSZ?7N8@/=YILA1FG(L,
MDJ@3XV6H<TN$!,FE,IR;^DH^&&Q;[6+<Y^6!$3V*J'OUC?;J0_<JKW$Z.U[K
MO<OUQNN\]^".N\KO16_])NF1AUJY4Q@'9XR#++*VM2+".MM8[XR:W[NI);E)
MP8LK6;ZY*<NK(>WUHII(83-=31&P;+J[D2GM;,Y00I3"F6(PZ^<@O-?*WT)R
M[2X0NU7R,ZB81C0C5LOUY.URD4[C^LWRPMM[0<IF(LDG\X%<-)'J<Z*OPS!2
M1$A!FN!ET5IN]3Y,"]PXB/2WZT/XV-KC .T(8EXTY'D?F*GIY!<[6+U:?,+I
M?!*LTIX'!RDKLG "6=)>10^6,8[*9H9FJU9FVP'G/@'CH*>-3.\#Y$ &CUW@
M>KF+5WE)INK&,GVS_IB7U3PE^R2M?LF?0EY.N#=HI4N@)3%(.0P0DK# F4A&
M9A^\PZTNM2T7'!TDA\IU,3"3QP;.#HJ8;.?\FB[ZU21:YS<=-$1)$I2V&I I
M\K!B$$JC9_;NA)O#3:.KU<=Q.(]W:QU'+&/C[M?3>E1JY)V\IR5MHQ;,OEJ>
MGKSX_'FY^(*S<R>;_*H/'_-O[R?6A>2C$V!"(8-2UG&LI40H7.G,/9.L/.M0
M[K/PUV$C[8F!Q9$$T@?8%N52@4_G=71"7E;GY1=<_CVO)SEX43M7@*OW@3*2
MOE*" 9D0"GU,P=U]5WL27T^M]74HL&:0:L;V#H+ EX?DS>=<2SKG)Q=]:U>3
M$GCPOGC03&.-9BO 9!GX*#DWBBOO6C]!/$K,.+45QP586XGT&G*];/)W^=]P
M=J/C6:UP6N>3FO&S?Y!UQQ6:MB[<9U=';FTH.&,Z5HO-2EE!Y,FK3 JLR$%'
M'C1BZ\R5#EH;3I)DW$:#4$K-%[-, NI40'COC$:ZX?, PW@?I>?K:&2X"U9V
M:62XDS3Z"%?=#LWHDHOG*D!TM0ELG:V'D5B4N2P2H]!";E7=]=6$.-M+];F(
MYBXL[@,B#P1F6"XB,?*1+4;:!"\9O/0)A'%,"X'>Y:V4[3<2T=Q)IEM%-'=A
M\-@^V\4N_K9<K"[C:JZ0'F6R '+R$Q03";R+"K++@8R]D)3ES]D[CWSVZ*(_
M5%H/Q"GW95TGDK_5[&]UJ]O?Q::*XV3BEUJ)QQBH* 20'T$[TPJ-Q8#D NR"
MAV=7',=S'Q8E;=G<@8]^L:\+XI-TR#,99<P@L0<C)]]2%V#<AVAR*FA;6[*W
M"!C'%V\/F<.YVP$T?B8FS%?Y@GAC@\JE=@3G9=/_@T-0/H(6D6?)4O&J]2RH
M6P2,TS9@.&CLS]TNINM<<.*"?+*OT&A?R'OC=3B04.3,!0>L)&%0!5-$\S*S
MFP2,4X<_'#CVY^ZHX-C<E+?Z?%[L(!1$Q7T&GH0F>->6PKDV:]$H_&:"%-_N
MO>"!#Q]G)M) 9L:AS.M"-SSBR%^'L$,I3#K:@M&:V%/-H^"< E&G>&/!DLJ1
M F8_C_M./ECH8Q!1=&"3/!-=O'IUK27_]+_T ?^8E(1:<S+&,6<\GUSG#'.
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MNIC'B[]<,I(N@ZP#YY!$2* "\=#'5"#YR)C@PJOF'1<.I7G<R,XQ$'I4J7:
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MG*U@9[]YV+426 ?8N^YY=3<&>NWT_'P]N##X_[^]*^MQZU;2[_-?"L-]>1G
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MO%/L7,:&:M*811>!&\9 ):O &U'JI6_-EV$F-._[MYF:<?'31MM;0&@/T7<
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M$]#/"]D!I$!\QA$K_KI2=;8.^%^I@/H>\VD<^:WSN_]O7IYQ\]*4*'Y0C G
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MYBO?RBP6@6>K\F(([6$EI';SD$VG]1L_O,FNX1L@_S72\3]02P,$%     @
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MH&4RRQ!7A(@SS94Y4ZE!(^@_,R:HWBI)S9=EC960O-HZV0#$??7IYGJ\<5Z
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M,#(S,#,S,5]D968N>&UL4$L! A0#%     @ YX&I5M7=$&6JIP  A]@  !0
M             ( !Z38" &5X96PM,C R,S S,S%?9S$N:G!G4$L! A0#%
M  @ YX&I5F8/9IMQKP  SS\' !4              ( !Q=X" &5X96PM,C R
M,S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( .>!J5:1^WNYIVP  -+U!  5
M          "  6F. P!E>&5L+3(P,C,P,S,Q7W!R92YX;6Q02P$"% ,4
M" #G@:E6,E" RT,(  #H)   '0              @ %#^P, 97AE;#(P,C,P
M,S,Q97AH:6)I=#,Q,3$P<2YH=&U02P$"% ,4    " #G@:E6@'J5 D0(  #,
M)   '0              @ '! P0 97AE;#(P,C,P,S,Q97AH:6)I=#,Q,C$P
M<2YH=&U02P$"% ,4    " #G@:E66/'ZSJ8%   )'   '0
M@ % # 0 97AE;#(P,C,P,S,Q97AH:6)I=#,R,3$P<2YH=&U02P4&      H
,"@"M @  (1($

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
